Extracts O +
of O +
the O +
creosote O +
bush O +
( O -
Larrea O +
tridentata O -
, O +
family O +
Zygophyllaceae O -
) O +
have O +
long O +
been O +
used O +
as O +
a O +
folk O +
remedy O +
for O +
Type O +
II O +
( O -
non O -
- O -
insulin B-Gene -
- O -
dependent O -
) O +
diabetes O +
by O +
native O +
Americans O +
in O +
southwestern O +
North O +
America O -
. O +

In O +
this O +
study O +
we O +
have O +
evaluated O +
the O +
metabolic O +
effects O +
of O +
masoprocol O -
, O +
a O +
pure O +
compound O +
isolated O +
from O +
the O +
creosote O +
bush O -
, O +
in O +
a O +
rat O +
model O +
of O +
Type O +
II O +
diabetes O -
. O +

Animals O +
were O +
fed O +
a O +
20 O -
% O +
fat O +
( O -
by O +
weight O -
) O +
diet O +
for O +
2 O +
weeks O +
prior O +
to O +
intravenous O +
injection O +
with O +
streptozotocin O +
( O -
STZ O -
, O +
0.19 O +
mmol O -
/ O -
kg O -
) O -
. O +

Diabetic O +
animals O +
( O -
glucose O +
16 O -
- O -
33 O +
mmol O -
/ O -
l O -
) O +
were O +
treated O +
with O +
vehicle O -
, O +
metformin O +
( O -
0.83 O +
mmol O -
/ O -
kg O +
body O +
weight O -
) O +
or O +
masoprocol O +
( O -
0.83 O +
mmol O -
/ O -
kg O +
body O +
weight O -
) O +
twice O +
a O +
day O +
for O +
4 O +
days O -
. O +

Masoprocol O +
treatment O +
lowered O +
glucose O +
concentrations O +
an O +
average O +
of O +
35 O -
% O +
compared O +
with O +
vehicle O +
( O -
14.2+ O -
/ O -
-1.1 O +
vs O +
21.7+ O -
/ O -
-1.0 O +
mmol O -
/ O -
l O -
, O +
p O +
< O +
0.001 O -
) O -
, O +
a O +
reduction O +
similar O +
to O +
metformin O +
treatment O +
( O -
12.8+ O -
/ O -
-0.9 O +
mmol O -
/ O -
l O -
) O -
, O +
without O +
any O +
change O +
in O +
insulin B-Gene +
concentration O -
. O +

Masoprocol O +
treatment O +
also O +
lowered O +
triglyceride O +
concentrations O +
80 O -
% O +
compared O +
with O +
vehicle O +
( O -
1.0+ O -
/ O -
-0.1 O +
vs O +
4.8+ O -
/ O -
-0.3 O +
mmol O -
/ O -
l O -
, O +
p O +
< O +
0.001 O -
) O -
, O +
a O +
reduction O +
far O +
greater O +
than O +
following O +
metformin O +
treatment O +
( O -
3.6+ O -
/ O -
-0.3 O +
mmol O -
/ O -
l O -
) O -
. O +

Non O -
- O -
esterified O +
fatty O +
acid O +
and O +
glycerol O +
concentration O +
were O +
decreased O +
by O +
approximately O +
65 O -
% O +
by O +
masoprocol O +
compared O +
with O +
vehicle O -
, O +
a O +
reduction O +
approximately O +
twice O +
as O +
great O +
as O +
seen O +
with O +
metformin O +
( O -
p O +
< O +
0.001 O -
) O -
. O +

The O +
effect O +
of O +
masoprocol O +
on O +
in O +
vivo O +
insulin B-Gene -
- O -
mediated O +
glucose O +
disposal O +
was O +
evaluated O +
by O +
infusing O +
fat O -
- O -
fed O -
/ O -
STZ O +
rats O +
with O +
glucose O +
( O -
0.22 O +
mmol O +
kg O +
x O +
min O -
( O -
-1 O -
) O -
) O +
and O +
insulin B-Gene +
( O -
30 O +
pmol O +
x O +
kg O +
x O +
min O -
( O -
-1 O -
) O -
) O +
for O +
5 O +
h. O +
In O +
response O +
to O +
the O +
infusion O -
, O +
steady O -
- O -
state O +
plasma O +
glucose O +
concentrations O +
were O +
reduced O +
30 O -
% O +
in O +
masoprocol O -
- O -
treated O +
animals O +
compared O +
with O +
vehicle O +
controls O +
( O -
p O +
< O +
0.05 O -
) O +
with O +
no O +
change O +
noted O +
in O +
rats O +
treated O +
with O +
metformin O -
. O +

The O +
effect O +
of O +
masoprocol O +
treatment O +
was O +
also O +
tested O +
in O +
primary O +
adipocytes O +
isolated O +
from O +
normal O +
animals O -
. O +

Adipocytes O +
treated O +
with O +
masoprocol O +
( O -
30 O +
micromol O -
/ O -
l O -
) O +
had O +
higher O +
basal O +
and O +
insulin B-Gene -
- O -
stimulated O +
glucose O +
clearance O +
than O +
did O +
adipocytes O +
treated O +
with O +
vehicle O +
( O -
p O +
< O -
0.05 O -
) O -
. O +

These O +
data O +
show O +
that O +
masoprocol O +
decreases O +
both O +
plasma O +
glucose O +
and O +
triglyceride O +
concentrations O +
in O +
fat O -
- O -
fed O -
/ O -
STZ O +
rats O -
, O +
presumably O +
as O +
a O +
result O +
of O +
its O +
ability O +
to O +
both O +
increase O +
glucose O +
disposal O +
and O +
decrease O +
lipolysis O -
. O +

The O +
induction O +
of O +
micronucleated O +
erythrocytes O +
by O +
diisopropylcarbodiimide O +
( O -
DIC O -
) O +
and O +
dicyclohexylcarbodiimide O +
( O -
DCC O -
) O +
was O +
investigated O +
as O +
part O +
of O +
a O +
U.S. O +
National O +
Toxicology O +
Program O +
( O -
NTP O -
) O +
evaluation O +
of O +
the O +
subchronic O +
toxicity O +
of O +
these O +
chemicals O -
. O +

Analysis O +
of O +
peripheral O +
blood O +
smears O +
from O +
male O +
and O +
female O +
B6C3F1 O +
mice O +
exposed O +
to O +
17.5 O -
- O -
140.0 O +
mg O +
DIC O -
/ O -
kg O -
/ O -
day O +
by O +
skin O +
painting O +
for O +
13 O +
weeks O +
revealed O +
dose O -
- O -
related O +
increases O +
in O +
the O +
frequency O +
of O +
micronucleated O +
normochromatic O +
erythrocytes O +
( O -
MN O -
- O -
NCE O -
) O +
in O +
both O +
sexes O -
. O +

Results O +
of O +
a O +
similar O +
13-week O +
peripheral O +
blood O +
micronucleus O +
( O -
MN O -
) O +
test O +
with O +
DCC O +
( O -
1.5 O -
- O -
12.0 O +
mg O -
/ O -
kg O -
/ O -
day O -
) O +
were O +
also O +
positive O -
, O +
although O +
the O +
increases O +
in O +
MN O -
- O -
NCE O +
were O +
not O +
as O +
great O +
as O +
those O +
observed O +
with O +
DIC O -
. O +

In O +
contrast O +
to O +
the O +
positive O +
results O +
of O +
the O +
subchronic O +
skin O -
- O -
painting O +
studies O +
in O +
mice O -
, O +
acute O +
bone O +
marrow O +
MN O +
studies O +
with O +
DIC O +
and O +
DCC O +
in O +
male O +
F344 O +
rats O -
, O +
using O +
intraperitoneal O +
( O -
i.p O -
. O -
) O +
injection O -
, O +
yielded O +
negative O +
results O -
. O +

Both O +
the O +
acute O +
and O +
the O +
subchronic O +
exposures O +
included O +
doses O +
that O +
produced O +
clinical O +
signs O +
of O +
toxicity O -
. O +

Acute O +
mouse O +
bone O +
marrow O +
MN O +
tests O +
with O +
DIC O +
administered O +
in O +
single O +
or O +
triple O +
i.p O -
. O +

injection O +
protocols O +
were O +
subsequently O +
conducted O +
to O +
determine O +
if O +
the O +
differing O +
responses O +
between O +
mice O +
and O +
rats O +
were O +
due O +
to O +
species O +
or O +
protocol O +
differences O -
. O +

The O +
results O +
of O +
these O +
acute O +
tests O +
were O +
negative O +
or O +
equivocal O -
. O +

Because O +
the O +
subchronic O +
studies O +
produced O +
positive O +
results O -
, O +
it O +
was O +
hypothesized O +
that O +
these O +
carbodiimides O +
required O +
multiple O +
treatments O +
over O +
an O +
extended O +
period O +
of O +
time O +
to O +
produce O +
an O +
increase O +
in O +
MN O -
- O -
erythrocytes O -
. O +

To O +
confirm O +
the O +
original O +
response O -
, O +
a O +
second O +
dermal O +
subchronic O +
study O +
was O +
conducted O +
with O +
DIC O -
; O +
the O +
protocol O +
was O +
modified O +
to O +
include O +
sequential O +
blood O +
samplings O +
to O +
permit O +
monitoring O +
MN O +
frequencies O +
over O +
time O -
. O +

The O +
data O +
demonstrated O +
a O +
small O +
but O +
consistent O +
induction O +
of O +
micronucleated O +
erythrocytes O +
in O +
mice O +
treated O +
with O +
DIC O +
by O +
skin O +
painting O -
. O +

Antibacterial O +
antibiotics O -
, O +
diperamycin O +
( O -
1 O -
) O +
was O +
produced O +
in O +
the O +
culture O +
broth O +
of O +
Streptomyces O +
griseoaurantiacus O +
MK393-AF2 O -
. O +

Various O +
spectroscopic O +
analyses O +
of O +
1 O +
suggested O +
that O +
1 O +
belonged O +
to O +
a O +
member O +
of O +
cyclic O +
hexadepsipeptide O +
antibiotic O -
. O +

Antibiotic O +
1 O +
had O +
potent O +
inhibitory O +
activity O +
against O +
various O +
Gram O -
- O -
positive O +
bacteria O +
including O +
Enterococcus O +
seriolicida O +
and O +
methicillin O -
- O -
resistant O +
Staphylococcus O +
aureus O -
. O +

Subcutaneous O +
tumor O +
induction O +
with O +
three O +
dose O +
levels O +
of O +
3-methylcholanthrene O +
( O -
MCA O -
) O -
, O +
benzo O -
[ O -
a O -
] O -
pyrene O +
( O -
BP O -
) O -
, O +
and O +
7,12-dimethylbenz O -
[ O -
a O -
] O -
anthracene O +
( O -
DMBA O -
) O +
in O +
two O +
vehicles O +
was O +
studied O +
in O +
C3H O -
/ O -
Anf O +
Cum O -
, O +
C57BL O -
/ O -
6 O +
Cum O -
, O +
DBA O -
/ O -
2J O -
, O +
and O +
( O -
C57BLXC3H O -
/ O -
Anf O -
) O -
F1 O +
( O -
BC3F1 O -
/ O -
Cum O -
) O +
mice O -
. O +

Median O +
tumor O +
dose O +
levels O +
were O +
significantly O +
lower O +
when O +
the O +
three O +
carcinogens O +
were O +
suspended O +
in O +
trioctanoin O -
. O +

When O +
beeswax O -
: O +
trioctanoin O +
( O -
B O -
: O -
T O -
) O +
was O +
used O +
as O +
a O +
vehicle O -
, O +
the O +
three O +
carcinogens O +
differed O +
in O +
their O +
abilities O +
to O +
be O +
absorbed O +
or O +
solubilized O +
from O +
the O +
vehicle O +
by O +
the O +
three O +
strains O +
of O +
mice O +
and O +
the O +
hybrid O -
. O +

In O +
C3H O -
/ O -
Anf O +
mice O -
, O +
BP O +
in O +
B O -
: O -
T O +
failed O +
to O +
produce O +
tumors O -
. O +

In O +
BC3F1 O +
mice O -
, O +
no O +
tumors O +
were O +
produced O +
by O +
MCA O -
, O +
BP O -
, O +
or O +
DMBA O +
in O +
B O -
: O -
T. O +
In O +
C57BL O -
/ O -
6 O +
mice O -
, O +
no O +
tumors O +
were O +
produced O +
with O +
DMBA O +
or O +
MCA O +
in O +
B O -
: O -
T. O +
In O +
DBA O -
/ O -
2 O +
mice O -
, O +
no O +
tumors O +
were O +
produced O +
by O +
BP O +
or O +
MCA O +
in O +
B O -
: O -
T. O +
These O +
results O +
indicated O +
that O +
the O +
interpretation O +
of O +
tumor O +
induction O +
results O +
obtained O +
with O +
B O -
: O -
T O +
vehicle O +
may O +
be O +
related O +
to O +
the O +
conditions O +
of O +
bioassay O +
rather O +
than O +
to O +
the O +
carcinogenic O +
potential O +
of O +
a O +
compound O -
. O +

DNA B-Gene -
- I-Gene -
dependent I-Gene +
protein I-Gene +
kinase I-Gene +
( O -
DNA B-Gene -
- I-Gene -
PK I-Gene -
) O +
and O +
poly B-Gene -
( I-Gene -
ADP I-Gene -
- I-Gene -
ribose I-Gene -
) I-Gene +
polymerase I-Gene +
( O -
PARP B-Gene -
) O +
are O +
activated O +
by O +
DNA O +
strand O +
breaks O +
and O +
participate O +
in O +
DNA O +
repair O -
. O +

We O +
investigated O +
the O +
interactive O +
effects O +
of O +
inhibitors O +
of O +
these O +
enzymes B-Gene +
[ O -
wortmannin O +
( O -
WM O -
) O -
, O +
which O +
inhibits O +
DNA B-Gene -
- I-Gene -
PK I-Gene -
, O +
and O +
8-hydroxy-2-methylquinazolin-4-one O +
( O -
NU1025 O -
) O -
, O +
a O +
PARP B-Gene +
inhibitor O -
] O +
on O +
cell O +
survival O +
and O +
DNA O +
double O -
- O -
strand O +
break O +
( O -
DSB O -
) O +
and O +
single O -
- O -
strand O +
break O +
( O -
SSB O -
) O +
rejoining O +
in O +
Chinese O +
hamster O +
ovary O -
- O -
K1 O +
cells O +
following O +
exposure O +
to O +
ionizing O +
radiation O +
( O -
IR O -
) O +
or O +
temozolomide O -
. O +

WM O +
( O -
20 O +
microM O -
) O +
or O +
NU1025 O +
( O -
300 O +
microM O -
) O +
potentiated O +
the O +
cytotoxicity O +
of O +
IR O +
with O +
dose O +
enhancement O +
factors O +
at O +
10 O -
% O +
survival O +
( O -
DEF10 O -
) O +
values O +
of O +
4.5 O +
+ O -
/- O +

0.6 O +
and O +
1.7 O +
+ O -
/- O +

0.2 O -
, O +
respectively O -
. O +

When O +
used O +
in O +
combination O -
, O +
a O +
DEF10 O +
of O +
7.8 O +
+ O -
/- O +

1.5 O +
was O +
obtained O -
. O +

WM O +
or O +
NU1025 O +
potentiated O +
the O +
cytotoxicity O +
of O +
temozolomide O -
, O +
and O +
an O +
additive O +
effect O +
on O +
the O +
DEF10 O +
value O +
was O +
obtained O +
with O +
the O +
combined O +
inhibitors O -
. O +

Using O +
the O +
same O +
inhibitor O +
concentrations O -
, O +
their O +
single O +
and O +
combined O +
effects O +
on O +
DSB O +
and O +
SSB O +
levels O +
following O +
IR O +
were O +
assessed O +
by O +
neutral O +
and O +
alkaline O +
elution O -
. O +

Cells O +
exposed O +
to O +
IR O +
were O +
post O -
- O -
incubated O +
for O +
30 O +
min O +
to O +
allow O +
repair O +
to O +
occur O -
. O +

WM O +
or O +
NU1025 O +
increased O +
net O +
DSB O +
levels O +
relative O +
to O +
IR O +
alone O +
( O -
DSB O +
levels O +
of O +
1.29 O +
+ O -
/- O +

0.04 O +
and O +
1.20 O +
+ O -
/- O +

0.05 O -
, O +
respectively O -
, O +
compared O +
with O +
1.01 O +
+ O -
/- O +

0.03 O +
for O +
IR O +
alone O -
) O +
and O +
the O +
combination O +
had O +
an O +
additive O +
effect O -
. O +

WM O +
had O +
no O +
effect O +
on O +
SSB O +
levels O -
, O +
either O +
alone O +
or O +
in O +
combination O +
with O +
NU1025 O -
. O +

SSB O +
levels O +
were O +
increased O +
to O +
1.27 O +
+ O -
/- O +

0.05 O +
with O +
NU1025 O +
compared O +
with O +
IR O +
alone O -
, O +
1.02 O +
+ O -
/- O +

0.04 O -
. O +

The O +
dose O -
- O -
dependent O +
effects O +
of O +
the O +
inhibitors O +
on O +
DSB O +
levels O +
showed O +
that O +
they O +
were O +
near O +
maximal O +
by O +
20 O +
microM O +
WM O +
and O +
300 O +
microM O +
NU1025 O -
. O +

DSB O +
repair O +
kinetics O +
were O +
studied O -
. O +

Both O +
inhibitors O +
increased O +
net O +
DSB O +
levels O +
over O +
a O +
3 O +
h O +
time O +
period O -
; O +
when O +
they O +
were O +
combined O -
, O +
net O +
DSB O +
levels O +
at O +
3 O +
h O +
were O +
identical O +
to O +
DSB O +
levels O +
immediately O +
post O -
- O -
IR O -
. O +

The O +
combined O +
use O +
of O +
DNA O +
repair O +
inhibitors O +
may O +
have O +
therapeutic O +
potential O -
. O +

Chemical O +
investigation O +
of O +
the O +
sponge O +
Spongia O +
matamata O +
collected O +
in O +
Yap O -
, O +
Micronesia O -
, O +
has O +
resulted O +
in O +
the O +
isolation O +
of O +
six O +
new O +
spongian O +
diterpenoids O -
, O +
2 O -
- O -
7 O -
, O +
along O +
with O +
the O +
known O +
compound O -
, O +
spongia-13 O -
( O -
16 O -
) O -
, O +
14-dien-19-oic O +
acid O +
( O -
1 O -
) O -
. O +

The O +
structures O +
were O +
determined O +
by O +
spectroscopic O +
methods O -
. O +

Meloxicam O +
[ O -
4-hydroxy-2-methyl O -
- O -
N- O -
( O -
5-methyl-2-thiazolyl O -
) O -
-2H-1,2-benzothiazine O +
-3-carboxamide-1 O -
, O +
1-dioxide O -
] O +
is O +
a O +
nonsteroidal O +
anti O -
- O -
inflammatory O +
drug O +
( O -
NSAID O -
) O +
of O +
the O +
oxicam O +
class O +
which O +
shows O +
preferential O +
inhibition O +
of O +
cyclo B-Gene -
- I-Gene -
oxygenase-2 I-Gene -
. O +

Meloxicam O +
has O +
a O +
plasma O +
half O -
- O -
life O +
of O +
approximately O +
20 O +
hours O -
, O +
making O +
it O +
convenient O +
for O +
once O -
- O -
daily O +
administration O -
. O +

Meloxicam O +
is O +
eliminated O +
after O +
biotransformation O +
to O +
4 O +
pharmacologically O +
inactive O +
metabolites O -
, O +
which O +
are O +
excreted O +
in O +
urine O +
and O +
faeces O -
. O +

Meloxicam O +
and O +
its O +
metabolites O +
bind O +
extensively O +
to O +
plasma B-Gene +
albumin I-Gene -
. O +

Substantial O +
concentrations O +
of O +
meloxicam O +
are O +
attained O +
in O +
synovial O +
fluid O -
, O +
the O +
proposed O +
site O +
of O +
action O +
in O +
chronic O +
inflammatory O +
arthropathies O -
. O +

Neither O +
moderate O +
renal O +
nor O +
hepatic O +
insufficiency O +
significantly O +
alter O +
the O +
pharmacokinetics O +
of O +
meloxicam O -
. O +

Dosage O +
adjustment O +
is O +
not O +
required O +
in O +
the O +
elderly O -
. O +

Drug O -
- O -
drug O +
interaction O +
studies O +
are O +
available O +
for O +
some O +
commonly O +
co O -
- O -
prescribed O +
medications O -
. O +

Concentration O -
- O -
dependent O +
therapeutic O +
and O +
toxicological O +
effects O +
have O +
yet O +
to O +
be O +
extensively O +
elucidated O +
for O +
this O +
NSAID O -
. O +

Recent O +
work O +
within O +
our O +
laboratory O +
has O +
focused O +
on O +
the O +
enzymes B-Gene +
we O +
hypothesize O +
are O +
involved O +
in O +
the O +
biosynthesis O +
of O +
bis O -
( O -
monoacylglycerol O -
) O -
phosphate O +
from O +
phosphatidylglycerol O -
. O +

Here O +
we O +
describe O +
a O +
transacylase B-Gene -
, O +
active O +
at O +
acidic O +
pH O +
values O -
, O +
isolated O +
from O +
a O +
macrophage O -
- O -
like O +
cell O +
line O -
, O +
RAW O +
264.7 O -
. O +

This O +
enzyme B-Gene +
acylates O +
the O +
head O +
group O +
glycerol O +
of O +
sn-3 O -
: O -
sn-1 O -
' O +
lysophosphatidylglycerol O +
to O +
form O +
sn-3 O -
: O -
sn-1 O -
' O +
bis O -
( O -
monoacylglycerol O -
) O -
phosphate O -
. O +

Here O +
we O +
demonstrate O +
that O +
this O +
enzyme B-Gene +
uses O +
two O +
lysophosphatidylglycerol O +
molecules O -
, O +
one O +
as O +
an O +
acyl O +
donor O +
and O +
another O +
as O +
an O +
acyl O +
acceptor O -
, O +
and O +
that O +
the O +
acyl O +
contributions O +
from O +
all O +
other O +
lipids O +
tested O +
are O +
comparatively O +
minor O -
. O +

This O +
enzyme B-Gene +
prefers O +
saturated O +
acyl O +
chains O +
to O +
monounsaturates O -
, O +
16 O +
and O +
18 O +
carbon O +
fatty O +
acids O +
over O +
14 O +
carbon O +
fatty O +
acids O -
, O +
and O +
saturated O +
acyl O +
chains O +
at O +
the O +
sn-1 O +
position O +
to O +
monounsaturated O +
acyl O +
chains O +
on O +
the O +
sn-2 O +
carbon O +
of O +
lysophosphatidylglycerol O -
. O +

We O +
present O +
data O +
which O +
show O +
the O +
transacylase B-Gene +
activity O +
depends O +
on O +
the O +
presence O +
of O +
a O +
lipid O -
- O -
water O +
interface O +
and O +
the O +
lipid O +
polymorphic O +
state O -
. O +

INTRODUCTION O +
We O +
have O +
recently O +
shown O +
that O +
rabbit O +
antibodies B-Gene +
to O +
the O +
p O -
- O -
azophenylphosphorylcholine O +
( O -
APPC O -
) O +
determinant O -
, O +
which O +
bears O +
2 O +
charges O +
of O +
opposite O +
sign O -
, O +
have O +
both O +
positively O +
and O +
negatively O +
charged O +
groups O +
in O +
their O +
binding O +
sites O +
( O -
Krausz O +
et O +
al. O -
, O +
1976 O -
) O -
. O +

The O +
positive O +
charge O +
is O +
contributed O +
by O +
the O +
guanidinium O +
group O +
of O +
arginine O +
and O +
the O +
negative O +
charge O +
is O +
contributed O +
by O +
the O +
carboxylate O +
group O +
of O +
either O +
a O +
glutamyl O +
or O +
aspartyl O +
residue O -
. O +

We O +
have O +
also O +
previously O +
shown O +
( O -
Grossberg O +
et O +
al. O -
, O +
1974 O -
) O +
that O +
the O +
phosphorylcholine O -
- O -
binding O +
mouse B-Gene +
myeloma I-Gene +
protein I-Gene -
, O +
HOPC-8 B-Gene -
, O +
similarly O +
contains O +
gaunidinium O +
and O +
carboxylate O +
groups O +
in O +
its O +
binding O +
site O -
. O +

In O +
an O +
attempt O +
to O +
gain O +
further O +
insight O +
into O +
the O +
nature O +
of O +
these O +
binding O +
sites O +
we O +
have O +
measured O +
the O +
relative O +
binding O +
constants O +
of O +
several O +
structurally O +
related O +
small O +
molecules O +
with O +
anti B-Gene -
- I-Gene -
APPC I-Gene +
antibodies I-Gene +
and O +
with O +
HOPC-8 B-Gene -
. O +

The O +
Krel O +
values O +
for O +
hapten O +
binding O +
to O +
the O +
rabbit O +
anti B-Gene -
- I-Gene -
APPC I-Gene +
antibodies I-Gene +
and O +
to O +
the O +
myeloma B-Gene +
protein I-Gene -
, O +
together O +
with O +
our O +
evidence O +
for O +
specific O +
functional O +
groups O +
in O +
the O +
binding O +
sites O -
, O +
have O +
allowed O +
us O +
to O +
draw O +
inferences O +
regarding O +
the O +
topography O +
of O +
the O +
binding O +
sites O +
of O +
anti B-Gene -
- I-Gene -
APPC I-Gene +
antibodies I-Gene +
and O +
HOPC-8 B-Gene -
. O +

* O +
This O +
work O +
was O +
supported O +
in O +
part O +
by O +
U.S. O +
Public O +
Health O +
Service O +
Research O +
Grants O +
CA-11656 O +
and O +
AI-03962 O +
from O +
the O +
National O +
Cancer O +
Institute O -
. O +

t O +
A O +
unit O +
of O +
the O +
New O +
York O +
State O +
Department O +
of O +
Health O -
. O +

$ O +
Abbreviations O +
used O -
: O +
APPC O -
, O +
p O -
- O -
azophenylphosphorylcholine O -
; O +
NPPC O -
, O +
p O -
- O -
nitrophenylphosphorylcholine O -
; O +
PC O -
, O +
phosphorylcholine O -
; O +
GPC O -
, O +
L O -
- O -
a O -
- O -
glycerophosphorylcholine O -
; O +
AcC O -
, O +
acetylcholine O -
; O +
I O -
- O -
Ap O -
, O +
p O -
- O -
iodophenyltrimethylammonium O -
; O +
PO3 O -
, O +
phenylphosphate O -
; O +
03 O +
, O +
phenylphosphonate O -
; O +
BBS O -
, O +
borate O +
buffered O +
saline O -
. O +

901 O +
MATERIALS O +
AND O +
METHODS O +
p O -
- O -
Diazonium O +
phenylphosphorylcholine O +
chloride O +
( O -
DPPC O -
) O +
This O +
was O +
prepared O +
according O +
to O +
Chesebro O +
& O +
Metzger O +
( O -
1972 O -
) O +
with O +
the O +
exception O +
that O +
in O +
the O +
diazotization O +
step O +
1.0 O +
N O +
HCl O +
rather O +
than O +
0.1 O +
N O +
HCl O +
was O +
used O +
( O -
Grossberg O +
et O +
al. O -
, O +
1974 O -
) O -
. O +

Haptens O +
Haptens O +
tested O +
were O +
reagent O +
grade O +
commercial O +
products O -
, O +
used O +
without O +
further O +
purification O -
. O +

Goat O +
anti B-Gene -
- I-Gene -
rabbit I-Gene +
IgG I-Gene +
This O +
serum O +
was O +
a O +
preparation O +
previously O +
described O +
( O -
Hoffman O +
et O +
al. O -
, O +
1971 O -
) O -
. O +

Rabbit O +
anti B-Gene -
- I-Gene -
mouse I-Gene +
IgA I-Gene +
This O +
serum O +
was O +
obtained O +
from O +
Dr. O +
Oliver O +
A. O +
Roholt O +
of O +
our O +
Department O -
. O +

It O +
was O +
prepared O +
by O +
hyperimmunization O +
of O +
rabbits O +
with O +
MOPC-315 B-Gene +
myeloma I-Gene +
protein I-Gene -
. O +

Anti B-Gene -
- I-Gene -
APPC I-Gene +
antibodies I-Gene +
The O +
preparation O +
of O +
rabbit O +
antisera O +
to O +
the O +
APPC O +
determinant O +
and O +
the O +
subsequent O +
isolation O +
and O +
purification O +
of O +
the O +
antibodies B-Gene +
from O +
individual O +
rabbits O +
by O +
specific O +
immunoadsorption O +
has O +
been O +
described O +
previously O +
( O -
Krausz O +
et O +
al. O -
, O +
1976 O -
) O -
. O +

In O +
the O +
present O +
work O +
preparations O +
from O +
rabbits O +
6055 O +
and O +
6057 O +
were O +
specifically O +
purified O +
anti B-Gene -
- I-Gene -
APPC I-Gene +
antibodies I-Gene +
and O +
the O +
preparation O +
from O +
rabbit O +
5920 O +
was O +
a O +
gamma B-Gene +
globulin I-Gene +
fraction O +
of O +
anti B-Gene -
- I-Gene -
APPC I-Gene +
serum O -
. O +

HOPC-8 B-Gene +
myeloma I-Gene +
protein I-Gene +
This O +
was O +
obtained O +
from O +
the O +
serum O +
of O +
tumor O -
- O -
bearing O +
mice O +
as O +
previously O +
described O +
( O -
Grossberg O +
et O +
al. O -
, O +
1974 O -
) O -
. O +

The O +
myeloma O +
tumor O +
was O +
obtained O +
through O +
the O +
courtesy O +
of O +
Dr. O +
Michael O +
Potter O -
, O +
National O +
Cancer O +
Institute O -
, O +
Bethesda O -
, O +
MD O -
. O +

L. O +
M. O +
KRAUSZ O -
, O +
A. O +
L. O +
GROSSBERG O +
and O +
D. O +
PRESSMAN O +
Rabbit B-Gene +
serum I-Gene +
albumin I-Gene +
( O -
RSA B-Gene -
) O +
This O +
was O +
Fraction O +
V O +
obtained O +
from O +
Pentex O -
, O +
Inc. O -
, O +
Kankakee O -
, O +
IL O -
. O +

RSA B-Gene -
- O -
APPC O +
This O +
was O +
prepared O +
by O +
reacting O +
160 O +
mg O +
of O +
RSA B-Gene +
in O +
about O +
10 O +
ml O +
of O +
pH O +
9.5 O +
borate O +
buffer O +
with O +
90 O +
umoles O +
of O +
DPPC O +
for O +
18 O +
hr O -
. O +

The O +
solution O +
was O +
then O +
dialyzed O +
against O +
pH O +
8 O +
z O +
BBS O -
, O +
stored O +
frozen O +
and O +
used O +
as O +
needed O -
. O +

The O +
entire O +
prep- O +
ae O +
aration O +
was O +
carried O +
out O +
at O +
4 O -
. O +

Radioiodination O +
of O +
RSA B-Gene -
- B-Gene -
APPC I-Gene +
RSA B-Gene -
- B-Gene -
APPC I-Gene +
was O +
trace O +
labeled O +
with O +
' O -
251 O +
by O +
a O +
modification O +
of O +
the O +
method O +
of O +
Greenwood O +
et O +
al. O +
( O -
1963 O -
) O -
. O +

Iodination O +
was O +
carried O +
out O +
in O +
0.45 O +
ml O +
of O +
pH O +
8 O +
BBS O +
containing O +
200 O +
Ug O +
( O -
ca O -
. O +

3 O +
n O -
- O -
mole O -
) O +
RSA B-Gene -
- B-Gene -
APPC I-Gene -
, O +
1 O +
n O -
- O -
mole O +
of O +
KI O -
, O +
0.4 O +
mCi O +
of O +
' O -
ZSI O +
and O +
300 O +
n O -
- O -
mole O +
of O +
chloromine O +
T. O +
The O +
reaction O +
was O +
allowed O +
to O +
proceed O +
for O +
30 O +
min O -
, O +
stopped O +
with O +
300 O +
n O -
- O -
mole O +
of O +
bisulfite O +
and O +
the O +
product O +
dialyzed O +
to O +
remove O +
free O +
" O -
' O -
I O +
and O +
reagents O -
. O +

Measurement O +
of O +
K O -
, O -
e O -
, O +
The O +
method O +
used O +
to O +
obtain O +
the O +
relative O +
binding O +
constants O +
for O +
the O +
various O +
haptens O +
is O +
based O +
on O +
the O +
technique O +
originally O +
developed O +
by O +
Skom O +
& O +
Talmadge O +
( O -
1958 O -
) O +
for O +
precipitating O +
antigen O -
- O -
antibody B-Gene +
complexes O +
with O +
antiglobulin B-Gene -
. O +

In O +
our O +
assay O +
the O +
primary O +
haptenic O +
determinant O -
, O +
p O -
- O -
azophenylphosphory1choline O -
, O +
was O +
coupled O +
to O +
rabbit B-Gene +
serum I-Gene +
albumin I-Gene +
which O +
was O +
then O +
trace O +
labeled O +
with O +
1251 O -
. O +

Labeled O +
antigen O +
was O +
mixed O +
with O +
varying O +
amounts O +
of O +
antibody B-Gene +
and O +
the O +
amount O +
of O +
antigen O +
bound O +
was O +
determined O +
by O +
precipitating O +
all O +
the O +
gamma B-Gene +
globulin I-Gene +
( O -
i.e. O +
bound O +
and O +
unbound O +
antibody B-Gene +
as O +
well O +
as O +
non O -
- O -
specific O +
y B-Gene +
globulin I-Gene -
) O +
with O +
goat O +
antiglobulin B-Gene +
antibody I-Gene +
and O +
measuring O +
the O +
radioactivity O +
associated O +
with O +
the O +
precipitate O -
. O +

Relative O +
binding O +
constants O +
( O -
K O -
, O -
e O -
, O -
) O +
for O +
the O +
different O +
haptens O +
were O +
determined O +
by O +
measuring O +
their O +
ability O +
to O +
inhibit O +
the O +
reaction O +
of O +
labeled O +
antigen O +
with O +
antibody B-Gene -
. O +

The O +
amount O +
of O +
antibody B-Gene +
was O +
chosen O +
so O +
that O +
about O +
60 O -
% O +
of O +
the O +
labeled O +
antigen O +
was O +
bound O +
by O +
antibody B-Gene +
in O +
the O +
absence O +
of O +
hapten O -
. O +

In O +
a O +
typical O +
determination O +
the O +
antigen O +
solution O +
was O +
made O +
to O +
contain O +
100 O +
ng O +
per O +
ml O +
of O +
1251-RSA O -
- B-Gene -
APPC I-Gene +
and O +
1 O +
mg O -
/ O -
ml O +
of O +
RSA B-Gene +
in O +
pH O +
8 O +
BBS O -
. O +

The O +
required O +
concentration O +
of O +
antibody B-Gene +
was O +
made O +
up O +
in O +
normal O +
rabbit O +
serum O +
diluted O +
1:5 O +
with O +
pH O +
8 O +
BBS O -
. O +

HOPC-8 B-Gene +
myeloma I-Gene +
protein I-Gene +
was O +
made O +
up O +
in O +
normal O +
mouse O +
serum O +
diluted O +
1:5 O -
. O +

To O +
0.1 O +
ml O +
of O +
antibody B-Gene +
( O -
or O +
HOPC-8 B-Gene -
) O +
solution O +
were O +
added O -
, O +
0.1 O +
ml O +
' B-Gene -
251-RSA I-Gene -
- I-Gene -
APPC I-Gene +
solution O +
and O +
0.1 O +
ml O +
hapten O +
solution O +
in O +
pH O +
8 O +
BBS O -
. O +

Hapten O +
concentrations O +
ranged O +
from O +
10 O -
' O +
to O +
10-'M. O +
In O +
one O +
sample O +
( O -
uninhibited O -
) O -
, O +
hapten O +
solution O +
was O +
replaced O +
by O +
buffer O +
to O +
determine O +
the O +
amount O +
of O +
antigen O +
precipitated O +
in O +
the O +
absence O +
of O +
hapten O -
. O +

Another O +
mixture O +
( O -
non O -
- O -
specific O +
control O -
) O +
contained O +
0.1 O +
ml O +
1:5 O +
diluted O +
normal O +
rabbit O +
( O -
or O +
mouse O -
) O +
serum O +
in O +
place O +
of O +
antibody B-Gene -
, O +
0.1 O +
ml O +
of O +
antigen O +
and O +
0.1 O +
ml O +
of O +
buffer O -
. O +

All O +
tubes O +
were O +
incubated O +
at O +
37 O +
for O +
30 O +
min O -
. O +

Then O +
0.2 O +
ml O +
of O +
anti B-Gene -
- I-Gene -
globulin I-Gene +
antiserum O +
was O +
added O +
to O +
all O +
tubes O -
. O +

The O +
amount O +
added O +
was O +
that O +
determined O +
to O +
be O +
sufficient O +
to O +
precipitate O +
all O +
the O +
globulin B-Gene +
in O +
the O +
mixture O -
. O +

Goat O +
anti B-Gene -
- I-Gene -
rabbit I-Gene +
y I-Gene -
- I-Gene -
globulin I-Gene +
was O +
used O +
to O +
precipitate O +
the O +
rabbit O +
antibodies B-Gene +
and O +
rabbit O +
anti B-Gene -
- I-Gene -
mouse I-Gene +
IgA I-Gene +
was O +
used O +
to O +
precipitate O +
the O +
HOPC-8 B-Gene +
myeloma I-Gene +
protein I-Gene -
. O +

The O +
reaction O +
mixtures O +
were O +
allowed O +
to O +
stand O +
at O +
room O +
temperature O +
for O +
1 O +
hr O -
, O +
and O +
then O +
stored O +
at O +
5 O +
overnight O -
. O +

The O +
tubes O +
were O +
centrifuged O -
, O +
the O +
supernatants O +
discarded O +
and O +
the O +
precipitates O +
washed O +
twice O +
with O +
saline O -
. O +

Radioactivity O +
in O +
the O +
precipitates O +
was O +
determined O -
. O +

All O +
determinations O +
were O +
done O +
in O +
duplicate O -
. O +

Per O +
cent O +
inhibition O +
is O +
given O +
by O -
: O +
Inhibition O +
= O +
f O +
1 O +
ANTI B-Gene -
- I-Gene -
APPC I-Gene +
# O -
6055 O +
loo O +
50 O +
01 O +
10 O -
- O -
6 O +
10 O -
- O -
5 O +
NPPC O +
GPC O -
, O +
Pc O +
P03 O +
I_AD O +
CHOLINE O +
10 O +
4 O +
10 O -
- O -
3 O +
10-z O +
10 O +
I O +
INHIBITOR O +
CONC O -
. O +

( O -
M O -
) O +
Fig. O +
1 O -
. O +

Plots O +
of O +
the O +
inhibition O +
by O +
haptens O +
of O +
the O +
binding O +
of O +
RSA B-Gene -
- B-Gene -
APPC I-Gene +
antigen O +
to O +
anti B-Gene -
- I-Gene -
APPC I-Gene +
antibody I-Gene +
from O +
rabbit O +
6055 O -
. O +

Values O +
determined O +
in O +
this O +
manner O +
were O +
reproducible O +
to O +
within O +
% O -
. O +

RESULTS O +
Plots O +
of O +
effect O +
of O +
hapten O +
on O +
antigen O +
binding O +
are O +
given O +
in O +
Fig. O +
1 O +
for O +
anti B-Gene -
- I-Gene -
APPC I-Gene +
from O +
rabbit O +
6055 O +
and O +
in O +
Fig. O +
2 O +
for O +
anti B-Gene -
- I-Gene -
APPC I-Gene +
from O +
rabbit O +
5920 O -
. O +

The O +
plots O +
for O +
anti B-Gene -
- I-Gene -
APPC I-Gene +
from O +
rabbit O +
6057 O -
, O +
were O +
essentially O +
identical O +
to O +
those O +
in O +
Fig. O +
1 O -
. O +

From O +
these O +
data O -
, O +
K O -
, O -
el O +
values O +
were O +
calculated O +
relative O +
to O +
the O +
most O +
inhibitory O +
hapten O -
, O +
NPPC O -
, O +
according O +
to O +
the O +
formula O -
: O +
_ O +
( O -
NPPC O -
) O +
at O +
50 O -
% O +
inhibition O +
K O -
" O -
' O +
( O -
HAPTEN O -
) O +
at O +
50 O -
% O +
inhibition O +
The O +
values O +
of O +
K O -
, O -
e O -
, O +
are O +
given O +
in O +
Table O +
1 O -
. O +

The O +
only O +
effective O +
inhibitors O +
observed O +
are O +
those O +
listed O +
in O +
Table O +
1 O -
, O +
having O +
K O -
, O -
e O -
, O +
values O +
> O +
0.0001 O -
. O +

It O +
is O +
interesting O +
that O +
the O +
p O -
- O -
iodophenyltrimethylammonium O +
ion O +
gave O +
detectable O +
inhibition O +
in O +
2 O +
instances O -
. O +

Twentyfive O +
other O +
haptens O +
were O +
tested O -
. O +

None O +
showed O +
appreciable O +
binding O +
to O +
anti B-Gene -
- I-Gene -
APPC I-Gene +
antibodies I-Gene -
. O +

Among O +
those O +
tested O +
were O +
negatively O +
and O +
positively O +
chargen O +
haptens O -
, O +
including O +
other O +
phenyltrimethylammonium O +
ions O +
and O +
ANTI B-Gene -
- I-Gene -
APPC I-Gene +
# O -
5920 O +
loo O +
50 O +
z O +
x O +
NPPC O -
, O +
GPC O +
I O -
- O -
AP O +
PC O +
CHOLINE O +
0 O +
10 O -
- O -
6 O +
10 O -
- O -
5 O +
10 O +
4 O +
10 O -
- O -
3 O +
10-z O +
10-I O +
INHIBITOR O +
CONC. O -
( O -
M O -
) O +
Fig. O +
2 O -
. O +

Plots O +
of O +
the O +
inhibition O +
by O +
haptens O +
of O +
the O +
binding O +
of O +
RSA B-Gene -
- O -
APPC O +
antigen O +
to O +
anti B-Gene -
- I-Gene -
APPC I-Gene +
antibody I-Gene +
from O +
rabbit O +
5920 O -
. O +

inhibited O +
sample O +
counts O -
/ O -
min O -
- O -
non O -
- O -
specific O +
control O +
counts O -
/ O -
min O +
uninhibited O +
sample O +
counts O -
/ O -
min O -
- O -
non O -
- O -
specific O +
control O +
counts O -
/ O -
min O +
x O +
100 O -
. O +

Specificity O +
of O +
Anti B-Gene -
- I-Gene -
p I-Gene -
- I-Gene -
Azophenylphosphorylcholine I-Gene +
Antibodies I-Gene +
Table O +
1 O -
. O +

Relative O +
binding O +
constants O +
of O +
haptens O +
for O +
anti B-Gene +
APPC I-Gene +
antibodies I-Gene +
Hapten O +
NPPC O +
t O -
.- O -
a O -
- O -
glycerophosphorylcholine O +
Phosphorylcholine O +
I O -
- O -
Ap O +
Choline O +
Phenylphosphonate O +
Phenylphosphate O +
Rabbit O +
No. O +
5920 O +
6055 O +
6057 O +
K O +
1.0 O +
0.015 O +
0.0003 O +
0.004 O +
0.0007 O +
0.0001 O +
0.0001 O +
1.0 O +
1.0 O +
0.019 O +
0.016 O +
0.0004 O +
0.0005 O +
0.0001 O +
< O +
0.0001 O +
0.00006 O +
0.00006 O +
0.0002 O +
< O +
0.0001 O +
0.0001 O +
< O +
0.0001 O +
several O +
phenylarsonates O +
and O +
sulfonates O -
. O +

A O +
representative O +
list O +
of O +
some O +
of O +
these O +
non O -
- O -
inhibitory O +
haptens O +
is O +
given O +
in O +
Table O +
2 O -
. O +

The O +
results O +
of O +
inhibition O +
studies O +
with O +
the O +
mouse B-Gene +
myeloma I-Gene +
protein I-Gene +
HOPC-8 I-Gene +
are O +
given O +
in O +
Fig. O +
3 O +
where O +
the O +
inhibition O +
curves O +
are O +
drawn O +
only O +
for O +
those O +
haptens O +
showing O +
significant O +
ability O +
to O +
inhibit O -
. O +

K O -
, O -
e O -
, O +
values O +
were O +
calculated O +
as O +
described O +
above O +
and O +
are O +
listed O +
in O +
Table O +
3 O -
. O +

For O +
comparison O -
, O +
Table O +
3 O +
also O +
lists O +
values O +
of O +
K O -
, O -
el O +
calculated O +
from O +
the O +
data O +
of O +
Leon O +
& O +
Young O +
( O -
1971 O -
) O +
for O +
TEPC-15 O +
in O +
a O +
system O +
using O +
the O +
C O -
- O -
polysaccharide O +
of O +
pneumococcus O +
as O +
an O +
antigen O -
. O +

There O +
is O +
adequate O +
serological O +
and O +
chemical O +
evidence O +
showing O +
that O +
HOPC-8 B-Gene +
and O +
TEPC-15 B-Gene +
are O +
nearly O +
identical O +
proteins O +
( O -
Potter O +
& O +
Lieberman O -
, O +
1970 O -
; O +
Hood O +
et O +
al. O -
, O +
1970 O -
) O -
. O +

The O +
values O +
in O +
Table O +
3 O +
show O +
the O +
close O +
correspondence O +
between O +
our O +
values O +
of O +
K O -
, O -
e O -
, O +
for O +
HOPC-8 B-Gene +
and O +
those O +
calculated O +
from O +
the O +
data O +
of O +
Leon O +
& O +
Young O +
for O +
TECP-15 B-Gene -
. O +

The O +
K O -
, O -
e O -
, O +
values O +
for O +
anti B-Gene -
- I-Gene -
APPC I-Gene +
from O +
rabbit O +
6055 O +
are O +
also O +
listed O +
in O +
Table O +
3 O +
to O +
facilitate O +
comparisons O +
with O +
HOPC-8 B-Gene -
. O +

In O +
order O +
to O +
assess O +
further O +
the O +
validity O +
of O +
the O +
inhibition O +
method O +
as O +
used O +
here O +
for O +
obtaining O +
Kre O -
, O +
values O -
, O +
we O +
have O +
compared O +
the O +
value O +
of O +
K O -
, O -
e O -
, O +
calculated O +
from O +
the O +
individual O +
binding O +
constants O +
of O +
HOPC-8 B-Gene +
for O +
phosphory1choline O +
( O -
PC O -
) O +
and O +
p O -
- O -
nitrophenylphosphorylcholine O +
( O -
NPPC O -
) O +
as O +
determined O +
by O +
equilibrium O +
dialysis O -
, O +
to O +
the O +
Kre O -
, O +
values O +
calculated O +
from O +
the O +
inhibition O +
data O -
. O +

As O +
measured O +
by O +
equilibrium O +
dialysis O +
with O +
HOPC-8 B-Gene +
the O +
binding O +
constant O +
for O +
PC O +
( O -
KPc O -
) O +
was O +
found O +
to O +
be O +
1.2 O +
x O +
106 O +
M-1 O +
and O +
for O +
NPPC O +
the O +
KNPPC O +
was O +
0.43 O +
x O +
106 O +
M-1 O +
( O -
Krausz O +
et O +
al. O -
, O +
1976 O -
) O -
. O +

The O +
ratio O +
of O +
the O +
two O +
is O -
: O +
1.20 O +
x O +
106 O +
_ O +
KPCIKNPPC O +
- O +
0.43 O +
x O +
106 O +
- O +
2.8 O -
. O +

Table O +
2 O -
. O +

Haptens O +
unable O +
to O +
inhibit O +
binding O +
of O +
RSA B-Gene -
- O -
APPC O +
to O +
anti B-Gene -
- I-Gene -
APPC I-Gene +
antibodies I-Gene -
" O +
Acetylcholine O +
Phenyltrimethylammonium O +
p O -
- O -
Aminophenyltrimethylammonium O +
chloride O +
Phenylarsonate O +
p O -
- O -
Nitrophenylarsonate O +
p O -
- O -
lodophenylarsonate O +
Hydroxyphenylazo O -
) O -
phenylarsonate O +
p O -
- O -
lodobenzenesulfonate O +
Naphthalene O -
- O -
l O -
- O -
sulfonate O +
5-Nitro-3-iodo-4-hydroxyphenylacetate O +
5-Nitro-4-hydroxyphenylacetate O +
Kre O -
, O +
< O -
0.0001 O -
, O +
relative O +
to O +
NPPC O -
, O +
which O +
is O +
equivalent O +
to O +
< O +
50 O -
% O +
inhibition O +
at O +
0.1 O +
M O +
hapten O +
concentration O -
. O +

903 O +
HOPC-8 O +
100 O +
PC O +
WPC O +
I O -
- O -
Ap O +
GPC O +
AcC O +
m O +
50 O +
z O -
_ O +
< O -
60P O +
Y O -
, O +
OOPO=3 O +
~ O +
OP O +
03 O +
0 O +
ITS O +
I O +
I O +
INHIBITOR O +
CONC O -
. O +

( O -
M O -
) O +
IT O +
2 O +
IT O +
l O +
Fig. O +
3 O -
. O +

Plots O +
of O +
the O +
inhibition O +
by O +
haptens O +
of O +
the O +
binding O +
of O +
RSA B-Gene -
- O -
APPC O +
antigen O +
to O +
mouse B-Gene +
myeloma I-Gene +
protein I-Gene +
HOPC-8 I-Gene -
. O +

The O +
ratio O +
obtained O +
using O +
K O -
, O -
e O -
, O +
values O +
obtained O +
by O +
hapten O +
inhibition O +
( O -
Table O +
3 O -
) O +
is O +
2.9 O -
, O +
a O +
satisfactory O +
agreement O -
. O +

DISCUSSION O +
The O +
relative O +
binding O +
constants O +
( O -
K O -
, O -
, O -
, O -
) O +
for O +
haptens O +
to O +
anti B-Gene -
- I-Gene -
APPC I-Gene +
antibodies I-Gene +
were O +
determined O +
by O +
hapten O +
inhibition O -
. O +

About O +
30 O +
potential O +
ligands O +
were O +
tested O +
and O +
only O +
5 O +
of O +
these O +
were O +
shown O +
to O +
bind O +
significantly O +
( O -
NPPC O -
, O +
glycerophosphorylcholine O -
, O +
I O -
- O -
Ap O -
, O +
choline O +
and O +
phosphorylcholine O -
) O -
. O +

The O +
values O +
of O +
K O -
, O -
, O -
, O +
obtained O +
with O +
the O +
several O +
haptens O +
allow O +
inferences O +
as O +
to O +
the O +
relative O +
importance O +
of O +
the O +
particular O +
structural O +
features O +
of O +
each O +
hapten O +
in O +
contributing O +
to O +
the O +
binding O +
energy O -
. O +

The O +
rabbit O +
anti B-Gene -
- I-Gene -
APPC I-Gene +
antibodies I-Gene +
studied O +
here O +
were O +
raised O +
against O +
a O +
hapten O +
having O +
3 O +
distinct O +
structural O +
features O -
- O -
a O +
p O -
- O -
azophenyl O +
group O -
, O +
a O +
negatively O +
charged O +
phosphoryl O +
ester O +
group O -
, O +
and O +
a O +
positively O +
charged O +
quarternary O +
ammonium O +
group O -
. O +

Of O +
these O -
, O +
the O +
one O +
apparently O +
very O +
important O +
for O +
binding O +
is O +
the O +
positively O +
charged O +
group O -
, O +
since O +
haptens O +
which O +
were O +
most O +
effective O +
in O +
inhibiting O +
the O +
binding O +
of O +
the O +
APPC O -
- O -
containing O +
antigen O +
to O +
antibody B-Gene +
contained O +
this O +
group O +
( O -
Table O +
1 O -
) O +
and O +
those O +
least O +
effective O +
did O +
not O -
. O +

Thus O -
, O +
removal O +
of O +
the O +
choline O +
group O +
from O +
phenylphosphorylcholine O +
decreases O +
its O +
binding O +
strength O +
by O +
a O +
factor O +
of O +
about O +
Table O +
3 O -
. O +

Comparison O +
of O +
K O -
, O -
e O -
, O +
values O +
for O +
HOPC-8 B-Gene -
, O +
TEPC-15 B-Gene +
and O +
a O +
rabbit O +
anti B-Gene -
- I-Gene -
APPC I-Gene +
antibody I-Gene +
Hapten O +
HOPC-8 B-Gene +
2.9 O +
1.0 O +
0.5 O +
0.033 O +
0.015 O +
0.01 O -
" O +
0.001 O +
< O +
0.0001 O +
Rabbit O +
anti B-Gene +
APPC I-Gene -
- O -
No O -
. O +

6055 O +
K O -
, O +
TEPC-15 B-Gene +
Phosphorylcholine O +
NPPC O +
-a O -
- O -
glycerophosphorylchole O +
I O -
- O -
Ap O +
Acetylcholine O +
Choline O +
Phenylphosphate O +
Phenylphosphonate O +
2.9 O +
0.0004 O +
1.0 O +
0.019 O +
0.0001 O +
0.0001 O +
0.008 O +
0.00006 O +
0.005 O +
0.0001 O +
- O +
0.0002 O +
- O +
0.27 O +
Calculated O +
from O +
the O +
data O +
of O +
Leon O +
& O +
Young O +
( O -
1971 O -
) O +
for O +
the O +
inhibition O +
of O +
binding O +
of O +
c O -
- O -
polysaccharide O +
of O +
Pneumococcus O -
. O +

The O +
values O +
were O +
obtained O +
by O +
setting O +
the O +
Kre O -
, O +
value O +
for O +
phosphorylchole O +
at O +
2.9 O +
and O +
calculating O +
the O +
other O +
values O +
relative O +
to O +
this O -
. O +

" O -
Estimated O +
from O +
the O +
value O +
of O +
Kre O -
, O +
for O +
choline O +
with O +
TEPC-15 B-Gene -
. O +

904 O +
L. O +
M. O +
KRAUSZ O -
, O +
A. O +
L. O +
GROSSBERG O +
and O +
D. O +
PRESSMAN O +
10,000 O +
since O +
K O -
, O -
e O -
, O +
for O +
phenylphosphate O +
was O +
at O +
least O +
this O +
much O +
smaller O +
than O +
the O +
K O -
, O -
e O -
, O +
for O +
NPPC O +
( O -
Table O +
1 O -
) O -
. O +

Moreover O -
, O +
p O -
- O -
iodophenyltrimethylammonium O +
gave O +
detectable O +
inhibition O +
with O +
one O +
anti B-Gene -
- I-Gene -
APPC I-Gene +
preparation O -
, O +
although O +
its O +
structure O +
is O +
otherwise O +
rather O +
different O +
from O +
the O +
choline O +
inhibitors O -
. O +

The O +
p O -
- O -
nitrophenyl O +
group O +
of O +
NPPC O +
contributes O +
very O +
effectively O +
to O +
the O +
specific O +
interaction O -
, O +
since O +
replacing O +
it O +
by O +
the O +
glycerol O +
group O +
decreases O +
the O +
binding O +
by O +
a O +
factor O +
of O +
50 O +
( O -
Table O +
1 O -
) O -
. O +

Similarly O -
, O +
removing O +
the O +
p O -
- O -
nitrophenyl O +
group O -
, O +
to O +
give O +
phosphorylcholine O -
, O +
decreases O +
the O +
binding O +
by O +
another O +
factor O +
of O +
50 O +
( O -
Table O +
1 O -
) O +
so O +
that O +
phosphorylcholine O +
binds O +
2500 O +
times O +
more O +
weakly O +
than O +
NPPC O -
. O +

The O +
negatively O +
charged O +
phosphoryl O +
group O +
apparently O +
interacts O +
only O +
to O +
a O +
small O +
extent O +
with O +
the O +
antibody B-Gene +
site O -
. O +

This O +
is O +
evident O +
from O +
the O +
fact O +
that O +
K O -
, O -
, O -
, O +
for O +
phosphorylcholine O +
is O +
only O +
6 O -
- O -
8 O +
times O +
greater O +
than O +
Kre O -
, O +
for O +
choline O +
for O +
2 O +
antibody B-Gene +
preparations O +
studied O +
and O +
is O +
actually O +
smaller O +
than O +
that O +
for O +
choline O +
for O +
the O +
third O +
antibody B-Gene +
preparation O +
( O -
Table O +
1 O -
) O -
. O +

In O +
addition O -
, O +
phenylphosphate O +
( O -
Table O +
2 O -
) O +
and O +
phenylphosphonate O +
( O -
Table O +
1 O -
) O +
show O +
only O +
weak O +
binding O +
to O +
the O +
antibodies B-Gene -
. O +

Thus O +
the O +
contribution O +
of O +
the O +
negative O +
charge O +
to O +
binding O +
is O +
not O +
great O -
, O +
in O +
spite O +
of O +
the O +
fact O +
that O +
we O +
have O +
previously O +
shown O +
( O -
Krausz O +
et O +
al. O -
, O +
1976 O -
) O +
that O +
a O +
positively O +
charged O +
arginyl O +
residue O +
is O +
present O +
in O +
the O +
anti B-Gene -
- I-Gene -
APPC I-Gene +
antibody I-Gene +
site O -
, O +
providing O +
a O +
basis O +
for O +
electrostatic O +
interaction O +
with O +
the O +
phosphoryl O +
group O -
. O +

When O +
the O +
rabbit O +
anti B-Gene -
- I-Gene -
APPC I-Gene +
antibodies I-Gene +
are O +
compared O +
to O +
the O +
mouse B-Gene +
myeloma I-Gene +
protein I-Gene -
, O +
HOPC-8 B-Gene -
, O +
some O +
very O +
obvious O +
differences O +
in O +
specificity O +
are O +
apparent O -
. O +

In O +
general O +
HOPC-8 B-Gene +
shows O +
broader O +
cross O -
- O -
reactivity O +
than O +
the O +
induced O +
rabbit O +
antibody B-Gene -
. O +

The O +
representative O +
comparison O +
of O +
K O -
, O -
e O -
, O +
values O +
( O -
relative O +
to O +
NPPC O -
) O +
given O +
in O +
Table O +
3 O -
, O +
indicates O +
that O +
many O +
more O +
of O +
the O +
compounds O +
listed O +
show O +
appreciable O +
binding O +
( O -
K O -
, O -
e O -
, O +
> O +
0.005 O -
) O +
to O +
HOPC-8 B-Gene +
than O +
to O +
rabbit O +
anti B-Gene -
- I-Gene -
APPC I-Gene -
. O +

In O +
addition O -
, O +
the O +
fine O +
specificity O +
of O +
HOPC-8 B-Gene +
is O +
quite O +
different O +
from O +
that O +
of O +
the O +
rabbit O +
antibody B-Gene -
, O +
since O +
the O +
relative O +
binding O +
constant O +
for O +
phosphorylcholine O +
is O +
10 O -
' O +
greater O +
with O +
HOPC-8 B-Gene +
than O +
with O +
rabbit O +
anti B-Gene -
- I-Gene -
APPC I-Gene -
. O +

The O +
binding O +
to O +
the O +
2 O +
proteins B-Gene +
differs O +
for O +
glycerophosphorylcholine O +
by O +
a O +
factor O +
of O +
25 O -
, O +
for O +
chohne O +
by O +
a O +
factor O +
of O +
100 O +
and O +
for O +
acetylcholine O +
by O +
a O +
factor O +
greater O +
than O +
100 O -
. O +

The O +
negatively O +
charged O +
phosphoryl O +
group O +
appears O +
to O +
be O +
much O +
more O +
important O +
for O +
binding O +
to O +
HOPC-8 B-Gene +
than O +
to O +
the O +
rabbit O +
antibody B-Gene -
, O +
since O +
the O +
K- O -
, O +
value O +
for O +
phosphorylcholine O +
is O +
greater O +
than O +
that O +
for O +
choline O +
by O +
a O +
factor O +
of O +
about O +
300 O +
in O +
the O +
case O +
of O +
HOPC-8 B-Gene -
. O +

For O +
rabbit O +
antibody B-Gene +
this O +
factor O +
is O +
only O +
about O +
10 O +
( O -
Table O +
3 O -
) O -
. O +

Moreover O -
, O +
phenylphosphate O +
binds O +
more O +
than O +
10 O +
times O +
more O +
strongly O +
to O +
HOPC-8 B-Gene +
than O +
to O +
anti B-Gene -
- I-Gene -
APPC I-Gene +
antibody I-Gene -
. O +

This O +
is O +
in O +
spite O +
of O +
the O +
fact O +
that O +
the O +
addition O +
of O +
the O +
p O -
- O -
nitrophenyl O +
group O +
to O +
phosphorylcholine O +
neither O +
adds O +
to O +
nor O +
subtracts O +
from O +
the O +
binding O +
energy O +
with O +
HOPC-8 B-Gene -
, O +
whereas O +
it O +
adds O +
a O +
great O +
deal O +
to O +
the O +
binding O +
energy O +
with O +
anti B-Gene -
- I-Gene -
APPC I-Gene +
antibody I-Gene -
. O +

The O +
fact O +
that O +
the O +
HOPC-8 B-Gene +
site O +
is O +
large O +
enough O +
to O +
accommodate O +
the O +
p O -
- O -
nitrophenyl O +
group O +
of O +
NPPC O +
with O +
little O +
steric O +
hindrance O +
is O +
of O +
interest O -
, O +
since O +
the O +
site O +
of O +
McPC-603 B-Gene +
protein O -
, O +
which O +
also O +
binds O +
phosphorylcholine O +
analogues O +
with O +
similar O +
although O +
not O +
identical O +
specificity O +
( O -
Leon O +
& O +
Young O -
, O +
1971 O -
) O +
also O +
can O +
accommodate O +
a O +
large O +
substituent O +
on O +
phosphorylcholine O -
. O +

Thus O -
, O +
the O +
X O -
- O -
ray O +
crystallographic O +
structure O +
studies O +
of O +
the O +
Fab O +
fragment O +
of O +
McPC-603 B-Gene +
as O +
summarized O +
by O +
Segal O +
et O +
al. O +
( O -
1974 O -
) O +
indicate O +
that O +
there O +
is O +
a O +
large O +
region O +
of O +
the O +
cleft O +
in O +
which O +
phosphorylcholine O +
is O +
bound O +
which O +
is O +
available O +
for O +
binding O +
additional O +
structure O -
. O +

Indeed O -
, O +
one O +
of O +
the O +
compounds O +
used O +
in O +
defining O +
the O +
site O +
region O +
was O +
2- O -
( O -
5'-acetoxy O -
- O -
mercury-2'-thiemyl O -
) O -
-ethylphosphory1choline O +
( O -
Padlan O +
et O +
al. O -
, O +
1973 O -
) O -
. O +

Our O +
studies O +
suggest O +
that O +
this O +
large O +
compound O +
might O +
bind O +
equally O +
as O +
well O +
to O +
the O +
HOPC-8 B-Gene +
site O +
as O +
to O +
the O +
McPC-603 B-Gene +
site O -
. O +

The O +
differences O +
between O +
HOPC-8 B-Gene +
sites O +
and O +
rabbit O +
anti B-Gene -
- I-Gene -
APPC I-Gene +
sites O +
are O +
interesting O +
in O +
view O +
of O +
the O +
fact O +
that O +
when O +
APPC O +
conjugated O +
to O +
protein B-Gene +
is O +
used O +
as O +
an O +
immunogen O +
in O +
the O +
BALB O -
/ O -
c O +
mouse O -
, O +
the O +
IgM O +
antibodies B-Gene +
elicited O +
are O +
largely O +
of O +
the O +
HOPC-8-TEPC-15 O +
idiotype O +
and O +
show O +
the O +
same O +
binding O +
characteristics O +
as O +
the O +
myeloma B-Gene +
proteins I-Gene +
( O -
Lee O +
it O +
al. O -
, O +
1974 O -
) O -
. O +

Thus O +
it O +
appears O +
that O +
the O +
receptor B-Gene +
sites I-Gene +
on O +
cells O +
responding O +
to O +
APPC O +
in O +
the O +
rabbits O +
we O +
used O +
are O +
quite O +
different O +
in O +
structure O +
from O +
sites O +
on O +
cells O +
which O +
respond O +
in O +
the O +
mouse O -
. O +

Furthermore O -
, O +
we O +
have O +
previously O +
observed O +
that O +
the O +
rabbit O +
antibodies B-Gene +
are O +
rather O +
heterogeneous O -
, O +
as O +
evidenced O +
by O +
their O +
non O -
- O -
linear O +
binding O +
curves O +
( O -
Krausz O +
et O +
al. O -
, O +
1976 O -
) O -
, O +
and O +
their O +
complex O +
isoelectric O +
focusing O +
patterns O +
( O -
Nutt O +
et O +
al. O -
, O +
1976 O -
) O -
. O +

Populations O +
of O +
anti B-Gene -
- I-Gene -
APPC I-Gene +
antibodies I-Gene +
produced O +
also O +
differ O +
from O +
rabbit O +
to O +
rabbit O +
as O +
evidenced O +
by O +
the O +
differences O +
in O +
binding O +
strength O +
for O +
p O -
- O -
iodophenyltrimethylammonium O +
and O +
for O +
choline O +
shown O +
by O +
antibodies B-Gene +
from O +
rabbits O +
6055 O +
and O +
5920 O +
( O -
Table O +
1 O -
) O -
. O +

On O +
the O +
other O +
hand O -
, O +
the O +
induced O +
mouse O +
antibodies B-Gene +
appear O +
to O +
be O +
essentially O +
monoclonal O +
products O +
( O -
Lee O +
et O +
al. O -
, O +
1974 O -
) O -
. O +

There O +
are O -
, O +
of O +
course O -
, O +
some O +
similarities O +
between O +
the O +
rabbit O +
antibodies B-Gene +
and O +
HOPC-8 B-Gene -
. O +

The O +
major O +
of O +
these O +
is O +
that O +
for O +
both O +
binding O +
sites O +
the O +
positively O +
charged O +
quarternary O +
ammonium O +
group O +
appears O +
to O +
be O +
the O +
immunodominant O +
group O -
, O +
since O +
those O +
haptens O +
not O +
containing O +
this O +
group O +
are O +
bound O +
very O +
poorly O +
in O +
both O +
cases O +
( O -
Table O +
3 O -
) O -
. O +

Thus O +
a O +
negatively O +
charged O +
carboxylate O +
group O +
which O +
would O +
interact O +
with O +
this O +
group O -
, O +
and O +
which O +
we O +
have O +
shown O +
to O +
be O +
present O +
in O +
the O +
combining O +
site O +
of O +
both O +
HOPC-8 B-Gene +
and O +
anti B-Gene -
- I-Gene -
APPC I-Gene +
antibodies I-Gene -
, O +
is O +
probably O +
the O +
most O +
important O +
common O +
feature O +
of O +
both O +
sites O -
. O +

The O +
above O +
considerations O +
allow O +
us O +
to O +
make O +
the O +
following O +
inferences O +
about O +
the O +
topography O +
of O +
the O +
antiAPPC B-Gene +
and O +
HOPC-8 B-Gene +
binding O +
sites O -
: O +
( O -
1 O -
) O +
The O +
anti B-Gene -
- I-Gene -
APPC I-Gene +
site O +
contains O +
a O +
region O +
closely O +
complementary O +
to O +
the O +
phenyl O +
group O +
of O +
APPC O -
, O +
so O +
that O +
an O +
appreciable O +
part O +
ofAhe O +
binding O +
interaction O +
occurs O +
in O +
this O +
region O -
. O +

The O +
HOPC-8 B-Gene +
site O +
accommodates O +
the O +
phenyl O +
group O +
with O +
little O +
interaction O +
energy O -
. O +

( O -
2 O -
) O +
An O +
arginyl O +
residue O +
in O +
the O +
HOPC-8 B-Gene +
site O +
contributes O +
a O +
positive O +
charge O +
which O +
interacts O +
strongly O +
with O +
the O +
negative O +
charge O +
on O +
the O +
phosphoryl O +
group O -
. O +

In O +
the O +
anti B-Gene -
- I-Gene -
APPC I-Gene +
site O -
, O +
which O +
also O +
contains O +
an O +
arginyl O +
residue O -
, O +
the O +
interaction O +
with O +
the O +
phosphoryl O +
group O +
is O +
much O +
weaker O -
, O +
and O +
therefore O +
the O +
2 O +
groups O +
are O +
probably O +
farther O +
apart O +
than O +
in O +
the O +
HOPC-8 B-Gene +
site O -
. O +

( O -
3 O -
) O +
Both O +
sites O +
interact O +
strongly O +
with O +
the O +
quaternary O +
ammonium O +
group O +
of O +
choline O +
and O +
thus O +
this O +
group O +
probably O +
closely O +
approaches O +
a O +
carboxylate O +
group O +
present O +
in O +
both O +
sites O -
. O +

Acknowledgements O -
- O -
We O +
thank O +
Messrs. O +
Robert O +
Hewson O -
, O +
Leonard O +
Rendina O +
and O +
Arthur O +
Trott O +
for O +
expert O +
technical O +
assistance O -
. O +

Specificity O +
of O +
Anti B-Gene -
- I-Gene -
p I-Gene -
- I-Gene -
Azophenylphosphorylcholine I-Gene +
Antibodies I-Gene +

Manganous O +
chloride O +
and O +
Congo O +
red O +
incorporated O +
into O +
blotting O +
paper O +
discs O +
have O +
been O +
used O +
to O +
differentiate O +
gonococci O +
from O +
meningococci O -
. O +

The O +
new O +
technique O +
is O +
simple O +
and O +
reliable O -
; O +
the O +
materials O +
for O +
the O +
test O +
are O +
inexpensive O -
. O +

The O +
method O +
will O +
increase O +
the O +
efficiency O +
of O +
distinguishing O +
between O +
the O +
pathogenic O +
Neisseria O +
in O +
any O +
clinical O +
bacteriology O +
laboratory O +
and O +
especially O +
in O +
those O +
in O +
the O +
tropical O +
areas O -
. O +

A O +
methodology O +
to O +
determine O +
the O +
intrinsic O +
capacities O +
of O +
a O +
microflora O +
to O +
degrade O +
gasoline O +
was O +
developed O -
, O +
in O +
particular O +
for O +
assessing O +
the O +
potential O +
of O +
autochtonous O +
populations O +
of O +
polluted O +
and O +
non O +
polluted O +
soils O +
for O +
natural O +
attenuation O +
and O +
engineered O +
bioremediation O -
. O +

A O +
model O +
mixture O +
( O -
GM23 O -
) O +
constituted O +
of O +
the O +
23 O +
most O +
representative O +
hydrocarbons O +
of O +
a O +
commercial O +
gasoline O +
was O +
used O -
. O +

The O +
capacities O +
of O +
the O +
microflorae O +
( O -
kinetics O +
and O +
extent O +
of O +
biodegradation O -
) O +
were O +
assessed O +
by O +
chromatographic O +
analysis O +
of O +
hydrocarbon O +
consumption O +
and O +
of O +
CO2 O +
production O -
. O +

The O +
degradation O +
of O +
the O +
components O +
of O +
GM23 O +
was O +
assayed O +
in O +
separate O +
incubations O +
of O +
each O +
component O +
and O +
in O +
the O +
complete O +
mixture O -
. O +

For O +
the O +
microflora O +
of O +
an O +
unpolluted O +
spruce O +
forest O +
soil O -
, O +
all O +
hydrocarbons O +
of O +
GM23 O +
except O +
cyclohexane O -
, O +
2,2,4- O +
and O +
2,3,4-trimethylpentane O +
isomers O +
were O +
degraded O +
to O +
below O +
detection O +
limit O +
in O +
28 O +
days O -
. O +

This O +
microflora O +
was O +
reinforced O +
with O +
two O +
mixed O +
microbial O +
communities O +
selected O +
from O +
gasoline O -
- O -
polluted O +
sites O +
and O +
shown O +
to O +
degrade O +
cyclohexane O +
and O +
2,2,4-trimethylpentane O -
. O +

With O +
the O +
reinforced O +
microflora O -
, O +
complete O +
degradation O +
of O +
GM23 O +
was O +
observed O -
. O +

The O +
degradation O +
patterns O +
of O +
individual O +
components O +
of O +
GM23 O +
were O +
similar O +
when O +
the O +
compounds O +
were O +
present O +
individually O +
or O +
in O +
the O +
GM23 O +
mixture O -
, O +
as O +
long O +
as O +
the O +
concentrations O +
of O +
2-ethyltoluene O +
and O +
trimethylbenzene O +
isomers O +
were O +
kept O +
sufficiently O +
low O +
( O -
< O +
or O +
= O +
35 O +
mg.l-1 O -
) O +
to O +
remain O +
below O +
their O +
inhibitory O +
level O -
. O +

The O +
first O +
acyclonucleosides O +
based O +
on O +
the O +
benzothiadiazine O +
dioxide O +
system O +
were O +
synthesized O +
following O +
the O +
silylation O +
procedure O -
. O +

Several O +
acyclic O +
moieties O -
, O +
including O +
acetoxyethoxymethyl O -
, O +
benzyloxymethyl O -
, O +
and O +
propargyloxymethyl O +
groups O -
, O +
were O +
introduced O -
. O +

Two O +
synthetic O +
strategies O +
were O +
designed O +
to O +
selectively O +
obtain O +
the O +
N-1 O +
or O +
N-3 O +
derivatives O -
. O +

Lipase B-Gene -
- O -
mediated O +
deacylation O +
was O +
used O +
for O +
the O +
deprotection O +
of O +
the O +
acyclonucleosides O -
. O +

Some O +
of O +
the O +
benzothiadiazine O +
dioxide O +
acyclonucleosides O -
, O +
in O +
particular O +
16 O -
, O +
proved O +
active O +
against O +
human O +
cytomegalovirus O +
( O -
CMV O -
) O +
at O +
concentrations O +
slightly O +
higher O +
than O +
that O +
found O +
for O +
ganciclovir O +
[ O -
50 O -
% O +
inhibitory O +
concentration O +
( O -
IC50 O -
) O +
= O +
3 O -
. O +
5 O -
- O -
3.7 O +
micrograms O -
/ O -
mL O -
, O +
cytotoxicity O +
( O -
CC50 O -
) O +
> O -
/= O +
40 O +
micrograms O -
/ O -
mL O -
, O +
MCC O +
= O +
20 O +
micrograms O -
/ O -
mL O -
] O -
. O +

Additionally O -
, O +
compound O +
16 O +
inhibited O +
the O +
replication O +
of O +
human O +
immunodeficiency O +
virus O +
type O +
1 O +
( O -
HIV-1 O -
) O +
and O +
HIV-2 O +
in O +
CEM O +
cells O +
at O +
concentrations O +
that O +
were O +
5-fold O +
lower O +
than O +
its O +
cytotoxic O +
concentration O -
. O +

To O +
examine O +
the O +
stereospecific O +
effects O +
of O +
lipoic O +
compounds O +
on O +
pyruvate O +
metabolism O -
, O +
the O +
effects O +
of O +
R O -
- O -
lipoic O +
acid O +
( O -
R O -
- O -
LA O -
) O -
, O +
S O -
- O -
lipoic O +
acid O +
( O -
S O -
- O -
LA O -
) O +
and O +
1,2-diselenolane-3-pentanoic O +
acid O +
( O -
Se O -
- O -
LA O -
) O +
on O +
the O +
activities O +
of O +
the O +
mammalian O +
pyruvate B-Gene +
dehydrogenase I-Gene +
complex I-Gene +
( O -
PDC B-Gene -
) O +
and O +
its O +
catalytic O +
components O +
were O +
investigated O -
. O +

Both O +
S O -
- O -
LA O +
and O +
R O -
- O -
LA O +
markedly O +
inhibited O +
PDC B-Gene +
activity O -
; O +
whereas O +
Se O -
- O -
LA O +
displayed O +
inhibition O +
only O +
at O +
higher O +
concentrations O -
. O +

Examination O +
of O +
the O +
effects O +
on O +
the O +
individual O +
catalytic O +
components O +
indicated O +
that O +
Se O -
- O -
LA O +
inhibited O +
the O +
pyruvate B-Gene +
dehydrogenase I-Gene +
component O -
; O +
whereas O +
R O -
- O -
LA O +
and O +
S O -
- O -
LA O +
inhibited O +
the O +
dihydrolipoamide B-Gene +
acetyltransferase I-Gene +
component O -
. O +

The O +
three O +
lipoic O +
compounds O +
lowered O +
dihydrolipoamide B-Gene +
dehydrogrenase I-Gene +
( O -
E3 O -
) O +
activity O +
in O +
the O +
forward O +
reaction O +
by O +
about O +
30 O +
to O +
45 O -
% O -
. O +

The O +
kinetic O +
data O +
of O +
E3 B-Gene +
showed O +
that O +
both O +
R O -
- O -
LA O +
and O +
Se O -
- O -
LA O +
are O +
used O +
as O +
substrates O +
by O +
E3 B-Gene +
for O +
the O +
reverse O +
reaction O -
. O +

Decarboxylation O +
of O +
[ O -
1 O -
- O -
14C O -
] O -
pyruvate O +
via O +
PDC B-Gene +
by O +
cultured O +
HepG2 O +
cells O +
was O +
not O +
affected O +
by O +
R O -
- O -
LA O -
, O +
but O +
moderately O +
decreased O +
with O +
S O -
- O -
LA O +
and O +
Se O -
- O -
LA O -
. O +

These O +
findings O +
indicate O +
that O +
( O -
i O -
) O +
purified O +
PDC B-Gene +
and O +
its O +
catalytic O +
components O +
are O +
affected O +
by O +
lipoic O +
compounds O +
based O +
on O +
their O +
stereoselectivity O -
; O +
and O +
( O -
ii O -
) O +
the O +
oxidation O +
of O +
pyruvate O +
by O +
intact O +
HepG2 O +
cells O +
is O +
not O +
inhibited O +
by O +
R O -
- O -
LA O -
. O +

The O +
later O +
finding O +
with O +
the O +
intact O +
cells O +
is O +
in O +
support O +
of O +
therapeutic O +
role O +
of O +
R O -
- O -
LA O +
as O +
an O +
antioxidant O -
. O +

A O +
highly O +
sensitive O +
pre O -
- O -
column O +
HPLC O +
method O +
for O +
simultaneous O +
determination O +
of O +
prolyl O +
dipeptides O -
, O +
Pro O +
and O +
Hyp O +
in O +
urine O +
was O +
developed O -
. O +

The O +
analytes O +
were O +
labelled O +
with O +
4- O -
( O -
5,6-dimethoxy-2-phthalimidinyl O -
) O -
-2-methoxyphenylsulfonyl O +
chloride O +
at O +
70 O +
degrees O +
C O +
for O +
20 O +
min O -
. O +

The O +
derivatives O +
separated O +
on O +
tandem O +
reversed O -
- O -
phase O +
columns O +
by O +
a O +
gradient O +
elution O +
and O +
were O +
monitored O +
with O +
fluorescence O +
detection O +
at O +
318 O +
nm O +
( O -
excitation O -
) O +
and O +
392 O +
nm O +
( O -
emission O -
) O -
. O +

The O +
detection O +
limits O +
for O +
prolyl O +
dipeptides O -
, O +
Pro O +
and O +
Hyp O +
were O +
1 O -
- O -
5 O +
fmol O -
/ O -
injection O +
( O -
S O -
/ O -
N O +
= O +
3 O -
) O -
. O +

Urine O +
samples O +
were O +
treated O +
with O +
o O -
- O -
phthalaldehyde O -
, O +
followed O +
by O +
purification O +
on O +
a O +
Bond O +
Elut O +
C18 O +
column O +
before O +
conducting O +
the O +
labelling O +
reaction O -
. O +

Pro O -
- O -
Hyp O -
, O +
Pro O -
- O -
Gly O +
and O +
Pro O -
- O -
Pro O +
were O +
identified O +
as O +
prolyl O +
dipeptides O +
in O +
urine O -
. O +

The O +
within O -
- O -
day O +
and O +
between O -
- O -
day O +
relative O +
standard O +
deviations O +
were O +
1.5 O -
- O -
4.8 O +
and O +
1.7 O -
- O -
5.8 O -
% O -
, O +
respectively O -
. O +

The O +
concentrations O +
of O +
Pro O -
- O -
Hyp O -
, O +
Pro O -
- O -
Gly O -
, O +
Pro O -
- O -
Pro O -
, O +
Pro O +
and O +
Hyp O +
in O +
normal O +
human O +
urine O +
were O +
97.6 O +
+ O -
/- O +

28.2 O -
, O +
2.74 O +
+ O -
/- O +

1.48 O -
, O +
2.08 O +
+ O -
/- O +

1.13 O -
, O +
6.71 O +
+ O -
/- O +

3.34 O +
and O +
2.30 O +
+ O -
/- O +

1.59 O +
nmol O -
/ O -
mg O +
creatinine O -
, O +
respectively O -
. O +

An O +
enzyme B-Gene +
with O +
lipase B-Gene +
and O +
esterase B-Gene +
activity O +
was O +
purified O +
from O +
bovine O +
pancreas O -
. O +

Furthermore O -
, O +
a O +
non O -
- O -
radioactive O +
lipase B-Gene +
assay O +
was O +
developed O +
which O +
is O +
100 O +
times O +
more O +
sensitive O +
than O +
the O +
conventional O +
methods O +
and O +
allowed O +
the O +
characterization O +
of O +
the O +
lipase B-Gene +
activity O +
of O +
the O +
enzyme B-Gene -
. O +

The O +
lipase B-Gene +
activity O +
increased O +
42 O +
times O +
in O +
the O +
presence O +
of O +
10 O +
mM O +
sodium O +
taurocholate O -
, O +
which O +
for O +
the O +
first O +
time O +
provides O +
direct O +
evidence O +
that O +
a O +
bile B-Gene +
salt I-Gene -
- I-Gene -
activated I-Gene +
lipase I-Gene +
( O -
bp B-Gene -
- I-Gene -
BAL I-Gene -
) O +
was O +
isolated O +
from O +
bovine O +
pancreas O -
. O +

This O +
conclusion O +
is O +
further O +
supported O +
by O +
the O +
fact O +
that O +
the O +
N O -
- O -
terminal O +
amino O +
acid O +
sequence O +
of O +
this O +
lipase B-Gene -
/ O -
esterase B-Gene +
is O +
88 O -
% O +
homologous O +
to O +
human O +
milk B-Gene +
BAL I-Gene +
and O +
human O +
pancreatic B-Gene +
BAL I-Gene -
. O +

Staining O +
with O +
various O +
lectins B-Gene +
showed O +
that O +
bp B-Gene -
- I-Gene -
BAL I-Gene +
is O +
a O +
glycoprotein B-Gene +
which O +
contains O +
fucose O +
residues O -
. O +

Previously O +
from O +
bovine O +
pancreas O +
a O +
lysophospholipase B-Gene +
has O +
been O +
purified O +
and O +
a O +
gene O +
was O +
cloned O +
and O +
sequenced O +
encoding O +
an O +
enzyme B-Gene +
with O +
cholesterol B-Gene +
esterase I-Gene -
/ O -
lysophospholipase B-Gene +
activity O -
. O +

Comparison O +
of O +
the O +
N O -
- O -
terminal O +
amino O +
acid O +
sequence O +
of O +
bp B-Gene -
- I-Gene -
BAL I-Gene +
with O +
the O +
deduced O +
amino O +
acid O +
sequence O +
of O +
the O +
latter O +
revealed O +
that O +
they O +
are O +
identical O -
. O +

Furthermore O -
, O +
the O +
molecular O +
weight O +
of O +
the O +
purified O +
bp B-Gene -
- I-Gene -
BAL I-Gene +
of O +
63,000 O -
, O +
as O +
estimated O +
by O +
SDS O -
- O -
PAGE O -
, O +
is O +
very O +
similar O +
to O +
that O +
of O +
the O +
purified O +
lysophospholipase B-Gene +
( O -
65,000 O -
) O +
and O +
to O +
the O +
theoretical O +
molecular O +
weight O +
of O +
65,147 O +
of O +
the O +
cholesterol B-Gene +
esterase I-Gene -
/ O -
lysophospholipase B-Gene -
. O +

These O +
data O +
suggest O +
that O +
these O +
three O +
enzymes B-Gene +
are O +
one O +
and O +
the O +
same O -
. O +

The O +
antioxidant O +
activity O +
of O +
Eriobotrya O +
japonica O +
was O +
determined O +
by O +
measuring O +
the O +
radical O +
scavenging O +
effect O +
on O +
DPPH O +
( O -
1,1-diphenyl-2-picrylhydrazyl O -
) O +
radical O +
and O +
lipid O +
peroxidation O +
produced O +
when O +
mouse O +
liver O +
homogenate O +
was O +
exposed O +
to O +
the O +
air O +
at O +
37 O +
degrees O +
C O -
, O +
using O +
2-thiobarbituric O +
acid O +
( O -
TBA O -
) O -
. O +

The O +
methanol O +
extract O +
and O +
its O +
fractions O +
of O +
Eriobotrya O +
japonica O +
leaves O +
showed O +
strong O +
antioxidant O +
activity O -
. O +

The O +
antioxidant O +
activity O +
of O +
EtOAc O +
and O +
n O -
- O -
BuOH O +
soluble O +
fractions O +
were O +
stronger O +
than O +
the O +
others O -
, O +
and O +
were O +
further O +
purified O +
by O +
repeated O +
silica O +
gel O -
, O +
MCl O +
gel O +
CHP-20P O -
, O +
and O +
Sephadex O +
LH-20 O +
column O +
chromatography O -
. O +

Antioxidant O +
chlorogenic O +
acid O -
, O +
quercetin-3-sambubioside O +
from O +
n O -
- O -
BuOH O +
fraction O -
, O +
and O +
methyl O +
chlorogenate O -
, O +
kaempferol- O +
and O +
quercetin-3-rhamnosides O -
, O +
together O +
with O +
the O +
inactive O +
ursolic O +
acid O +
and O +
2 O +
alpha O -
- O -
hydroxyursolic O +
acid O +
from O +
EtOAc O +
fraction O +
were O +
isolated O -
. O +

Antioxidant O +
flavonoids O +
and O +
chlorogenic O +
acid O +
also O +
showed O +
prominent O +
inhibitory O +
activity O +
against O +
free O +
radical O +
generation O +
in O +
dichlorofluorescein O +
( O -
DCF O -
) O +
method O -
. O +

The O +
synthesis O +
and O +
the O +
antimicrobial O +
properties O +
of O +
a O +
new O +
series O +
of O +
cephalosporinic O +
beta O -
- O -
lactam O +
antibiotics O +
is O +
described O -
. O +

The O +
data O +
reported O +
in O +
the O +
present O +
paper O +
show O +
the O +
potential O +
of O +
this O +
type O +
of O +
substituted O +
cephalosporins O +
as O +
new O +
anti O +
Gram O -
- O -
positive O +
antibiotic O +
drugs O -
. O +

In O +
fact O -
, O +
all O +
compounds O +
tested O +
showed O +
a O +
good O +
in O +
vitro O +
antibacterial O +
activity O +
against O +
the O +
most O +
relevant O +
Gram O -
- O -
positive O +
pathogens O +
including O +
resistant O +
species O +
that O +
currently O +
represent O +
unmet O +
medical O +
need O -
. O +

On O +
the O +
contrary O -
, O +
the O +
new O +
synthesized O +
compounds O +
were O +
found O +
to O +
be O +
completely O +
devoid O +
of O +
any O +
activity O +
on O +
Gram O -
- O -
negative O +
bacteria O +
up O +
to O +
a O +
concentration O +
of O +
the O +
single O +
agent O +
of O +
128 O +
microg O -
/ O -
ml O -
. O +

The O +
hydroxylation O +
at O +
C-2 O +
of O +
testosterone O +
and O +
5alpha O -
- O -
dihydrotestosterone O +
is O +
measured O +
by O +
isolation O +
of O +
HTO O +
after O +
incubating O +
" O -
metabolically O +
labile O -
" O +
tritium O +
labeled O +
steroids O +
with O +
the O +
enzymes B-Gene -
. O +

After O +
hydroxylation O +
of O +
testosterone O +
in O +
rat O +
liver O +
2alpha O -
- O -
hydroxytestosterone O +
was O +
isolated O +
and O +
identified O +
by O +
gaschromatography O +
and O +
mass O +
spectra O -
. O +

Oxamniquine O +
( O -
1,2,3,4-tetrahydro-2- O -
[ O -
( O -
isopropylamino O -
) O -
methyl O -
] O -
-7-nitro-6-quinoline O +
methanol O -
) O +
is O +
an O +
antischistosomal O +
agent O +
that O +
is O +
indicated O +
for O +
the O +
treatment O +
of O +
S. O +
mansoni O +
( O -
intestinal O +
schistosomiasis O -
) O +
infection O -
. O +

It O +
has O +
been O +
shown O +
to O +
inhibit O +
DNA O -
, O +
RNA O +
and O +
protein B-Gene +
synthesis O +
in O +
schistosomes O -
. O +

The O +
oral O +
bioavailability O +
of O +
oxamniquine O +
is O +
good O -
, O +
effective O +
plasma O +
levels O +
are O +
achieved O +
in O +
11.5 O +
h O +
[ O -
1 O -
] O +
. O +

Oxamniquine O +
is O +
the O +
subject O +
of O +
a O +
monograph O +
in O +
the O +
US O +
Pharmacopoeia O +
( O -
USP O +
XXIII O -
) O +
[ O -
2 O -
] O +
whereby O +
a O +
spectrophotometric O +
method O +
is O +
recommended O +
for O +
its O +
determination O -
, O +
whether O +
in O +
its O +
pure O +
form O +
or O +
in O +
capsules O -
. O +

Other O +
reported O +
methods O +
include O +
spectrophotometry O +
[ O -
3,4 O -
] O +
, O +
non O -
- O -
aqueous O +
titration O +
[ O -
5 O -
] O +
, O +
gas O +
chromatography O +
[ O -
6 O -
] O +
, O +
high O -
- O -
performance O +
liquid O +
chromatography O +
[ O -
711 O -
] O +
, O +
polarography O +
[ O -
12 O -
] O +
, O +
capillary O +
electrophoresis O +
[ O -
9 O -
] O +
, O +
flow O -
- O -
injection O +
analysis O +
[ O -
13 O -
] O +
and O +
cyclic O +
voltammetry O +
[ O -
14 O -
] O +
. O +

The O +
above O -
- O -
mentioned O +
methods O +
are O +
either O +
not O +
sufficiently O +
sensitive O +
or O +
are O +
tedious O +
and O +
require O +
highly O +
sophisticated O +
instrumentation O -
. O +

Therefore O -
, O +
there O +
is O +
still O +
a O +
need O +
for O +
a O +
much O +
more O +
sensitive O +
and O +
simple O +
method O +
for O +
the O +
determination O +
of O +
oxamniquine O -
, O +
especially O +
in O +
biological O +
fluids O -
. O +

Fluorimetry O -
, O +
by O +
virtue O +
of O +
its O +
high O +
sensitivity O -
, O +
meets O +
this O +
requirement O -
. O +

Reviewing O +
the O +
literature O +
revealed O +
that O +
no O +
fluorimetric O +
methods O +
were O +
reported O +
for O +
oxamniquine O -
. O +

As O +
for O +
2-cyanoacetamide O -
, O +
it O +
has O +
been O +
recently O +
used O +
for O +
the O +
determination O +
of O +
aminoglycosides O +
[ O -
15 O -
] O +
, O +
reducing O +
carbohydrates O +
[ O -
1618 O -
] O +
, O +
enzymatic O +
degradation O +
products O +
of O +
reducing O +
polysaccharides O +
[ O -
19 O -
] O +
and O +
catecholamines O +
[ O -
20,21 O -
] O +
. O +

The O +
aim O +
of O +
the O +
present O +
work O +
is O +
to O +
study O +
the O +
reaction O +
of O +
the O +
reduced O +
derivative O +
( O -
nitroso O -
) O +
of O +
oxamniquine O +
with O +
2-cyanoacetamide O +
in O +
an O +
attempt O +
to O +
develop O +
a O +
sensitive O +
fluorimetric O +
method O +
to O +
be O +
used O +
for O +
its O +
determination O +
in O +
biological O +
fluids O -
. O +

2 O +
Experimental O +
2.1 O +
Apparatus O +
An O +
Aminco O -
- O -
Bowman O +
Model O +
J4 O +
-9860 O +
spectrofluorometer O +
was O +
used O +
with O +
the O +
excitation O +
and O +
emission O +
slits O +
set O +
at O +
5 O +
mm O -
. O +

A O +
1-cm O +
quartz O +
cell O +
was O +
used O +
for O +
all O +
measurements O -
. O +

2.2 O +
Materials O +
and O +
reagents O +
All O +
the O +
chemicals O +
used O +
were O +
of O +
analytical O +
reagent O +
grade O -
, O +
while O +
the O +
solvents O +
were O +
of O +
the O +
spectroscopic O +
grade O -
. O +

A O +
pure O +
drug O +
sample O +
of O +
oxamniquine O +
was O +
kindly O +
supplied O +
by O +
Pfizer O +
( O -
Sandwich O -
, O +
UK O -
) O +
and O +
was O +
used O +
as O +
received O -
. O +

2-Cyanoacetamide O +
was O +
purchased O +
from O +
Aldrich O +
Chemical O +
Co. O +
Plasma O +
was O +
obtained O +
from O +
Mansoura O +
University O +
Hospital O -
, O +
Mansoura O +
( O -
Egypt O -
) O +
and O +
urine O +
was O +
obtained O +
from O +
healthy O +
volunteers O -
. O +

Freshly O +
prepared O +
10 O -
% O +
aqueous O +
solution O +
of O +
calcium O +
chloride O +
and O +
4 O -
% O +
aqueous O +
solution O +
of O +
2-cyanoacetamide O +
were O +
prepared O +
and O +
used O +
throughout O +
the O +
study O -
. O +

2.2.1 O +
Stock O +
solution O +
Dissolve O +
20 O +
mg O +
of O +
oxamniquine O +
in O +
100 O +
of O +
methanol O -
. O +

Make O +
serial O +
dilutions O +
with O +
water O +
to O +
obtain O +
a O +
final O +
concentration O +
of O +
20 O +
g O -
/ O -
ml O -
. O +

2.3 O +
Procedure O +
2.3.1 O +
Preparation O +
of O +
the O +
calibration O +
curve O +
Transfer O +
aliquots O +
of O +
oxamniquine O +
final O +
stock O +
solution O +
into O +
a O +
series O +
of O +
25 O +
ml O +
standard O +
flasks O +
so O +
that O +
the O +
final O +
drug O +
concentration O +
is O +
in O +
the O +
range O +
0.080.88 O +
g O -
/ O -
ml O -
. O +

Add O +
to O +
each O +
flask O +
1205 O +
mg O +
of O +
zinc O +
dust O +
and O +
12 O +
ml O +
of O +
calcium O +
chloride O +
solution O -
. O +

Shake O +
well O +
and O +
leave O +
to O +
stand O +
for O +
20 O +
min O -
. O +

Filter O +
the O +
excess O +
zinc O +
powder O -
. O +

Add O +
1 O +
ml O +
of O +
2-cyanoacetamide O +
solution O +
to O +
the O +
filtrate O -
, O +
then O +
heat O +
on O +
a O +
boiling O +
water O +
bath O +
for O +
1 O +
h. O +
Cool O +
and O +
fill O +
to O +
the O +
mark O +
in O +
25 O +
ml O +
standard O +
flask O +
with O +
water O -
. O +

Measure O +
the O +
fluorescence O +
of O +
the O +
filtrate O +
using O +
370 O +
nm O +
as O +
the O +
excitation O +
wavelength O +
and O +
450 O +
nm O +
as O +
the O +
emission O +
wavelength O -
. O +

A O +
blank O +
reagent O +
is O +
prepared O +
simultaneously O -
. O +

Plot O +
the O +
values O +
of O +
the O +
% O +
relative O +
intensity O +
against O +
the O +
final O +
concentration O +
in O +
g O -
/ O -
ml O +
to O +
get O +
the O +
calibration O +
graph O -
. O +

Alternatively O -
, O +
the O +
regression O +
equation O +
is O +
derived O -
. O +

2.3.2 O +
Determination O +
of O +
oxamniquine O +
in O +
spiked O +
human O +
plasma O +
and O +
urine O +
A O +
standard O +
calibration O +
curve O +
was O +
prepared O +
daily O +
by O +
spiking O +
blank O +
plasma O +
or O +
urine O +
with O +
varying O +
amounts O +
of O +
oxamniquine O -
. O +

A O +
stock O +
solution O +
containing O +
10 O +
g O -
/ O -
ml O +
of O +
oxamniquine O +
was O +
freshly O +
prepared O -
. O +

Control O +
samples O +
of O +
plasma O +
or O +
urine O +
were O +
spiked O +
with O +
different O +
quantities O +
of O +
oxamniquine O +
to O +
give O +
a O +
final O +
drug O +
concentration O +
of O +
0.20.8 O +
g O -
/ O -
ml O -
. O +

Add O +
0.8 O +
ml O +
of O +
1 O +
M O +
NaOH O +
with O +
gentle O +
shaking O +
to O +
1.0 O +
ml O +
of O +
the O +
spiked O +
urine O +
or O +
plasma O -
. O +

The O +
solution O +
was O +
then O +
vortexed O +
with O +
3 O -
 O -
5 O +
ml O +
of O +
ether O +
for O +
2 O +
min O +
then O +
centrifuged O +
at O +
2500 O +
rpm O +
for O +
5 O +
min O -
. O +

The O +
resulting O +
supernatant O +
was O +
then O +
evaporated O +
to O +
dryness O +
under O +
nitrogen O +
at O +
ambient O +
temperature O -
. O +

The O +
resulting O +
residue O +
was O +
dissolved O +
in O +
5 O +
ml O +
of O +
methanol O +
and O +
then O +
made O +
up O +
to O +
10 O +
ml O +
with O +
water O +
in O +
a O +
volumetric O +
flask O -
. O +

The O +
procedure O +
described O +
in O +
Section O +
2.3.1 O +
was O +
then O +
applied O -
. O +

A O +
blank O +
experiment O +
using O +
plasma O +
or O +
urine O +
without O +
the O +
drug O +
was O +
carried O +
out O +
simultaneously O -
. O +

The O +
content O +
of O +
oxamniquine O +
was O +
then O +
determined O +
from O +
the O +
previously O +
plotted O +
calibration O +
graphs O -
. O +

3 O +
Results O +
and O +
discussion O +
The O +
nitro O +
group O +
is O +
reported O +
to O +
be O +
reduced O +
into O +
the O +
corresponding O +
nitroso O +
group O +
upon O +
reduction O +
with O +
Zn O -
/ O -
CaCl2 O +
[ O -
22 O -
] O +
. O +

This O +
process O +
was O +
confirmed O +
by O +
testing O +
for O +
the O +
nitroso O +
group O +
using O +
sodium O +
nitroprusside O +
[ O -
23 O -
] O +
. O +

The O +
nitroso O +
compounds O +
were O +
reported O +
to O +
react O +
with O +
active O +
methylene O +
containing O +
compounds O +
with O +
the O +
production O +
of O +
the O +
corresponding O +
imines O +
[ O -
24 O -
] O +
. O +

The O +
latter O +
is O +
proposed O +
to O +
undergo O +
a O +
ring O -
- O -
closing O +
reaction O +
with O +
the O +
elimination O +
of O +
one O +
molecule O +
of O +
ammonia O +
and O +
the O +
production O +
of O +
the O +
3-cyanooxazazepin-2-one O +
derivative O -
, O +
which O +
is O +
the O +
fluorescent O +
product O -
. O +

A O +
proposal O +
of O +
reaction O +
pathway O +
is O +
suggested O +
in O +
Scheme O +
1 O +
. O +

A O +
highly O +
fluorescent O +
product O +
with O +
max O +
excitation O +
at O +
370 O +
nm O +
and O +
max O +
emission O +
of O +
450 O +
nm O +
was O +
obtained O +
( O -
Fig. O +
1 O +
) O -
. O +

3.1 O +
Study O +
of O +
the O +
experimental O +
conditions O +
The O +
factors O +
affecting O +
the O +
production O +
of O +
nitroso O +
derivative O +
were O +
first O +
studied O -
. O +

All O +
factors O +
were O +
kept O +
constant O +
except O +
one O -
, O +
which O +
was O +
changed O +
in O +
turn O +
to O +
study O +
its O +
effect O -
. O +

Any O +
amount O +
of O +
zinc O +
powder O +
in O +
the O +
range O +
100300 O +
mg O +
was O +
found O +
to O +
give O +
the O +
same O +
results O -
; O +
therefore O +
1205 O +
mg O +
were O +
used O +
throughout O +
the O +
work O -
. O +

As O +
for O +
calcium O +
chloride O +
solution O +
121 O +
ml O +
of O +
10 O -
% O +
( O -
wt. O -
/ O -
vol O -
. O -
) O +

aqueous O +
solution O +
was O +
found O +
to O +
give O +
maximum O +
fluorescence O -
. O +

Larger O +
volumes O +
caused O +
slight O +
decrease O +
in O +
fluorescence O -
. O +

Increasing O +
the O +
reduction O +
time O +
( O -
at O +
room O +
temperature O -
) O +
was O +
found O +
to O +
increase O +
the O +
fluorescence O +
up O +
to O +
20 O +
min O -
, O +
after O +
which O +
time O +
the O +
fluorescence O +
intensity O +
remained O +
unchanged O -
. O +

3.2 O +
Factors O +
affecting O +
the O +
development O +
of O +
the O +
fluorophore O +
The O +
effect O +
of O +
the O +
concentration O +
of O +
2-cyanoacetamide O +
was O +
studied O +
by O +
using O +
increasing O +
volumes O +
of O +
4 O -
% O +
aqueous O +
solution O -
. O +

It O +
was O +
found O +
that O +
1.00.1 O +
ml O +
is O +
appropriate O +
for O +
maximum O +
fluorescence O +
intensity O -
; O +
larger O +
volumes O +
caused O +
no O +
further O +
increase O +
in O +
fluorescence O -
. O +

The O +
temperature O +
and O +
time O +
of O +
heating O +
were O +
also O +
studied O -
. O +

It O +
was O +
concluded O +
that O +
heating O +
in O +
a O +
boiling O +
water O -
- O -
bath O +
for O +
1 O +
h O +
gave O +
the O +
highest O +
fluorescence O +
readings O -
. O +

Longer O +
heating O +
time O +
caused O +
a O +
decrease O +
in O +
fluorescence O +
as O +
shown O +
in O +
Fig. O +
2 O +
. O +

After O +
optimizing O +
the O +
conditions O -
, O +
it O +
was O +
found O +
that O +
the O +
relation O +
between O +
the O +
% O +
relative O +
intensity O +
( O -
% O +
RI O -
) O +
and O +
final O +
concentration O +
of O +
oxamniquine O +
was O +
rectilinear O +
over O +
the O +
range O +
0.080.88 O +
g O -
/ O -
ml O +
with O +
a O +
minimum O +
detectability O +
( O -
S O +
/N O +
= O -
2 O -
) O +
of O +
8 O +
ng O -
/ O -
ml O +
( O -
Fig. O +
3 O +
) O -
. O +

The O +
linear O +
regression O +
analysis O +
of O +
the O +
results O +
gave O +
the O +
following O +
equation:% O +
RI O +
= O -
0.0358 O -
+ O -
107.4C O +
( O -
r=0.9999 O -
) O +
where O +
C O +
= O -
final O +
concentration O +
in O +
g O -
/ O -
ml O -
, O +
% O +
RI O -
= O -
relative O +
fluorescence O +
intensity O +
and O +
r O +
= O -
correlation O +
coefficient O -
. O +

Statistical O +
analysis O +
of O +
the O +
results O +
of O +
analysis O +
of O +
authentic O +
sample O +
of O +
oxamniquine O +
obtained O +
by O +
both O +
the O +
proposed O +
method O +
and O +
the O +
official O +
method O +
[ O -
2 O -
] O +
revealed O +
no O +
significant O +
difference O +
between O +
the O +
two O +
methods O +
regarding O +
the O +
accuracy O +
and O +
precision O -
, O +
as O +
indicated O +
by O +
the O +
F O +
-test O +
and O +
Student O -
's O +
t O +
-test O -
, O +
respectively O +
[ O -
25 O -
] O +
. O +

Oxamniquine O +
is O +
readily O +
absorbed O +
following O +
oral O +
ingestion O -
, O +
and O +
a O +
peak O +
concentration O +
in O +
plasma O +
occurs O +
within O +
about O +
3 O +
h. O +
The O +
presence O +
of O +
food O +
significantly O +
delays O +
absorption O +
and O +
limits O +
the O +
concentration O +
achieved O +
in O +
plasma O +
during O +
the O +
first O +
several O +
hours O +
after O +
administration O -
. O +

Urinary O +
excretion O +
is O +
the O +
major O +
route O +
of O +
elimination O +
in O +
humans O +
[ O -
26 O -
] O +
. O +

Oxamniquine O +
is O +
given O +
orally O +
in O +
a O +
dose O +
of O +
250 O +
mg O +
three O +
times O +
daily O -
; O +
this O +
leads O +
to O +
a O +
final O +
blood O +
level O +
concentration O +
of O +
about O +
5 O +
g O -
/ O -
ml O -
, O +
i.e. O +
higher O +
than O +
the O +
upper O +
limit O +
of O +
the O +
working O +
range O +
of O +
the O +
proposed O +
method O -
. O +

Thus O -
, O +
the O +
high O +
sensitivity O +
of O +
the O +
proposed O +
method O +
allowed O +
the O +
determination O +
of O +
oxamniquine O +
in O +
biological O +
fluids O -
. O +

Table O +
1 O +
shows O +
the O +
results O +
for O +
the O +
fluorimetric O +
determination O +
of O +
a O +
pure O +
sample O +
of O +
oxamniquine O -
, O +
while O +
Table O +
2 O +
shows O +
the O +
results O +
of O +
the O +
fluorometric O +
determination O +
of O +
oxamniquine O +
in O +
spiked O +
urine O +
and O +
plasma O +
samples O -
, O +
respectively O -
. O +

The O +
extraction O +
procedure O +
described O +
by O +
Woolhouse O +
and O +
Wood O +
[ O -
6 O -
] O +
was O +
adopted O +
here O -
. O +

The O +
results O +
are O +
satisfactorily O +
accurate O +
and O +
precise O -
. O +

In O +
conclusion O -
, O +
a O +
highly O +
sensitive O +
and O +
accurate O +
method O +
was O +
developed O +
for O +
the O +
determination O +
of O +
oxamniquine O +
in O +
urine O +
and O +
plasma O -
. O +

Although O +
the O +
previously O +
reported O +
methods O +
[ O -
6,7 O -
] O +
for O +
its O +
determination O +
in O +
biological O +
fluids O +
may O +
be O +
less O +
time O -
- O -
consuming O -
, O +
the O +
proposed O +
method O +
is O -
, O +
however O -
, O +
more O +
sensitive O +
and O +
does O +
not O +
need O +
complicated O +
instrumentation O -
. O +

The O +
relationship O +
between O +
taurine O +
and O +
aging O +
of O +
brain O +
neural O +
cells O +
was O +
studied O +
by O +
using O +
primary O +
human O +
fetal O +
brain O +
neural O +
cells O +
cultured O +
in O +
serum O -
- O -
free O +
medium O -
. O +

The O +
results O +
indicated O +
that O +
the O +
activity O +
of O +
superoxide B-Gene +
dismutase I-Gene +
( O -
SOD B-Gene -
) O +
was O +
significantly O +
higher O +
in O +
taurine O +
added O +
group O +
than O +
the O +
control O +
group O +
cultured O +
for O +
6 O -
, O +
9 O +
and O +
15 O +
days O +
( O -
P O +
< O +
0.05 O -
) O -
. O +

With O +
different O +
taurine O +
levels O -
, O +
the O +
SOD B-Gene +
activities O +
of O +
50 O +
mg O -
/ O -
L O +
and O +
200 O +
mg O -
/ O -
L O +
taurine O +
groups O +
were O +
significantly O +
higher O +
than O +
the O +
control O +
group O +
cultured O +
for O +
6 O +
days O +
( O -
P O +
< O +
0.05 O -
) O -
. O +

After O +
3-day O +
culture O -
, O +
the O +
activity O +
of O +
glutathione B-Gene +
peroxidase I-Gene +
( O -
GSH B-Gene -
- I-Gene -
Px I-Gene -
) O +
in O +
the O +
taurine O +
added O +
group O +
was O +
significantly O +
higher O +
than O +
the O +
control O +
group O +
( O -
P O +
< O +
0.05 O -
) O -
. O +

The O +
membrane O +
lipid O +
fluidity O +
of O +
neural O +
cells O +
decreased O +
with O +
time O +
in O +
control O +
group O -
, O +
but O +
was O +
stable O +
in O +
the O +
group O +
treated O +
with O +
taurine O -
. O +

The O +
fluidity O +
was O +
more O +
stable O +
in O +
the O +
groups O +
treated O +
with O +
50 O -
, O +
200 O +
and O +
400 O +
mg O -
/ O -
L O +
groups O +
cultured O +
for O +
6 O +
days O -
, O +
compared O +
with O +
the O +
control O +
group O +
( O -
P O +
< O +
0.05 O +
or O +
0.01 O -
) O -
. O +

The O +
present O +
study O +
showed O +
that O +
taurine O +
is O +
necessary O +
for O +
maintaining O +
membrane O +
lipid O +
fluidity O +
of O +
neural O +
cells O +
in O +
proper O +
levels O -
, O +
and O +
plays O +
an O +
important O +
role O +
in O +
postponing O +
the O +
aging O +
process O +
of O +
brain O +
neural O +
cells O -
. O +

A O +
combination O +
of O +
atovaquone O +
and O +
proguanil O +
has O +
been O +
found O +
to O +
be O +
quite O +
effective O +
in O +
treating O +
malaria O -
, O +
with O +
little O +
evidence O +
of O +
the O +
emergence O +
of O +
resistance O +
when O +
atovaquone O +
was O +
used O +
as O +
a O +
single O +
agent O -
. O +

We O +
have O +
examined O +
possible O +
mechanisms O +
for O +
the O +
synergy O +
between O +
these O +
two O +
drugs O -
. O +

While O +
proguanil O +
by O +
itself O +
had O +
no O +
effect O +
on O +
electron O +
transport O +
or O +
mitochondrial O +
membrane O +
potential O +
( O -
DeltaPsim O -
) O -
, O +
it O +
significantly O +
enhanced O +
the O +
ability O +
of O +
atovaquone O +
to O +
collapse O +
DeltaPsim O +
when O +
used O +
in O +
combination O -
. O +

This O +
enhancement O +
was O +
observed O +
at O +
pharmacologically O +
achievable O +
doses O -
. O +

Proguanil O +
acted O +
as O +
a O +
biguanide O +
rather O +
than O +
as O +
its O +
metabolite O +
cycloguanil O +
( O -
a O +
parasite B-Gene +
dihydrofolate I-Gene +
reductase I-Gene +
[ O -
DHFR B-Gene -
] O +
inhibitor O -
) O +
to O +
enhance O +
the O +
atovaquone O +
effect O -
; O +
another O +
DHFR B-Gene +
inhibitor O -
, O +
pyrimethamine O -
, O +
also O +
had O +
no O +
enhancing O +
effect O -
. O +

Proguanil O -
- O -
mediated O +
enhancement O +
was O +
specific O +
for O +
atovaquone O -
, O +
since O +
the O +
effects O +
of O +
other O +
mitochondrial O +
electron O +
transport O +
inhibitors O -
, O +
such O +
as O +
myxothiazole O +
and O +
antimycin O -
, O +
were O +
not O +
altered O +
by O +
inclusion O +
of O +
proguanil O -
. O +

Surprisingly O -
, O +
proguanil O +
did O +
not O +
enhance O +
the O +
ability O +
of O +
atovaquone O +
to O +
inhibit O +
mitochondrial O +
electron O +
transport O +
in O +
malaria O +
parasites O -
. O +

These O +
results O +
suggest O +
that O +
proguanil O +
in O +
its O +
prodrug O +
form O +
acts O +
in O +
synergy O +
with O +
atovaquone O +
by O +
lowering O +
the O +
effective O +
concentration O +
at O +
which O +
atovaquone O +
collapses O +
DeltaPsim O +
in O +
malaria O +
parasites O -
. O +

This O +
could O +
explain O +
the O +
paradoxical O +
success O +
of O +
the O +
atovaquone O -
- O -
proguanil O +
combination O +
even O +
in O +
regions O +
where O +
proguanil O +
alone O +
is O +
ineffective O +
due O +
to O +
resistance O -
. O +

The O +
results O +
also O +
suggest O +
that O +
the O +
atovaquone O -
- O -
proguanil O +
combination O +
may O +
act O +
as O +
a O +
site O -
- O -
specific O +
uncoupler O +
of O +
parasite O +
mitochondria O +
in O +
a O +
selective O +
manner O -
. O +

To O +
develop O +
positron O -
- O -
emitting O +
tracers O +
for O +
positron O +
emission O +
tomography O +
( O -
PET O -
) O +
studies O -
, O +
ex O +
vivo O +
autoradiography O +
( O -
ARG O -
) O +
is O +
a O +
useful O +
technique O +
to O +
demonstrate O +
the O +
distribution O +
of O +
the O +
tracer O +
in O +
the O +
brain O +
as O +
well O +
as O +
in O +
the O +
whole O +
body O -
. O +

A O +
recent O +
advent O +
of O +
radioluminography O +
using O +
phosphor O -
- O -
imaging O +
plates O +
( O -
12 O -
, O +
14 O -
) O +
has O +
enabled O +
the O +
ex O +
vivo O +
ARG O +
to O +
be O +
applied O +
to O +
ultrashort O -
- O -
lived O +
11 O +
C O -
- O -
labeled O +
tracers O -
. O +

Yanai O +
et O +
al. O +
reported O +
a O +
potential O +
of O +
the O +
imaging O +
plates O +
for O +
receptor O +
ARG O +
with O +
11 O +
C O -
- O -
labeled O +
ligands O +
compared O +
with O +
tritiated O +
ligands O +
( O -
25 O -
) O +
. O +

Planas O +
et O +
al. O +
( O -
18 O -
) O +
characterized O +
a O +
cholinesterase B-Gene +
inhibitor O +
[ O -
11 O +
C O -
] O -
physostigmine O +
using O +
a O +
similar O +
type O +
storage O +
phosphor O +
plates O -
. O +

We O +
also O +
used O +
imaging O +
plates O +
to O +
characterize O +
newly O +
developed O +
11 O +
C O -
- O -
labeled O +
receptor B-Gene +
ligands O +
( O -
3 O -
, O +
10 O -
, O +
16 O -
) O +
. O +

Because O +
the O +
intensity O +
of O +
photo O -
- O -
stimulated O -
- O -
luminescence O +
( O -
PSL O -
) O +
is O +
linearly O +
proportional O +
to O +
the O +
radioactivity O +
in O +
a O +
wide O +
range O -
, O +
ARG O +
images O +
expressed O +
as O +
PSL O +
is O +
considered O +
to O +
reflect O +
the O +
quantitative O +
distribution O +
of O +
radioactivity O -
. O +

Recently O -
, O +
Sihver O +
et O +
al. O +
( O -
21 O -
) O +
have O +
quantitatively O +
evaluated O +
in O +
vitro O +
ARG O +
with O +
storage O +
phosphor O +
plates O +
and O +
11 O +
C O -
- O -
flumazenil O -
. O +

In O +
the O +
present O +
paper O -
, O +
we O +
describe O +
quantitative O +
evaluation O +
of O +
ex O +
vivo O +
and O +
in O +
vitro O +
ARG O +
using O +
an O +
imaging O +
plate O +
and O +
a O +
11 O +
C O -
- O -
labeled O +
dopamine B-Gene +
D2 I-Gene +
-like I-Gene +
receptor I-Gene +
ligand O -
, O +
[ O -
11 O +
C O -
] O -
nemonapride O +
( O -
[ O -
11 O +
C O -
] O -
YM-09151 O -
- O -
2 O -
) O +
( O -
5 O -
, O +
6 O -
, O +
8 O -
, O +
9 O -
, O +
11 O -
) O +
. O +

Its O +
tritiated O +
compound O +
has O +
been O +
used O +
widely O +
for O +
pharmacological O +
studies O +
as O +
one O +
of O +
representative O +
dopamine B-Gene +
D2 I-Gene +
-like I-Gene +
receptor I-Gene +
ligands O -
. O +

We O +
report O +
the O +
presence O +
of O +
saturable O +
binding O +
sites O +
for O +
[ O -
11 O +
C O -
] O -
nemonapride O +
in O +
the O +
cortex O +
beside O +
the O +
dopamine B-Gene +
D2 I-Gene +
-like I-Gene +
receptors I-Gene +
in O +
the O +
striatum O +
both O +
ex O +
vivo O +
and O +
in O +
vitro O -
. O +

Materials O +
and O +
methods O +
[ O -
11 O +
C O -
] O -
Nemonapride O +
( O -
9 O -
) O +
and O +
[ O -
11 O +
C O -
] O -
SCH O +
23390 O +
( O -
4 O -
) O +
were O +
synthesized O +
by O +
11 O +
C O -
- O -
methylation O +
of O +
the O +
corresponding O +
desmethyl O +
compound O +
with O +
[ O -
11 O +
C O -
] O -
methyl O +
iodide O +
by O +
the O +
method O +
previously O +
described O -
. O +

The O +
specific O +
activity O +
of O +
the O +
compounds O +
was O +
measured O +
as O +
follows O -
. O +

The O +
radioactivity O +
( O -
MBq O -
) O +
of O +
an O +
appropriate O +
volume O +
of O +
tracer O +
solution O +
was O +
measured O +
by O +
a O +
radioisotope O +
calibrator O +
( O -
type O +
CRC-712 O -
, O +
Capintec O +
Inc. O -
, O +
Ramsey O -
, O +
NJ O -
) O -
, O +
and O +
a O +
part O +
of O +
the O +
solution O +
was O +
applied O +
to O +
high O -
- O -
performance O +
liquid O +
chromatography O +
( O -
HPLC O -
) O +
to O +
determine O +
the O +
mass O +
( O -
nmol O -
) O +
of O +
the O +
compounds O +
based O +
on O +
the O +
ultraviolet O +
( O -
UV O -
) O +
response O +
to O +
the O +
authentic O +
sample O -
. O +

Male O +
Wistar O +
rats O +
( O -
810 O +
weeks O +
old O -
) O +
were O +
obtained O +
from O +
Tokyo O +
Laboratory O +
Animals O +
Company O +
( O -
Tokyo O -
, O +
Japan O -
) O -
. O +

The O +
animal O +
studies O +
were O +
approved O +
by O +
the O +
Animal O +
Care O +
and O +
Use O +
Committee O +
of O +
Tokyo O +
Metropolitan O +
Institute O +
of O +
Gerontology O -
. O +

Calibration O +
of O +
PSL O +
Relationship O +
between O +
PSL O +
and O +
radioactivity O +
on O +
filter O +
paper O +
A O +
solution O +
of O +
11 O +
C O -
- O -
tracer O +
was O +
prepared O +
at O +
the O +
concentration O +
of O +
100 O +
MBq O -
/ O -
mL O +
measured O +
with O +
a O +
radioisotope O +
calibrator O +
( O -
t O +
= O +
0 O +
min O -
, O +
26 O +
min O +
after O +
end O +
of O +
bombardment O +
[ O -
EOB O -
] O -
) O -
. O +

The O +
solution O +
was O +
diluted O +
to O +
0.0310 O +
MBq O -
/ O -
mL O -
, O +
and O +
10 O +
L O +
of O +
each O +
diluted O +
solution O +
( O -
0.3100 O +
kBq O -
) O +
was O +
loaded O +
on O +
six O +
pieces O +
of O +
filter O +
paper O +
( O -
5 O +
mm O +
 O +
5 O +
mm O -
, O +
0.23 O +
 O +
0.05 O +
mm O +
thickness O -
, O +
Toyo O +
Roshi O +
Kaisha O -
, O +
Tokyo O -
, O +
Japan O -
) O -
. O +

Three O +
pieces O +
of O +
the O +
filter O +
paper O +
were O +
exposed O +
on O +
an O +
imaging O +
plate O +
of O +
type O +
IP O +
BAS O +
SR O +
( O -
FUJIX O +
Fuji O +
Photo O +
Film O +
Co. O -
, O +
Tokyo O -
, O +
Japan O -
) O +
until O +
the O +
decay O -
- O -
out O +
of O +
11 O +
C O +
( O -
t O +
= O +
20 O +
h O -
) O -
. O +

The O +
activity O +
at O +
the O +
start O +
of O +
contact O +
ranged O +
from O +
1.05 O +
to O +
2990 O +
Bq O +
( O -
t O +
= O +
35.5 O +
min O -
) O -
. O +

At O +
the O +
same O +
time O -
, O +
the O +
radioactivity O +
( O -
cpm O -
) O +
of O +
the O +
other O +
three O +
pieces O +
of O +
the O +
filter O +
paper O +
was O +
measured O +
with O +
a O +
well O -
- O -
type O +
auto O -
- O -
gamma O +
counter O +
( O -
type O +
1282 O +
Compugamma O +
CS O -
, O +
Wallac O +
Oy O -
, O +
Turku O -
, O +
Finland O -
) O +
for O +
15 O +
s O -
, O +
and O +
the O +
cpm O -
/ O -
Bq O +
was O +
computed O +
with O +
decay O +
correction O -
. O +

The O +
PSL O +
values O +
over O +
the O +
entire O +
piece O +
of O +
filter O +
paper O +
( O -
25 O +
mm2 O +
) O +
were O +
measured O +
with O +
a O +
bioimaging O +
analyzer O +
of O +
type O +
BAS O +
2500 O +
( O -
FUJIX O +
Fuji O +
Photo O +
Film O +
Co. O -
, O +
Tokyo O -
, O +
Japan O -
) O -
, O +
to O +
compute O +
the O +
PSL O +
per O +
Bq O +
at O +
the O +
start O +
of O +
contact O -
. O +

Reproducibility O +
between O +
imaging O +
plates O +
The O +
filter O +
paper O +
provided O +
with O +
the O +
11 O +
C O -
- O -
radioactivity O +
as O +
described O +
above O +
and O +
the O +
autoradiographic O +
[ O -
14 O +
C O -
] O -
micro O -
- O -
scales O +
( O -
1.1131.73 O +
kBq O -
/ O -
g O -
) O +
( O -
Amersham O +
International O +
plc O -
. O -
, O +
Buckinghamshire O -
, O +
England O -
) O +
were O +
exposed O +
to O +
five O +
imaging O +
plates O +
of O +
the O +
same O +
type O +
for O +
4 O +
h O +
to O +
examine O +
the O +
reproducibility O +
between O +
imaging O +
plates O -
; O +
the O +
PSL O +
of O +
the O +
micro O -
- O -
scales O +
were O +
measured O +
as O +
PSL O -
/ O -
mm2 O +
. O +

Ex O +
vivo O +
autoradiography O +
Effect O +
of O +
section O +
thickness O +
[ O -
11 O +
C O -
] O -
Nemonapride O +
( O -
143 O +
MBq O -
/ O -
4.3 O +
nmol O -
) O +
was O +
injected O +
intravenously O +
into O +
a O +
rat O +
( O -
235 O +
g O -
) O +
( O -
t O +
= O +
0 O +
min O -
, O +
29 O +
min O +
after O +
EOB O -
) O -
. O +

Fifteen O +
minutes O +
later O -
, O +
the O +
rat O +
was O +
killed O +
and O +
the O +
brain O +
was O +
removed O -
. O +

The O +
brain O +
at O +
the O +
bregma O +
( O -
17 O -
) O +
was O +
cut O +
into O +
10- O -
, O +
15- O -
, O +
20- O -
, O +
30- O -
, O +
75- O -
, O +
100- O -
, O +
and O +
150-m O +
thick O +
coronal O +
sections O +
using O +
a O +
cryotome O +
( O -
Bright O +
Instruments O +
Co. O +
Ltd. O -
, O +
UK O -
) O +
at O +
15 O -
 O -
C O -
. O +

The O +
brain O +
sections O +
were O +
thaw O -
- O -
mounted O +
on O +
glass O +
plates O +
( O -
20 O +
 O +
32 O +
mm2 O +
) O +
that O +
were O +
precoated O +
with O +
3 O -
% O +
3-aminopropyltriethoxysilane O +
in O +
acetone O -
. O +

The O +
sections O +
were O +
dried O +
on O +
a O +
hot O +
plate O +
at O +
60 O -
 O -
C O +
and O +
apposed O +
placed O +
on O +
an O +
imaging O +
plate O +
( O -
t O +
= O +
110 O +
min O -
) O -
. O +

The O +
tracer O +
uptake O +
was O +
visualized O +
as O +
described O +
above O -
. O +

Regions O +
of O +
interest O +
( O -
ROIs O -
) O +
were O +
placed O +
on O +
the O +
striatum O +
( O -
68 O +
mm2 O +
) O +
and O +
on O +
the O +
cerebral O +
cortex O +
( O -
68 O +
mm2 O +
) O -
, O +
and O +
the O +
PSL O -
/ O -
mm2 O +
values O +
were O +
measured O -
. O +

From O +
the O +
other O +
rat O +
( O -
230 O +
g O -
) O +
given O +
[ O -
11 O +
C O -
] O -
nemonapride O +
( O -
136 O +
MBq O -
/ O -
4.4 O +
nmol O -
) O -
, O +
the O +
coronal O +
brain O +
sections O +
with O +
10- O -
, O +
15- O -
, O +
20- O -
, O +
30- O -
, O +
75- O -
, O +
100- O -
, O +
and O +
150-m O +
thickness O +
were O +
also O +
obtained O +
as O +
described O +
above O -
. O +

The O +
whole O +
section O +
was O +
measured O +
for O +
the O +
radioactivity O +
( O -
cpm O -
) O +
with O +
an O +
auto O -
- O -
gamma O +
counter O +
for O +
15 O +
s. O +

The O +
effect O +
of O +
section O +
thickness O +
was O +
evaluated O -
, O +
assuming O +
equal O +
radioactivity O +
concentration O +
between O +
corresponding O +
regions O +
or O +
whole O +
brains O +
in O +
neighboring O +
sections O +
at O +
the O +
bregma O -
. O +

Relationship O +
between O +
PSL O +
and O +
radioactivity O +
on O +
the O +
brain O +
section O +
To O +
obtain O +
coronal O +
brain O +
sections O +
having O +
a O +
wider O +
range O +
of O +
radioactivity O -
, O +
ex O +
vivo O +
ARG O +
was O +
performed O +
with O +
[ O -
11 O +
C O -
] O -
SCH O +
23390 O -
, O +
which O +
is O +
more O +
concentrated O +
in O +
the O +
striatum O +
than O +
[ O -
11 O +
C O -
] O -
nemonapride O -
. O +

[ O -
11 O +
C O -
] O -
SCH O +
23390 O +
( O -
236 O +
MBq O -
/ O -
11.1 O +
nmol O +
and O +
47 O +
MBq O -
/ O -
2.2 O +
nmol O -
) O +
was O +
injected O +
intravenously O +
into O +
two O +
rats O +
( O -
t O +
= O +
0 O +
min O -
, O +
30 O +
min O +
after O +
EOB O -
) O -
. O +

The O +
rats O +
were O +
killed O +
15 O +
min O +
later O -
, O +
and O +
25 O +
pairs O +
of O +
the O +
adjacent O +
coronal O +
brain O +
sections O +
with O +
20-m O +
thickness O +
were O +
prepared O +
throughout O +
the O +
brain O +
as O +
described O +
above O -
. O +

One O +
set O +
of O +
the O +
brain O +
sections O +
was O +
applied O +
to O +
an O +
imaging O +
plate O +
until O +
decay O -
- O -
out O +
to O +
measure O +
the O +
PSL O +
for O +
the O +
whole O +
section O -
, O +
and O +
the O +
other O +
set O +
was O +
measured O +
for O +
the O +
radioactivity O +
( O -
cpm O -
) O +
with O +
an O +
auto O -
- O -
gamma O +
counter O +
( O -
t O +
= O +
102 O +
min O -
) O -
. O +

Then O +
the O +
PSL O -
/ O -
cpm O +
was O +
calculated O +
for O +
each O +
brain O +
section O -
. O +

Regional O +
brain O +
uptake O +
of O +
[ O -
11 O +
C O -
] O -
nemonapride O +
measured O +
by O +
ex O +
vivo O +
ARG O +
and O +
tissue O +
sampling O +
method O +
[ O -
11 O +
C O -
] O -
Nemonapride O +
( O -
82.696.7 O +
MBq O -
/ O -
2.15.7 O +
nmol O -
) O +
was O +
injected O +
intravenously O +
into O +
four O +
rats O +
( O -
260290 O +
g O -
) O -
. O +

They O +
were O +
killed O +
30 O +
min O +
later O +
and O +
the O +
brains O +
were O +
removed O -
. O +

From O +
a O +
half O +
brain O +
hemisphere O -
, O +
three O +
pairs O +
of O +
adjacent O +
coronal O +
brain O +
sections O +
with O +
20-m O +
thickness O +
were O +
cut O +
near O +
bregma O -
. O +

The O +
radioactivity O +
( O -
cpm O -
) O +
of O +
one O +
set O +
of O +
section O +
was O +
measured O +
with O +
an O +
auto O -
- O -
gamma O +
counter O +
and O +
converted O +
to O +
Bq O -
. O +

The O +
other O +
section O +
was O +
exposed O +
to O +
an O +
imaging O +
plate O +
to O +
measure O +
the O +
PSL O +
for O +
the O +
whole O +
section O +
as O +
described O +
above O -
, O +
and O +
the O +
PSL O -
/ O -
Bq O +
was O +
calculated O +
assuming O +
that O +
the O +
pair O +
of O +
adjacent O +
brain O +
sections O +
had O +
the O +
same O +
radioactivity O -
. O +

ROIs O +
were O +
placed O +
on O +
the O +
striatum O +
and O +
on O +
the O +
cortex O +
to O +
measure O +
the O +
PSL O +
for O +
the O +
regional O +
brain O +
section O +
volume O +
( O -
mm2 O +
 O +
0.02 O +
mm O -
) O -
, O +
which O +
was O +
converted O +
to O +
Bq O -
/ O -
mL. O +
Then O -
, O +
the O +
uptake O +
of O +
[ O -
11 O +
C O -
] O -
nemonapride O +
by O +
the O +
striatum O +
or O +
cortex O +
was O +
assessed O +
as O +
the O +
percent O +
of O +
the O +
injected O +
dose O +
per O +
milliliter O +
of O +
tissue O +
( O -
% O -
ID O -
/ O -
mL O -
) O -
. O +

From O +
the O +
other O +
hemisphere O +
the O +
striatum O +
and O +
cortex O +
were O +
dissected O +
and O +
weighed O -
, O +
and O +
the O +
radioactivity O +
of O +
the O +
tissues O +
was O +
measured O +
with O +
an O +
auto O -
- O -
gamma O +
counter O -
. O +

The O +
uptake O +
was O +
expressed O +
as O +
the O +
percent O +
of O +
the O +
injected O +
dose O +
per O +
gram O +
of O +
tissue O +
( O -
% O -
ID O -
/ O -
g O -
) O -
. O +

Effect O +
of O +
carrier O +
dose O +
To O +
measure O +
the O +
receptor B-Gene +
binding O +
capacity O +
quantitatively O +
in O +
ex O +
vivo O +
ARG O -
, O +
the O +
amount O +
of O +
injected O +
carrier O +
ligand O +
must O +
be O +
sufficiently O +
small O +
to O +
avoid O +
saturation O +
effect O -
. O +

To O +
determine O +
if O +
the O +
carrier O +
amount O +
of O +
nemonapride O +
meets O +
this O +
requirement O +
under O +
the O +
specific O +
activity O +
of O +
current O +
experimental O +
condition O -
, O +
the O +
effect O +
of O +
carrier O +
dose O +
on O +
the O +
regional O +
uptake O +
of O +
[ O -
11 O +
C O -
] O -
nemonapride O +
was O +
evaluated O +
by O +
tissue O +
sampling O -
. O +

[ O -
11 O +
C O -
] O -
Nemonapride O +
with O +
various O +
amount O +
of O +
carrier O +
( O -
10 O +
MBq O -
/ O -
0.027500 O +
nmol O -
) O +
was O +
injected O +
into O +
rats O +
( O -
227 O +
 O +
12 O +
g O -
) O -
, O +
and O +
the O +
uptake O +
( O -
% O -
ID O -
/ O -
g O -
) O +
by O +
the O +
striatum O -
, O +
cortex O -
, O +
and O +
cerebellum O +
was O +
measured O +
at O +
30 O +
min O +
after O +
the O +
injection O +
by O +
the O +
tissue O +
sampling O +
method O +
as O +
described O +
above O -
. O +

In O +
vitro O +
autoradiography O +
Effect O +
of O +
section O +
thickness O +
In O +
vitro O +
ARG O +
with O +
[ O -
11 O +
C O -
] O -
nemonapride O +
was O +
performed O +
according O +
to O +
the O +
method O +
of O +
Przedborski O +
et O +
al. O +
( O -
19 O -
) O +
with O +
a O +
slight O +
modification O -
. O +

Coronal O +
rat O +
brain O +
sections O +
with O +
10- O -
, O +
20- O -
, O +
30- O -
, O +
75- O -
, O +
100- O -
, O +
and O +
150-m O +
thickness O +
near O +
the O +
bregma O +
( O -
17 O -
) O +
were O +
prepared O -
. O +

The O +
brain O +
sections O +
were O +
pre O -
- O -
incubated O +
in O +
100 O +
mL O +
50 O +
mM O +
Tris O -
- O -
HCl O -
, O +
pH O +
7.4 O -
, O +
containing O +
120 O +
mM O +
NaCl O +
for O +
30 O +
min O +
at O +
room O +
temperature O -
. O +

Then O -
, O +
the O +
same O +
buffer O +
containing O +
100 O +
kBq O -
/ O -
mL O +
( O -
25 O +
TBq O -
/ O -
mmol O -
) O +
[ O -
11 O +
C O -
] O -
nemonapride O +
was O +
prepared O +
( O -
t O +
= O +
0 O +
min O -
, O +
29 O +
min O +
after O +
EOB O -
) O -
, O +
in O +
which O +
all O +
the O +
sections O +
were O +
incubated O +
for O +
30 O +
min O +
at O +
37 O -
 O -
C O -
. O +

After O +
being O +
washed O +
with O +
ice O -
- O -
cold O +
50 O +
mM O +
Tris O -
- O -
HCl O +
( O -
pH O +
7.4 O -
) O +
containing O +
120 O +
mM O +
NaCl O -
, O +
the O +
brain O +
sections O +
were O +
dried O +
on O +
a O +
hot O +
plate O +
at O +
60 O -
 O -
C O -
, O +
and O +
then O +
contacted O +
on O +
an O +
imaging O +
plate O +
( O -
t O +
= O +
58 O +
min O -
) O +
until O +
the O +
activity O +
decayed O +
out O +
( O -
t O +
= O +
20 O +
h O -
) O +
. O +

The O +
binding O +
of O +
11 O +
C O +
was O +
measured O +
as O +
the O +
PSL O -
/ O -
mm2 O +
over O +
the O +
ROIs O +
placed O +
in O +
the O +
same O +
manner O +
as O +
in O +
the O +
ex O +
vivo O +
ARG O -
, O +
and O +
the O +
effect O +
of O +
section O +
thickness O +
was O +
evaluated O -
. O +

The O +
other O +
set O +
of O +
the O +
brain O +
section O +
was O +
also O +
assayed O +
as O +
described O +
above O +
and O +
the O +
radioactivity O +
( O -
cpm O -
) O +
of O +
the O +
whole O +
section O +
was O +
measured O +
with O +
a O +
gamma O +
counter O -
. O +

Saturation O +
of O +
[ O -
11 O +
C O -
] O -
nemonapride O +
binding O +
The O +
buffer O +
containing O +
various O +
concentrations O +
( O -
0.156 O -
, O +
0.313 O -
, O +
0.625 O -
, O +
1.25 O -
, O +
and O +
2.50 O +
nM O -
) O +
of O +
[ O -
11 O +
C O -
] O -
nemonapride O +
( O -
21 O +
TBq O -
/ O -
mmol O -
) O +
was O +
prepared O +
( O -
t O +
= O +
0 O +
min O -
, O +
40 O +
min O +
after O +
EOB O -
) O -
, O +
and O +
six O +
brain O +
sections O +
with O +
20-m O +
thickness O +
were O +
incubated O +
for O +
30 O +
min O +
at O +
37 O -
 O -
C O +
in O +
each O +
buffer O +
as O +
described O +
above O -
. O +

Nonspecific O +
binding O +
was O +
determined O +
by O +
incubating O +
adjacent O +
six O +
sections O +
in O +
the O +
medium O +
to O +
which O +
haloperidol O +
was O +
added O +
to O +
a O +
final O +
concentration O +
of O +
20 O +
M. O +
Three O +
brain O +
sections O +
in O +
each O +
assay O +
were O +
exposed O +
on O +
an O +
imaging O +
plate O +
( O -
t O +
= O +
85 O +
min O -
) O +
to O +
measure O +
the O +
PSL O +
values O -
, O +
and O +
the O +
adjacent O +
three O +
sections O +
were O +
measured O +
for O +
radioactivity O +
( O -
cpm O -
) O -
. O +

Then O -
, O +
the O +
PSL O -
/ O -
Bq O +
calculated O +
as O +
described O +
above O +
was O +
converted O +
to O +
concentration O +
of O +
receptor B-Gene -
- O -
bound O +
ligand O +
( O -
nmol O -
/ O -
mL O +
tissue O -
) O +
using O +
the O +
specific O +
activity O +
of O +
the O +
ligand O -
. O +

Scatchard O +
plot O -
, O +
bound O +
ligand O +
( O -
nmol O -
/ O -
mL O +
tissue O -
) O +
versus O +
bound O +
ligand O -
/ O -
free O +
ligand O +
( O -
nmol O -
/ O -
mL O +
tissue O -
/ O -
nM O -
) O -
, O +
was O +
carried O +
out O -
. O +

Results O +
and O +
discussion O +
Relationship O +
between O +
PSL O +
and O +
radioactivity O +
on O +
filter O +
paper O +
Figure O +
1 O +
shows O +
the O +
PSL O +
values O +
of O +
the O +
standard O +
sample O +
on O +
filter O +
paper O -
. O +

The O +
PSL O +
values O +
were O +
linearly O +
proportional O +
to O +
the O +
11 O +
C O +
radioactivity O +
( O -
Bq O -
) O +
measured O +
with O +
a O +
radioisotope O +
calibrator O +
( O -
Fig. O +
1A O -
) O +
, O +
and O +
the O +
ratio O +
was O +
10.7 O +
PSL O -
/ O -
Bq O +
at O +
the O +
start O +
of O +
contact O -
. O +

Because O +
each O +
sample O +
presented O +
uniform O +
activity O +
distribution O +
within O +
the O +
piece O +
of O +
filter O +
paper O -
, O +
the O +
PSL O +
of O +
the O +
standard O +
sample O +
on O +
the O +
filter O +
paper O +
was O +
expressed O +
as O +
a O +
linear O +
function O +
of O +
radioactivity O +
in O +
the O +
range O +
from O +
0.4 O +
to O +
1110 O +
PSL O -
/ O -
mm2 O +
( O -
0.04104 O +
Bq O -
/ O -
mm2 O +
) O +
in O +
the O +
present O +
study O -
. O +

The O +
linearity O +
between O +
the O +
radioisotope O +
calibrator O +
and O +
the O +
well O -
- O -
type O +
gamma O +
counter O +
was O +
also O +
confirmed O -
, O +
the O +
ratio O +
being O +
40.1 O +
cpm O -
/ O -
Bq O -
. O +

Reproducibility O +
between O +
imaging O +
plates O +
When O +
the O +
11 O +
C O -
- O -
samples O +
on O +
filter O +
paper O +
and O +
standard O +
[ O -
14 O +
C O -
] O -
micro O -
- O -
scales O +
were O +
exposed O +
to O +
five O +
imaging O +
plates O -
, O +
the O +
coefficient O +
variation O +
( O -
SD O -
/ O -
mean O -
) O +
of O +
the O +
five O +
plates O +
for O +
11 O +
C O -
- O -
sensitivity O +
and O +
14 O +
C O -
- O -
sensitivity O +
was O +
2.43.2 O -
% O +
at O +
17.4164 O +
PSL O -
/ O -
mm2 O +
and O +
2.66.9 O -
% O +
at O +
5.236.6 O +
PSL O -
/ O -
mm2 O +
, O +
respectively O -
. O +

The O +
variation O +
for O +
11 O +
C O +
was O +
comparable O +
to O +
that O +
for O +
14 O +
C O -
, O +
which O +
confirmed O +
the O +
reliability O +
of O +
our O +
homemade O +
standard O +
source O +
on O +
filter O +
paper O -
. O +

Effect O +
of O +
section O +
thickness O +
Figure O +
2 O +
shows O +
representative O +
autoradiograms O +
of O +
[ O -
11 O +
C O -
] O -
nemonapride O +
by O +
ex O +
vivo O +
and O +
in O +
vitro O +
ARG O -
. O +

High O +
11 O +
C O +
density O +
was O +
observed O +
in O +
the O +
caudate O +
putamen O -
, O +
nucleus O +
accumbens O -
, O +
and O +
olfactory O +
tubercle O -
, O +
consistent O +
with O +
the O +
well O -
- O -
known O +
distribution O +
of O +
dopamine B-Gene +
D2 I-Gene +
receptors I-Gene -
. O +

Figure O +
3 O +
illustrates O +
the O +
relationship O +
between O +
brain O +
section O +
thickness O +
and O +
PSL O +
values O +
measured O +
by O +
ex O +
vivo O +
and O +
in O +
vitro O +
ARG O -
. O +

The O +
PSL O -
/ O -
mm2 O +
value O +
for O +
ex O +
vivo O +
ARG O +
was O +
not O +
linearly O +
proportional O +
to O +
the O +
slice O +
thickness O +
( O -
Fig. O +
3A O -
) O +
, O +
suggesting O +
that O +
the O +
absorption O +
of O +
radiation O +
increases O +
as O +
the O +
section O +
thickness O +
increases O -
, O +
because O +
it O +
is O +
reasonably O +
assumed O +
that O +
the O +
radioactivity O +
of O +
[ O -
11 O +
C O -
] O -
nemonapride O +
was O +
uniformly O +
distributed O +
throughout O +
the O +
thickness O +
in O +
the O +
striatum O +
and O +
cortex O +
near O +
the O +
bregma O -
. O +

On O +
the O +
other O +
hand O -
, O +
a O +
deviation O +
from O +
the O +
linear O +
function O +
was O +
much O +
larger O +
for O +
the O +
in O +
vitro O +
ARG O +
than O +
for O +
the O +
ex O +
vivo O +
ARG O -
, O +
and O +
the O +
PSL O -
/ O -
mm2 O +
values O +
reached O +
a O +
plateau O +
both O +
in O +
the O +
striatum O +
and O +
cortex O +
for O +
over O +
100-m O +
thick O +
sections O -
. O +

This O +
finding O +
is O +
probably O +
because O +
diffusion O +
of O +
the O +
11 O +
C O -
- O -
tracer O +
into O +
the O +
brain O +
tissue O +
was O +
not O +
completed O +
in O +
thick O +
brain O +
sections O +
during O +
the O +
incubation O +
period O -
, O +
and O +
the O +
binding O +
did O +
not O +
reach O +
an O +
equilibrium O +
state O -
. O +

The O +
explanation O +
was O +
approved O +
by O +
measurement O +
of O +
radioactivity O +
of O +
the O +
whole O +
brain O +
sections O +
with O +
a O +
gamma O +
counter O +
( O -
Fig. O +
3C O -
) O +
. O +

The O +
radioactivity O +
was O +
linearly O +
proportional O +
to O +
the O +
slice O +
thickness O +
in O +
ex O +
vivo O +
ARG O -
, O +
but O +
not O +
in O +
in O +
vitro O +
ARG O -
. O +

Relationship O +
between O +
PSL O +
and O +
radioactivity O +
on O +
the O +
brain O +
section O +
Figure O +
4 O +
shows O +
relationship O +
between O +
the O +
PSL O +
value O +
and O +
the O +
radioactivity O +
of O +
11 O +
C O +
on O +
the O +
whole O +
section O +
with O +
20-m O +
thickness O +
and O +
for O +
the O +
entire O +
piece O +
of O +
25-mm2 O +
filter O +
paper O +
with O +
230-m O +
thickness O -
. O +

The O +
PSL O +
was O +
found O +
to O +
be O +
linearly O +
proportional O +
to O +
the O +
radioactivity O +
within O +
the O +
brain O +
sections O +
or O +
filter O +
paper O -
, O +
although O +
the O +
coefficient O +
was O +
different O +
between O +
the O +
two O +
materials O +
because O +
of O +
different O +
thickness O +
as O +
suggested O +
from O +
Figure O +
2 O +
. O +

Therefore O -
, O +
the O +
PSL O +
value O +
can O +
be O +
converted O +
to O +
the O +
radioactivity O +
expressed O +
as O +
Bq O +
unit O -
, O +
if O +
the O +
radioactivity O +
of O +
the O +
adjacent O +
brain O +
sections O +
with O +
the O +
same O +
thickness O +
is O +
measured O +
with O +
a O +
gamma O -
- O -
counter O -
. O +

Table O +
1 O +
summarizes O +
the O +
uptake O +
of O +
[ O -
11 O +
C O -
] O -
nemonapride O +
by O +
the O +
striatum O +
and O +
cortex O +
measured O +
by O +
ex O +
vivo O +
ARG O +
and O +
by O +
the O +
tissue O +
sampling O -
. O +

Comparable O +
values O +
of O +
the O +
striatal O +
and O +
cortical O +
uptake O +
were O +
obtained O +
by O +
the O +
two O +
methods O -
, O +
nevertheless O +
the O +
technical O +
problem O +
that O +
the O +
nonstriatal O +
region O +
might O +
be O +
contaminated O +
with O +
the O +
striatal O +
sample O +
in O +
the O +
tissue O +
sampling O -
, O +
and O +
the O +
fact O +
that O +
the O +
uptake O +
of O +
[ O -
11 O +
C O -
] O -
nemonapride O +
is O +
less O +
homogeneous O +
in O +
the O +
striatum O +
than O +
in O +
the O +
cortex O -
. O +

Therefore O -
, O +
ex O +
vivo O +
ARG O +
may O +
be O +
a O +
suitable O +
method O +
to O +
quantitatively O +
evaluate O +
small O +
regions O +
such O +
as O +
nucleus O +
accumbens O +
and O +
olfactory O +
tubercles O -
. O +

Effect O +
of O +
carrier O +
dose O +
To O +
evaluate O +
the O +
carrier O +
dose O +
on O +
the O +
regional O +
brain O +
uptake O +
of O +
[ O -
11 O +
C O -
] O -
nemonapride O -
, O +
the O +
uptake O +
was O +
measured O +
by O +
tissue O +
sampling O +
method O -
. O +

As O +
shown O +
in O +
Figure O +
5 O +
, O +
at O +
the O +
dose O +
of O +
22 O +
nmol O -
/ O -
kg O +
the O +
uptake O +
was O +
slightly O +
decreased O -
, O +
though O +
not O +
statistically O +
significant O -
. O +

In O +
the O +
regional O +
brain O +
distribution O +
study O +
with O +
ex O +
vivo O +
ARG O +
and O +
tissue O +
sampling O +
( O -
Table O +
1 O -
) O +
, O +
the O +
injected O +
doses O +
were O +
320330 O +
MBq O -
/ O -
kg O +
as O +
radioactivity O +
and O +
8.120 O +
nmol O -
/ O -
kg O +
as O +
carrier O +
amounts O -
. O +

Therefore O -
, O +
the O +
injected O +
carrier O +
dose O +
of O +
[ O -
11 O +
C O -
] O -
nemonapride O +
slightly O +
exceeded O +
to O +
the O +
optimum O +
condition O -
. O +

However O -
, O +
because O +
the O +
PSL O -
/ O -
mm2 O +
values O +
measured O +
in O +
the O +
cortex O +
were O +
1214 O +
at O +
6570 O +
min O +
after O +
the O +
tracer O +
injection O +
( O -
at O +
3540 O +
min O +
after O +
the O +
exposing O +
time O -
) O +
in O +
the O +
study O +
described O +
in O +
Table O +
1 O +
, O +
the O +
injected O +
dose O +
for O +
the O +
[ O -
11 O +
C O -
] O -
nemonapride O +
can O +
be O +
reasonably O +
reduced O +
to O +
approximately O +
one O -
- O -
tenth O +
within O +
the O +
linearity O +
range O +
for O +
the O +
PSL O -
/ O -
mm2 O +
( O -
> O -
0.4 O +
in O +
Fig. O +
1 O +
) O -
, O +
although O +
statistical O +
noise O +
is O +
increased O -
. O +

Therefore O -
, O +
the O +
quantitative O +
ex O +
vivo O +
ARG O +
method O +
using O +
imaging O +
plates O +
presented O +
in O +
this O +
study O +
is O +
applicable O +
to O +
quantitative O +
measurement O +
of O +
the O +
receptor B-Gene +
binding O +
capacity O +
with O +
[ O -
11 O +
C O -
] O -
nemonapride O -
. O +

It O +
can O +
also O +
be O +
applied O +
to O +
other O +
dopamine B-Gene +
receptor I-Gene +
ligands O +
such O +
as O +
[ O -
11 O +
C O -
] O -
raclopride O -
, O +
[ O -
11 O +
C O -
] O -
N O +
-methylspiperone O -
, O +
and O +
[ O -
11 O +
C O -
] O -
SCH O +
23390 O +
( O -
data O +
not O +
shown O -
) O -
, O +
although O +
the O +
uptake O +
depends O +
in O +
the O +
ligand O -
. O +

Figure O +
5 O +
also O +
showed O +
that O +
a O +
saturable O +
uptake O +
of O +
[ O -
11 O +
C O -
] O -
nemonapride O +
was O +
observed O +
in O +
the O +
cortex O +
and O +
cerebellum O +
besides O +
in O +
the O +
striatum O -
, O +
which O +
was O +
preliminarily O +
suggested O +
by O +
a O +
previous O +
report O +
( O -
5 O -
) O +
. O +

In O +
vitro O +
[ O -
11 O +
C O -
] O -
Nemonapride O +
binding O +
to O +
the O +
striatum O +
and O +
cortex O +
In O +
previous O +
studies O +
on O +
in O +
vitro O +
binding O +
of O +
radiolabeled O +
nemonapride O +
( O -
[ O -
3 O +
H O -
] O -
YM-09151 O -
- O -
2 O -
) O +
at O +
room O +
temperature O -
, O +
the O +
tracer O +
binding O +
reached O +
equilibrium O +
after O +
90 O +
min O +
( O -
2 O -
, O +
15 O -
, O +
24 O -
) O +
. O +

In O +
our O +
preliminary O +
experiment O -
, O +
when O +
the O +
incubation O +
was O +
carried O +
out O +
at O +
37 O -
 O -
C O +
to O +
accelerate O +
the O +
equilibration O -
, O +
the O +
[ O -
11 O +
C O -
] O -
nemonapride O +
binding O +
reached O +
a O +
maximal O +
level O +
at O +
30 O +
min O +
( O -
data O +
not O +
shown O -
) O -
, O +
which O +
enabled O +
the O +
use O +
of O +
the O +
short O -
- O -
lived O +
11 O +
C O -
- O -
ligand O -
. O +

The O +
specific O +
activity O +
of O +
[ O -
11 O +
C O -
] O -
nemonapride O +
was O +
reasonably O +
high O +
( O -
25 O +
TBq O -
/ O -
mmol O +
at O +
the O +
start O +
of O +
assay O +
in O +
the O +
present O +
study O -
) O +
compared O +
with O +
conventional O +
in O +
vitro O +
ARG O +
using O +
3 O +
H O -
- O -
labeled O +
compounds O -
. O +

Thus O +
the O +
in O +
vitro O +
ARG O +
with O +
[ O -
11 O +
C O -
] O -
nemonapride O +
is O +
a O +
practicable O +
technique O -
. O +

The O +
period O +
required O +
from O +
the O +
end O +
of O +
radiosynthesis O +
to O +
the O +
exposing O +
the O +
brain O +
slice O +
to O +
imaging O +
plate O +
was O +
approximately O +
90 O +
min O -
. O +

A O +
saturation O +
binding O +
experiment O +
showed O +
a O +
specific O +
binding O +
of O +
[ O -
11 O +
C O -
] O -
nemonapride O +
to O +
the O +
striatum O +
and O +
cortex O +
( O -
Fig. O +
6A O -
) O +
. O +

Scatchard O +
analysis O +
indicated O +
a O +
Kd O +
of O +
730 O +
pM O +
and O +
an O +
apparent O +
Bmax O +
of O +
160 O +
nmol O -
/ O -
mL O +
tissue O +
in O +
the O +
striatum O +
and O +
a O +
Kd O +
of O +
1.5 O +
nM O +
and O +
a O +
Bmax O +
of O +
29 O +
nmol O -
/ O -
mL O +
tissue O +
in O +
the O +
cortex O -
. O +

The O +
Kd O +
value O +
of O +
730 O +
pM O +
for O +
the O +
striatum O +
is O +
in O +
the O +
same O +
order O +
as O +
those O +
obtained O +
with O +
in O +
vitro O +
ARG O +
by O +
Unis O +
et O +
al. O +
( O -
626 O +
pM O -
) O +
( O -
24 O -
) O +
and O +
Yokoyama O +
et O +
al. O +
( O -
315 O +
pM O -
) O +
( O -
26 O -
) O +
, O +
but O +
is O +
larger O +
than O +
those O +
( O -
2182 O +
pM O -
) O +
measured O +
by O +
the O +
membrane O +
binding O +
assay O +
( O -
1 O -
, O +
13 O -
, O +
15 O -
, O +
23 O -
) O +
or O +
with O +
in O +
vitro O +
ARG O +
( O -
2 O -
) O +
. O +

These O +
differences O +
may O +
be O +
caused O +
by O +
the O +
assay O +
conditions O +
such O +
as O +
incubation O +
time O -
, O +
temperature O -
, O +
blockers O +
used O +
to O +
evaluate O +
the O +
nonspecific O +
binding O -
, O +
other O +
medium O +
components O -
, O +
and O +
slice O +
thickness O +
in O +
ARG O -
. O +

The O +
saturation O +
kinetics O +
may O +
also O +
be O +
different O +
between O +
the O +
membrane O +
homogenate O +
and O +
the O +
brain O +
slice O -
. O +

An O +
in O +
vivo O +
saturation O +
binding O +
experiment O +
in O +
Figure O +
6 O +
revealed O +
the O +
presence O +
of O +
saturable O +
binding O +
sites O +
for O +
[ O -
11 O +
C O -
] O -
nemonapride O +
in O +
the O +
cortex O +
and O +
striatum O -
. O +

This O +
finding O +
was O +
also O +
revealed O +
by O +
an O +
ex O +
vivo O +
study O +
( O -
Fig. O +
5 O -
) O +
, O +
which O +
also O +
suggested O +
the O +
presence O +
of O +
saturable O +
binding O +
sites O +
in O +
the O +
cerebellum O -
. O +

The O +
specific O +
binding O +
evaluated O +
with O +
a O +
haloperidol O -
- O -
blockade O +
was O +
lower O +
than O +
the O +
nonspecific O +
binding O +
in O +
the O +
cortex O +
( O -
Fig. O +
6A O +
-2 O -
) O -
. O +

Kazawa O +
et O +
al. O +
( O -
13 O -
) O +
demonstrated O +
that O +
[ O -
3 O +
H O -
] O -
nemonapride O +
binding O +
in O +
the O +
cortical O +
membrane O +
was O +
displaced O +
by O +
sulpiride O +
or O +
by O +
haloperidol O -
. O +

They O +
also O +
showed O +
that O +
these O +
binding O +
sites O +
were O +
apparently O +
different O +
from O +
serotonin-2 B-Gene +
receptors I-Gene -
. O +

The O +
unknown O +
binding O +
sites O +
may O +
be O +
dopamine B-Gene +
D4 I-Gene +
receptors I-Gene -
, O +
because O +
haloperidol O -
, O +
but O +
not O +
raclopride O -
, O +
displaced O +
the O +
uptake O +
( O -
20 O -
) O +
. O +

Sigma B-Gene +
receptors I-Gene +
may O +
be O +
another O +
candidate O +
for O +
the O +
unknown O +
binding O +
sites O -
. O +

Helmeste O +
et O +
al. O +
( O -
7 O -
) O +
suggested O +
that O +
nemonapride O +
also O +
has O +
an O +
affinity O +
for O +
sigma B-Gene +
receptors I-Gene -
, O +
which O +
was O +
evaluated O +
by O +
a O +
blocking O +
study O +
with O +
a O +
selective O +
sigma B-Gene +
receptor I-Gene +
ligand O -
, O +
R O +
( O -
 O -
) O -
-N O +
- O -
( O -
3-phenyl O -
- O -
n O +
-propyl O -
) O -
-1-phenyl-2-aminopropane O +
( O -
PPAP O -
) O -
. O +

Preliminary O +
findings O +
indicated O +
that O +
the O +
[ O -
11 O +
C O -
] O -
nemonapride O +
uptake O +
was O +
reduced O +
by O +
carrier O +
nemonapride O +
or O +
by O +
haloperidol O +
in O +
the O +
striatum O -
, O +
cortex O -
, O +
and O +
cerebellum O +
of O +
the O +
mouse O +
brain O -
, O +
but O +
that O +
other O +
sigma B-Gene +
receptor I-Gene +
ligands O +
such O +
as O +
PPAP O -
, O +
( O -
+ O -
) O -
-SKF10047 O -
, O +
R O +
( O -
+ O -
) O -
-3- O -
( O -
3-hydroxyphenyl O -
) O -
-N O +
-propylpiperidine O +
hydrochloride O +
( O -
R O +
[ O -
+ O -
] O -
-3-PPP O -
) O +
and O +
NE-100 O +
( O -
22 O -
) O +
did O +
not O +
reduce O +
the O +
[ O -
11 O +
C O -
] O -
nemonapride O +
uptake O +
by O +
the O +
striatum O +
( O -
unpublished O +
data O -
) O -
. O +

The O +
in O +
vivo O +
affinity O +
of O +
the O +
[ O -
11 O +
C O -
] O -
nemonapride O +
for O +
sigma B-Gene +
receptors I-Gene +
is O +
under O +
investigation O -
. O +

So O +
far O -
, O +
we O +
confirmed O +
in O +
ex O +
vivo O +
and O +
in O +
vitro O +
experiments O +
that O +
the O +
saturable O +
binding O +
sites O +
of O +
[ O -
11 O +
C O -
] O -
nemonapride O +
are O +
present O +
in O +
the O +
cortex O +
( O -
and O +
probably O +
in O +
the O +
cerebellum O -
) O +
although O +
their O +
characteristics O +
remain O +
unknown O -
. O +

Acknowledgements O +
This O +
work O +
was O +
supported O +
by O +
a O +
Grant O -
- O -
in O -
- O -
Aid O +
for O +
Scientific O +
Research O +
( O -
B O -
) O +
No. O +
10558115 O +
from O +
the O +
Ministry O +
of O +
Education O -
, O +
Science O -
, O +
Sports O +
and O +
Culture O -
, O +
Japan O -
. O +

Perillyl O +
alcohol O +
is O +
a O +
hydroxylated O +
metabolite O +
of O +
d O +
-limonene O +
[ O -
13 O -
] O +
, O +
which O +
is O +
the O +
major O -
, O +
naturally O +
occurring O +
monoterpene O +
present O +
in O +
orange O +
peel O +
oil O -
. O +

Perillyl O +
alcohol O +
is O +
also O +
found O +
in O +
lavender O -
, O +
mints O -
, O +
and O +
celery O +
seeds O -
. O +

It O +
has O +
been O +
shown O +
that O +
d O +
-limonene O +
and O +
metabolites O +
possess O +
chemopreventative O +
and O +
chemotherapeutic O +
activity O +
against O +
human O +
malignancies O +
with O +
low O +
toxicity O +
[ O -
48 O -
] O +
. O +

d O +
-Limonene O +
is O +
extensively O +
metabolized O +
( O -
Scheme O +
1 O -
) O +
in O +
animals O +
[ O -
15 O -
] O +
and O +
in O +
humans O +
[ O -
9,10 O -
] O +
and O +
perillic O +
acid O +
and O +
dihydroperillic O +
acid O +
were O +
found O +
to O +
be O +
the O +
major O +
circulating O +
metabolites O +
[ O -
13,5,6 O -
] O +
and O +
for O +
perillyl O +
alcohol O +
[ O -
11 O -
] O +
. O +

Metabolites O +
of O +
limonene O +
with O +
intermediate O +
polarity O +
such O +
as O +
perillyl O +
alcohol O -
, O +
perillic O +
acid O +
methyl O +
ester O +
and O +
perillaldehyde O +
were O +
found O +
to O +
be O +
more O +
potent O +
inhibitors O +
of O +
isoprenylation O +
of O +
the O +
p2126 B-Gene +
kDa I-Gene +
protein I-Gene -
, O +
which O +
is O +
involved O +
in O +
cell O +
growth O +
and O +
proliferation O +
[ O -
7 O -
] O +
, O +
than O +
limonene O +
itself O -
. O +

In O +
vivo O -
, O +
perillyl O +
alcohol O +
was O +
also O +
found O +
to O +
be O +
more O +
active O +
than O +
d O +
-limonene O +
[ O -
47,1214 O -
] O +
. O +

Phillips O +
et O +
al. O +
[ O -
11 O -
] O +
conducted O +
a O +
pharmacokinetic O +
study O +
of O +
perillyl O +
alcohol O +
in O +
dogs O +
using O +
a O +
GC O -
 O -
MS O +
method O +
with O +
a O +
sensitivity O +
limit O +
of O +
0.25 O +
g O -
/ O -
ml O -
, O +
but O +
were O +
unable O +
to O +
detect O +
the O +
parent O +
drug O +
in O +
circulation O -
. O +

In O +
order O +
to O +
understand O +
the O +
pharmacokinetic O +
and O +
disposition O +
characteristics O +
of O +
perillyl O +
alcohol O -
, O +
the O +
development O +
of O +
a O +
more O +
sensitive O +
quantitation O +
assay O +
method O +
is O +
necessary O -
. O +

The O +
present O +
report O +
describes O +
a O +
sensitive O +
GC O -
 O -
MS O +
method O +
for O +
the O +
measurement O +
of O +
perillyl O +
alcohol O +
and O +
its O +
metabolites O +
in O +
plasma O +
using O +
the O +
stable O +
isotope O -
- O -
labelled O +
analogs O +
as O +
the O +
internal O +
standards O -
. O +

A O +
derivatization O +
procedure O +
is O +
also O +
used O +
to O +
facilitate O +
the O +
GC O +
separation O +
and O +
mass O +
spectrometric O +
detection O -
. O +

2 O +
Materials O +
and O +
methods O +
2.1 O +
Chemicals O +
and O +
reagents O +
( O -
S O +
) O -
- O -
( O -
 O -
) O -
-Perillyl O +
alcohol O +
( O -
POH O -
) O +
was O +
purchased O +
from O +
Aldrich O +
( O -
Milwaukee O -
, O +
WI O -
, O +
USA O -
) O -
. O +

Perillic O +
acid O +
( O -
PA O -
) O -
, O +
cis- O +
/trans- O +
dihydroperillic O +
acid O +
( O -
cis- O +
/trans- O +
DHPA O -
, O +
cis- O +
/trans- O +
4 O -
( O -
1-methylethenyl O -
) O -
cyclohexane-1-carboxylic O +
acid O -
) O -
, O +
perillyl O +
alcohol O -
- O -
d3 O +
( O -
POH O -
- O -
d3 O +
) O +
and O +
perillic O +
acid O -
- O -
d2 O +
-13 O +
C O +
( O -
13 O +
C O -
- O -
PA O -
- O -
d2 O +
) O +
( O -
Fig. O +
1 O +
) O +
were O +
synthesized O +
according O +
to O +
the O +
literature O +
method O +
[ O -
15 O -
] O +
. O +

POH O -
- O -
d3 O +
was O +
used O +
as O +
the O +
internal O +
standard O +
for O +
POH O -
, O +
whereas O +
13 O +
C O -
- O -
PA O -
- O -
d2 O +
was O +
used O +
as O +
the O +
internal O +
standard O +
for O +
PA O +
and O +
cis- O -
/ O -
trans O +
-DHPA O -
. O +

Cis- O +
and O +
trans- O +
1-carboxy-4-methylcyclohexane O +
were O +
purchased O +
from O +
Aldrich O -
. O +

The O +
chemical O +
purity O +
of O +
all O +
these O +
synthetic O +
compounds O +
as O +
well O +
as O +
the O +
isotope O +
purity O +
of O +
labeled O +
compounds O +
was O +
99 O -
% O -
. O +

N O -
,- O -
O O +
-Bis- O -
( O -
trimethylsilyl O -
) O -
silyltrifluoroacetamide O +
( O -
BSTFA O -
) O +
was O +
obtained O +
from O +
Pierce O +
( O -
Rockford O -
, O +
IL O -
, O +
USA O -
) O -
. O +

Acetonitrile O +
( O -
HPLC O +
grade O -
) O +
was O +
purchased O +
from O +
Fisher O +
Scientific O +
( O -
Pittsburgh O -
, O +
PA O -
, O +
USA O -
) O -
. O +

All O +
other O +
organic O +
solvents O +
and O +
reagents O +
purchased O +
from O +
Fisher O +
Scientific O +
were O +
of O +
reagent O +
grade O -
. O +

2.2 O +
Sample O +
extraction O +
To O +
each O +
of O +
a O +
set O +
of O +
16 O -
 O -
125-mm O +
disposable O +
tubes O +
was O +
added O +
appropriate O +
amounts O +
of O +
the O +
internal O +
standards O +
in O +
acetonitrile O +
followed O +
by O +
gentle O +
evaporation O +
of O +
the O +
solvent O +
with O +
a O +
stream O +
of O +
nitrogen O -
. O +

A O +
plasma O +
sample O +
( O -
0.5 O +
ml O +
or O +
less O -
) O +
was O +
then O +
added O +
and O +
the O +
content O +
mixed O -
. O +

The O +
sample O +
volume O +
of O +
less O +
than O +
0.5 O +
ml O +
was O +
made O +
up O +
to O +
0.5 O +
ml O +
by O +
addition O +
of O +
blank O +
mouse O +
or O +
human O +
plasma O -
. O +

Acetonitrile O +
( O -
1.0 O +
ml O -
) O +
was O +
added O +
to O +
precipitate O +
the O +
protein B-Gene -
. O +

The O +
mixture O +
was O +
centrifuged O +
at O +
500 O +
g O +
for O +
3 O +
min O -
. O +

The O +
supernatant O +
was O +
transferred O +
to O +
a O +
new O +
set O +
of O +
disposable O +
tubes O +
and O +
was O +
acidified O +
by O +
addition O +
of O +
10 O +
l O +
of O +
3 O +
M O +
HCl O -
. O +

The O +
extraction O +
was O +
accomplished O +
with O +
3 O -
 O -
2 O +
ml O +
methylene O +
chloride O +
by O +
vigorously O +
mixing O +
on O +
a O +
vortex O -
- O -
mixer O +
for O +
10 O +
s O -
, O +
followed O +
by O +
centrifugation O +
at O +
500 O +
g O +
for O +
3 O +
min O -
. O +

The O +
methylene O +
chloride O +
extracts O +
were O +
combined O +
and O +
evaporated O +
to O +
dryness O +
by O +
a O +
stream O +
of O +
N2 O +
. O +

Forty O +
l O +
of O +
60 O -
% O +
BSTFA O +
in O +
acetonitrile O +
was O +
then O +
added O -
. O +

The O +
content O +
was O +
allowed O +
to O +
stand O +
at O +
room O +
temperature O +
for O +
5 O +
min O +
before O +
analysis O +
by O +
GC O -
 O -
MS O -
. O +

2.3 O +
GC O -
 O -
MS O +
analysis O +
GC O -
 O -
MS O +
analysis O +
of O +
the O +
analytes O +
was O +
performed O +
on O +
a O +
Finnigan O +
MAT O +
ITS40 O +
( O -
Finnigan O +
MAT O -
, O +
San O +
Jose O -
, O +
CA O -
, O +
USA O -
) O +
coupled O +
to O +
a O +
3300 O -
/ O -
3400 O +
Model O +
Varian O +
gas O +
chromatograph O +
( O -
Walnut O +
Creek O -
, O +
CA O -
, O +
USA O -
) O -
. O +

The O +
gas O +
chromatograph O +
was O +
equipped O +
with O +
a O +
DB-5 O +
fused O -
- O -
silica O +
capillary O +
column O +
( O -
30 O +
m O -
 O -
0.25 O +
mm O -
) O +
wall O -
- O -
coated O +
with O +
0.25 O +
mm O +
of O +
cross O -
- O -
linked O +
95 O -
% O +
methyl- O +
and O +
5 O -
% O +
phenyl O -
- O -
polysiloxane O +
( O -
J&W O +
Scientific O -
, O +
Folsom O -
, O +
CA O -
, O +
USA O -
) O +
and O +
an O +
autosampler O +
( O -
Finnigan O +
MAT O -
) O -
. O +

Ultra O -
- O -
high O +
purity O +
helium O +
was O +
used O +
as O +
the O +
carrier O +
gas O +
with O +
a O +
head O +
pressure O +
of O +
15 O +
psi O +
( O -
ca O -
. O +

105 O +
Pa O -
) O -
. O +

The O +
injection O +
port O +
and O +
the O +
transfer O +
line O +
were O +
set O +
at O +
270 O -
 O -
C O -
. O +

The O +
oven O +
temperature O +
was O +
initiated O +
at O +
100 O -
 O -
C O +
for O +
1 O +
min O -
, O +
and O +
was O +
ramped O +
to O +
250 O -
 O -
C O +
at O +
15 O -
 O -
C O -
/ O -
min O -
, O +
then O +
increased O +
to O +
280 O -
 O -
C O +
at O +
30 O -
 O -
C O -
/ O -
min O -
. O +

The O +
column O +
was O +
held O +
at O +
250 O -
 O -
C O +
for O +
1 O +
min O -
. O +

Analysis O +
was O +
performed O +
using O +
chemical O +
ionization O +
mode O +
and O +
ammonia O +
was O +
used O +
as O +
the O +
reagent O +
gas O -
. O +

Quantitation O +
was O +
performed O +
in O +
the O +
selected O +
ion O +
monitor O +
mode O +
by O +
measuring O +
the O +
base O +
peak O +
of O +
either O +
MH+ O +
or O +
the O +
fragment O +
ions O +
characteristic O +
of O +
the O +
trimethylsilylated O +
derivatives O +
of O +
the O +
analytes O +
and O +
their O +
respective O +
internal O +
standards O -
. O +

The O +
peak O +
area O +
ratio O +
method O +
was O +
used O +
in O +
construction O +
of O +
the O +
calibration O +
curves O -
. O +

2.4 O +
13 O +
C O -
- O -
NMR O +
analysis O +
13 O +
C O -
- O -
NMR O +
spectra O +
were O +
recorded O +
on O +
either O +
a O +
Brucker O +
NR-250 O +
spectrometer O +
at O +
a O +
radio O +
frequency O +
of O +
62.89 O +
MHz O +
or O +
a O +
Brucker O +
AM-500 O +
spectrometer O +
at O +
a O +
radio O +
frequency O +
of O +
125.77 O +
MHz O +
with O +
tetramethylsilane O +
as O +
the O +
internal O +
standard O +
and O +
CDCl3 O +
as O +
the O +
solvent O -
. O +

2.5 O +
Separation O +
of O +
cis- O +
and O +
trans- O +
dihydroperillic O +
acid O +
A O +
mixture O +
of O +
synthetic O +
cis- O +
and O +
trans- O +
dihydroperillic O +
acids O +
was O +
separated O +
by O +
thin O -
- O -
layer O +
chromatography O -
. O +

The O +
mixture O +
( O -
10 O +
mg O -
) O +
was O +
dissolved O +
in O +
a O +
small O +
volume O +
of O +
CH2 O +
Cl2 O +
and O +
the O +
solution O +
was O +
applied O +
onto O +
a O +
precoated O +
silica O +
gel O +
G O +
60 O +
thin O -
- O -
layer O +
plate O +
( O -
EM O +
Merck O -
, O +
thickness O +
0.2 O +
mm O -
, O +
20 O -
 O -
20 O +
cm O -
) O -
. O +

This O +
plate O +
was O +
developed O +
ascendingly O +
with O +
50:1 O +
CH2 O +
Cl2 O +
MeOH O +
on O +
a O +
lined O +
tank O +
for O +
one O +
full O -
- O -
length O -
. O +

Under O +
UV O +
light O +
visualization O -
, O +
two O +
overlapping O +
spots O +
( O -
ca O -
. O +
50 O -
% O -
) O +
( O -
R O +
f O +
0.550.76 O -
) O +
were O +
seen O +
and O +
the O +
upper O +
portion O +
of O +
the O +
faster O -
- O -
running O +
spot O +
( O -
R O +
f O +
0.720.76 O -
) O +
was O +
scrapped O +
off O +
and O +
eluted O +
with O +
CH2 O +
Cl2 O +
. O +

The O +
collected O +
compound O +
( O -
ca O -
. O +

2 O +
mg O -
) O +
was O +
found O +
to O +
be O +
the O +
pure O +
component O +
corresponding O +
to O +
a O +
retention O +
time O +
of O +
6.3 O +
min O +
on O +
GC O -
 O -
MS O +
using O +
the O +
condition O +
as O +
described O +
above O -
. O +

The O +
lower O +
portion O +
of O +
the O +
spot O +
was O +
also O +
collected O +
and O +
GC O -
 O -
MS O +
still O +
showed O +
a O +
mixture O +
of O +
cis O -
/ O -
trans O +
-DHPA O +
with O +
retention O +
times O +
of O +
6.3 O +
and O +
6.7 O +
min O -
. O +

Attempts O +
to O +
further O +
resolve O +
these O +
components O +
were O +
unsuccessful O -
. O +

2.6 O +
Assay O +
characterization O +
and O +
validation O +
Detection O +
limit O +
was O +
measured O +
by O +
reducing O +
the O +
amount O +
of O +
each O +
analyte O +
until O +
the O +
signal O -
- O -
to O -
- O -
noise O +
equaled O +
to O +
four O -
, O +
which O +
is O +
defined O +
as O +
the O +
detection O +
limit O -
. O +

The O +
recovery O +
was O +
estimated O +
by O +
comparing O +
the O +
ratio O +
of O +
the O +
extracted O +
analytes O +
to O +
the O +
unextracted O +
internal O +
standard O +
with O +
that O +
of O +
the O +
unextracted O +
pairs O -
. O +

Within O -
- O -
run O +
precision O +
for O +
POH O -
, O +
PA O -
, O +
cis- O +
and O +
trans- O +
DHPA O +
was O +
determined O +
by O +
analyzing O +
six O +
replicates O +
at O +
each O +
concentration O +
on O +
the O +
same O +
day O -
. O +

The O +
concentrations O +
used O +
were O -
: O +
for O +
POH O +
at O +
2 O -
, O +
4 O -
, O +
20 O -
, O +
200 O +
and O +
2000 O +
ng O -
/ O -
ml O -
, O +
for O +
PA O +
at O +
40 O -
, O +
200 O -
, O +
and O +
2000 O +
ng O -
/ O -
ml O -
, O +
and O +
for O +
cis- O +
and O +
trans- O +
DHPA O +
each O +
at O +
20 O -
, O +
100 O -
, O +
and O +
1000 O +
ng O -
/ O -
ml O -
. O +

Between O -
- O -
run O +
precision O +
was O +
evaluated O +
by O +
analyzing O +
the O +
variation O +
of O +
the O +
slopes O +
of O +
six O +
standard O +
curves O +
for O +
each O +
analyte O +
obtained O +
on O +
six O +
different O +
days O -
. O +

2.7 O +
Pilot O +
animal O +
study O +
The O +
femoral O +
and O +
jugular O +
veins O +
of O +
a O +
Sprague O -
- O -
Dawley O +
rat O +
weighing O +
350 O +
g O +
were O +
cannulated O +
under O +
ether O +
anesthesia O -
. O +

Three O +
hours O +
after O +
recovery O -
, O +
the O +
animal O +
was O +
given O +
neat O +
perillyl O +
alcohol O +
( O -
ca O -
. O +

22 O +
l O -
) O +
at O +
23 O +
mg O -
/ O -
kg O +
i.v O -
. O +

via O +
the O +
femoral O +
cannula O +
over O +
30 O +
s O +
followed O +
by O +
a O +
rinse O +
of O +
0.5 O +
ml O +
normal O +
saline O -
. O +

At O +
the O +
time O +
schedule O +
of O +
0 O -
, O +
3 O -
, O +
5 O -
, O +
10 O -
, O +
30 O -
, O +
60 O -
, O +
120 O -
, O +
180 O -
, O +
240 O -
, O +
300 O -
, O +
360 O -
, O +
480 O -
, O +
720 O -
, O +
960 O -
, O +
1200 O -
, O +
and O +
1440 O +
min O +
following O +
dosing O -
, O +
approximately O +
0.2 O +
ml O +
of O +
heparinized O +
blood O +
each O +
was O +
withdrawn O +
from O +
the O +
jugular O +
vein O +
cannula O -
. O +

Plasma O +
was O +
separated O +
by O +
centrifugation O -
. O +

An O +
aliquot O +
of O +
each O +
plasma O +
sample O +
was O +
appropriately O +
diluted O +
with O +
blank O +
rat O +
plasma O +
to O +
make O +
up O +
to O +
0.5 O +
ml O -
. O +

Under O +
this O +
condition O -
, O +
the O +
measured O +
concentrations O +
were O +
in O +
the O +
range O +
of O +
the O +
calibration O -
- O -
curve O -
. O +

To O +
each O +
plasma O +
sample O +
was O +
added O +
200 O +
ng O +
of O +
the O +
internal O +
standard O +
followed O +
by O +
an O +
addition O +
of O +
1.0 O +
ml O +
acetonitrile O +
to O +
precipitate O +
the O +
protein B-Gene -
. O +

The O +
mixture O +
was O +
centrifuged O +
at O +
2000 O +
g O +
for O +
5 O +
m. O +
The O +
supernatant O +
was O +
removed O +
and O +
frozen O +
at O +
20 O -
 O -
C O +
until O +
analysis O -
. O +

2.8 O +
Preliminary O +
clinical O +
study O +
The O +
clinical O +
study O +
is O +
a O +
part O +
of O +
an O +
ongoing O +
Phase O +
I O +
evaluation O +
of O +
POH O +
as O +
a O +
chemopreventative O +
agent O +
at O +
the O +
Cleveland O +
Clinic O +
Foundation O -
. O +

The O +
Phase O +
I O +
protocol O +
was O +
approved O +
by O +
the O +
Institution O +
Review O +
Board O +
( O -
IRB O -
) O +
at O +
the O +
Cleveland O +
Clinic O +
Foundation O -
. O +

Subjects O +
with O +
a O +
personal O +
history O +
of O +
AJCC O +
Stage O +
I O -
 O -
IIIa O +
breast O +
cancer O +
who O +
have O +
undergone O +
definitive O +
resection O +
with O +
curative O +
intent O +
and O +
who O +
have O +
completed O +
all O +
adjuvant O +
radiation O +
therapy O -
, O +
chemotherapy O -
, O +
and O +
reversible O +
hormone O +
therapy O +
are O +
eligible O +
to O +
enroll O +
in O +
this O +
study O -
. O +

All O +
subjects O +
were O +
in O +
good O +
general O +
health O +
with O +
adequate O +
major O +
organ O +
functions O +
and O +
ECOG O +
Performance O +
Status O +
of O +
01 O -
. O +

Patients O +
were O +
treated O +
at O +
the O +
Cleveland O +
Clinic O +
Foundation O -
, O +
Cleveland O -
, O +
Ohio O -
. O +

The O +
current O +
study O +
was O +
limited O +
to O +
patients O +
at O +
the O +
first O +
of O +
the O +
five O +
dose O +
levels O -
. O +

Dose O +
at O +
0.5 O +
g O -
/ O -
m2 O +
was O +
given O +
as O +
capsules O -
, O +
which O +
were O +
supplied O +
by O +
the O +
National O +
Cancer O +
Institute O -
. O +

Following O +
dosing O -
, O +
blood O +
samples O +
were O +
drawn O +
at O +
0 O +
( O -
predose O -
) O -
, O +
0.25 O -
, O +
0.5 O -
, O +
0.75 O -
, O +
1.0 O -
, O +
1.5 O -
, O +
2.0 O -
, O +
3.0 O -
, O +
4.0 O -
, O +
6.0 O -
, O +
8.0 O -
, O +
10.0 O -
, O +
and O +
24 O +
h. O +
Plasma O +
was O +
separated O +
from O +
red O +
blood O +
cells O +
by O +
centrifugation O +
and O +
kept O +
frozen O +
at O +
20 O -
 O -
C O +
until O +
shipment O -
. O +

All O +
frozen O +
specimens O +
were O +
then O +
shipped O +
in O +
a O +
dry O -
- O -
ice O +
container O +
( O -
overnight O -
) O +
to O +
Dr. O +
Chan O -
's O +
Laboratory O +
at O +
the O +
Ohio O +
State O +
University O -
. O +

Plasma O +
samples O +
were O +
analyzed O +
in O +
the O +
same O +
manner O +
as O +
the O +
rat O +
plasma O +
samples O -
. O +

2.9 O +
Quality O +
control O +
and O +
stability O +
Two O +
sets O +
of O +
spiked O +
plasma O +
samples O +
consisting O +
of O +
three O +
concentration O +
levels O -
, O +
20 O -
, O +
50 O -
, O +
and O +
100 O +
ng O -
/ O -
ml O +
of O +
POH O -
, O +
PA O -
, O +
cis- O +
/trans- O +
DHPA O +
were O +
prepared O +
and O +
frozen O +
at O +
20 O -
 O -
C O -
. O +

One O +
frozen O +
set O +
was O +
sent O +
to O +
the O +
Laboratory O +
at O +
the O +
Cleveland O +
Clinic O +
Foundation O +
by O +
overnight O +
courier O +
service O +
in O +
dry O -
- O -
ice O -
. O +

After O +
storage O +
for O +
approximately O +
one O +
week O +
at O +
20 O -
 O -
C O -
, O +
the O +
same O +
samples O +
were O +
returned O +
by O +
courier O +
service O +
to O +
the O +
Ohio O +
State O +
University O +
Laboratory O -
. O +

Another O +
set O +
of O +
samples O +
were O +
maintained O +
frozen O +
at O +
the O +
Ohio O +
State O +
University O +
Laboratory O +
for O +
the O +
same O +
duration O +
until O +
analysis O -
. O +

Drug O +
and O +
metabolite O +
levels O +
were O +
analyzed O +
in O +
these O +
two O +
sets O +
of O +
samples O +
at O +
the O +
same O +
time O +
and O +
the O +
results O +
were O +
compared O -
. O +

3 O +
Results O +
3.1 O +
Analysis O +
of O +
perillyl O +
alcohol O +
and O +
its O +
metabolites O +
The O +
GC O -
 O -
MS O +
mass O +
spectra O +
of O +
POH O -
, O +
PA O +
and O +
cis- O +
/trans- O +
DHPA O +
and O +
their O +
internal O +
standards O -
, O +
POH O -
- O -
d3 O +
and O +
13 O +
C O -
- O -
PA O -
- O -
d2 O +
are O +
shown O +
in O +
Fig. O +
1 O +
. O +

As O +
shown O -
, O +
silylated O +
POH O +
and O +
its O +
internal O +
standard O +
each O +
showed O +
the O +
base O +
peak O +
at O +
m O -
/ O -
z O +
135 O +
and O +
138 O +
corresponding O +
to O +
their O +
C O -
 O -
O O +
cleavages O -
. O +

MH+ O +
ions O +
as O +
their O +
TMS O +
derivatives O +
at O +
m O -
/ O -
z O +
239 O +
and O +
m O -
/ O -
z O +
242 O -
, O +
respectively O -
, O +
were O +
detected O +
for O +
PA O +
and O +
13 O +
C O -
- O -
PA O -
- O -
d2 O +
as O +
the O +
base O +
peak O -
, O +
and O +
also O +
for O +
cis- O +
/trans- O +
DHPA O +
at O +
m O -
/ O -
z O +
241 O +
at O +
55 O -
% O +
relative O +
abundance O -
. O +

These O +
ions O +
were O +
used O +
for O +
subsequent O +
quantitation O -
. O +

On O +
this O +
basis O -
, O +
a O +
typical O +
set O +
of O +
GC O +
mass O +
chromatograms O +
of O +
human O +
and O +
rat O +
plasma O +
extracts O +
is O +
shown O +
in O +
Fig. O +
2 O +
. O +

As O +
shown O -
, O +
all O +
analytes O +
were O +
detected O +
as O +
symmetrical O +
peaks O +
and O +
cis- O +
and O +
trans- O +
DHPA O +
were O +
well O +
resolved O -
. O +

The O +
retention O +
times O +
of O +
the O +
analytes O +
were O -
: O +
POH O -
/ O -
POH O -
- O -
d3 O +
at O +
6.2 O +
min O -
, O +
PA O -
/ O -
13 O +
C O -
- O -
PA O -
- O -
d2 O +
at O +
7.3 O +
min O -
, O +
cis- O +
DHPA O +
at O +
6.3 O +
min O -
, O +
and O +
trans- O +
DHPA O +
at O +
6.7 O +
min O -
. O +

The O +
assignments O +
of O +
cis- O +
and O +
trans- O +
DHPA O +
are O +
described O +
below O +
and O +
coincided O +
with O +
those O +
of O +
Phillips O +
et O +
al. O +
[ O -
11 O -
] O +
. O +

No O +
interference O +
peaks O +
at O +
the O +
selected O +
ion O +
regions O +
were O +
found O +
in O +
the O +
human O +
or O +
rat O +
plasma O +
blank O -
, O +
except O +
for O +
low O +
levels O +
of O +
signal O +
contributed O +
by O +
the O +
internal O +
standards O -
. O +

These O +
interference O +
contributions O +
were O +
due O +
to O +
incomplete O +
isotope O +
labeling O +
and O +
were O +
all O +
< O -
2 O -
% O -
. O +

Thus O -
, O +
the O +
ions O +
monitored O +
at O +
m O -
/ O -
z O +
135 O -
, O +
138 O -
, O +
239 O -
, O +
242 O +
and O +
241 O +
were O +
considered O +
to O +
be O +
highly O +
specific O +
and O +
sensitive O +
for O +
detecting O +
POH O +
and O +
its O +
metabolites O -
. O +

3.2 O +
Assignments O +
of O +
cis- O +
and O +
trans- O +
DHPA O +
Phillips O +
et O +
al. O +
[ O -
11 O -
] O +
using O +
GC O -
 O -
MS O +
method O +
with O +
electron O -
- O -
impact O +
ionization O +
partially O +
resolved O +
the O +
underivatized O +
cis- O +
and O +
trans- O +
DHPA O -
. O +

On O +
the O +
basis O +
of O +
the O +
different O +
mass O +
spectral O +
fragmentation O +
patterns O +
of O +
these O +
two O +
isomers O +
augmented O +
by O +
a O +
quantum O +
mechanical O +
calculation O +
to O +
correlate O +
the O +
configuration O +
and O +
mass O +
fragmentation O +
preference O -
, O +
they O +
assigned O +
the O +
smaller O +
component O +
with O +
a O +
shorter O +
retention O +
time O +
as O +
the O +
cis- O +
isomer O +
and O +
the O +
larger O +
slower O -
- O -
eluting O +
component O +
as O +
the O +
trans- O +
isomer O -
. O +

Since O +
we O +
employed O +
derivatization O +
in O +
our O +
GC O -
 O -
MS O +
assay O -
, O +
direct O +
correlation O +
of O +
our O +
system O +
with O +
those O +
of O +
Philips O +
et O +
al. O +
was O +
difficult O -
. O +

Therefore O -
, O +
we O +
resorted O +
to O +
use O +
an O +
alternative O +
method O +
for O +
the O +
assignment O +
of O +
these O +
isomers O -
. O +

Using O +
thin O +
layer O +
chromatographic O +
separation O -
, O +
we O +
were O +
able O +
to O +
partially O +
resolve O +
the O +
two O +
isomers O -
. O +

The O +
faster O +
running O +
spot O +
was O +
enriched O +
and O +
accumulated O -
. O +

The O +
GC O -
 O -
MS O +
showed O +
that O +
the O +
enriched O +
component O +
had O +
a O +
retention O +
time O +
of O +
6.3 O +
min O -
. O +

The O +
H O -
- O -
decoupled O +
13 O +
C O -
- O -
NMR O +
spectrum O +
of O +
the O +
synthetic O +
mixture O +
of O +
cis- O +
and O +
trans- O +
DHPA O +
showed O +
sets O +
of O +
doublets O +
at O +
180.97 O +
and O +
181.65 O +
ppm O +
corresponding O +
to O +
the O +
-COOH O +
signals O -
, O +
at O +
149.76 O +
and O +
149.96 O +
ppm O +
corresponding O +
to O +
C-1 O -
, O +
at O +
108.54 O +
and O +
108.75 O +
ppm O +
corresponding O +
to O +
C-2 O -
, O +
at O +
44.15 O +
and O +
44.55 O +
ppm O +
corresponding O +
to O +
C-4 O -
, O +
at O +
39.37 O +
and O +
42.98 O +
ppm O +
corresponding O +
to O +
C-1 O -
, O +
and O +
at O +
above O +
40 O +
ppm O +
for O +
the O +
remaining O +
carbons O +
and O +
the O +
side O +
chain O +
methyl O -
. O +

The O +
carbon O +
chemical O +
shift O +
assignments O +
were O +
based O +
on O +
the O +
H O -
- O -
coupling O -
, O +
H O -
- O -
decoupling O +
data O -
, O +
and O +
comparison O +
with O +
known O +
assignments O +
of O +
several O +
monoterpenes O +
and O +
cyclohexane O +
systems O +
[ O -
1618 O -
] O +
. O +

However O -
, O +
the O +
H O -
- O -
decoupled O +
13 O +
C O -
- O -
NMR O +
spectrum O +
of O +
the O +
above O +
described O +
enriched O +
component O +
failed O +
to O +
show O +
signals O +
with O +
adequate O +
intensity O +
at O +
the O +
downfield O +
region O +
( O -
180 O +
ppm O -
) O +
but O +
signals O +
above O +
120 O +
ppm O +
were O +
clearly O +
discernible O +
with O +
unequal O +
intensity O -
, O +
consistent O +
with O +
the O +
enrichment O -
. O +

Based O +
on O +
the O +
cyclohexanol O +
system O -
, O +
chemical O +
shift O +
of O +
C-1 O +
appears O +
to O +
be O +
most O +
sensitive O +
to O +
cis- O +
/trans- O +
isomerism O +
[ O -
18 O -
] O +
. O +

Thus O -
, O +
13 O +
C O -
- O -
NMR O +
spectra O +
of O +
cis- O +
and O +
trans- O +
1,4-methyl O +
cyclohexanol O +
show O +
C-1 O +
at O +
66.2 O +
and O +
70.0 O +
ppm O -
, O +
respectively O -
, O +
and O +
cis- O +
and O +
trans- O +
1,4-t O -
- O -
butylcyclohexanol O +
show O +
C-1 O +
at O +
65.0 O +
and O +
70.4 O +
ppm O -
, O +
respectively O -
. O +

In O +
both O +
cases O +
C-1s O +
for O +
the O +
cis- O +
isomer O +
are O +
several O +
ppm O +
upfield O +
from O +
the O +
trans- O +
isomer O -
. O +

The O +
enriched O +
DHPA O +
isomer O +
showed O +
only O +
a O +
singlet O +
at O +
39.36 O +
ppm O +
of O +
C-1 O +
with O +
the O +
more O +
downfield O +
signal O +
missing O -
. O +

This O +
suggests O +
that O +
the O +
enriched O +
DHPA O +
isomer O +
may O +
be O +
the O +
cis- O +
isomer O -
. O +

This O +
possibility O +
was O +
further O +
supported O +
by O +
examination O +
of O +
the O +
13 O +
C O -
- O -
NMR O +
spectra O +
of O +
synthetic O +
cis- O +
and O +
trans- O +
1-carboxyl-4-methylcyclohexanes O +
which O +
showed O +
C-1 O +
chemical O +
shifts O +
at O +
31.32 O +
and O +
34.21 O +
ppm O -
, O +
respectively O -
. O +

Again O -
, O +
the O +
C-1 O +
of O +
cis- O +
isomer O +
shows O +
nearly O +
3 O +
ppm O +
upfield O +
from O +
that O +
of O +
the O +
trans- O +
isomer O -
. O +

In O +
order O +
to O +
correlate O +
the O +
GC O -
 O -
MS O +
retention O +
times O +
of O +
the O +
silyl O +
derivatives O +
of O +
these O +
cyclohexane O +
isomers O +
with O +
their O +
stereochemistry O -
, O +
cis- O +
and O +
trans- O +
1-carboxyl-4-methylcyclohexane O +
were O +
silylated O +
with O +
BSTFA O -
. O +

The O +
GC O -
 O -
MS O +
showed O +
that O +
the O +
cis- O +
isomer O +
gave O +
a O +
retention O +
time O +
of O +
4.12 O +
min O +
while O +
the O +
trans- O +
isomer O +
gave O +
a O +
retention O +
time O +
of O +
4.28 O +
min O +
using O +
the O +
similar O +
temperature O +
programming O +
and O +
column O +
as O +
those O +
of O +
DHPA O -
. O +

On O +
this O +
basis O -
, O +
it O +
was O +
concluded O +
that O +
the O +
DHPA O +
isomer O +
with O +
the O +
shorter O +
retention O +
time O +
was O +
the O +
cis- O +
isomer O +
and O +
that O +
with O +
the O +
longer O +
retention O +
time O +
was O +
the O +
isomer O +
with O +
trans- O +
configuration O -
. O +

Interestingly O -
, O +
the O +
assignment O +
appeared O +
to O +
be O +
the O +
same O +
as O +
those O +
of O +
Philips O +
et O +
al. O +
[ O -
11 O -
] O +
, O +
based O +
on O +
the O +
relative O +
retention O +
times O +
of O +
the O +
underivatized O +
compounds O +
and O +
the O +
relative O +
amount O +
of O +
the O +
DHPA O +
found O +
as O +
metabolite O +
in O +
vivo O -
. O +

3.3 O +
Within O -
- O -
run O +
validation O +
When O +
plotting O +
the O +
peak O +
area O +
ratios O +
between O +
the O +
analyte O +
and O +
the O +
internal O +
standard O +
against O +
the O +
added O +
concentrations O +
of O +
the O +
analytes O +
a O +
linear O +
relationship O +
was O +
obtained O +
within O +
the O +
concentration O +
ranges O +
monitored O +
for O +
all O +
analytes O -
. O +

In O +
both O +
human O +
and O +
rat O +
plasma O -
, O +
for O +
POH O +
linearity O +
was O +
demonstrated O +
from O +
2 O +
to O +
2000 O +
ng O -
/ O -
ml O -
, O +
for O +
PA O +
and O +
trans- O +
DHPA O +
from O +
10 O +
to O +
1000 O +
ng O -
/ O -
ml O -
, O +
and O +
for O +
cis- O +
DHPA O +
20 O +
to1000 O +
ng O -
/ O -
ml O -
. O +

The O +
routine O +
sensitivity O +
limit O +
was O +
found O +
to O +
be O +
2 O +
ng O -
/ O -
ml O +
for O +
POH O -
, O +
10 O +
ng O -
/ O -
ml O +
for O +
PA O +
and O +
trans- O +
DHPA O -
, O +
and O +
20 O +
ng O -
/ O -
ml O +
for O +
cis- O +
DHPA O -
. O +

The O +
within O -
- O -
run O +
validation O +
data O +
for O +
POH O +
and O +
metabolites O +
in O +
rat O +
and O +
human O +
plasma O +
are O +
shown O +
in O +
Table O +
1 O +
. O +

Also O +
shown O +
in O +
the O +
same O +
table O +
are O +
the O +
accuracy O +
data O -
. O +

As O +
shown O -
, O +
the O +
% O +
C.V. O +
values O +
ranged O +
from O +
0.5 O +
to O +
8 O -
% O +
with O +
the O +
majority O +
falling O +
below O +
5 O -
% O +
and O +
a O +
mean O +
accuracy O +
value O +
of O +
98.6 O -
% O -
. O +

3.4 O +
Between O -
- O -
run O +
validation O +
The O +
between O -
- O -
run O +
variation O +
for O +
POH O +
in O +
human O +
plasma O +
was O +
5.5 O -
% O +
and O +
6.3 O -
% O +
in O +
rat O +
plasma O +
as O +
measured O +
by O +
the O +
slopes O +
of O +
six O +
calibration O +
curves O +
in O +
each O +
medium O +
at O +
six O +
different O +
occasions O +
( O -
Table O +
2 O +
) O -
. O +

At O +
each O +
case O -
, O +
the O +
mean O +
intercept O +
is O +
less O +
than O +
2 O +
ng O -
/ O -
ml O +
equivalent O -
. O +

The O +
between O -
- O -
run O +
C.V.s O +
for O +
PA O +
by O +
similar O +
measurements O +
were O +
5.5 O -
% O +
in O +
human O +
plasma O +
and O +
3.4 O -
% O +
in O +
rat O +
plasma O -
, O +
all O +
n O +
= O -
6 O -
. O +

The O +
between O -
- O -
run O +
C.V.s O +
for O +
cis- O +
DHPA O +
in O +
human O +
and O +
rat O +
plasma O +
were O +
6.9 O -
% O +
and O +
5.1 O -
% O -
, O +
respectively O +
( O -
n O +
= O -
6 O -
) O -
. O +

The O +
between O -
- O -
run O +
C.V.s O +
for O +
trans- O +
DHPA O +
were O +
5.0 O +
and O +
6.3 O -
% O -
, O +
respectively O +
( O -
n O +
= O -
6 O -
) O +
( O -
Table O +
2 O +
) O -
. O +

In O +
these O +
cases O -
, O +
the O +
mean O +
intercepts O +
for O +
the O +
calibration O +
curves O +
of O +
the O +
metabolites O +
were O +
less O +
than O +
5 O +
ng O -
/ O -
ml O +
analyte O +
equivalent O -
. O +

3.5 O +
Recovery O +
and O +
quality O +
control O +
The O +
recovery O +
values O +
of O +
POH O -
, O +
PA O -
, O +
cis- O +
and O +
trans- O +
DHPA O +
from O +
the O +
entire O +
procedure O +
were O -
: O +
98 O -
% O -
, O +
59 O -
% O -
, O +
64 O -
% O +
and O +
72 O -
% O +
in O +
human O +
plasma O +
and O +
90 O -
% O -
, O +
77 O -
% O -
, O +
69 O -
% O +
and O +
76 O -
% O +
in O +
rat O +
plasma O -
, O +
respectively O -
. O +

There O +
was O +
less O +
than O +
3 O -
% O +
variation O +
for O +
POH O +
and O +
metabolite O +
levels O +
in O +
plasma O +
samples O +
kept O +
at O +
20 O -
 O -
C O +
over O +
the O +
course O +
of O +
four O +
weeks O +
and O +
there O +
was O +
no O +
appreciable O +
difference O +
in O +
the O +
samples O +
tested O +
through O +
mailing O +
via O +
the O +
courier O +
service O -
. O +

3.6 O +
Preliminary O +
pharmacokinetics O +
of O +
perillyl O +
alcohol O +
and O +
its O +
metabolites O +
in O +
a O +
rat O +
Fig. O +
3 O +
shows O +
a O +
plasma O +
concentration O -
 O -
time O +
profile O +
of O +
POH O +
and O +
metabolites O +
in O +
the O +
rat O +
given O +
POH O +
at O +
23 O +
mg O -
/ O -
kg O +
i.v O -
. O +

As O +
shown O -
, O +
POH O +
was O +
detected O +
in O +
circulation O +
up O +
to O +
360 O +
min O +
with O +
the O +
initial O +
concentration O +
at O +
2089 O +
ng O -
/ O -
ml O -
. O +

The O +
concentrations O +
declined O +
biexponentially O +
with O +
a O +
terminal O +
half O -
- O -
life O +
of O +
approximately O +
135 O +
min O -
. O +

PA O +
appeared O +
in O +
plasma O +
in O +
the O +
first O +
sample O +
at O +
3 O +
min O +
and O +
peaked O +
at O +
10 O +
at O +
8893 O +
ng O -
/ O -
ml O +
and O +
declined O +
approximately O +
monoexponentially O +
to O +
about O +
35 O +
ng O -
/ O -
ml O +
at O +
720 O +
min O -
. O +

Cis O +
- O +
and O +
trans- O +
DHPA O +
appeared O +
in O +
plasma O +
at O +
about O +
10 O +
min O +
and O +
peaked O +
at O +
about O +
60 O +
min O +
and O +
also O +
declined O +
monoexponentially O -
. O +

The O +
plasma O +
levels O +
of O +
the O +
trans- O +
metabolite O +
were O +
significantly O +
higher O +
than O +
those O +
of O +
the O +
cis- O +
isomer O -
. O +

An O +
unknown O +
metabolite O -
, O +
labeled O +
as O +
M2 O -
, O +
was O +
also O +
detected O +
in O +
plasma O +
at O +
high O +
levels O +
and O +
this O +
metabolite O +
has O +
the O +
same O +
m O -
/ O -
z O +
value O +
as O +
PA O +
but O +
with O +
a O +
retention O +
time O +
of O +
8.3 O +
min O -
. O +

M2 O +
appeared O +
in O +
plasma O +
at O +
3 O +
min O +
at O +
2070 O +
ng O -
/ O -
ml O +
PA O +
equivalent O +
and O +
peaked O +
at O +
10 O +
min O +
at O +
levels O +
over O +
6000 O +
ng O -
/ O -
ml O -
. O +

Although O +
the O +
initial O +
levels O +
of O +
this O +
metabolite O +
were O +
slightly O +
lower O +
than O +
those O +
of O +
PA O -
, O +
the O +
levels O +
after O +
2 O +
h O +
exceeded O +
those O +
of O +
PA O +
after O +
and O +
were O +
detectable O +
even O +
at O +
1440 O +
min O -
. O +

The O +
plasma O +
half O -
- O -
life O +
was O +
approximately O +
3 O +
h. O +
3.7 O +
Preliminary O +
pharmacokinetics O +
of O +
perillyl O +
alcohol O +
and O +
its O +
metabolites O +
in O +
a O +
patient O +
The O +
plasma O +
concentration O -
 O -
time O +
profiles O +
of O +
POH O +
and O +
its O +
metabolites O +
were O +
measured O +
in O +
a O +
patient O +
who O +
received O +
a O +
p.o O -
. O +

dose O +
at O +
500 O +
mg O -
/ O -
m2 O +
and O +
the O +
results O +
are O +
shown O +
in O +
Fig. O +
4 O +
. O +

As O +
shown O -
, O +
POH O -
, O +
PA O -
, O +
cis- O +
and O +
trans- O +
DHPA O +
were O +
all O +
detectable O +
in O +
plasma O -
. O +

POH O +
was O +
detectable O +
at O +
3.5 O +
ng O -
/ O -
ml O +
at O +
0.75 O +
h O +
and O +
peaked O +
at O +
5.0 O +
ng O -
/ O -
ml O +
at O +
1.5 O +
h. O +
The O +
levels O +
then O +
declined O +
monoexponentially O +
with O +
a O +
half O -
- O -
life O +
of O +
approximately O +
2.3 O +
h. O +
The O +
AUC O +
value O +
was O +
22 O +
ng O -
/ O -
ml O +
h. O +
The O +
most O +
abundant O +
metabolite O +
in O +
circulation O +
was O +
PA O +
which O +
peaked O +
slowly O +
at O +
11400 O +
ng O -
/ O -
ml O +
at O +
about O +
1.5 O +
h. O +
PA O +
was O +
formed O +
rapidly O +
following O +
the O +
POH O +
administration O -
, O +
and O +
remained O +
at O +
a O +
steady O -
- O -
state O +
for O +
12 O +
h O +
before O +
declining O -
. O +

The O +
level O +
then O +
declined O +
monoexponentially O +
to O +
about O +
40 O +
ng O -
/ O -
ml O +
at O +
8 O +
h O +
and O +
became O +
undetectable O +
thereafter O -
. O +

Similar O +
to O +
the O +
case O +
in O +
the O +
rat O -
, O +
cis- O +
DHPA O +
levels O +
were O +
lower O +
than O +
those O +
of O +
trans O -
. O +

Two O +
previously O +
undescribed O +
metabolites O +
were O +
detected O +
in O +
circulation O -
. O +

M1 O +
gave O +
a O +
retention O +
time O +
of O +
7.7 O +
min O +
and O +
M2 O +
gave O +
a O +
retention O +
of O +
8.3 O +
min O -
, O +
which O +
appears O +
identical O +
to O +
the O +
one O +
described O +
in O +
the O +
rat O -
. O +

Both O +
of O +
these O +
metabolites O +
gave O +
the O +
MH+ O +
ion O +
identical O +
to O +
that O +
of O +
PA O -
. O +

Levels O +
of O +
M2 O +
were O +
lower O +
than O +
those O +
of O +
PA O +
but O +
higher O +
than O +
those O +
of O +
M1 O -
. O +

M2 O +
peaked O +
at O +
over O +
1000 O +
ng O -
/ O -
ml O +
at O +
3 O +
h O -
, O +
and O +
M1 O +
peaked O +
at O +
76 O +
ng O -
/ O -
ml O +
at O +
1 O +
h. O +
4 O +
Discussion O +
Previous O +
GC O +
and O +
GC O -
 O -
MS O +
methods O +
failed O +
to O +
detect O +
POH O +
in O +
plasma O +
presumably O +
because O +
of O +
inadequate O +
sensitivity O +
[ O -
11 O -
] O +
. O +

The O +
reason O +
for O +
the O +
low O +
sensitivity O +
may O +
be O +
due O +
to O +
the O +
use O +
of O +
electron O +
impact O +
mass O +
spectrometry O +
for O +
detection O -
. O +

Excess O +
fragmentation O +
under O +
the O +
EI O +
condition O +
significantly O +
reduced O +
the O +
assay O +
sensitivity O -
. O +

Moreover O -
, O +
POH O +
and O +
its O +
metabolites O +
such O +
as O +
PA O +
are O +
still O +
rather O +
polar O -
. O +

Tailing O +
of O +
their O +
GC O +
peaks O +
may O +
also O +
reduce O +
the O +
assay O +
sensitivity O -
. O +

The O +
present O +
method O +
used O +
a O +
soft O +
ammonia O +
chemical O +
ionization O -
, O +
which O +
could O +
reduce O +
fragmentation O +
and O +
increase O +
the O +
relative O +
abundance O +
of O +
the O +
ion O -
. O +

Additionally O -
, O +
we O +
also O +
found O +
that O +
BSTFA O +
derivatization O +
of O +
POH O +
and O +
its O +
metabolites O +
reduced O +
tailing O +
and O +
further O +
reduced O +
fragmentation O +
and O +
enhanced O +
sensitivity O -
. O +

Another O +
improvement O +
of O +
our O +
analytical O +
method O +
was O +
to O +
use O +
the O +
stable O +
isotopically O +
labeled O +
POH O +
and O +
PA O +
as O +
the O +
internal O +
standard O +
that O +
provided O +
the O +
excellent O +
C.V.s O +
obtained O -
. O +

Thus O -
, O +
the O +
current O +
assay O +
provided O +
more O +
than O +
a O +
hundred O -
- O -
fold O +
improvement O +
in O +
sensitivity O +
over O +
the O +
previous O +
GC O -
 O -
MS O +
method O -
, O +
and O +
made O +
it O +
possible O +
to O +
detect O +
circulating O +
POH O +
following O +
POH O +
administration O -
. O +

The O +
use O +
of O +
derivatization O +
and O +
a O +
capillary O +
column O +
in O +
this O +
method O +
also O +
permitted O +
the O +
complete O +
separation O +
of O +
cis- O +
and O +
trans- O +
DHPA O +
( O -
Fig. O +
3 O +
) O -
. O +

The O +
earlier O +
eluting O +
peak O +
( O -
6.3 O +
min O -
) O +
was O +
assigned O +
to O +
be O +
the O +
cis- O +
isomer O -
, O +
based O +
on O +
the O +
NMR O +
method O +
and O +
this O +
assignment O +
is O +
identical O +
to O +
those O +
of O +
Philip O +
et O +
al. O +
[ O -
11 O -
] O +
who O +
assigned O +
their O +
earlier O +
eluting O +
component O +
in O +
the O +
partially O +
resolved O +
pair O +
as O +
the O +
cis- O +
isomer O -
. O +

Both O +
the O +
preliminary O +
rat O +
and O +
human O +
pharmacokinetic O +
data O +
show O +
that O +
POH O +
was O +
detectable O +
in O +
circulation O +
for O +
the O +
first O +
time O +
following O +
POH O +
administration O -
. O +

Metabolites O +
of O +
POH O +
were O +
detected O +
in O +
high O +
levels O +
in O +
both O +
rat O +
and O +
human O +
plasma O -
. O +

PA O +
appeared O +
very O +
rapidly O +
in O +
circulation O +
and O +
rose O +
to O +
high O +
concentrations O -
, O +
suggesting O +
that O +
POH O +
underwent O +
rapid O +
metabolism O -
. O +

Both O +
cis- O +
and O +
trans- O +
DHPA O +
were O +
unequivocally O +
detected O +
in O +
the O +
human O +
and O +
in O +
the O +
rat O +
and O +
their O +
formation O +
as O +
a O +
mixture O +
was O +
previously O +
under O +
debate O +
[ O -
11 O -
] O +
. O +

Two O +
previously O +
undescribed O +
metabolites O +
were O +
detected O +
in O +
significant O +
levels O +
in O +
human O +
plasma O +
and O +
one O +
also O +
in O +
the O +
rat O -
. O +

These O +
two O +
metabolites O +
as O +
their O +
silylated O +
derivatives O +
gave O +
the O +
parent O +
ion O +
( O -
MH+ O +
) O +
at O +
m O -
/ O -
z O +
239 O +
identical O +
to O +
that O +
of O +
silylated O +
PA O +
but O +
with O +
different O +
retention O +
times O -
. O +

Characterization O +
of O +
these O +
metabolites O +
is O +
currently O +
underway O -
. O +

Thus O -
, O +
the O +
current O +
method O +
is O +
useful O +
to O +
support O +
preclinical O +
and O +
clinical O +
investigations O +
of O +
disposition O +
of O +
perillyl O +
alcohol O -
. O +

5 O +
Conclusion O +
A O +
GC O -
 O -
MS O +
stable O +
isotope O -
- O -
dilution O +
method O +
has O +
been O +
developed O +
for O +
the O +
analysis O +
of O +
perillyl O +
alcohol O +
and O +
its O +
metabolites O +
in O +
human O +
and O +
animal O +
plasma O +
and O +
the O +
method O +
has O +
been O +
validated O -
. O +

Unchanged O +
perillyl O +
alcohol O +
in O +
plasma O +
was O +
detected O +
in O +
human O +
and O +
animal O +
circulation O +
for O +
the O +
first O +
time O -
. O +

Isomers O +
of O +
a O +
reduced O +
metabolite O +
DHPA O +
have O +
been O +
total O +
resolved O +
and O +
detected O +
and O +
their O +
previous O +
cis- O +
and O +
trans- O +
assignments O +
verified O +
by O +
alternate O +
techniques O -
. O +

Two O +
new O +
metabolites O +
were O +
also O +
detected O -
. O +

This O +
GC O -
 O -
MS O +
can O +
be O +
applied O +
to O +
investigate O +
preclinical O +
and O +
clinical O +
pharmacokinetics O +
of O +
perillyl O +
alcohol O +
both O +
as O +
a O +
chemopreventative O +
and O +
chemotherapeutical O +
agent O -
. O +

Acknowledgments O +
This O +
study O +
was O +
in O +
part O +
supported O +
by O +
PHS O +
Contract O +
NCI O -
- O -
CN-55083070 O -
, O +
Task O +
22 O -
, O +
awarded O +
to O +
the O +
Cleveland O +
Clinic O +
Foundation O +
subcontracted O +
to O +
the O +
Ohio O +
State O +
University O +
and O +
by O +
P30 O +
CA16058 O +
by O +
the O +
National O +
Cancer O +
Institute O -
. O +

Eosinophils O +
may O +
play O +
important O +
roles O +
in O +
allergic O +
diseases O +
such O +
as O +
asthma O +
and O +
atopic O +
dermatitis O -
) O -
' O +
2 O +
In O +
such O +
diseases O -
, O +
eosinophiis O +
migrate O +
to O +
inflammatory O +
sites O +
and O +
degranulate O +
eytotoxic O +
proteins B-Gene +
such O +
as O +
major O +
basic O +
protein B-Gene +
and O +
eosinophil B-Gene -
- I-Gene -
derived I-Gene +
neurotoxin I-Gene +
( O -
EDN B-Gene -
) O -
. O +

The O +
cytotoxic O +
proteins B-Gene +
damage O +
tissues O +
and O +
cause O +
physiologic O +
abnormalities O +
in O +
patients O +
with O +
allergic O +
diseases O -
. O +

Therefore O -
, O +
cosinophil O +
degranulation O +
inhibitors O +
may O +
be O +
anti O -
- O -
allergic O +
drugs O -
. O +

Recently O -
, O +
we O +
found O +
that O +
sulochrin O +
( O -
6 O -
) O -
, O +
a O +
metabolite O +
of O +
fungi O -
, O +
was O +
a O +
specific O +
inhibitor O +
of O +
eosinophil O +
degranulation3 O +
and O +
also O +
inhibited O +
eosinophll O +
activation O +
and O +
chemotaxis O -
. O +

* O +
We O +
report O +
here O +
the O +
effects O +
of O +
ortho- O +
substituent O +
groups O +
on O +
inhibitory O +
activity O +
to O +
eosinophil O +
degranulation O -
. O +

Chemistry O +
Sulochrin O +
( O -
6 O -
) O +
was O +
synthesized O +
as O +
shown O +
in O +
scheme O +
1 O -
. O +

Benzoic O +
acid O +
benzyl O +
ester O +
( O -
5 O -
) O +
was O +
obtained O +
by O +
the O +
condensation O +
of O +
2-bromo O +
benzyl O +
alcohol O +
( O -
2 O -
) O +
and O +
benzoic O +
acid O +
( O -
4 O -
) O -
. O +

Anion O +
induced O +
rearrangement O +
of O +
( O -
5 O -
) O +
gave O +
1- O +
benzoyl O +
benzyl O +
alcohol O -
, O +
which O +
was O +
oxidized O +
to O +
benzoyl O +
benzoic O +
acid O +
without O +
isolation.5 O -
' O +
6 O +
Esterification O +
of O +
the O +
benzoyl O +
benzoic O +
acid O +
followed O +
by O +
debenzylatinn O +
afforded O +
sulochrin O +
( O -
6 O -
) O -
.7 O +
All O +
other O +
sulochrin O +
derivatives O +
except O +
for O +
( O -
9 O -
) O +
were O +
obtained O +
through O +
a O +
modified O +
methodology O -
. O +

Compound O +
9 O +
was O +
prepared O +
as O +
shown O +
in O +
scheme O +
2 O -
. O +

Results O +
and O +
Discussion O +
The O +
derivatives O +
of O +
sulochrin O +
( O -
6 O -
) O +
were O +
examined O +
for O +
their O +
inba"oitory O +
activity O +
against O +
eosinophil O +
degranulation O +
as O +
descn'bed O +
previously.3 O +
At O +
first O -
, O +
ester O +
derivatives O +
were O +
synthesized O +
to O +
examine O +
the O +
structure O -
- O -
activity O +
relationship O -
. O +

As O +
shown O +
in O +
Table O +
la O -
, O +
alkyl O +
esters O +
( O -
11 O -
- O -
15 O -
) O +
retained O +
activity O -
, O +
and O +
in O +
particular O -
, O +
n O -
- O -
butyl O +
and O +
see O -
- O -
butyl O +
esters O +
0960 O -
- O -
894X O -
/ O -
99 O -
/ O -
$ O +
- O +
see O +
front O +
matter O +
1999 O +
Elsevier O +
Science O +
Ltd. O +
All O +
rights O +
reserved O -
. O +

Pll O -
: O +
S0960 O -
- O -
894X O -
( O -
99 O -
) O -
00305 O -
- O -
4 O +
1946 O +
H. O +
Ohashi O +
et O +
al. O +
/ O +
Bioorg O -
. O +

Med O -
. O +

Chem O -
. O +

Lett O -
. O +

9 O +
( O -
1999 O -
) O +
1945 O -
- O -
1948 O +

Scheme O +
I O +
OH O +
OBn O +
a O -
, O -
b O -
, O -
c O -
, O -
d O +
Br O +
Me O -
" O +
< O -
~ O +
OH O +
Me O -
" O +
" O -
~ O +
OBn O +
COOMe O +
" O -
~OH O +
e O -
, O -
f O +
1 O +
2 O +
3 O +
4 O +
O O +
OBn O +
7 O +
~ O +
-~ O +
OMe O +
QH13 O +
! O +

r O +
2 O +
+ O +
4 O +
P O +
5~ O +
15 O +
T O +
" O -
Br O +
BnO O -
" O +
- O -
.. O +

: O -
I O +
" O -
Me O +
h O -
, O -
i O -
, O -
j O -
, O -
k O -
, O -
I O +
I O -
" O +
~1 O +
- O +
1 O -
" O +
g O +
OMe O +
MeOOC O +
O O +
OH O +
9 O +
8 O +
5 O +
6 O +
( O -
Sulochrln O -
) O +
( O -
a O -
) O +
BnBr O -
, O +
K O -
~ O -
O~ O -
/ O -
CH3CN O -
/ O -
reflux,33 O -
% O -
; O +
( O -
b O -
) O +
Me O +
zSO4,K O -
~ O -
CO3 O -
/ O -
CHaCN O -
/ O -
reflux,96 O -
% O -
; O +
( O -
c O -
) O +
UAIH4 O -
/ O -
I'HF,96 O -
% O -
; O +
( O -
d O -
) O +
NBS O -
/ O -
CCI4,43 O -
% O -
; O +
( O -
e O -
) O +
BnBr O -
, O +
l O -
~ O -
COa O -
/ O -
DMF O -
/ O -
reflux,74 O -
% O -
; O +
( O -
f O -
) O +
t O -
- O -
BuOWiPr O -
= O -
O O -
/ O -
reflux,93 O -
% O -
; O +
( O -
g O -
) O +
DEAD O -
/ O -
PPh O -
. O +

VrHF,82 O -
% O -
; O +
( O -
h O -
) O +
n O -
- O -
BuLi O -
/ O -
1"HF,-78"C,45 O -
% O -
; O +
( O -
i O -
) O +
PDC O -
/ O -
DMF,54 O -
% O -
; O +
( O -
j O -
) O +
BudNH4 O -
) O -
KMnO,~=yddlne,81 O -
% O -
; O +
( O -
k O -
) O +
Mel O +
K2CO O -
~ O -
JDMF O -
; O +
( O -
I O -
) O +
Pd O -
( O -
OH O -
) O -
rCarbon O -
/ O -
EtOH O -
/ O -
Cyclohexene O -
/ O -
refiux O +
81 O -
% O +
Scheme O +
2 O +
Me O -
~ O -
OMe O +
o~ O +
OMe O +
OH O +
MeO O -
~ O -
OMe O -
~ O -
MeO'~OMe O +
. O +

HO O -
~ O -
Me O +
" O -
COOH O +
m O +
" O -
~ O +
" O -
COCI O +
n O -
, O -
p O +
7 O +
8 O +
O O +
OH O +
( O -
m O -
) O +
SOCle O -
; O +
( O -
n O -
) O +
n O -
- O -
BuLi O -
/ O -
THF O -
, O +
-4YC,15 O -
% O -
; O +
( O -
P O -
) O +
BBrdCH O -
= O -
Cle,64 O -
% O +
( O -
13 O +
and O +
14 O -
) O +
showed O +
more O +
potent O +
activity O +
than O +
sulochrin O +
( O -
6 O -
) O -
. O +

On O +
thc O +
other O +
hand O -
, O +
decarboxyl O +
and O +
flee O +
carboxylic O +
acid O +
derivatives O +
( O -
9 O +
and O +
10 O -
) O +
did O +
not O +
show O +
any O +
activity O +
even O +
at O +
10 O +
pM. O +
These O +
results O +
suggest O +
that O +
the O +
existence O +
of O +
H. O +
Ohashi O +
et O +
al. O -
/ O +
Bioorg O -
. O +

Med O -
. O +

Chem O -
. O +

Lett O -
. O +

9 O +
( O -
1999 O -
) O +
1945 O -
- O -
1948 O +
1947 O +
Table O +
la O +
Effects O +
of O +
alkylester O +
on O +
eoslnophll O +
degranulation O +
OMe O +
OH O +
R1 O +
O O +
OH O +
Compound O +
R O -
, O +
ICso O +
( O -
mlcroM O -
) O +
Sulochrin O +
( O -
6 O -
) O +
9 O +
10 O +
11 O +
12 O +
13 O +
14 O +
15 O +
COOCHa O +
H O +
COOH O +
COOCH2CHa O +
COOCH O -
= O -
CH O -
= O -
CHa O +
COOCH O -
= O -
CH2CH O -
= O -
CHa O +
COO O -
( O -
CH O -
) O -
CHaCH O -
= O -
CHa O +
COO O -
( O -
CH= O -
) O -
sCH.~ O +
0.1 O +
> O -
10 O +
> O -
10 O +
0.1 O +
0.1 O +
0.04 O +
0.03 O +
0.3 O +
Table O +
lb O +
Effects O +
of O +
phenolic O +
hydroxyl O +
groups O +
on O +
eoslnophil O +
degranulation O +
Sulochdn O +
( O -
6 O -
) O +
HO-,~zFtz O +
12~ O +
16 O +
17 O +
MeOOC O +
O O +
OR O -
, O +
19 O +
2O O +
Compound O +
R2 O +
FL~ O +
P~ O +
ICs0 O +
( O -
microM O -
) O +
H O +
Me O +
H O +
Me O +
H O +
H O +
Me O +
H O +
Me O +
Me O +
Me O +
H O +
( O -
CH2 O -
) O -
2OH O +
H O +
H O +
Me O +
H O +
( O -
CH= O -
) O -
=OH O +
0.1 O +
0.4 O +
0.3 O +
> O -
10 O +
> O -
10 O +
> O -
10 O +
alkyl O +
ester O +
at O +
C-6 O +
position O +
is O +
essential O +
and O +
see O -
- O -
butyl O +
ester O +
is O +
most O +
suitable O +
for O +
activity O -
. O +

Next O -
, O +
we O +
examined O +
the O +
importance O +
of O +
methoxy O +
and O +
hydroxyl O +
groups O +
at O +
C-2 O -
, O +
C-12 O +
and O +
C-16 O +
positions O +
( O -
Table O +
lb O -
) O -
. O +

Compared O +
to O +
sulochrin O +
( O -
6 O -
) O -
, O +
19 O +
showed O +
much O +
less O +
activity O -
. O +

Activity O +
of O +
16 O +
approached O +
that O +
of O +
sulochrin O +
( O -
6 O -
) O +
after O +
methylation O +
of O +
hydroxyl O +
group O +
at O +
C-12 O +
position O +
in O +
19 O -
. O +

Furthermore O -
, O +
compound O +
17 O +
also O +
showed O +
activity O -
. O +

These O +
results O +
indicate O +
that O +
at O +
least O +
one O +
methoxy O +
group O +
at O +
C-2 O +
or O +
( O -
2 O -
- O -
12 O +
position O +
is O +
required O +
for O +
activity O -
. O +

Compound O +
18 O -
, O +
in O +
which O +
two O +
methoxy O +
groups O +
at O +
C-12 O +
and O +
( O -
2 O -
- O -
16 O +
positions O +
on O +
the O +
ring O +
B O +
were O +
introduced O -
, O +
showed O +
much O +
less O +
activity O +
than O +
16 O +
or O +
17 O -
. O +

Furthermore O -
, O +
compound O +
20 O +
also O +
lost O +
activity O -
. O +

These O +
results O +
indicate O +
that O +
at O +
least O +
one O +
free O +
hydroxyl O +
group O +
at O +
ortho O -
- O -
position O +
on O +
the O +
ring O +
B O +
is O +
required O +
for O +
activity O -
, O +
suggesting O +
that O +
hydrogen O +
bond O +
between O +
16-OH O +
and O +
carbunyl O +
at O +
( O -
2 O -
- O -
10 O +
might O +
contn'bute O +
to O +
activity O -
. O +

We O +
have O +
recently O +
shown O +
that O +
substituents O +
at O +
ortho O -
- O -
positions O +
showed O +
effect O +
on O +
the O +
conformation O +
from O +
the O +
analysis O +
of O +
crystal O +
structures O +
of O +
suiochrin O +
derivatives O -
, O -
a O +
The O +
hydrogen O +
bond O +
between O +
16-OH O +
and O +
earbonyl O +
at O +
C-10 O +
may O +
contribute O +
to O +
the O +
conformation O +
where O +
the O +
ring O +
B O +
and O +
the O +
central O +
carbunyl O +
planes O +
are O +
co O -
- O -
planner O +
and O +
cross O +
at O +
a O +
right O +
angle O +
to O +
the O +
1948 O +
1 O -
t O -
. O +

Ohashi O +
et O +
al. O +
/ O +
Bioorg O -
. O +

Med O -
. O +

Chem O -
. O +

Lett O -
. O +

9 O +
( O -
1999 O -
) O +
1945 O -
- O -
1948 O +
ring O +
A. O +
This O +
conformation O +
would O +
be O +
inaccess O -
~ O -
le O +
to O +
the O +
less O +
active O +
compounds O +
that O +
lack O +
the O +
hydrogen O +
bond O -
, O +
supporting O +
the O +
speculation O -
. O +

Compounds O +
10 O +
and O +
19 O -
, O +
which O +
have O +
more O +
hydrophilic O +
substitution O +
at O +
ortho O -
- O -
positions O -
, O +
lost O +
activity O -
. O +

Therefore O -
, O +
hydrophobicity O +
is O +
also O +
important O +
for O +
activity O -
. O +

In O +
conclusion O -
, O +
we O +
found O +
that O +
i O +
) O +
alkylester O +
at O +
C-6 O +
position O +
is O +
required O -
; O +
ii O +
) O +
see O -
- O -
butyl O +
ester O +
at O +
C-6 O +
position O +
is O +
optimal O +
for O +
activity O -
; O +
ill O +
) O +
optimal O +
hydrophobicity O +
of O +
the O +
ortho O -
- O -
substituents O +
may O +
exist O -
; O +
and O +
iv O -
) O +
the O +
conformation O +
of O +
sulochrin O +
may O +
influence O +
to O +
the O +
inlu'bitory O +
activity O +
against O +
eosinophil O +
degranulation O -
. O +

Acknowledgements O +

We O +
thank O +
to O +
Dr. O +
Masakazu O +
Sakalo'bara O +
for O +
critical O +
reading O +
of O +
this O +
manuscript O -
. O +

An O +
accurate O +
estimation O +
of O +
the O +
onset O +
of O +
oestrus O +
in O +
cows O +
is O +
vital O +
to O +
the O +
cost O -
- O -
efficient O +
application O +
of O +
artificial O +
insemination O +
( O -
AI O -
) O +
procedures O +
( O -
Ball O -
, O +
1982 O +
) O -
. O +

The O +
steroid O +
hormone O +
progesterone O -
, O +
which O +
is O +
secreted O +
by O +
the O +
corpus O +
luteum O -
, O +
functions O +
to O +
prepare O +
the O +
uterus O +
for O +
pregnancy O +
and O +
to O +
maintain O +
pregnancy O +
following O +
conception O -
. O +

Fluctuations O +
in O +
the O +
level O +
of O +
secreted O +
progesterone O +
are O +
reflected O +
throughout O +
the O +
oestrus O +
cycle O +
by O +
the O +
concentration O +
of O +
the O +
hormone O +
present O +
in O +
cows O -
' O +
milk O -
. O +

It O +
follows O +
that O +
by O +
monitoring O +
milk O +
progesterone O +
concentration O +
it O +
has O +
been O +
possible O +
accurately O +
to O +
predict O +
the O +
onset O +
of O +
oestrus O -
; O +
using O +
enzyme O +
immunoassay O +
methodology O +
( O -
Foulkes O +
et O +
al. O -
, O +
1982a O +
) O -
, O +
it O +
has O +
been O +
demonstrated O +
that O +
optimum O +
fertility O +
rates O +
can O +
be O +
achieved O +
when O +
AI O +
is O +
performed O +
on O +
the O +
third O +
day O +
of O +
sustained O +
low O +
milk O +
progesterone O +
concentration O +
( O -
Foulkes O +
et O +
al. O -
, O +
1982b O -
; O +
Foulkes O +
and O +
Goodey O -
, O +
1988 O +
) O -
. O +

The O +
search O +
for O +
a O +
rapid O -
, O +
convenient O +
and O +
inexpensive O +
means O +
of O +
frequently O +
monitoring O +
milk O +
progesterone O +
levels O +
in O +
a O +
herd O +
of O +
animals O +
has O +
led O +
into O +
research O +
toward O +
a O +
user O -
- O -
friendly O +
on O -
- O -
the O -
- O -
farm O +
device O -
. O +

One O +
such O +
approach O +
is O +
a O +
disposable O +
screen O -
- O -
printed O +
amperometric O +
biosensor O -
. O +

Previously O -
, O +
we O +
described O +
the O +
development O +
of O +
a O +
prototype O +
progesterone O +
biosensor O +
comprising O +
mAb B-Gene +
immobilised O +
on O +
the O +
working O +
surface O +
of O +
a O +
screen O -
- O -
printed O +
carbon O +
electrode O +
( O -
SPCE O -
) O -
. O +

It O +
operated O +
in O +
a O +
competitive O +
immunoassay O +
format O -
, O +
relying O +
upon O +
a O +
reduction O +
in O +
the O +
binding O +
of O +
enzyme O -
- O -
labelled O +
progesterone O +
in O +
the O +
presence O +
of O +
endogenous O +
milk O +
progesterone O -
. O +

Initial O +
proof O -
- O -
of O -
- O -
principle O +
was O +
provided O +
from O +
experiments O +
conducted O +
in O +
aqueous O +
buffer O +
solution O +
using O +
phenyl O +
phosphate O +
as O +
substrate O +
for O +
the O +
enzyme B-Gene +
alkaline B-Gene +
phosphatase I-Gene -
, O +
with O +
a O +
chronoamperometric O +
readout O +
dependent O +
on O +
the O +
oxidation O +
of O +
phenol O +
at O +
a O +
potential O +
of O +
+ O -
700 O +
mV O +
versus O +
SCE O +
( O -
Hart O +
et O +
al. O -
, O +
1997 O +
) O -
. O +

Operating O +
at O +
this O +
relatively O +
high O +
electrode O +
potential O -
, O +
however O -
, O +
it O +
was O +
not O +
possible O +
to O +
obtain O +
a O +
calibration O +
in O +
milk O -
, O +
due O +
to O +
variable O +
adsorption O -
, O +
at O +
the O +
electrode O +
surface O -
, O +
of O +
electroactive O +
species O +
present O +
within O +
this O +
complex O +
matrix O +
( O -
Pemberton O +
et O +
al. O -
, O +
1998 O +
) O -
; O +
even O +
washing O +
with O +
solvents O +
of O +
varying O +
polarity O +
did O +
not O +
remove O +
the O +
interferent O -
. O +

For O +
this O +
reason O -
, O +
it O +
is O +
desirable O +
to O +
reduce O +
the O +
operating O +
potential O +
to O +
below O +
that O +
required O +
to O +
oxidise O +
the O +
interferent O -
. O +

In O +
order O +
to O +
achieve O +
this O +
objective O -
, O +
two O +
potentially O +
useful O +
enzyme B-Gene +
substrates O -
, O +
1-naphthyl O +
phosphate O +
( O -
1-NP O -
) O +
and O +
4-aminophenyl O +
phosphate O +
( O -
4-APP O -
) O -
, O +
may O +
be O +
considered O -
. O +

These O +
are O +
hydrolysed O +
to O +
their O +
corresponding O +
phenols O -
, O +
1-naphthol O +
and O +
4-aminophenol O -
, O +
on O +
reaction O +
with O +
alkaline O +
phosphatase O -
. O +

Both O +
4-APP O +
( O -
Tang O +
et O +
al. O -
, O +
1988 O -
; O +
Pemberton O +
et O +
al. O -
, O +
1998 O -
; O +
Schreiber O +
et O +
al. O -
, O +
1997 O +
) O +
and O +
1-NP O +
( O -
Athey O +
et O +
al. O -
, O +
1993 O -
; O +
Fernandez O -
- O -
Sanchez O +
and O +
Costa O -
- O -
Garcia O -
, O +
1997 O +
) O +
have O +
been O +
investigated O +
previously O +
in O +
immunoassay O +
systems O -
, O +
but O +
no O +
detailed O +
comparative O +
studies O +
of O +
their O +
performance O +
have O +
been O +
reported O +
at O +
SPCEs O -
. O +

The O +
purpose O +
of O +
the O +
present O +
study O +
was O +
to O +
compare O +
the O +
electrochemical O +
behaviour O +
of O +
1-naphthol O +
and O +
4-aminophenol O +
at O +
bare O +
and O +
antibody B-Gene -
- O -
coated O +
SPCEs O +
and O +
to O +
determine O +
which O +
phenol O +
would O +
be O +
the O +
more O +
compatible O +
with O +
biosensor O +
operation O -
. O +

Their O +
phosphorylated O +
derivatives O +
were O +
then O +
evaluated O +
as O +
substrates O +
for O +
use O +
with O +
a O +
milk O +
progesterone O +
immunosensor O -
. O +

This O +
paper O +
describes O +
the O +
results O +
of O +
these O +
studies O -
. O +

2 O +
Experimental O +
2.1 O +
Chemicals O +
and O +
reagents O +
Chemicals O +
used O +
were O +
of O +
AR O -
- O -
grade O +
and O +
were O +
purchased O +
from O +
Merck O +
( O -
Poole O -
, O +
Dorset O -
, O +
UK O -
) O -
. O +

Water O +
for O +
the O +
preparation O +
of O +
buffer O +
solutions O +
was O +
drawn O +
from O +
a O +
Milli O -
- O -
Q O +
Water O +
Purification O +
System O +
( O -
Millipore O +
UK O -
, O +
Watford O -
, O +
UK O -
) O -
. O +

Carbonate O +
coating O +
buffer O +
( O -
CB O -
) O +
comprised O +
0.015 O +
mol O -
/ O -
dm O +
Na2 O +
CO3 O +
and O +
0.035 O +
mol O -
/ O -
dm3 O +
NaHCO3 O +
at O +
a O +
pH O +
of O +
9.6 O -
. O +

Diethanolamine O -
- O -
HCl O +
buffer O +
( O -
DB O -
; O +
0.1 O +
mol O -
/ O -
dm3 O +
) O +
was O +
adjusted O +
to O +
a O +
final O +
pH O +
of O +
7.2 O +
or O +
9.8 O -
. O +

MgCl2 O +
at O +
a O +
concentration O +
of O +
0.01 O +
mol O -
/ O -
dm3 O +
was O +
included O +
in O +
pH9.8 O +
DB O +
as O +
a O +
cofactor O +
for O +
alkaline B-Gene +
phosphatase I-Gene -
. O +

Before O +
final O +
dilution O +
in O +
DB O -
, O +
4-aminophenol O +
( O -
Sigma O -
- O -
Aldrich O +
Company O -
, O +
Poole O -
, O +
Dorset O -
, O +
UK O -
) O +
was O +
dissolved O +
in O +
0.1 O +
mol O -
/ O -
dm3 O +
NaOH O -
; O +
1-naphthol O +
( O -
Acros O +
Organics O -
, O +
Loughborough O -
, O +
Leics O -
, O +
UK O -
) O +
was O +
dissolved O +
directly O +
in O +
DB O -
. O +

A O +
polyclonal O +
rabbit O +
antibody B-Gene +
( O -
IgG O +
fraction O -
) O +
against O +
sheep O +
IgG B-Gene +
was O +
purchased O +
from O +
Sigma O -
- O -
Aldrich O +
( O -
rIg O -
) O -
. O +

Sheep O +
monoclonal B-Gene +
antibody I-Gene +
( O -
mAb B-Gene -
) O +
against O +
progesterone O +
( O -
Groves O +
et O +
al. O -
, O +
1990 O +
) O +
was O +
kindly O +
provided O +
by O +
Ridgeway O +
Science O +
Ltd. O +
in O +
the O +
form O +
of O +
culture O +
supernatant O -
. O +

A O +
solution O +
containing O +
alkaline B-Gene -
- I-Gene -
phosphatase I-Gene -
- B-Gene -
labelled I-Gene +
progesterone I-Gene +
( O -
AP B-Gene -
- I-Gene -
prog I-Gene -
) O +
was O +
obtained O +
from O +
the O +
same O +
source O -
. O +

Unlabelled O +
progesterone O +
( O -
f.wt.=314.5 O -
) O +
was O +
purchased O +
from O +
Sigma O -
- O -
Aldrich O -
. O +

4-APP O +
( O -
monosodium O +
salt O -
) O +
and O +
1-NP O +
were O +
purchased O +
from O +
ICN O +
Biomedicals O +
Ltd. O -
, O +
Thame O -
, O +
Oxon O -
, O +
UK O +
and O +
Acros O +
Organics O -
, O +
respectively O -
. O +

Whole O +
milk O +
test O +
samples O +
from O +
six O +
different O +
Fresian O +
Holstein O +
dairy O +
cows O +
at O +
various O +
stages O +
of O +
their O +
oestrus O +
cycles O +
were O +
obtained O +
from O +
Ridgeway O +
Science O +
Ltd. O +
These O +
samples O +
were O +
collected O +
following O +
agitation O +
of O +
the O +
complete O +
milking O +
jar O +
after O +
morning O +
milking O +
of O +
cows O -
. O +

One O +
Lactab O +
MkIII O +
tablet O +
( O -
Thompson O +
and O +
Capper O +
Ltd. O -
, O +
Runcorn O -
, O +
Cheshire O -
, O +
UK O -
) O +
containing O +
30 O +
mg O +
potassium O +
dichromate O +
was O +
added O +
to O +
every O +
25 O +
ml O +
milk O +
as O +
a O +
preservative O -
. O +

Samples O +
were O +
then O +
stored O +
at O +
4 O -
 O -
C O +
where O +
they O +
were O +
stable O +
for O +
up O +
to O +
3 O +
months O -
. O +

In O +
the O +
present O +
study O -
, O +
assays O +
were O +
performed O +
after O +
21 O +
days O +
of O +
storage O -
. O +

Standards O +
containing O +
known O +
concentrations O +
of O +
progesterone O +
were O +
prepared O +
by O +
dissolving O +
progesterone O +
in O +
methanol O +
at O +
1 O +
mg O -
/ O -
ml O -
, O +
aliquoting O +
a O +
known O +
volume O +
into O +
a O +
glass O +
tube O +
and O +
evaporating O +
the O +
methanol O +
under O +
N2 O +
before O +
adding O +
to O +
whole O +
milk O +
( O -
sampled O +
and O +
preserved O +
as O +
above O -
) O +
from O +
an O +
oestrus O +
cow O +
( O -
containing O +
< O -
1 O +
ng O -
/ O -
ml O +
progesterone O -
) O -
. O +

Serial O +
dilutions O +
were O +
then O +
performed O +
in O +
the O +
same O +
milk O +
over O +
the O +
desired O +
concentration O +
range O -
. O +

2.2 O +
Biosensor O +
preparation O +
Carbon O +
electrodes O +
( O -
3 O -
 O -
3 O +
mm O +
working O +
area O -
) O +
were O +
screen O -
- O -
printed O +
using O +
code O +
D14 O +
ink O +
formulation O +
onto O +
PVC O +
backing O +
card O +
at O +
Gwent O +
Electronic O +
Materials O +
Ltd. O +
( O -
Mamhilad O -
, O +
Gwent O -
, O +
UK O -
) O +
as O +
described O +
elsewhere O +
( O -
Sprules O +
et O +
al. O -
, O +
1996 O +
) O -
. O +

Individual O +
screen O -
- O -
printed O +
electrodes O +
( O -
SPCEs O -
) O +
were O +
coated O +
with O +
rIg O +
( O -
to O +
capture O +
and O +
orientate O +
the O +
mAb B-Gene -
) O +
and O +
mAb B-Gene +
as O +
described O +
previously O +
( O -
Hart O +
et O +
al. O -
, O +
1997 O +
) O -
. O +

For O +
these O +
studies O -
, O +
a O +
1 O -
/ O -
20 O +
dilution O +
of O +
mAb B-Gene +
was O +
applied O +
to O +
the O +
electrodes O -
, O +
being O +
chosen O +
empirically O +
as O +
the O +
highest O +
dilution O +
giving O +
an O +
optimum O +
sigmoidal O +
calibration O +
plot O +
for O +
progesterone O +
measured O +
colorimetrically O +
( O -
see O +
Pemberton O +
et O +
al. O -
, O +
1998 O +
) O -
. O +

These O +
are O +
referred O +
to O +
as O +
mAb B-Gene -
- O -
SPCEs O -
. O +

2.3 O +
Instrumentation O +
Electrochemical O +
procedures O +
were O +
carried O +
out O +
using O +
an O +
E612 O +
VA O +
Scanner O +
and O +
an O +
E611 O +
VA O +
Detector O +
( O -
Metrohm O -
, O +
Herisau O -
, O +
Switzerland O -
) O +
attached O +
to O +
a O +
Linseis O +
LY18100 O +
x O +
y O +
plotter O +
( O -
Recorder O +
Laboratory O +
Services O -
, O +
Sutton O -
, O +
Surrey O -
, O +
UK O -
) O -
. O +

A O +
Viglen O +
486 O +
Sx O +
computer O +
was O +
used O +
for O +
simulation O +
of O +
cyclic O +
voltammograms O +
using O +
the O +
simulation O +
program O +
CVSIM O +
( O -
Gosser O -
, O +
1993 O +
) O -
. O +

The O +
simple O +
' O -
E O +
r O +
' O -
, O +
mechanism O +
for O +
a O +
one O -
- O -
electron O +
oxidation O +
of O +
a O +
solution O +
species O +
at O +
the O +
working O +
electrode O +
was O +
used O +
to O +
estimate O +
values O +
for O +
k O +
het O +
from O +
simulations O +
of O +
the O +
oxidation O +
of O +
4-aminophenol O +
at O +
bare O +
and O +
mAb B-Gene -
- O -
coated O +
SPCEs O -
. O +

Common O +
electroactive O +
species O +
parameters O +
were O -
: O +
C O +
red O +
= O -
1 O +
mM O -
, O +
C O +
ox O +
= O -
0.0 O +
mM O -
, O +
D O +
= O -
5 O -
 O -
106 O +
cm2 O +
/s O -
; O +
and O +
common O +
experimental O +
settings O +
were O -
: O +
number O +
of O +
half O +
cycles=2 O -
, O +
A O +
= O -
0.09 O +
cm2 O +
, O +
E O +
i O +
= O -
0.3 O +
V O -
, O +
E O +
s O +
= O -
+ O -
1.0 O +
V O -
, O +
E O +
f O +
= O -
0.3 O +
V O -
, O +
v O +
= O -
0.05 O +
vs1 O +
. O +

Parameters O +
specific O +
for O +
reaction O +
at O +
a O +
bare O +
SPCE O +
were O -
: O +
E O +
0 O -
/ O +
= O -
0.050 O +
V O -
, O +
 O +
= O -
0.533 O +
and O +
for O +
reaction O +
at O +
a O +
mAb B-Gene -
- O -
coated O +
SPCE O +
were O -
: O +
E O +
0 O -
/ O +
= O -
0.037 O +
V O -
, O +
 O +
= O -
0.400 O -
. O +

2.4 O +
Cyclic O +
voltammetry O +
and O +
chronoamperometry O +
Cyclic O +
voltammetric O +
studies O +
were O +
conducted O +
using O +
10 O +
ml O +
analyte O +
volumes O +
in O +
a O +
glass O +
voltammetric O +
cell O -
. O +

Individual O +
working O +
SPCEs O +
or O +
mAb O -
- O -
SPCEs O +
were O +
used O +
in O +
a O +
3-electrode O +
configuration O +
in O +
conjunction O +
with O +
a O +
saturated O +
calomel O +
reference O +
and O +
platinum O +
counter O +
electrode O -
. O +

Chronoamperometric O +
measurements O +
were O +
made O +
by O +
using O +
individual O +
working O +
mAb B-Gene -
- O -
SPCEs O -
, O +
together O +
with O +
a O +
saturated O +
calomel O +
electrode O +
functioning O +
as O +
a O +
combined O +
counter O -
/ O -
reference O +
electrode O +
in O +
a O +
two O +
electrode O +
configuration O -
. O +

In O +
this O +
way O +
it O +
was O +
possible O +
to O +
perform O +
measurements O +
using O +
a O +
small O +
( O -
0.5 O +
ml O -
) O +
volume O +
of O +
enzyme B-Gene +
substrate O +
solution O +
in O +
a O +
conical O +
polypropylene O +
cell O -
. O +

2.5 O +
Electrochemical O +
immunoassay O +
procedure O +
Milk O +
samples O +
were O +
mixed O +
with O +
AP B-Gene -
- I-Gene -
prog I-Gene +
solution O +
in O +
the O +
ratio O +
3:5 O +
( O -
this O +
combination O +
gave O +
a O +
maximum O +
signal O -
: O -
noise O +
ratio O -
) O -
. O +

Eight O +
microlitre O +
volumes O +
of O +
these O +
mixtures O +
were O +
added O +
to O +
the O +
surface O +
of O +
individual O +
mAb B-Gene -
- O -
SPCEs O -
. O +

After O +
30 O +
min O +
at O +
room O +
temperature O +
( O -
1825 O -
 O -
C O -
; O +
RT O -
) O -
, O +
the O +
electrodes O +
were O +
washed O +
three O +
times O +
in O +
DB O -
, O +
pH O +
9.8 O -
, O +
then O +
placed O +
in O +
0.5 O +
ml O +
DB O -
, O +
pH O +
9.8 O +
or O +
the O +
same O +
buffer O +
containing O +
5 O +
mmol O -
/ O -
dm3 O +
4-APP O +
or O +
1-NP O -
. O +

After O +
5 O +
min O +
( O -
a O +
compromise O +
between O +
maximum O +
enzyme B-Gene +
activity O +
and O +
speed O +
of O +
assay O +
for O +
multiple O +
samples O -
) O -
, O +
the O +
working O +
electrode O +
potential O +
was O +
stepped O +
from O +
open O +
circuit O +
to O +
+ O -
200 O +
or O +
+ O -
300 O +
mV O +
versus O +
SCE O -
, O +
respectively O +
and O +
the O +
peak O +
current O +
( O -
i O +
p O +
) O +
response O +
was O +
recorded O -
. O +

Calibration O +
graphs O +
were O +
obtained O +
by O +
plotting O +
i O +
p O +
values O +
in O +
the O +
presence O +
of O +
an O +
enzyme B-Gene +
substrate O +
minus O +
background O +
i O +
p O +
values O +
in O +
buffer O +
only O +
for O +
each O +
known O +
standard O +
progesterone O +
concentration O +
( O -
y O +
-axis O -
) O +
against O +
progesterone O +
concentration O +
( O -
x O +
-axis O -
) O -
. O +

For O +
each O +
unknown O +
cow O +
sample O -
, O +
a O +
similar O +
subtraction O +
of O +
the O +
buffer O +
blank O +
i O +
p O +
value O +
was O +
performed O +
before O +
using O +
the O +
calibration O +
plot O +
by O +
interpolation O +
to O +
obtain O +
an O +
estimate O +
of O +
progesterone O +
concentration O -
. O +

The O +
relationship O +
between O +
readings O +
obtained O +
by O +
EIA O +
and O +
electrochemical O +
assays O +
was O +
investigated O +
using O +
linear O +
regression O +
analysis O -
. O +

3 O +
Results O +
and O +
discussion O +
3.1 O +
Electrochemistry O +
of O +
4-aminophenol O -
, O +
1-naphthol O +
and O +
corresponding O +
monophosphates O +
The O +
electrochemical O +
behaviour O +
of O +
the O +
enzyme B-Gene +
substrates O +
4-APP O +
and O +
1-NP O -
, O +
and O +
their O +
hydrolysis O +
products O -
, O +
4-aminophenol O +
and O +
1-naphthol O -
, O +
was O +
examined O +
by O +
cyclic O +
voltammetry O +
at O +
unmodified O +
SPCEs O +
( O -
Fig. O +
1 O +
) O -
. O +

4-Aminophenol O +
showed O +
well O -
- O -
defined O +
oxidation O +
and O +
reduction O +
peaks O +
and O +
the O +
E O +
p O +
value O +
indicated O +
that O +
the O +
electrode O +
reaction O +
was O +
quasi O -
- O -
reversible O +
( O -
Fig. O +
1 O +
( O -
a O -
) O -
) O -
. O +

The O +
anodic O +
potential O +
( O -
E O +
pa O +
) O +
was O +
well O +
below O +
that O +
required O +
for O +
the O +
oxidation O +
of O +
the O +
corresponding O +
monophosphate O -
, O +
4-APP O +
( O -
Fig. O +
1 O +
( O -
b O -
) O -
) O -
. O +

In O +
contrast O -
, O +
1-naphthol O +
gave O +
only O +
an O +
oxidation O +
peak O +
at O +
+ O -
230 O +
mV O +
( O -
Fig. O +
1 O +
( O -
c O -
) O -
) O -
, O +
which O +
could O +
be O +
due O +
to O +
the O +
electrode O +
reaction O +
itself O +
giving O +
an O +
electro O -
- O -
inactive O +
product O -
, O +
or O +
to O +
the O +
oxidised O +
naphthol O +
product O +
undergoing O +
an O +
irreversible O +
chemical O +
reaction O -
. O +

1-NP O +
( O -
Fig. O +
1 O +
( O -
d O -
) O -
) O +
was O +
not O +
electrochemically O +
active O +
over O +
the O +
potential O +
range O +
studied O -
. O +

At O +
this O +
stage O -
, O +
it O +
appeared O +
that O +
the O +
anodic O +
signals O +
for O +
either O +
4-aminophenol O +
or O +
1-naphthol O +
could O +
be O +
used O +
as O +
the O +
basis O +
for O +
an O +
immunoassay O +
for O +
progesterone O -
. O +

Further O +
studies O +
were O +
therefore O +
performed O +
to O +
gain O +
a O +
better O +
understanding O +
of O +
the O +
voltammetric O +
behaviour O +
of O +
these O +
two O +
phenols O -
. O +

The O +
cyclic O +
voltammetric O +
behaviour O +
of O +
4-aminophenol O +
and O +
1-naphthol O +
was O +
next O +
compared O +
at O +
naked O +
and O +
mAb B-Gene -
- O -
SPCEs O +
( O -
Fig. O +
2 O +
) O -
. O +

For O +
both O +
analytes O -
, O +
the O +
presence O +
of O +
the O +
antibodies B-Gene +
increased O +
the O +
background O +
oxidation O +
signal O +
at O +
potentials O +
above O +
+ O -
0.5 O +
V O +
( O -
Fig. O +
2 O +
( O -
b O -
, O +
d O -
) O -
) O -
, O +
but O +
the O +
magnitude O +
of O +
the O +
overall O +
peak O +
currents O +
were O +
the O +
same O +
as O +
obtained O +
at O +
naked O +
SPCEs O +
( O -
Fig. O +
2 O +
( O -
a O -
, O +
c O -
) O -
) O -
. O +

However O -
, O +
in O +
the O +
case O +
of O +
4aminophenol O -
, O +
the O +
oxidation O +
peak O +
became O +
broader O +
in O +
the O +
presence O +
of O +
the O +
antibodies B-Gene +
and O +
showed O +
a O +
small O +
positive O +
E O +
p O +
shift O +
( O -
30 O +
mV O -
, O +
Fig. O +
2 O +
( O -
a O -
, O +
b O -
) O -
) O -
. O +

In O +
the O +
case O +
of O +
1-naphthol O -
, O +
there O +
was O +
also O +
a O +
small O +
positive O +
E O +
p O +
shift O +
( O -
10 O +
mV O -
) O +
in O +
the O +
presence O +
of O +
the O +
antibodies B-Gene +
( O -
Fig. O +
2 O +
( O -
c O -
, O +
d O -
) O -
) O -
. O +

Further O +
comparison O +
of O +
the O +
electrochemistry O +
of O +
4-aminophenol O +
and O +
1-naphthol O -
, O +
at O +
naked O +
and O +
mAb B-Gene -
- O -
coated O +
SPCEs O -
, O +
was O +
obtained O +
by O +
performing O +
cyclic O +
voltammetry O +
at O +
various O +
scan O +
rates O -
. O +

The O +
relationship O +
produced O +
during O +
cyclic O +
voltammetry O +
between O +
peak O +
current O +
( O -
i O +
p O +
) O +
and O +
v O +
1 O -
/ O -
2 O +
is O +
described O +
by O +
the O +
Randles O -
- O -
Sevcik O +
equation O -
, O +
modified O +
for O +
irreversible O +
systems O -
: O +

Cv O +
1 O -
/ O -
2 O +
ip O +
= O -
( O -
2.99 O -
 O -
10 O +
5 O +
) O +
 O +
n O -
( O -
na O +
) O -
1 O -
/ O -
2 O +
AD1 O -
/ O -
2 O +
( O -
Heineman O +
and O +
Kissinger O -
, O +
1984 O +
) O +
where O +
i O +
p O +
= O -
peak O +
current O +
( O -
A O -
) O -
, O +
n O +
= O -
number O +
of O +
electrons O -
, O +
n O +
a O +
= O -
electron O +
transfer O +
coefficient O -
, O +
A O +
= O -
working O +
electrode O +
area O +
( O -
cm2 O +
) O -
, O +
D O +
= O -
diffusion O +
coefficient O +
( O -
cm2 O +
/s O -
) O -
, O +
C= O +
bulk O +
concentration O +
of O +
analyte O +
( O -
mmoles O -
/ O -
ml O -
) O +
and O +
v O +
= O -
scan O +
rate O +
( O -
mV O -
/ O -
s O -
) O -
. O +

Plots O +
of O +
i O +
p O +
versus O +
v O +
1 O -
/ O -
2 O +
for O +
both O +
analytes O +
at O +
naked O +
and O +
mAb B-Gene -
- O -
SPCEs O +
are O +
shown O +
in O +
Fig. O +
3 O +
. O +

In O +
the O +
case O +
of O +
4-aminophenol O -
, O +
there O +
is O +
evidence O +
that O +
the O +
presence O +
of O +
the O +
mAb B-Gene +
results O +
in O +
lower O +
i O +
p O +
values O +
at O +
all O +
scan O +
rates O +
compared O +
with O +
naked O +
SPCEs O +
( O -
Fig. O +
3 O +
( O -
a O -
) O -
) O -
. O +

These O +
observations O +
suggest O +
that O +
the O +
mAb B-Gene +
may O +
slow O +
the O +
diffusion O +
of O +
4-AP O +
towards O +
the O +
electrode O +
surface O -
, O +
and O +
may O +
combine O +
with O +
polyphenols O +
to O +
reduce O +
the O +
working O +
area O +
available O +
for O +
the O +
oxidation O +
of O +
4-AP O -
. O +

In O +
contrast O -
, O +
ip O +
values O +
obtained O +
for O +
1-naphthol O +
at O +
naked O +
and O +
mAb B-Gene -
- O -
SPCEs O +
are O +
almost O +
superimposed O +
for O +
scan O +
rates O +
up O +
to O +
200 O +
mVs1 O +
( O -
Fig. O +
3 O +
( O -
b O -
) O -
) O -
. O +

This O +
suggests O +
that O +
the O +
antibody B-Gene +
coating O +
has O +
little O +
effect O +
on O +
the O +
diffusional O +
characteristics O +
of O +
1-naphthol O -
. O +

Electron O +
transfer O +
coefficients O +
( O -
n O +
a O +
) O +
were O +
calculated O +
for O +
naked O +
and O +
mAb B-Gene -
- O -
SPCEs O +
as O +
described O +
previously O +
( O -
Galus O -
, O +
1976 O +
) O -
. O +

For O +
4-aminophenol O -
, O +
these O +
values O +
were O +
0.533 O +
and O +
0.400 O -
, O +
respectively O -
; O +
this O +
decrease O +
indicates O +
that O +
the O +
antibody B-Gene +
layer O +
partially O +
inhibits O +
the O +
electron O +
transfer O +
step O -
, O +
possibly O +
due O +
to O +
steric O +
hindrance O -
. O +

A O +
computer O +
simulation O +
program O +
( O -
CVSIM O -
, O +
Gosser O -
, O +
1993 O +
) O +
was O +
used O +
to O +
simulate O +
cyclic O +
voltammograms O +
for O +
4-aminophenol O +
in O +
order O +
to O +
obtain O +
values O +
for O +
the O +
electrochemical O +
rate O +
constant O -
. O +

Using O +
the O +
above O +
n O +
a O +
values O -
, O +
it O +
was O +
found O +
that O +
the O +
heterogeneous O +
rate O +
constant O +
( O -
k O +
het O +
) O +
for O +
the O +
mAb B-Gene -
- O -
SPCEs O +
was O +
3.0 O -
 O -
104 O +
/cm O +
s1 O +
, O +
whereas O +
k O +
het O +
for O +
a O +
naked O +
SPCE O +
was O +
calculated O +
to O +
be O +
6.5 O -
 O -
104 O +
cm O +
s1 O +
. O +

The O +
slower O +
rate O +
constant O +
obtained O +
with O +
the O +
mAb B-Gene -
- O -
SPCEs O +
supports O +
the O +
suggestion O +
of O +
partial O +
inhibition O +
discussed O +
above O -
. O +

Finally O -
, O +
the O +
n O +
a O +
values O +
were O +
calculated O +
for O +
1-naphthol O +
at O +
naked- O +
and O +
mAb B-Gene -
- O -
SPCEs O -
, O +
to O +
be O +
0.53 O +
and O +
0.60 O -
, O +
respectively O -
. O +

These O +
values O +
suggest O +
that O +
the O +
antibody B-Gene +
coating O +
does O +
not O +
inhibit O +
the O +
rate O +
of O +
electron O +
transfer O +
during O +
the O +
oxidation O +
of O +
this O +
phenol O -
. O +

Fig. O +
4 O +
( O -
a O -
) O +
shows O +
the O +
effect O +
of O +
scan O +
rate O +
on O +
the O +
anodic O +
peak O +
potential O +
for O +
4-aminophenol O -
, O +
at O +
naked O +
and O +
antibody B-Gene -
- O -
coated O +
SPCEs O -
. O +

True O +
reversible O +
reactions O +
do O +
not O +
show O +
shifts O +
of O +
E O +
p O +
with O +
scan O +
rate O -
, O +
inferring O +
that O +
the O +
oxidation O +
reactions O +
at O +
both O +
types O +
of O +
SPCE O +
appear O +
to O +
be O +
quasi O -
- O -
reversible O +
over O +
the O +
range O +
studied O -
. O +

In O +
contrast O -
, O +
at O +
scan O +
rates O +
above O +
100 O +
mVs1 O +
, O +
1-naphthol O +
appears O +
to O +
show O +
more O +
reversible O +
behaviour O +
at O +
both O +
SPCEs O +
than O +
4-aminophenol O -
. O +

This O +
may O +
be O +
explained O +
by O +
a O +
slow O +
chemical O +
follow O -
- O -
up O +
reaction O +
( O -
possibly O +
polymerisation O -
) O +
for O +
1-naphthol O +
after O +
the O +
initial O +
electron O +
transfer O +
step O -
. O +

It O +
should O +
also O +
be O +
noted O +
that O +
the O +
peak O +
potential O +
for O +
the O +
oxidation O +
of O +
1-naphthol O +
obtained O +
at O +
the O +
mAb B-Gene -
- O -
SPCE O +
at O +
200 O +
mVs1 O +
is O +
+ O -
0.38 O +
V O -
; O +
for O +
4-aminophenol O +
at O +
this O +
electrode O +
the O +
E O +
p O +
value O +
was O +
+ O -
0.28 O +
V. O +
All O +
of O +
the O +
above O +
observations O +
using O +
cyclic O +
voltammetry O +
suggested O +
that O +
1-NP O +
would O +
be O +
a O +
suitable O +
candidate O +
for O +
the O +
chronoamperometric O +
immunoassay O -
. O +

Although O +
the O +
magnitude O +
of O +
the O +
anodic O +
response O +
was O +
lower O +
than O +
that O +
seen O +
for O +
4-aminophenol O +
at O +
equivalent O +
concentration O -
, O +
the O +
hydrolysis O +
product O -
, O +
1-naphthol O -
, O +
appeared O +
capable O +
of O +
producing O +
a O +
significant O +
and O +
unimpeded O +
oxidation O +
signal O +
at O +
mAb B-Gene -
- O -
SPCEs O -
. O +

3.2 O +
Establishing O +
the O +
operating O +
potential O +
for O +
chronoamperometric O +
detection O +
of O +
l O -
- O -
naphthol O +
Previous O +
cyclic O +
voltammograms O +
with O +
SPCEs O +
( O -
Pemberton O +
et O +
al. O -
, O +
1998 O +
) O +
have O +
demonstrated O +
the O +
presence O -
, O +
in O +
milk O -
, O +
of O +
electroactive O +
species O +
capable O +
of O +
adsorbing O +
onto O +
the O +
electrode O +
surface O +
and O +
being O +
oxidised O +
to O +
produce O +
anodic O +
signals O +
capable O +
of O +
interfering O +
with O +
the O +
operation O +
of O +
the O +
immunosensor O +
by O +
chronoamperometry O -
. O +

Using O +
4-APP O +
as O +
enzyme B-Gene +
substrate O +
it O +
was O +
possible O +
to O +
select O +
an O +
operating O +
potential O +
of O +
+ O -
200 O +
mV O -
, O +
well O +
below O +
the O +
potential O +
required O +
to O +
oxidise O +
adsorbed O +
milk O +
species O +
( O -
Pemberton O +
et O +
al. O -
, O +
1998 O +
) O -
. O +

In O +
order O +
to O +
confirm O +
that O +
1-naphthol O +
could O +
be O +
detected O +
amperometrically O +
and O +
to O +
establish O +
an O +
operating O +
potential O +
for O +
use O +
in O +
the O +
assay O -
, O +
chronoamperometric O +
measurement O +
of O +
a O +
1 O +
mM O +
1-naphthol O +
solution O +
was O +
performed O +
over O +
a O +
range O +
of O +
operating O +
potentials O +
at O +
mAb B-Gene -
- O -
SPCEs O +
which O +
had O +
been O +
incubated O +
with O +
enzyme B-Gene -
- O -
labelled O +
progesterone O +
either O +
in O +
buffer O +
solution O +
or O +
in O +
milk O -
. O +

Fig. O +
5 O +
shows O +
that O +
in O +
order O +
to O +
avoid O +
signals O +
due O +
to O +
the O +
oxidation O +
of O +
electroactive O +
species O +
within O +
milk O -
, O +
it O +
would O +
be O +
necessary O +
to O +
operate O +
below O +
+ O -
400 O +
mV. O +
It O +
was O +
necessary O +
to O +
operate O +
at O +
+ O -
600 O +
mV O +
to O +
achieve O +
the O +
maximum O +
current O +
signal O +
from O +
chronoamperometry O +
of O +
1-naphthol O -
. O +

However O -
, O +
it O +
was O +
still O +
possible O +
to O +
obtain O +
over O +
50 O -
% O +
of O +
this O +
response O +
at O +
+ O -
300 O +
mV O +
which O +
was O +
therefore O +
chosen O +
as O +
the O +
operating O +
potential O +
for O +
the O +
biosensor O -
. O +

3.3 O +
Analysis O +
of O +
cows O -
' O +
milk O -
- O -
comparison O +
of O +
enzyme B-Gene +
substrates O +
4-APP O +
and O +
1-NP O +
In O +
order O +
to O +
compare O +
the O +
performance O +
of O +
the O +
immunosensor O +
using O +
1-NP O +
as O +
an O +
enzyme B-Gene +
substrate O +
with O +
its O +
performance O +
using O +
4-APP O -
, O +
milk O +
samples O +
obtained O +
from O +
a O +
number O +
of O +
different O +
cows O +
were O +
analysed O +
for O +
progesterone O +
content O +
using O +
both O +
approaches O -
. O +

The O +
results O +
were O +
then O +
compared O +
with O +
those O +
obtained O +
using O +
a O +
commercial O +
EIA O +
( O -
Ridgeway O +
Science O +
Ltd. O -
; O +
accuracy=8 O -
% O +
inter O -
- O -
assay O +
C.V. O -
, O +
sensitivity=0.6 O +
ng O -
/ O -
ml O -
) O +
by O +
reference O +
to O +
a O +
standard O +
curve O +
of O +
absorbance O +
reading O +
versus O +
progesterone O +
concentration O +
( O -
Sauer O +
et O +
al. O -
, O +
1986 O +
) O -
. O +

Fig. O +
6 O +
( O -
a O -
) O +
shows O +
the O +
calibration O +
curve O +
obtained O +
using O +
4-APP O +
as O +
substrate O +
to O +
measure O +
progesterone O +
milk O +
standards O +
over O +
the O +
concentration O +
range O -
, O +
050 O +
ng O -
/ O -
ml O -
, O +
before O +
and O +
after O +
background O +
subtraction O -
. O +

Precision O +
for O +
triplicate O +
sensors O +
at O +
each O +
concentration O +
ranged O +
from O +
5.3 O +
to O +
18.3 O -
% O -
. O +

The O +
readings O +
obtained O +
for O +
six O +
cows O -
' O +
milk O +
samples O -
, O +
together O +
with O +
those O +
obtained O +
using O +
the O +
standard O +
EIA O +
are O +
shown O +
on O +
a O +
correlation O +
plot O +
for O +
the O +
two O +
sets O +
of O +
values O +
( O -
Fig. O +
6 O +
( O -
b O -
) O -
) O -
. O +

Reasonable O +
agreement O +
( O -
r O +
= O -
0.840 O -
) O +
was O +
obtained O +
between O +
the O +
two O +
methods O -
. O +

One O +
calibration O +
curve O +
obtained O +
using O +
1-NP O +
is O +
shown O +
in O +
Fig. O +
7 O +
( O -
a O -
) O -
, O +
before O +
and O +
after O +
adjustment O +
for O +
background O +
current O -
. O +

Precision O +
for O +
triplicate O +
sensors O +
at O +
each O +
concentration O +
was O +
improved O +
compared O +
with O +
the O +
4-APP O +
assay O +
and O +
ranged O +
from O +
4.1 O +
to O +
12.4 O -
% O -
; O +
this O +
may O +
have O +
been O +
due O +
to O +
the O +
improved O +
solubility O +
of O +
the O +
1-naphthyl O +
phosphate O +
over O +
the O +
4-APP O -
. O +

Readings O +
obtained O +
for O +
the O +
same O +
six O +
cows O -
' O +
milk O +
samples O +
tested O +
above O +
are O +
shown O +
on O +
a O +
correlation O +
plot O +
comparing O +
these O +
values O +
with O +
those O +
obtained O +
by O +
EIA O +
( O -
Fig. O +
7 O +
( O -
b O -
) O -
) O -
. O +

The O +
result O +
was O +
a O +
close O +
agreement O +
between O +
the O +
two O +
sets O +
of O +
readings O +
and O +
an O +
improved O +
correlation O +
( O -
r O +
= O -
0.946 O -
) O +
over O +
the O +
4-APP O +
assay O -
. O +

4 O +
Conclusion O +
In O +
summary O -
, O +
the O +
above O +
results O +
have O +
demonstrated O +
that O +
by O +
using O +
1-naphthyl O +
phosphate O +
( O -
1-NP O -
) O +
as O +
enzyme B-Gene +
substrate O -
, O +
it O +
is O +
possible O +
to O +
develop O +
an O +
amperometric O +
screen O -
- O -
printed O +
immunosensor O +
for O +
milk O +
progesterone O +
based O +
on O +
the O +
detection O +
of O +
the O +
product O -
, O +
1-naphthol O +
at O +
an O +
operating O +
potential O +
of O +
+ O -
300 O +
mV. O +
The O +
required O +
detection O +
limit O +
of O +
25 O +
ng O -
/ O -
ml O +
( O -
Bulman O -
, O +
1979 O -
; O +
Sauer O +
et O +
al. O -
, O +
1986 O +
) O +
was O +
achieved O +
using O +
this O +
approach O -
. O +

Examination O +
of O +
the O +
electrochemistry O +
of O +
1-naphthol O +
itself O +
indicated O +
that O +
it O +
was O +
readily O +
oxidisable O +
at O +
the O +
surface O +
of O +
an O +
SPCE O +
in O +
the O +
presence O +
or O +
absence O +
of O +
immobilised O +
antibody B-Gene -
. O +

This O +
was O +
a O +
potential O +
advantage O +
over O +
4-aminophenol O +
which O +
appeared O +
to O +
suffer O +
from O +
a O +
diffusional O +
barrier O -
, O +
most O +
probably O +
as O +
a O +
result O +
of O +
the O +
formation O +
of O +
polyphenols O +
at O +
the O +
electrode O +
surface O -
. O +

Although O +
the O +
operating O +
potential O +
required O +
for O +
oxidation O +
of O +
1-naphthol O +
was O +
100 O +
mV O +
higher O +
than O +
that O +
used O +
for O +
the O +
detection O +
of O +
4-aminophenol O -
, O +
the O +
1-naphthol O +
assay O +
operated O +
below O +
the O +
oxidation O +
potential O +
of O +
milkborne O +
interferents O +
and O +
did O +
not O +
suffer O +
from O +
a O +
loss O +
of O +
sensitivity O -
. O +

Indeed O -
, O +
a O +
closer O +
agreement O +
than O +
that O +
achieved O +
using O +
4-APP O +
was O +
obtained O +
with O +
an O +
established O +
EIA O +
method O +
for O +
milk O +
samples O +
taken O +
from O +
different O +
cows O +
having O +
varying O +
background O +
responses O -
. O +

Furthermore O -
, O +
this O +
correlation O +
was O +
also O +
better O +
than O +
that O +
obtained O +
using O +
4-APP O +
in O +
a O +
previous O +
study O +
on O +
milk O +
samples O +
taken O +
from O +
a O +
single O +
animal O +
( O -
Pemberton O +
et O +
al. O -
, O +
1998 O +
) O -
. O +

Since O +
1-NP O +
is O +
inexpensive O -
, O +
readily O +
soluble O +
and O +
easy O +
to O +
obtain O -
, O +
the O +
screenprinted O +
immunosensor O +
when O +
used O +
in O +
combination O +
with O +
this O +
substrate O +
may O +
hold O +
promise O +
for O +
future O +
development O +
into O +
a O +
device O +
for O +
large O -
- O -
scale O +
milk O +
monitoring O -
. O +

Acknowledgements O +
The O +
authors O +
wish O +
to O +
thank O +
R. O +
Pittson O +
and O +
his O +
staff O +
at O +
Gwent O +
Electronic O +
Materials O +
Ltd. O -
( O -
GEM O -
) O -
, O +
Mamhilad O -
, O +
Gwent O +
for O +
supplying O +
the O +
SPCEs O -
. O +

Drs O +
D.J. O +
Groves O +
and O +
B.A. O +
Morris O +
from O +
the O +
Heterohybridoma O +
Antibody O +
Group O -
, O +
Department O +
of O +
Biochemistry O -
, O +
University O +
of O +
Surrey O +
are O +
gratefully O +
acknowledged O +
as O +
the O +
originators O +
of O +
the O +
mAb B-Gene -
. O +

Financial O +
support O +
for O +
this O +
project O +
was O +
provided O +
by O +
the O +
HEFCE O -
. O +

Ferbam O +
[ O -
iron O -
( O -
III O -
) O +
dimethyldithiocarbamate O -
] O +
is O +
a O +
well O +
known O +
dithiocarbamate O +
effective O +
fungicide O +
widely O +
used O +
against O +
a O +
variety O +
of O +
plant O +
pathogenic O +
fungi O -
. O +

Ferbam O +
is O +
generally O +
determined O +
by O +
the O +
carbon O +
disulphide O +
evolution O +
method O +
based O +
on O +
its O +
decomposition O +
by O +
hot O +
mineral O +
acids O +
to O +
amine O +
and O +
carbon O +
disulfide O +
using O +
different O +
approaches O +
[ O -
1 O -
] O +
. O +

Ferbam O +
is O +
also O +
determined O +
by O +
converting O +
it O +
into O +
moybdenum O +
[ O -
2 O -
] O +
, O +
copper O +
[ O -
3 O -
] O +
and O +
1,10-phenanthroline O +
[ O -
4 O -
] O +
complexes O -
. O +

McLeod O +
and O +
McCulley O +
[ O -
5 O -
] O +
determined O +
dithiocarbamate O +
fungicides O +
by O +
headspace O +
gas O +
chromatography O +
of O +
the O +
carbon O +
disulphide O +
evolved O +
in O +
controlled O +
conditions O +
from O +
foodstuffs O +
and O +
similar O +
methods O +
were O +
also O +
given O +
by O +
the O +
Committee O +
for O +
Analytical O +
Methods O +
[ O -
6 O -
] O +
. O +

However O -
, O +
all O +
these O +
methods O +
suffer O +
from O +
the O +
following O +
disadvantages O -
: O +
( O -
a O -
) O +
Methods O +
other O +
than O +
gas O +
chromatography O +
are O +
indirect O -
, O +
time O +
consuming O +
and O +
sensitivity O +
is O +
low O -
. O +

( O -
b O -
) O +
Gas O +
chromatographic O +
methods O +
are O +
sensitive O +
but O +
suffer O +
from O +
lack O +
of O +
the O +
selectivity O +
since O +
all O +
dithiocarbamate O +
fungicides O +
evolve O +
carbon O +
disulphide O +
on O +
acid O +
hydrolysis O -
. O +

( O -
c O -
) O +
Spectrophotometric O +
methods O +
suffer O +
the O +
interference O +
of O +
various O +
ions O -
. O +

Capillary O +
electrophoresis O +
[ O -
7,8 O -
] O +
, O +
is O +
a O +
microvolume O +
separation O +
technique O +
increasingly O +
achieving O +
recognition O +
for O +
its O +
use O +
in O +
the O +
separation O +
of O +
inorganic O +
and O +
organic O +
compounds O -
. O +

The O +
key O +
features O +
of O +
this O +
technique O +
are O +
its O +
very O +
short O +
analysis O +
time O +
and O +
small O +
sample O +
volumes O +
in O +
the O +
nanoliter O +
and O +
picoliter O +
range O -
. O +

Capillary O +
electrophoresis O +
has O +
been O +
used O +
for O +
the O +
determination O +
of O +
sodium O +
dimethyldithiocarbamate O +
using O +
sulphonic O +
acid O +
polymer O +
coated O +
capillary O +
columns O +
at O +
pH O +
6.5 O +
using O +
sodium O +
phosphate O +
buffer O +
[ O -
9 O -
] O +
. O +

Liang O +
et O +
al. O +
used O +
diode O +
array O +
detection O +
and O +
factor O +
analysis O +
for O +
the O +
determination O +
of O +
dithiocarbamates O +
[ O -
10 O -
] O +
. O +

In O +
another O +
approach O -
, O +
solid O -
- O -
phase O +
extraction O +
was O +
used O +
to O +
separate O +
dithiocarbamates O +
with O +
other O +
pesticides O +
[ O -
11 O -
] O +
. O +

The O +
extensive O +
studies O +
of O +
metal O -
 O -
aminopolycarboxylate O +
complexes O +
are O +
reviewed O +
by O +
Timerbaev O +
[ O -
12 O -
] O +
. O +

This O +
report O +
is O +
concerned O +
with O +
the O +
investigation O +
of O +
the O +
potential O +
of O +
capillary O +
electrophoresis O +
in O +
the O +
determination O +
of O +
Ferbam O -
. O +

As O +
will O +
be O +
demonstrated O +
in O +
this O +
report O -
, O +
capillary O +
electrophoresis O +
with O +
its O +
precision O +
instrumentation O +
and O +
small O +
sample O +
requirements O +
is O +
well O +
suited O +
for O +
the O +
determination O +
of O +
Ferbam O -
. O +

Here O -
, O +
we O +
present O +
a O +
relatively O +
simple O +
and O +
selective O +
capillary O +
electrophoretic O +
method O +
by O +
converting O +
Fe O -
( O -
III O -
) O +
present O +
in O +
Ferbam O +
into O +
Fe O -
( O -
III O -
) O -
EDTA O +
complex O -
. O +

The O +
chemical O +
structure O +
of O +
Ferbam O +
is O +
as O +
follows O -
: O +
[ O -
( O -
CH3 O +
) O -
2 O +
NC O -
( O -
S O -
) O -
2 O +
] O -
3 O +
Fe O -
. O +

2 O +
Experimental O +
2.1 O +
Instrumentation O +
Separations O +
were O +
performed O +
on O +
a O +
Thermo O +
Separation O +
Products O +
100 O +
CE O -
- O -
system O +
equipped O +
with O +
an O +
UV O +
absorbance O +
detector O -
. O +

Fused O +
silica O +
capillaries O +
of O +
75 O +
cm O +
long O +
( O -
45 O +
cm O +
to O +
the O +
detector O -
) O -
 O -
100 O +
m O +
I.D. O +
were O +
used O -
. O +

The O +
solutes O +
were O +
injected O +
in O +
the O +
hydrodynamic O +
mode O +
by O +
vacuum O +
injection O +
for O +
2 O +
s. O +
TSP O +
1000 O +
software O +
was O +
used O +
for O +
the O +
data O +
acquisition O -
. O +

Detection O +
was O +
performed O +
by O +
direct O +
UV O +
absorbance O +
at O +
254 O +
nm O -
. O +

All O +
experiments O +
were O +
conducted O +
at O +
251 O -
 O -
C O -
. O +

2.2 O +
Reagents O +
and O +
solutions O +
All O +
chemicals O +
used O +
were O +
of O +
analytical O -
- O -
reagent O +
grade O +
and O +
doubly O +
distilled O +
water O +
was O +
used O +
for O +
the O +
preparation O +
of O +
solutions O +
and O +
all O +
dilutions O -
. O +

2.2.1 O +
Ferbam O +
solution O +
Ferbam O +
was O +
obtained O +
from O +
Riedel O -
- O -
de O +
Han O +
( O -
Germany O -
) O +
and O +
used O +
as O +
received O -
. O +

Ferbam O +
solution O +
was O +
prepared O +
by O +
decomposing O +
its O +
20 O +
mg O +
with O +
concentrated O +
nitric O +
acid O +
( O -
510 O +
ml O -
) O +
and O +
heated O +
till O +
all O +
the O +
fumes O +
were O +
ceased O +
( O -
almost O +
to O +
dryness O -
) O +
and O +
dissolved O +
the O +
residue O +
in O +
12 O +
ml O +
of O +
concentrated O +
HCl O +
and O +
diluted O +
upto O +
3040 O +
ml O +
and O +
pH O +
adjusted O +
in O +
the O +
range O +
23 O +
using O +
dilute O +
NaOH O +
and O +
finally O +
diluted O +
to O +
100 O +
ml O +
in O +
a O +
calibrated O +
flask O -
. O +

The O +
recovery O +
of O +
iron O -
( O -
III O -
) O +
from O +
Ferbam O +
was O +
checked O +
by O +
titrating O +
it O +
using O +
Variamine O +
Blue O +
B O +
as O +
indicator O +
[ O -
13 O -
] O +
. O +

Working O +
solutions O +
of O +
lower O +
concentrations O +
were O +
prepared O +
by O +
appropriate O +
dilutions O +
with O +
distilled O +
water O -
. O +

2.2.2 O +
EDTA O +
solution O +
Stock O +
solution O +
of O +
EDTA O +
( O -
0.5 O +
mM O +
) O +
as O +
disodium O +
salt O +
was O +
prepared O +
in O +
distilled O +
water O -
. O +

2.2.3 O +
Buffer O +
solution O +
Electrophoretic O +
buffer O +
solution O +
was O +
prepared O +
from O +
boric O +
acid O +
50 O +
mM O +
and O +
adjusting O +
the O +
desired O +
pH O +
by O +
adding O +
0.1 O +
M O +
NaOH O +
solution O -
. O +

2.3 O +
Procedures O +
2.3.1 O +
Basic O +
procedure O +
The O +
capillary O +
was O +
rinsed O +
with O +
1 O +
M O +
NaOH O -
, O +
0.1 O +
M O +
NaOH O +
and O +
water O +
for O +
2 O +
min O -
, O +
respectively O -
, O +
then O +
equilibrated O +
with O +
the O +
carrier O +
electrolyte O +
for O +
2 O +
min O -
. O +

Between O +
all O +
electrophoretic O +
separations O +
the O +
capillary O +
was O +
rinsed O +
for O +
2 O +
min O +
with O +
carrier O +
electrolyte O -
. O +

All O +
electrolyte O +
solutions O +
were O +
filtered O +
through O +
a O +
0.45 O +
m O +
membrane O +
filter O -
. O +

2.3.2 O +
Preparation O +
of O +
standard O +
calibration O +
graph O +
A O +
series O +
of O +
standard O +
solutions O +
of O +
Ferbam O +
were O +
mixed O +
with O +
EDTA O +
( O -
1 O +
ml O -
) O +
and O +
diluted O +
to O +
2 O +
ml O +
with O +
distilled O +
water O +
and O +
injected O +
into O +
the O +
capillary O +
under O +
the O +
optimised O +
conditions O +
to O +
test O +
the O +
linearity O +
of O +
the O +
calibration O +
graph O -
. O +

2.3.3 O +
Determination O +
of O +
Ferbam O +
in O +
grains O +
The O +
method O +
was O +
applied O +
for O +
the O +
determination O +
of O +
Ferbam O +
from O +
wheat O +
grains O -
. O +

A O +
known O +
amount O +
of O +
Ferbam O +
in O +
acetonitrile O +
was O +
crushed O +
with O +
10 O +
g O +
of O +
wheat O +
grains O +
and O +
shaken O +
mechanically O +
with O +
chloroform O +
( O -
100 O +
ml O -
) O +
for O +
1 O +
h. O +
The O +
mixture O +
was O +
filtered O +
and O +
the O +
residue O +
in O +
the O +
funnel O +
was O +
washed O +
with O +
chloroform O +
( O -
3 O -
 O -
10 O +
ml O -
) O -
. O +

The O +
extracts O +
were O +
evaporated O +
to O +
dryness O +
and O +
solution O +
was O +
prepared O +
as O +
discussed O +
above O +
and O +
determined O +
by O +
the O +
general O +
procedure O -
. O +

Untreated O +
samples O +
were O +
taken O +
as O +
reference O +
and O +
the O +
results O +
indicated O +
good O +
recoveries O +
in O +
all O +
cases O -
. O +

The O +
results O +
of O +
the O +
determinations O +
are O +
given O +
in O +
Table O +
1 O +
. O +

3 O +
Results O +
and O +
discussion O +
A O +
typical O +
capillary O +
electropherogram O +
of O +
Ferbam O +
at O +
pH O +
9.0 O +
is O +
shown O +
in O +
Fig. O +
1 O +
. O +

It O +
shows O +
a O +
sharp O +
peak O +
with O +
baseline O +
resolution O -
. O +

In O +
order O +
to O +
determine O +
the O +
best O +
experimental O +
conditions O +
( O -
peak O +
efficiency O -
, O +
analysis O +
time O -
) O +
borate O -
, O +
phosphate O +
and O +
acetate O +
buffer O +
of O +
pH O +
9.0 O -
, O +
7.0 O +
and O +
4.5 O -
, O +
respectively O +
of O +
1.2550 O +
mM O +
were O +
investigated O +
and O +
compared O -
. O +

It O +
was O +
observed O +
that O +
below O +
pH O +
7.0 O +
in O +
phosphate O +
and O +
acetate O +
buffer O +
good O +
peak O +
were O +
not O +
observed O -
. O +

A O +
well O +
defined O +
peak O +
was O +
obtained O +
in O +
between O +
25 O +
and O +
50 O +
mM O +
borate O +
buffer O +
of O +
pH O +
9.0 O -
. O +

It O +
was O +
observed O +
that O +
the O +
migration O +
time O +
was O +
more O +
at O +
the O +
higher O +
concentrations O +
of O +
the O +
borate O +
buffer O -
. O +

Above O +
25 O +
mM O +
concentration O +
of O +
borate O +
buffer O +
there O +
was O +
a O +
considerable O +
increase O +
in O +
the O +
migration O +
time O +
of O +
the O +
both O +
analytes O -
, O +
resulting O +
in O +
an O +
increase O +
in O +
the O +
analysis O +
time O -
. O +

Therefore O -
, O +
25 O +
mM O +
of O +
borate O +
buffer O +
concentration O +
was O +
preferred O -
. O +

The O +
influence O +
of O +
the O +
applied O +
voltage O +
was O +
also O +
studied O +
by O +
increasing O +
the O +
applied O +
voltage O -
. O +

The O +
retention O +
time O +
decreases O +
with O +
increasing O +
voltage O -
. O +

Therefore O -
, O +
+ O -
30 O +
kV O +
was O +
applied O +
to O +
get O +
the O +
shortest O +
time O -
. O +

A O +
linear O +
relationship O +
between O +
peak O +
height O +
and O +
concentrations O +
were O +
obtained O +
in O +
the O +
range O +
3.5500 O +
g O -
/ O -
ml O +
with O +
an O +
correlation O +
coefficient O +
of O +
0.9994 O -
. O +

The O +
linear O +
regression O +
equation O +
for O +
the O +
calibration O +
curve O +
is O +
y O +
= O -
0.0001x O +
+ O -
0.0003 O -
. O +

Aliquots O +
containing O +
50 O +
g O -
/ O -
ml O +
of O +
give O +
a O +
relative O +
standard O +
deviation O +
of O +
2.9 O -
% O +
in O +
analysis O -
. O +

Ferbam O -
, O +
if O +
present O +
with O +
other O +
water O +
soluble O +
dithiocarbamates O +
such O +
as O +
nabam O -
, O +
metham O -
, O +
sodium O +
diethyldithiocarbamate O -
, O +
etc O -
. O -
, O +
can O +
easily O +
be O +
separated O +
by O +
extraction O +
with O +
chloroform O -
; O +
Nabam O +
and O +
others O +
will O +
remain O +
in O +
the O +
aqueous O +
phase O +
which O +
can O +
then O +
be O +
analysed O +
by O +
the O +
basic O +
procedure O +
[ O -
14 O -
] O +
. O +

Furthermore O -
, O +
our O +
experiments O +
have O +
shown O +
that O +
Ferbam O +
can O +
be O +
determined O +
directly O +
in O +
the O +
presence O +
of O +
metal O +
ions O +
like O +
Co O -
( O -
II O -
) O -
, O +
Zn O -
( O -
II O -
) O -
, O +
Cu O -
( O -
II O -
) O +
and O +
Ni O -
( O -
II O -
) O +
without O +
any O +
interference O -
, O +
whereas O -
, O +
these O +
metal O +
ions O +
strongly O +
interfere O +
in O +
the O +
spectrophotometric O +
methods O +
[ O -
2,3 O -
] O +
. O +

These O +
results O +
are O +
similar O +
to O +
as O +
reported O +
by O +
earlier O +
workers O +
[ O -
12,15 O -
] O +
. O +

4 O +
Conclusions O +
Capillary O +
electrophoresis O +
provides O +
an O +
important O +
tool O +
in O +
the O +
hands O +
of O +
the O +
analytical O +
chemists O +
for O +
the O +
determination O +
of O +
Ferbam O -
. O +

The O +
detection O +
limit O +
( O -
S O +
/N O +
=3 O -
) O +
using O +
this O +
method O +
is O +
0.7 O +
g O -
/ O -
ml O +
( O -
0.7 O +
mg O -
/ O -
kg O -
) O +
of O +
Ferbam O +
which O +
is O +
better O +
than O +
1 O +
g O -
/ O -
ml O +
of O +
Nitowski O +
et O +
al. O -
's O +
[ O -
9 O -
] O +
method O +
reported O +
for O +
dimethyldithiocarbamate O +
using O +
sulphonic O +
acid O +
polymer O -
- O -
coated O +
capillary O +
columns O -
. O +

As O +
most O +
of O +
the O +
cations O +
and O +
anions O +
do O +
not O +
interfere O +
in O +
the O +
determination O +
of O +
Ferbam O -
, O +
moreover O -
, O +
the O +
simplicity O +
and O +
small O +
sample O +
volume O +
requirements O +
makes O +
it O +
advantageous O +
to O +
other O +
chromatographic O +
techniques O -
. O +

Thus O -
, O +
the O +
usefulness O +
of O +
capillary O +
electrophoresis O +
as O +
a O +
tool O +
for O +
checking O +
the O +
amount O +
of O +
Ferbam O +
is O +
successfully O +
demonstrated O -
. O +

Acknowledgements O +
One O +
of O +
the O +
authors O +
( O -
A.K.M. O -
) O +
thanks O +
the O +
AvH O +
Foundation O -
, O +
Bonn O -
, O +
Germany O +
for O +
financial O +
assistance O -
. O +

l O +
-cis O +
Diltiazem O -
, O +
the O +
enantiomer O +
of O +
diltiazem O +
( O -
d O +
-cis O +
diltiazem O -
) O -
, O +
has O +
100 O +
times O +
less O +
Ca2 B-Gene -
+ I-Gene +
channel I-Gene +
blocking O +
activity O +
than O +
diltiazem O +
( O -
Ikeda O +
et O +
al. O -
, O +
1991 O -
) O +
. O +

l O +
-cis O +
Diltiazem O +
is O +
not O +
a O +
simple O +
inactive O +
stereoisomer O +
but O +
has O +
been O +
established O +
as O +
a O +
unique O +
pharmacological O +
tool O +
( O -
Caretta O +
et O +
al. O -
, O +
1979 O -
) O +
. O +

For O +
example O -
, O +
l O +
-cis O +
diltiazem O -
, O +
but O +
not O +
diltiazem O -
, O +
inhibits O +
the O +
cGMP B-Gene -
- I-Gene -
gated I-Gene +
cation I-Gene +
channel I-Gene +
in O +
rod O +
cells O +
( O -
Stern O +
et O +
al. O -
, O +
1986 O -
; O +
Quandt O +
et O +
al. O -
, O +
1991 O -
) O +
. O +

Interestingly O -
, O +
there O +
have O +
been O +
several O +
reports O +
indicating O +
that O +
l O +
-cis O +
diltiazem O +
protects O +
against O +
ischemic O +
cardiac O +
injury O -
. O +

For O +
example O -
, O +
l O +
-cis O +
diltiazem O +
produces O +
a O +
high O +
recovery O +
of O +
cardiac O +
function O +
after O +
ischemia O -
/ O -
reperfusion O +
and O +
inhibits O +
the O +
increase O +
of O +
non O -
- O -
esterified O +
fatty O +
acids O +
during O +
ischemia O +
in O +
isolated O -
, O +
perfused O +
working O +
rat O +
heart O +
( O -
Nasa O +
et O +
al. O -
, O +
1990 O -
; O +
Xiao O +
et O +
al. O -
, O +
1997 O -
) O +
. O +

Recently O -
, O +
our O +
laboratory O +
has O +
reported O +
that O +
treatment O +
with O +
l O +
-cis O +
diltiazem O +
reduced O +
infarct O +
size O +
without O +
affecting O +
any O +
hemodynamic O +
parameter O +
in O +
rabbit O +
heart O +
in O +
vivo O +
( O -
Nishida O +
et O +
al. O -
, O +
1999 O -
) O +
. O +

Since O +
l O +
-cis O +
diltiazem O +
has O +
a O +
much O +
less O +
potent O +
Ca2 B-Gene -
+ I-Gene +
channel I-Gene +
blocking O +
action O +
than O +
diltiazem O -
, O +
it O +
has O +
been O +
suggested O +
that O +
l O +
-cis O +
diltiazem O +
protects O +
against O +
ischemia O -
/ O -
reperfusion O +
injury O +
with O +
a O +
mechanism O +
other O +
than O +
Ca2 B-Gene -
+ I-Gene +
channel I-Gene +
blockade O -
. O +

We O +
have O +
also O +
demonstrated O +
that O +
treatment O +
with O +
l O +
-cis O +
diltiazem O +
before O +
reperfusion O +
also O +
reduced O +
infarct O +
size O +
in O +
ischemic O +
rabbit O +
heart O +
( O -
Nishida O +
et O +
al. O -
, O +
1999 O -
) O +
. O +

Ca2 O -
+ O +
overload O +
at O +
reperfusion O +
after O +
ischemia O +
( O -
Allen O +
and O +
Orchard O -
, O +
1983 O -
) O +
and O +
reoxygenation O +
after O +
hypoxia O +
( O -
Poole O -
- O -
Wilson O +
et O +
al. O -
, O +
1984 O -
) O +
have O +
been O +
considered O +
to O +
be O +
involved O +
in O +
the O +
final O +
stage O +
of O +
ischemia O -
/ O -
reperfusion O +
injury O +
of O +
cardiac O +
myocytes O +
( O -
Nayler O -
, O +
1981 O -
; O +
Farber O -
, O +
1982 O -
; O +
Steenbergen O +
et O +
al. O -
, O +
1990 O -
) O +
. O +

Thus O -
, O +
it O +
is O +
postulated O +
that O +
l O +
-cis O +
diltiazem O +
elicits O +
a O +
cardioprotective O +
action O +
via O +
the O +
attenuation O +
of O +
Ca2 O -
+ O +
overload O +
after O +
reperfusion O -
. O +

In O +
terms O +
of O +
energy O +
metabolism O -
, O +
ischemic O +
insults O +
can O +
be O +
simulated O -
, O +
in O +
part O -
, O +
by O +
controlled O +
metabolic O +
inhibition O -
. O +

Li O +
et O +
al. O +
( O -
1989 O -
) O +
has O +
reported O +
that O +
the O +
myocytes O +
were O +
reversibly O +
ATP O -
- O -
depleted O +
by O +
metabolic O +
inhibitors O -
. O +

Thus O -
, O +
myocardial O +
Ca2 O -
+ O +
overload O +
induced O +
by O +
ischemia O +
and O +
reperfusion O +
is O +
considered O +
to O +
be O +
simply O +
mimicked O -
, O +
in O +
part O -
, O +
by O +
treatment O +
with O +
carbonyl O +
cyanide O +
m O +
-chrolophenylhydrazone O +
( O -
CCCP O -
) O -
, O +
a O +
mitochondrial O +
uncoupler O -
, O +
followed O +
by O +
washout O +
of O +
CCCP O -
. O +

In O +
order O +
to O +
assess O +
the O +
effect O +
of O +
l O +
-cis O +
diltiazem O +
on O +
reperfusion O -
- O -
induced O +
Ca2 O -
+ O +
overload O -
, O +
we O +
used O +
a O +
model O +
for O +
Ca2 O -
+ O +
overload O +
by O +
metabolic O +
inhibition O +
and O +
energy O +
repletion O +
in O +
isolated O +
guinea O +
pig O +
cardiomyocytes O -
. O +

We O +
also O +
assessed O +
the O +
effect O +
of O +
other O +
drugs O -
, O +
Ca2 B-Gene -
+ I-Gene +
channel I-Gene +
blockers O +
and O +
Na+ O +
/Ca2 O -
+ O +
exchanger O +
blockers O -
, O +
to O +
clarify O +
the O +
mechanism O +
for O +
Ca2 O -
+ O +
overload O +
in O +
this O +
model O -
. O +

2 O +
Materials O +
and O +
methods O +
2.1 O +
Preparation O +
of O +
single O +
cells O +
Ventricular O +
myocytes O +
were O +
isolated O +
enzymatically O +
from O +
the O +
hearts O +
of O +
male O +
Hartley O +
guinea O +
pigs O +
( O -
weight O +
250500 O +
g O -
) O +
according O +
to O +
the O +
method O +
described O +
( O -
Kurokawa O +
et O +
al. O -
, O +
1997 O -
) O +
. O +

The O +
animals O +
were O +
anaesthetized O +
with O +
sodium O +
pentobarbital O +
( O -
50 O +
mg O -
/ O -
kg O -
, O +
i.p O -
. O -
) O +
and O +
the O +
ascending O +
aorta O +
was O +
cannulated O +
in O +
situ O +
under O +
artificial O +
respiration O -
. O +

The O +
heart O +
was O +
perfused O +
with O +
Ca2 O -
+ O +
-free O +
Tyrode O +
solution O +
for O +
10 O +
min O -
, O +
followed O +
by O +
the O +
same O +
solution O +
containing O +
collagenase B-Gene +
for O +
714 O +
min O +
at O +
a O +
perfusion O +
rate O +
of O +
810 O +
ml O -
/ O -
min O +
via O +
a O +
Langendorff O +
apparatus O +
at O +
37 O -
 O -
C O -
. O +

Subsequently O -
, O +
the O +
enzyme B-Gene +
solution O +
was O +
washed O +
out O +
with O +
a O +
high O +
K+ O +
, O +
Ca2 O -
+ O +
-free O +
solution O +
( O -
Kraftbrhe O +
( O -
KB O -
) O +
solution O -
, O +
Isenberg O +
and O +
Klckner O -
, O +
1982 O +
) O -
. O +

The O +
ventricular O +
myocytes O +
were O +
dissociated O +
by O +
gentle O +
stirring O +
of O +
the O +
tissue O +
fragments O +
at O +
37 O -
 O -
C O -
. O +

The O +
dissociated O +
cells O +
were O +
stored O +
in O +
KB O +
solution O +
at O +
4 O -
 O -
C O -
, O +
and O +
were O +
used O +
up O +
to O +
10 O +
h O +
after O +
isolation O -
. O +

Nominally O +
Ca2 O -
+ O +
-free O +
solution O +
had O +
the O +
following O +
composition O +
( O -
mM O -
) O -
: O +
NaCl O +
135 O -
, O +
KCl O +
5.4 O -
, O +
MgCl2 O +
1 O -
, O +
glucose O +
5.8 O -
, O +
HEPES O +
5 O +
( O -
pH O +
7.4 O -
, O +
adjusted O +
with O +
tris O -
) O -
. O +

Normal O +
Tyrode O +
solution O +
was O +
made O +
by O +
adding O +
1.8 O +
mM O +
CaCl2 O +
to O +
nominally O +
Ca2 O -
+ O +
-free O +
solution O -
. O +

The O +
collagenase B-Gene +
solutions O +
were O +
prepared O +
by O +
adding O +
collagenase B-Gene +
( O -
110 O +
units O -
/ O -
ml O +
Collagenase B-Gene +
S-1 I-Gene -
, O +
Nitta O +
Gelatin O -
, O +
Osaka O -
, O +
Japan O -
; O +
200220 O +
units O -
/ O -
ml O +
collagenase B-Gene -
, O +
Yakult O -
, O +
Tokyo O -
. O +

Japan O -
) O +
and O +
10.8 O +
nM O +
CaCl2 O +
to O +
Ca2 O -
+ O +
-free O +
Tyrode O +
solution O -
, O +
or O +
by O +
combining O +
collagenase B-Gene +
( O -
0.145 O +
U O -
/ O -
ml O +
collagenase B-Gene +
A I-Gene -
, O +
Boehringer O +
Mannheim O -
, O +
Japan O -
) O +
and O +
protease B-Gene +
( O -
0.156 O +
units O -
/ O -
ml O +
protease B-Gene +
type I-Gene +
IX I-Gene -
, O +
Sigma O -
, O +
St. O +
Louis O -
, O +
MO O -
, O +
USA O -
) O +
to O +
Ca2 O -
+ O +
-free O +
Tyrode O +
solution O -
. O +

The O +
KB O +
solution O +
contained O +
( O -
mM O -
) O -
: O +
potassium O +
glutamate O +
70 O -
, O +
KCl O +
20 O -
, O +
oxalic O +
acid O +
10 O -
, O +
KH2 O +
PO4 O +
10 O -
, O +
taurine O +
10 O -
, O +
glucose O +
5.8 O -
, O +
HEPES O +
5 O -
, O +
EGTA O +
0.5 O +
( O -
pH O +
7.4 O -
, O +
adjusted O +
with O +
KOH O -
) O -
. O +

2.2 O +
Measurement O +
of O +
fluorescence O +
ratio O +
of O +
fura-2 O +
in O +
cardiac O +
myocytes O +
For O +
measurement O +
of O +
a O +
change O +
in O +
[ O -
Ca2 O -
+ O +
] O -
i O +
of O +
cardiac O +
myocytes O -
, O +
a O +
Ca2 O -
+ O +
-sensitive O +
fluorescent O +
dye O -
, O +
fura-2 O -
/ O -
acetoxymethylester O +
( O -
fura-2 O -
/ O -
AM O -
) O -
, O +
was O +
used O -
. O +

Fura-2 O -
/ O -
AM O +
( O -
1 O +
mM O -
, O +
dissolved O +
in O +
dimethylsulfoxide O -
, O +
DMSO O -
) O +
was O +
prepared O +
in O +
KB O +
solution O +
and O +
applied O +
to O +
isolated O +
myocytes O +
at O +
a O +
final O +
concentration O +
of O +
10 O +
M. O +
After O +
the O +
cell O +
suspension O +
had O +
been O +
incubated O +
for O +
10 O +
min O +
at O +
37 O -
 O -
C O -
, O +
the O +
cells O +
settled O +
out O +
and O +
became O +
loosely O +
attached O +
to O +
the O +
bottom O +
of O +
the O +
chamber O -
. O +

Then O +
the O +
fura-2-loaded O +
myocytes O +
were O +
washed O +
and O +
superfused O +
( O -
45 O +
ml O -
/ O -
min O -
, O +
37 O -
 O -
C O -
) O +
with O +
normal O +
Tyrode O +
solution O +
containing O +
1.8 O +
mM O +
Ca2 O -
+ O +
for O +
30 O +
min O -
. O +

The O +
myocytes O +
were O +
illuminated O +
with O +
a O +
dual O +
wavelength O +
fluorometer O +
( O -
CAM-230 O -
, O +
Japan O +
Spectroscopic O -
, O +
Tokyo O -
, O +
Japan O -
) O -
. O +

Video O +
images O +
were O +
digitized O -
, O +
using O +
an O +
Argus-50 O -
/ O -
Ca O +
system O +
( O -
Hamamatsu O +
Photonics O -
) O -
. O +

The O +
fluorescence O +
ratio O +
was O +
calculated O +
from O +
the O +
value O +
of O +
the O +
fluorescence O +
intensity O +
at O +
500 O +
nm O +
with O +
340- O +
and O +
380-nm O +
excitation O -
. O +

The O +
digital O +
images O +
were O +
obtained O +
every O +
5 O +
min O +
from O +
just O +
before O +
treatment O +
with O +
CCCP O +
till O +
the O +
end O +
of O +
the O +
experiment O -
. O +

2.3 O +
Evaluation O +
of O +
morphological O +
changes O +
of O +
cardiac O +
myocytes O +
Cells O +
lightly O +
attached O +
to O +
the O +
perfusion O +
chamber O +
were O +
superfused O +
with O +
normal O +
Tyrode O +
solution O +
at O +
37 O -
 O -
C O -
. O +

After O +
30 O +
min O +
of O +
stabilization O -
, O +
a O +
rod O -
- O -
shaped O +
cell O +
was O +
selected O +
randomly O +
from O +
those O +
within O +
the O +
microscopic O +
field O +
of O +
the O +
chamber O -
. O +

Caffeine O +
( O -
5 O +
mM O -
) O +
was O +
added O +
for O +
1 O +
min O +
to O +
the O +
chamber O +
in O +
order O +
to O +
confirm O +
that O +
the O +
function O +
of O +
the O +
intracellular O +
Ca2 O -
+ O +
store O +
of O +
the O +
myocyte O +
was O +
maintained O -
. O +

After O +
washing O +
out O +
of O +
the O +
caffeine O +
for O +
5 O +
min O -
, O +
the O +
morphology O +
of O +
the O +
myocyte O +
was O +
recorded O +
as O +
a O +
digital O +
image O +
using O +
the O +
Argus-50 O -
/ O -
Ca O +
system O -
. O +

To O +
examine O +
the O +
morphological O +
change O +
of O +
the O +
myocyte O -
, O +
the O +
morphology O +
of O +
the O +
same O +
cell O +
was O +
also O +
recorded O +
at O +
the O +
end O +
of O +
chemical O +
ischemia O +
and O +
also O +
at O +
the O +
end O +
of O +
30-min O +
reperfusion O -
. O +

After O +
Ca2 O -
+ O +
measurement O -
, O +
the O +
morphological O +
change O +
was O +
analyzed O +
by O +
measuring O +
the O +
area O +
of O +
the O +
myocyte O -
. O +

The O +
cell O +
surface O +
area O +
was O +
calculated O +
from O +
the O +
digitized O +
image O +
of O +
the O +
cell O +
and O +
the O +
post O -
- O -
ischemic O +
value O +
was O +
expressed O +
as O +
percentage O +
of O +
the O +
pre O -
- O -
ischemic O +
value O -
. O +

2.4 O +
Experimental O +
protocols O +
In O +
order O +
to O +
determine O +
the O +
optimal O +
condition O +
of O +
the O +
Ca2 O -
+ O +
overload O +
model O +
by O +
metabolic O +
inhibition O +
and O +
energy O +
repletion O -
, O +
we O +
performed O +
some O +
preliminary O +
experiments O -
. O +

We O +
first O +
followed O +
a O +
protocol O +
for O +
metabolic O +
inhibition O -
, O +
using O +
Tyrode O +
solution O +
containing O +
normal O +
Ca2 O -
+ O +
and O +
1 O +
M O +
of O +
CCCP O -
. O +

However O -
, O +
the O +
myocytes O +
exposed O +
to O +
CCCP O +
for O +
1015 O +
min O +
showed O +
a O +
rigor O +
contraction O +
with O +
an O +
increase O +
in O +
[ O -
Ca2 O -
+ O +
] O -
i O +
, O +
but O +
failed O +
to O +
show O +
Ca2 O -
+ O +
overload O +
on O +
washout O +
of O +
CCCP O +
( O -
energy O +
repletion O -
) O +
after O +
the O +
transition O +
to O +
rigor O +
contraction O +
( O -
the O +
sign O +
of O +
ATP O +
depletion O -
) O -
. O +

These O +
cells O +
showed O +
neither O +
further O +
[ O -
Ca2 O -
+ O +
] O -
i O +
increase O +
nor O +
morphological O +
changes O +
after O +
energy O +
repletion O -
. O +

To O +
improve O +
the O +
efficacy O +
of O +
the O +
assessment O +
of O +
reperfusion O +
injury O -
, O +
we O +
used O +
Ca2 O -
+ O +
-free O +
Tyrode O +
solution O +
for O +
metabolic O +
inhibition O -
, O +
since O +
it O +
was O +
reported O +
that O +
cells O +
in O +
the O +
low O +
Ca2 O -
+ O +
solution O +
remain O +
rod O -
- O -
shaped O +
for O +
a O +
longer O +
period O +
against O +
metabolic O +
inhibition O +
( O -
Li O +
et O +
al. O -
, O +
1988 O -
) O +
. O +

We O +
also O +
examined O +
the O +
dose O -
- O -
dependent O +
effects O +
of O +
CCCP O +
( O -
100 O +
nM O -
, O +
1 O +
and O +
3 O +
M O -
) O -
, O +
and O +
confirmed O +
that O +
1 O +
M O +
of O +
CCCP O +
was O +
the O +
most O +
stable O +
to O +
induce O +
Ca2 O -
+ O +
overload O +
after O +
energy O +
repletion O -
. O +

Based O +
on O +
these O +
experiments O -
, O +
we O +
established O +
the O +
standard O +
procedure O +
as O +
follows O -
. O +

After O +
confirmation O +
of O +
the O +
integrity O +
of O +
the O +
myocardial O +
store O +
functions O +
described O +
in O +
the O +
previous O +
section O -
, O +
Ca2 O -
+ O +
-free O +
Tyrode O +
containing O +
CCCP O +
( O -
1 O +
M O -
) O +
was O +
perfused O +
for O +
40 O +
min O +
at O +
a O +
perfusion O +
rate O +
of O +
23 O +
ml O -
/ O -
min O -
. O +

Ca2 O -
+ O +
overload O +
was O +
induced O +
by O +
washout O +
of O +
CCCP O +
with O +
normal O +
Tyrode O +
solution O +
for O +
30 O +
min O +
at O +
a O +
perfusion O +
rate O +
of O +
45 O +
ml O -
/ O -
min O -
. O +

In O +
this O +
study O -
, O +
we O +
employed O +
the O +
following O +
two O +
protocols O -
: O +
( O -
A O -
) O +
before O +
metabolic O +
inhibition O -
, O +
in O +
which O +
drugs O +
were O +
included O +
throughout O +
the O +
experiment O -
, O +
and O +
( O -
B O -
) O +
before O +
energy O +
repletion O -
, O +
in O +
which O +
drugs O +
were O +
included O +
from O +
5 O +
min O +
before O +
energy O +
repletion O +
to O +
the O +
end O +
of O +
the O +
experiment O -
. O +

2.5 O +
Calibration O +
for O +
Ca2 O -
+ O +
concentration O +
The O +
maximum O +
ratio O +
( O -
R O +
max O +
) O +
unique O +
to O +
individual O +
cells O +
was O +
obtained O +
at O +
the O +
end O +
of O +
each O +
experiment O +
by O +
applying O +
ionomycin O +
( O -
2 O +
M O -
) O +
to O +
the O +
normal O +
Tyrode O +
solution O -
. O +

The O +
minimum O +
ratio O +
( O -
R O +
min O +
) O +
was O +
obtained O +
by O +
applying O +
EGTA O +
( O -
10 O +
mM O -
) O +
to O +
the O +
ionomycin O +
containing O +
Tyrode O +
solution O -
. O +

Both O +
R O +
max O +
and O +
R O +
min O +
values O +
were O +
obtained O +
under O +
steady O +
state O +
conditions O -
. O +

[ O -
Ca2 O -
+ O +
] O -
i O +
was O +
calculated O +
from O +
the O +
following O +
formula O -
: O +
[ O -
Ca2 O -
+ O +
] O -
i O +
( O -
nM O -
) O -
= O -
( O -
R O +
R O +
min O +
) O -
K O +
d O +
F O +
min O +
/ O -
( O -
( O -
R O +
max O +
R O +
) O -
F O +
max O +
) O -
) O -
, O +
where O +
R O +
is O +
the O +
ratio O +
obtained O +
from O +
the O +
experiment O -
, O +
F O +
means O +
the O +
fluorescence O +
intensity O +
at O +
380-nm O +
excitation O -
, O +
and O +
K O +
d O +
is O +
the O +
dissociation O +
constant O +
defined O +
as O +
224 O +
nM. O +
2.6 O +
Chemicals O +
l O +
-cis O +
Diltiazem O +
and O +
diltiazem O +
were O +
kind O +
gifts O +
from O +
Tanabe O +
Seiyaku O +
( O -
Osaka O -
, O +
Japan O -
) O -
. O +

A O +
specific O +
inhibitor O +
of O +
Na+ O +
/Ca2 O -
+ O +
exchanger O -
, O +
2- O -
[ O -
2- O -
[ O -
4- O -
( O -
4-nitrobenzyloxy O -
) O +
phenyl O -
] O +
ethyl O -
] O +
isothiourea O +
methanesulphonate O +
( O -
KB O -
- O -
R7943 O -
) O -
, O +
was O +
a O +
kind O +
gift O +
from O +
Kanebo O +
( O -
Osaka O -
, O +
Japan O -
) O -
. O +

CCCP O +
was O +
purchased O +
from O +
Sigma O -
. O +

2.7 O +
Statistical O +
analysis O +
All O +
data O +
were O +
expressed O +
as O +
meansS.E.M. O +
The O +
time O +
course O +
data O +
( O -
Ca2 O -
+ O +
measurement O -
) O +
were O +
divided O +
into O +
two O +
events O -
, O +
during O +
40 O +
min O +
of O +
metabolic O +
inhibition O +
and O +
during O +
30-min O +
energy O +
repletion O -
, O +
and O +
repeated O +
measures O +
two O -
- O -
way O +
analysis O +
of O +
variance O +
was O +
used O -
. O +

If O +
there O +
was O +
no O +
interaction O +
between O +
the O +
drug O +
factor O +
and O +
the O +
time O +
factor O -
, O +
Bonferroni O -
/ O -
Dunn O +
( O -
Dunn O -
's O +
Procedure O +
for O +
Comparing O +
a O +
Control O +
to O +
All O +
other O +
Means O -
) O +
post O -
- O -
hoc O +
test O +
was O +
done O +
thereafter O -
. O +

One O -
- O -
way O +
analysis O +
of O +
variance O +
( O -
ANOVA O -
) O +
followed O +
by O +
the O +
Bonferroni O -
/ O -
Dunn O +
post O -
- O -
hoc O +
test O +
was O +
used O +
for O +
the O +
cell O +
size O +
data O -
. O +

All O +
statistical O +
analyses O +
were O +
performed O +
using O +
Super O +
ANOVA O -
 O +
( O -
Abacus O +
Concepts O -
, O +
Berkeley O -
, O +
CA O -
) O -
. O +

Differences O +
were O +
considered O +
to O +
be O +
statistically O +
significant O +
when O +
the O +
P O +
value O +
was O +
less O +
than O +
0.05 O -
. O +

3 O +
Results O +
3.1 O +
Cell O +
selection O +
In O +
all O +
the O +
experiments O -
, O +
rod O -
- O -
shaped O +
myocytes O +
as O +
shown O +
in O +
Fig. O +
1A O +
were O +
selected O -
. O +

A O +
single O +
myocyte O +
was O +
further O +
selected O +
for O +
the O +
ischemia O +
experiment O -
, O +
based O +
on O +
the O +
criterion O +
that O +
it O +
showed O +
a O +
transient O +
[ O -
Ca2 O -
+ O +
] O -
i O +
increase O +
on O +
treatment O +
with O +
5 O +
mM O +
caffeine O +
( O -
Fig. O +
1B O -
) O +
. O +

The O +
cells O -
, O +
which O +
did O +
not O +
satisfy O +
these O +
criteria O -
, O +
or O +
which O +
changed O +
morphologically O +
after O +
the O +
treatment O +
with O +
caffeine O -
, O +
were O +
excluded O -
. O +

3.2 O +
Changes O +
in O +
[ O -
Ca2 O -
+ O +
] O -
i O +
by O +
metabolic O +
inhibition O +
and O +
energy O +
repletion O +
Fig. O +
2 O +
represents O +
the O +
change O +
in O +
time O +
course O +
of O +
[ O -
Ca2 O -
+ O +
] O +

i O +
in O +
the O +
absence O +
and O +
the O +
presence O +
of O +
drugs O -
. O +

Before O +
CCCP O +
treatment O -
, O +
the O +
[ O -
Ca2 O -
+ O +
] O -
i O +
of O +
all O +
cells O +
used O +
were O +
almost O +
identical O +
in O +
level O +
( O -
about O +
100 O +
nM O -
) O -
. O +

In O +
the O +
control O +
myocytes O -
, O +
[ O -
Ca2 O -
+ O +
] O -
i O +
did O +
not O +
change O +
during O +
40 O +
min O +
of O +
CCCP O +
treatment O -
. O +

After O +
washout O +
of O +
CCCP O -
, O +
[ O -
Ca2 O -
+ O +
] O -
i O +
increased O +
dramatically O +
within O +
5 O +
min O +
and O +
continued O +
to O +
increase O +
until O +
the O +
end O +
of O +
energy O +
repletion O -
. O +

In O +
order O +
to O +
confirm O +
that O +
this O +
[ O -
Ca2 O -
+ O +
] O -
i O +
increase O +
was O +
not O +
due O +
to O +
the O +
simple O +
entry O +
of O +
extracellular O +
Ca2 O -
+ O +
when O +
Ca2 O -
+ O +
-free O +
Tyrode O +
was O +
replaced O +
by O +
normal O +
Tyrode O -
, O +
we O +
performed O +
the O +
same O +
perfusion O +
protocol O +
without O +
CCCP O +
treatment O -
. O +

We O +
observed O +
that O +
the O +
[ O -
Ca2 O -
+ O +
] O -
i O +
showed O +
a O +
small O +
( O -
2030 O +
nM O -
) O -
, O +
but O +
not O +
significant O -
, O +
increase O +
at O +
5 O +
min O +
after O +
energy O +
repletion O -
. O +

Therefore O -
, O +
the O +
Ca2 O -
+ O +
overload O +
observed O +
here O +
is O +
considered O +
to O +
be O +
induced O +
by O +
the O +
injury O +
due O +
to O +
metabolic O +
inhibition O +
and O +
energy O +
repletion O -
. O +

Furthermore O -
, O +
Ni2 O -
+ O +
( O -
5 O +
mM O -
) O +
and O +
KB O -
- O -
R7943 O +
( O -
10 O +
M O -
) O -
, O +
known O +
as O +
inhibitors O +
of O +
the O +
Na+ O +
/Ca2 O -
+ O +
exchanger O -
, O +
completely O +
blocked O +
the O +
initial O +
rise O +
of O +
[ O -
Ca2 O -
+ O +
] O -
i O +
after O +
washout O +
of O +
CCCP O +
( O -
P O +
< O -
0.01 O +
vs. O +
control O -
) O +
and O +
continued O +
to O +
attenuate O +
the O +
[ O -
Ca2 O -
+ O +
] O -
i O +
increase O +
during O +
30 O +
min O +
of O +
energy O +
repletion O -
. O +

However O -
, O +
nitrendipine O +
( O -
10 O +
M O -
) O -
, O +
a O +
dihydropyridine O +
Ca2 B-Gene -
+ I-Gene +
channel I-Gene +
blocker O -
, O +
failed O +
to O +
attenuate O +
the O +
[ O -
Ca2 O -
+ O +
] O -
i O +
increase O +
after O +
washout O +
of O +
CCCP O -
. O +

Nicardipine O +
( O -
10 O +
M O -
) O -
, O +
another O +
dihydropyridine O +
Ca2 B-Gene -
+ I-Gene +
channel I-Gene +
blocker O -
, O +
also O +
failed O +
to O +
attenuate O +
the O +
[ O -
Ca2 O -
+ O +
] O -
i O +
increase O +
( O -
see O +
Table O +
1 O +
) O -
. O +

Thus O -
, O +
the O +
[ O -
Ca2 O -
+ O +
] O -
i O +
increase O +
in O +
this O +
model O +
was O +
suggested O +
to O +
be O +
mediated O -
, O +
not O +
by O +
L B-Gene -
- I-Gene -
type I-Gene +
Ca2 I-Gene -
+ I-Gene +
channels I-Gene +
but O +
by O +
the O +
Na+ O +
/Ca2 O -
+ O +
exchanger O -
. O +

As O +
for O +
the O +
treatment O +
with O +
drugs O +
before O +
metabolic O +
inhibition O +
( O -
protocol O +
( O -
A O -
) O -
) O -
, O +
diltiazem O +
( O -
3 O +
M O -
) O +
and O +
l O +
-cis O +
diltiazem O +
( O -
10 O +
M O -
) O -
, O +
but O +
not O +
l O +
-cis O +
diltiazem O +
( O -
3 O +
M O -
) O +
significantly O +
attenuated O +
the O +
[ O -
Ca2 O -
+ O +
] O -
i O +
increase O +
during O +
energy O +
repletion O +
( O -
Fig. O +
3A O -
) O +
. O +

As O +
for O +
the O +
treatment O +
with O +
drugs O +
5 O +
min O +
before O +
washout O +
of O +
CCCP O +
( O -
protocol O +
( O -
B O -
) O -
) O -
, O +
3 O +
M O +
of O +
diltiazem O -
, O +
which O +
was O +
effective O +
in O +
protocol O +
( O -
A O -
) O -
, O +
failed O +
to O +
attenuate O +
the O +
[ O -
Ca2 O -
+ O +
] O -
i O +
increase O -
. O +

However O -
, O +
a O +
higher O +
concentration O +
of O +
diltiazem O +
( O -
10 O +
M O -
) O +
could O +
significantly O +
attenuate O +
the O +
[ O -
Ca2 O -
+ O +
] O -
i O +
increase O +
after O +
energy O +
repletion O +
( O -
Fig. O +
3B O -
) O +
. O +

l O +
-cis O +
Diltiazem O +
( O -
10 O +
M O -
) O +
also O +
attenuated O +
the O +
[ O -
Ca2 O -
+ O +
] O -
i O +
increase O +
( O -
P O +
< O -
0.01 O +
vs. O +
control O -
) O -
. O +

3.3 O +
Morphological O +
change O +
of O +
the O +
cell O +
after O +
energy O +
repletion O +
Cells O -
, O +
which O +
showed O +
a O +
rigor O +
contraction O +
during O +
CCCP O +
treatment O -
, O +
were O +
all O +
excluded O +
from O +
the O +
experiments O -
. O +

Table O +
1 O +
represents O +
the O +
morphological O +
change O +
in O +
cell O +
size O +
caused O +
by O +
metabolic O +
inhibition O +
and O +
energy O +
repletion O +
in O +
the O +
absence O +
and O +
the O +
presence O +
of O +
drugs O -
, O +
accompanied O +
by O +
[ O -
Ca2 O -
+ O +
] O -
i O +
. O +

Compared O +
with O +
the O +
control O -
, O +
l O +
-cis O +
diltiazem O +
( O -
10 O +
M O -
) O -
, O +
diltiazem O +
( O -
10 O +
M O -
) O -
, O +
Ni2 O -
+ O +
( O -
5 O +
mM O -
) O +
and O +
KB O -
- O -
R7943 O +
( O -
10 O +
M O -
) O -
, O +
added O +
5 O +
min O +
before O +
washout O +
of O +
CCCP O -
, O +
all O +
reduced O +
the O +
cell O +
shortening O +
( O -
P O +
< O -
0.05 O -
) O -
, O +
and O +
these O +
effects O +
correlated O +
well O +
with O +
the O +
attenuation O +
in O +
[ O -
Ca2 O -
+ O +
] O -
i O +
increase O -
. O +

Treatment O +
with O +
diltiazem O +
( O -
3 O +
M O -
) O +
failed O +
to O +
reduce O +
the O +
contraction O -
, O +
which O +
correlated O +
with O +
the O +
increase O +
in O +
[ O -
Ca2 O -
+ O +
] O -
i O +
. O +

Neither O +
nitrendipine O +
( O -
10 O +
M O -
) O +
nor O +
nicardipine O +
( O -
10 O +
M O -
) O +
attenuated O +
the O +
contraction O +
or O +
the O +
[ O -
Ca2 O -
+ O +
] O -
i O +
increase O +
after O +
energy O +
repletion O -
. O +

4 O +
Discussion O +
4.1 O +
Increase O +
in O +
[ O -
Ca2 O -
+ O +
] O -
i O +
by O +
metabolic O +
inhibition O +
and O +
energy O +
repletion O +
in O +
guinea O +
pig O +
isolated O +
myocytes O +
Isolated O +
cardiomyocytes O +
are O +
reversibly O +
made O +
ATP O -
- O -
depleted O +
by O +
CCCP O -
, O +
a O +
reversible O +
inhibitor O +
of O +
mitochondrial O +
oxidative O +
phosphorylation O +
( O -
Li O +
et O +
al. O -
, O +
1989 O -
) O +
. O +

The O +
myocytes O -
, O +
which O +
show O +
a O +
rigor O +
contraction O +
on O +
metabolic O +
inhibition O +
are O +
reported O +
to O +
have O +
depressed O +
Ca2 O -
+ O +
overload O -
, O +
because O +
the O +
activity O +
of O +
the O +
Na+ O +
/Ca2 O -
+ O +
exchanger O +
is O +
inhibited O +
by O +
energy O +
depletion O +
( O -
Li O +
et O +
al. O -
, O +
1988 O -
; O +
Collins O +
et O +
al. O -
, O +
1992 O -
) O +
. O +

Li O +
et O +
al. O +
( O -
1988 O -
) O +
have O +
also O +
reported O +
that O +
cells O +
maintaining O +
a O +
low O +
[ O -
Ca2 O -
+ O +
] O -
i O +
level O +
remain O +
rod O -
- O -
shaped O +
for O +
a O +
longer O +
period O +
against O +
metabolic O +
inhibition O -
. O +

Since O +
our O +
aim O +
was O +
to O +
assess O +
the O +
effect O +
of O +
l O +
-cis O +
diltiazem O +
on O +
reperfusion O -
- O -
induced O +
Ca2 O -
+ O +
overload O +
in O +
vitro O -
, O +
we O +
followed O +
a O +
protocol O +
with O +
Ca2 O -
+ O +
-free O +
Tyrode O +
solution O -
, O +
which O +
improves O +
the O +
efficacy O +
of O +
the O +
assessment O +
of O +
reperfusion O +
injury O -
. O +

Using O +
this O +
type O +
of O +
model O -
, O +
we O +
could O +
partially O +
simulate O +
the O +
ischemia O -
/ O -
reperfusion O -
- O -
induced O +
Ca2 O -
+ O +
overload O +
in O +
vitro O +
by O +
metabolic O +
inhibition O +
and O +
energy O +
repletion O -
. O +

A O +
marked O +
[ O -
Ca2 O -
+ O +
] O -
i O +
increase O +
was O +
observed O +
after O +
washout O +
of O +
CCCP O +
with O +
Ca2 O -
+ O +
-containing O +
Tyrode O +
solution O -
. O +

This O +
[ O -
Ca2 O -
+ O +
] O -
i O +
increase O +
was O +
suppressed O +
by O +
Ni2 O -
+ O +
or O +
KB O -
- O -
R7943 O -
, O +
a O +
specific O +
inhibitor O +
of O +
the O +
Na+ O +
/Ca2 O -
+ O +
exchanger O -
, O +
but O +
was O +
not O +
suppressed O +
by O +
nitrendipine O +
or O +
nicardipine O +
( O -
Fig. O +
2 O -
) O +
. O +

These O +
results O +
indicate O +
that O +
the O +
[ O -
Ca2 O -
+ O +
] O -
i O +
increase O +
by O +
energy O +
repletion O +
occurred O +
via O +
the O +
Na+ O +
/Ca2 O -
+ O +
exchanger O -
, O +
but O +
not O +
through O +
the O +
dihydropyridine O -
- O -
sensitive O +
Ca2 B-Gene -
+ I-Gene +
channel I-Gene +
in O +
this O +
model O -
. O +

4.2 O +
Cardioprotective O +
effect O +
of O +
l O +
-cis O +
diltiazem O +
on O +
Ca2 O -
+ O +
overload O +
in O +
guinea O +
pig O +
myocytes O +
In O +
the O +
present O +
study O -
, O +
l O +
-cis O +
diltiazem O +
and O +
diltiazem O +
attenuated O +
both O +
the O +
[ O -
Ca2 O -
+ O +
] O -
i O +
increase O +
and O +
the O +
cell O +
shortening O +
induced O +
by O +
CCCP O -
. O +

Itogawa O +
et O +
al. O +
( O -
1996 O -
) O +
demonstrated O +
that O +
both O +
l O +
-cis O +
diltiazem O +
and O +
diltiazem O +
attenuated O +
veratridine O -
- O -
induced O +
Ca2 O -
+ O +
overload O +
and O +
hypercontracture O +
in O +
isolated O +
rat O +
hearts O -
. O +

However O -
, O +
this O +
is O +
not O +
direct O +
evidence O +
that O +
l O +
-cis O +
diltiazem O +
actually O +
protects O +
against O +
ischemia O -
/ O -
reperfusion O +
injury O +
by O +
inhibiting O +
Ca2 O -
+ O +
overload O -
. O +

In O +
the O +
present O +
study O -
, O +
we O +
mimicked O +
the O +
phenomenon O +
of O +
ischemia O -
/ O -
reperfusion O +
injury O +
in O +
the O +
chamber O +
and O +
our O +
data O +
are O +
the O +
first O +
demonstration O +
that O +
both O +
l O +
-cis O +
diltiazem O +
and O +
diltiazem O +
protect O +
against O +
the O +
Ca2 O -
+ O +
overload O +
induced O +
by O +
metabolic O +
inhibition O +
and O +
energy O +
repletion O +
in O +
the O +
same O +
concentration O +
range O -
. O +

This O +
observation O -
, O +
together O +
with O +
the O +
observation O +
that O +
nitrendipine O +
and O +
nicardipine O +
were O +
without O +
effect O -
, O +
suggests O +
that O +
their O +
effects O +
are O +
independent O +
of O +
L B-Gene -
- I-Gene -
type I-Gene +
Ca2 I-Gene -
+ I-Gene +
channel I-Gene +
blocking O -
. O +

This O +
possibility O +
is O +
also O +
supported O +
by O +
the O +
results O +
of O +
a O +
previous O +
study O +
in O +
our O +
laboratory O +
showing O +
that O +
l O +
-cis O +
diltiazem O +
( O -
10 O +
M O -
) O +
as O +
well O +
as O +
diltiazem O +
( O -
3 O +
M O -
) O +
worked O +
to O +
preserve O +
high O -
- O -
energy O +
phosphates O +
in O +
the O +
ischemia O -
 O -
reperfusion O +
model O +
of O +
isolated O +
guinea O +
pig O +
hearts O +
( O -
submitted O +
for O +
publication O -
) O -
. O +

In O +
the O +
present O +
study O -
, O +
inclusion O +
of O +
diltiazem O +
( O -
3 O +
M O -
) O +
throughout O +
the O +
experiment O +
attenuated O +
the O +
[ O -
Ca2 O -
+ O +
] O -
i O +
increase O +
during O +
reperfusion O +
( O -
Fig. O +
3A O -
) O +
. O +

However O -
, O +
the O +
addition O +
of O +
diltiazem O +
( O -
3 O +
M O -
) O -
, O +
started O +
5 O +
min O +
before O +
reperfusion O -
, O +
failed O +
to O +
attenuate O +
the O +
[ O -
Ca2 O -
+ O +
] O -
i O +
increase O +
( O -
Fig. O +
3B O -
) O +
. O +

Thus O -
, O +
we O +
suggest O +
that O +
some O +
events O +
during O +
chemical O +
ischemia O -
, O +
which O +
could O +
be O +
affected O +
by O +
diltiazem O -
, O +
might O +
be O +
involved O +
in O +
the O +
Ca2 O -
+ O +
overload O +
during O +
reperfusion O +
( O -
Watts O +
et O +
al. O -
, O +
1990 O -
; O +
Sakamoto O +
et O +
al. O -
, O +
1997 O -
) O +
. O +

4.3 O +
Cardioprotective O +
mechanism O +
by O +
l O +
-cis O +
diltiazem O +
on O +
Ca2 O -
+ O +
overload O +
by O +
metabolic O +
inhibition O +
and O +
energy O +
repletion O +
In O +
the O +
present O +
model O -
, O +
the O +
[ O -
Ca2 O -
+ O +
] O -
i O +
increase O +
after O +
energy O +
repletion O +
was O +
inhibited O +
by O +
both O +
Ni2 O -
+ O +
and O +
KB O -
- O -
R7943 O +
( O -
Fig. O +
2 O -
) O +
. O +

Concerning O +
the O +
[ O -
Ca2 O -
+ O +
] O -
i O +
increase O +
in O +
this O +
model O -
, O +
the O +
L B-Gene -
- I-Gene -
type I-Gene +
Ca2 I-Gene -
+ I-Gene +
channel I-Gene +
does O +
not O +
seem O +
to O +
be O +
involved O -
. O +

This O +
is O +
because O +
the O +
dihydropyridine O +
Ca2 B-Gene -
+ I-Gene +
channel I-Gene +
blockers O -
, O +
nitrendipine O +
and O +
nicardipine O -
, O +
affected O +
neither O +
[ O -
Ca2 O -
+ O +
] O -
i O +
increase O +
nor O +
cell O +
shortening O +
( O -
Table O +
1 O -
) O +
. O +

The O +
inhibition O +
of O +
the O +
Na+ O +
/Ca2 O -
+ O +
exchanger O +
may O +
afford O +
protection O +
from O +
metabolic O +
inhibition O +
and O +
energy O +
repletion O -
. O +

A O +
previous O +
report O +
has O +
demonstrated O +
that O +
the O +
intracellular O +
Na+ O +
concentration O +
( O -
[ O -
Na+ O +
] O -
i O +
) O +
is O +
increased O +
by O +
metabolic O +
inhibition O +
in O +
guinea O +
pig O +
myocytes O +
( O -
Satoh O +
et O +
al. O -
, O +
1995 O -
) O +
. O +

This O +
indicates O +
that O +
Na+ O +
overload O +
caused O +
during O +
metabolic O +
inhibition O +
is O +
important O +
in O +
this O +
model O -
. O +

Itogawa O +
et O +
al. O +
( O -
1996 O -
) O +
previously O +
reported O +
that O +
l O +
-cis O +
diltiazem O +
inhibited O +
veratridine O -
- O -
induced O +
Na+ O +
overload O +
in O +
rat O +
cardiac O +
myocytes O -
. O +

Haigney O +
et O +
al. O +
( O -
1992 O -
) O +
reported O +
that O +
the O +
[ O -
Na+ O +
] O -
i O +
increase O +
seen O +
during O +
hypoxia O +
is O +
potentiated O +
after O +
rigor O +
contraction O +
in O +
isolated O +
rat O +
myocytes O -
. O +

They O +
also O +
suggested O +
that O +
inactivation O -
- O -
resistant O +
Na+ B-Gene +
channels I-Gene +
were O +
involved O +
in O +
this O +
[ O -
Na+ O +
] O -
i O +
increase O -
. O +

We O +
demonstrated O +
in O +
the O +
present O +
study O +
that O +
both O +
l O +
-cis O +
diltiazem O +
and O +
diltiazem O +
at O +
10 O +
M O -
, O +
when O +
introduced O +
5 O +
min O +
before O +
washout O +
of O +
CCCP O -
, O +
attenuated O +
cell O +
shortening O +
after O +
energy O +
repletion O +
( O -
Fig. O +
3B O -
) O +
. O +

Thus O -
, O +
it O +
is O +
speculated O +
that O +
both O +
l O +
-cis O +
diltiazem O +
and O +
diltiazem O +
attenuate O +
Ca2 O -
+ O +
overload O +
by O +
inhibiting O +
the O +
[ O -
Na+ O +
] O -
i O +
accumulation O +
early O +
after O +
energy O +
repletion O -
. O +

In O +
conclusion O -
, O +
we O +
first O +
demonstrated O +
that O +
l O +
-cis O +
diltiazem O +
attenuated O +
the O +
Ca2 O -
+ O +
overload O +
caused O +
by O +
metabolic O +
inhibition O +
and O +
energy O +
repletion O +
in O +
guinea O +
pig O +
myocytes O -
. O +

The O +
cardioprotective O +
action O +
of O +
l O +
-cis O +
diltiazem O +
evidenced O +
in O +
the O +
present O +
work O +
merits O +
further O +
research O -
, O +
since O +
l O +
-cis O +
diltiazem O +
could O +
become O +
a O +
lead O +
compound O +
for O +
investigating O +
protection O +
against O +
ischemia O -
/ O -
reperfusion O +
injury O -
. O +

Acknowledgements O +
The O +
authors O +
wish O +
to O +
thank O +
Dr. O +
Satomi O +
Adachi O -
- O -
Akahane O +
( O -
University O +
of O +
Tokyo O -
) O +
for O +
the O +
helpful O +
discussions O +
and O +
Mr. O +
Shoichi O +
Kanda O -
, O +
Ms. O +
Maki O +
Urata O -
, O +
and O +
Mr. O +
Taichiro O +
Tomida O +
( O -
University O +
of O +
Tokyo O -
) O +
for O +
the O +
kind O +
assistance O +
with O +
cell O +
preparation O -
. O +

We O +
thank O +
Tanabe O +
Seiyaku O +
for O +
the O +
kind O +
gift O +
of O +
l O +
-cis O +
diltiazem O +
and O +
diltiazem O -
. O +

We O +
thank O +
Kanebo O +
for O +
the O +
kind O +
gift O +
of O +
KB O -
- O -
R O +
7943 O -
. O +

This O +
work O +
was O +
supported O +
by O +
a O +
Grant O -
- O -
in O -
- O -
Aid O +
for O +
Scientific O +
Research O +
from O +
the O +
Ministry O +
of O +
Education O -
, O +
Science O -
, O +
Sports O +
and O +
Culture O -
, O +
Japan O -
. O +

Dopamine O +
( O -
DA O -
) O +
is O +
a O +
neurotransmitter O +
that O +
plays O +
a O +
fundamental O +
role O +
in O +
the O +
control O +
of O +
a O +
variety O +
of O +
physiological O +
functions O +
including O +
locomotor O +
movement O -
, O +
learning O -
, O +
reward O +
behavior O -
, O +
and O +
hormone O +
synthesis O +
and O +
release O +
[ O -
40 O -
] O +
. O +

However O -
, O +
overflow O +
of O +
DA O +
in O +
the O +
brain O +
has O +
been O +
suggested O +
to O +
participate O +
in O +
certain O +
neurodegenerative O +
processes O -
. O +

These O +
include O +
ischemia O +
[ O -
6 O -
] O +
, O +
hypoxia O +
[ O -
2 O -
] O +
, O +
and O +
neurotoxicities O +
induced O +
by O +
excitatory O +
amino O +
acids O +
[ O -
16 O -
] O +
and O +
methamphetamine O +
[ O -
38 O -
] O +
. O +

In O +
all O +
of O +
the O +
above O +
cases O -
, O +
striatal O +
DA O +
availability O +
in O +
the O +
brain O +
is O +
significantly O +
increased O -
. O +

For O +
example O -
, O +
the O +
striatal O +
DA O +
concentration O +
rapidly O +
reaches O +
concentrations O +
as O +
high O +
as O +
0.2 O +
mM O +
after O +
ligation O +
of O +
the O +
cervical O +
artery O +
in O +
the O +
gerbil O +
ischemic O +
model O +
[ O -
45 O -
] O +
. O +

Depletion O +
of O +
endogenous O +
DA O +
by O +
chemical O +
lesion O +
of O +
the O +
nigrostriatal O +
dopaminergic O +
pathway O +
reduces O +
ischemic O +
insult O +
to O +
the O +
striatum O +
[ O -
17 O -
] O +
. O +

Direct O +
intrastriatal O +
injections O +
of O +
DA O +
result O +
in O +
apoptosis O +
and O +
neurodegeneration O +
[ O -
18 O -
, O +
19 O -
] O +
. O +

This O +
DA O +
neurotoxicity O +
is O +
believed O +
to O +
be O +
mediated O +
through O +
a O +
DA O -
- O -
oxidation O -
- O -
associated O +
pathway O -
. O +

DA O +
oxidative O +
stress O +
is O +
also O +
assumed O +
to O +
be O +
a O +
major O +
pathological O +
factor O +
that O +
contributes O +
to O +
dopaminergic O +
neuronal O +
degeneration O +
in O +
Parkinson O -
's O +
disease O +
[ O -
14 O -
] O +
. O +

We O +
have O +
recently O +
demonstrated O +
that O +
DA O +
induces O +
apoptosis O +
involving O +
the O +
oxidation O -
 O -
JNK O -
 O -
c O -
- O -
Jun O +
activation O +
pathway O +
in O +
in O +
vitro O +
cell O +
cultures O +
[ O -
32 O -
] O +
and O +
activation O +
of O +
transcription O +
factors O +
AP-1 B-Gene +
and O +
NF B-Gene -
- I-Gene -
B I-Gene +
in O +
an O +
in O +
vivo O +
rat O +
model O +
[ O -
29 O -
] O +
. O +

Direct O +
intrastriatal O +
injections O +
of O +
high O +
concentrations O +
of O +
DA O +
in O +
rats O +
also O +
result O +
in O +
activation O +
of O +
astrocytes O +
as O +
indicated O +
by O +
an O +
increase O +
of O +
glial B-Gene +
fibrillary I-Gene +
acidic I-Gene +
protein I-Gene +
( O -
GFAP B-Gene -
) O +
immunocytochemical O +
staining O +
and O +
astrocyte O +
proliferation O +
determined O +
by O +
[ O -
3 O +
H O +
] O -
R05 O -
- O -
4864 O +
binding O +
to O +
peripheral O +
benzodiazepine B-Gene +
receptors I-Gene +
on O +
astrocytes O +
[ O -
15 O -
] O +
. O +

Astrocytes O +
are O +
the O +
intimate O +
partners O +
of O +
neurons O +
and O +
play O +
important O +
physiological O +
roles O +
in O +
the O +
maintenance O +
of O +
the O +
microenvironment O +
of O +
neurons O -
, O +
including O +
sequestration O +
and O +
metabolism O +
of O +
various O +
neurotransmitters O -
, O +
and O +
production O +
of O +
proinflammatory O +
and O +
immunomodulatory O +
cytokines O +
and O +
neuropeptides O +
[ O -
50 O -
] O +
. O +

In O +
the O +
rat O +
ischemic O +
model O -
, O +
activated O +
striatal O +
astrocytes O +
appear O +
to O +
play O +
a O +
protective O +
role O +
for O +
DA O -
- O -
innervated O +
neurons O +
[ O -
51 O -
] O +
. O +

In O +
a O +
cell O +
culture O +
system O -
, O +
striatal O +
astrocytes O +
were O +
also O +
shown O +
to O +
have O +
a O +
protective O +
effect O +
against O +
hydrogen O +
peroxide O +
toxicity O +
in O +
dopaminergic O +
neurons O +
[ O -
24 O -
] O +
. O +

Nevertheless O -
, O +
the O +
mechanism O +
by O +
which O +
DA O +
activates O +
astrocytes O +
is O +
unknown O -
. O +

To O +
investigate O +
potential O +
signaling O +
of O +
activation O +
of O +
astrocytes O +
by O +
DA O -
, O +
we O +
have O +
chosen O +
a O +
rat O +
C6 O +
glioma O +
cell O +
line O +
stably O +
expressing O +
DA B-Gene +
D2L I-Gene +
receptors I-Gene +
based O +
on O +
the O +
following O +
reasons O -
. O +

( O -
1 O -
) O +
C6 O +
glioma O +
cells O +
have O +
been O +
widely O +
used O +
as O +
a O +
model O +
of O +
glial O +
phenotype O +
[ O -
5 O -
, O +
39 O -
] O +
. O +

( O -
2 O -
) O +
Recent O +
evidence O +
suggests O +
that O +
D2 B-Gene +
receptors I-Gene +
are O +
expressed O +
in O +
striatal O +
astrocytes O -
. O +

Physiologically O -
, O +
DA O +
can O +
induce O +
membrane O +
hyperpolarization O +
in O +
the O +
majority O +
of O +
astrocytes O +
from O +
the O +
striatum O -
, O +
which O +
can O +
be O +
inhibited O +
by O +
application O +
of O +
domperidone O -
, O +
a O +
D2 B-Gene +
receptor I-Gene +
antagonist O +
[ O -
21 O -
] O +
. O +

D2 B-Gene +
antagonists O -
, O +
[ O -
3 O +
H O +
] O -
domperidone O +
and O +
[ O -
3 O +
H O +
] O -
spiperone O -
, O +
can O +
specifically O +
label O +
striatal O +
astrocytes O +
[ O -
20 O -
] O +
. O +

D2 B-Gene +
receptor I-Gene +
mRNA O +
can O +
be O +
detected O +
by O +
either O +
in O +
situ O +
hybridization O +
or O +
polymerase B-Gene +
chain O +
reaction O +
from O +
astrocytes O +
in O +
striatum O -
, O +
an O +
area O +
enriched O +
with O +
dopaminergic O +
termini O -
, O +
but O +
not O +
astrocytes O +
in O +
cerebellum O -
, O +
which O +
receives O +
little O +
dopaminergic O +
innervation O +
[ O -
4 O -
] O +
. O +

This O +
region O -
- O -
specific O +
expression O +
of O +
D2 B-Gene +
receptors I-Gene +
suggests O +
that O +
dopaminergic O +
neurons O +
may O +
physiologically O +
influence O +
astrocyte O +
functions O -
. O +

( O -
3 O -
) O +
C6-D2L O +
cells O +
stably O +
express O +
recombinant O +
D2L B-Gene +
DA I-Gene +
receptors I-Gene +
[ O -
36 O -
] O +
. O +

The O +
expression O +
level O +
of O +
D2 B-Gene +
receptors I-Gene +
in O +
C6-D2L O +
cells O +
is O +
about O +
188 O +
fmol O -
/ O -
mg O +
protein O -
, O +
which O +
is O +
close O +
to O +
that O +
in O +
striatal O +
membranes O +
( O -
400 O +
fmol O -
/ O -
mg O +
protein O -
) O +
[ O -
30 O -
, O +
37 O -
] O +
. O +

( O -
4 O -
) O +
Like O +
native O +
neuronal O +
D2 B-Gene +
receptors I-Gene -
, O +
the O +
binding O +
of O +
agonist O +
to O +
D2 B-Gene +
receptors I-Gene +
in O +
the O +
C6-D2L O +
cells O +
is O +
functionally O +
coupled O +
to O +
pertussis B-Gene -
- I-Gene -
toxin I-Gene -
- O -
sensitive O +
G B-Gene +
proteins I-Gene -
, O +
resulting O +
in O +
inhibition O +
of O +
adenylate B-Gene +
cyclase I-Gene +
[ O -
49 O -
] O +
and O +
activation O +
of O +
both O +
extracellular B-Gene +
signal I-Gene -
- I-Gene -
regulated I-Gene +
kinases I-Gene +
( O -
ERKs B-Gene -
) O +
and O +
c B-Gene -
- I-Gene -
Jun I-Gene +
N I-Gene -
- I-Gene -
terminal I-Gene +
kinase I-Gene +
( O -
JNK B-Gene -
) O +
[ O -
30 O -
] O +
. O +

Given O +
the O +
fact O +
of O +
C6 O +
glial O +
phenotype O +
and O +
D2 B-Gene +
receptors I-Gene +
in O +
striatal O +
astrocytes O -
, O +
the O +
biological O +
functions O +
stimulated O +
by O +
D2 B-Gene +
receptors I-Gene +
observed O +
in O +
C6-D2L O +
cells O +
may O +
mimic O +
those O +
produced O +
in O +
vivo O -
. O +

Thus O -
, O +
this O +
C6-D2L O +
cell O +
line O +
may O +
serve O +
as O +
a O +
good O +
in O +
vitro O +
cell O +
culture O +
model O +
for O +
studies O +
of O +
DA O +
regulation O +
of O +
glial O +
response O -
. O +

Using O +
this O +
C6-D2L O +
cell O +
line O -
, O +
we O +
have O +
previously O +
reported O +
that O +
nanomolar O +
levels O +
of O +
DA O +
stimulate O +
cell O +
proliferation O +
through O +
activation O +
of O +
both O +
ERKs B-Gene +
and O +
JNK B-Gene +
[ O -
30 O -
] O +
. O +

In O +
the O +
present O +
study O -
, O +
we O +
have O +
found O +
that O +
high O +
concentrations O +
( O -
micromolar O +
levels O -
) O +
of O +
DA O +
stimulate O +
a O +
delayed O +
mitogenesis O +
compared O +
to O +
that O +
induced O +
by O +
the O +
nanomolar O +
levels O +
of O +
DA O -
. O +

This O +
DA O -
- O -
stimulated O +
mitogenesis O +
requires O +
D2-receptor B-Gene -
- O -
mediated O +
intracellular O +
redox O -
 O -
tyrosine B-Gene +
kinase I-Gene +
cascade O -
, O +
but O +
does O +
not O +
need O +
ERK B-Gene +
activation O -
. O +

In O +
addition O -
, O +
micromolar O +
levels O +
of O +
DA O +
also O +
increase O +
GFAP B-Gene +
expression O -
, O +
which O +
is O +
linked O +
to O +
a O +
D2-receptor B-Gene -
- O -
independent O +
p38 B-Gene +
MAPK I-Gene +
activation O -
. O +

2 O +
Materials O +
and O +
methods O +
2.1 O +
Materials O +
Antibodies B-Gene +
against O +
phosphorylated O +
tyrosine O +
( O -
PY99 O -
) O +
and O +
ERK2 B-Gene +
were O +
purchased O +
from O +
Santa O +
Cruz O +
Biotechnology O +
( O -
Santa O +
Cruz O -
, O +
CA O -
) O -
. O +

Antibodies B-Gene +
against O +
phospho B-Gene -
- I-Gene -
specific I-Gene +
ERK I-Gene +
and O +
phospho B-Gene -
- I-Gene -
specific I-Gene +
p38 I-Gene +
MAPK I-Gene +
were O +
from O +
New O +
England O +
Biolabs O +
( O -
Beverly O -
, O +
MA O -
) O -
. O +

DA O -
, O +
( O -
+ O -
) O -
- O +
and O +
( O -
 O -
) O -
-butaclamol O +
hydrochloride O -
, O +
and O +
( O -
 O -
) O -
-quinpirole O +
hydrochloride O +
were O +
from O +
Research O +
Biochemicals O +
International O +
( O -
Natick O -
, O +
MA O -
) O -
. O +

PD098059 O -
, O +
p38 B-Gene +
inhibitor O +
SB O +
203580 O -
, O +
diphenyleneiodonium O +
chloride O +
( O -
DPI O -
) O -
, O +
Herbimycin O +
A O -
, O +
Wortmannin O -
, O +
H7 O -
, O +
and O +
staurosporine O +
were O +
from O +
Calbiochem O +
( O -
San O +
Diego O -
, O +
CA O -
) O -
. O +

Pertussis B-Gene +
toxin I-Gene +
( O -
PTX B-Gene -
) O +
and O +
N O +
-acetyl O -
- O -
l O +
-cysteine O +
( O -
NAC O -
) O +
were O +
from O +
Sigma O +
( O -
St. O +
Louis O -
, O +
MO O -
) O -
. O +

[ O -
3 O +
H O +
] O -
Thymidine O +
was O +
purchased O +
form O +
Amersham O +
( O -
Arlington O +
Heights O -
, O +
IL O -
) O -
. O +

Genistein O +
was O +
from O +
Gibco O +
BRL O +
( O -
Gaithersburg O -
, O +
MD O -
) O -
. O +

Hoechst O +
33342 O +
was O +
from O +
Molecular O +
Probes O +
( O -
Eugene O -
, O +
OR O -
) O -
. O +

2.2 O +
Cell O +
culture O +
and O +
treatments O +
Stably O +
transfected O +
C6-D2L O +
cells O +
were O +
prepared O +
as O +
described O +
[ O -
46 O -
] O +
and O +
maintained O +
in O +
Dulbecco O -
's O +
modified O +
Eagle O -
's O +
medium O +
( O -
DMEM O -
) O +
supplemented O +
with O +
5 O -
% O +
fetal O +
bovine O +
serum O +
and O +
5 O -
% O +
donor O +
calf O +
serum O +
with O +
penicillin O -
/ O -
streptomycin O +
and O +
puromycin O +
( O -
2 O +
g O -
/ O -
ml O -
) O -
. O +

The O +
wild O -
- O -
type O +
C6 O +
cells O +
were O +
maintained O +
in O +
the O +
above O +
medium O +
without O +
puromycin O -
. O +

For O +
tyrosine O +
phosphorylation O +
and O +
GFAP B-Gene +
studies O -
, O +
the O +
cells O +
were O +
starved O +
with O +
serum O -
- O -
free O +
medium O +
containing O +
0.025 O -
% O +
ascorbic O +
acid O +
for O +
68 O +
h O +
and O +
then O +
stimulated O +
with O +
indicated O +
reagents O -
. O +

All O +
reagents O +
were O +
prepared O +
or O +
diluted O +
with O +
DMEM O +
plus O +
0.025 O -
% O +
ascorbic O +
acid O -
. O +

For O +
inhibitory O +
experiments O -
, O +
all O +
inhibitory O +
reagents O +
except O +
PTX B-Gene +
were O +
added O +
0.5 O +
h O +
( O -
PTX B-Gene +
for O +
6 O +
h O -
) O +
prior O +
to O +
stimulation O +
with O +
DA O -
. O +

2.3 O +
Lysate O +
preparation O +
After O +
stimulation O -
, O +
the O +
cells O +
were O +
immediately O +
washed O +
twice O +
using O +
cold O +
PBS O +
and O +
then O +
solubilized O +
with O +
ice O -
- O -
cold O +
buffer O +
consisting O +
of O +
25 O +
mM O +
Hepes O -
, O +
pH O +
7.5 O -
, O +
300 O +
mM O +
NaCl O -
, O +
1.5 O +
mM O +
MgCl2 O +
, O +
0.2 O +
mM O +
EDTA O -
, O +
0.1 O -
% O +
Triton O +
X-100 O -
, O +
20 O +
mM O +
 O -
- O -
glycerophosphate O -
, O +
0.1 O +
mM O +
sodium O +
orthovanadate O -
, O +
0.5 O +
mM O +
DTT O -
, O +
100 O +
g O -
/ O -
ml O +
PMSF O -
, O +
and O +
2 O +
g O -
/ O -
ml O +
leupeptin O -
. O +

Cellular O +
extracts O +
were O +
cleared O +
by O +
centrifugation O +
for O +
30 O +
min O +
at O +
14,000 O +
rpm O +
at O +
4 O -
 O -
C O -
. O +

The O +
supernatants O +
were O +
saved O +
and O +
the O +
protein O +
concentration O +
was O +
determined O +
using O +
Bio O -
- O -
Rad O +
protein O +
reagent O -
. O +

For O +
determination O +
of O +
GFAP B-Gene -
, O +
the O +
cell O +
lysates O +
were O +
prepared O +
as O +
follows O -
. O +

Stimulated O +
cells O +
were O +
scraped O +
and O +
collected O +
by O +
centrifugation O +
for O +
5 O +
min O +
at O +
3000 O +
rpm O -
. O +

The O +
cell O +
pellets O +
were O +
washed O +
once O +
with O +
cold O +
PBS O -
, O +
pH O +
7.4 O -
, O +
solubilized O +
with O +
hot O +
lysis O +
buffer O +
( O -
8090 O -
 O -
C O -
) O +
containing O +
10 O +
mM O +
Tris O -
 O -
HCl O -
, O +
pH O +
7.6 O -
, O +
150 O +
mM O +
NaCl O -
, O +
0.5 O +
mm O +
EDTA O -
, O +
1 O +
mM O +
EGTA O -
, O +
1 O -
% O +
sodium O +
dodecyl O +
sulfate O +
( O -
SDS O -
) O -
, O +
1 O +
mM O +
sodium O +
orthovanadate O -
, O +
1 O +
mM O +
PMSF O -
, O +
1 O +
g O -
/ O -
ml O +
pepstatin O +
A O -
, O +
and O +
2 O +
g O -
/ O -
ml O +
aprotinin B-Gene -
, O +
and O +
heated O +
for O +
20 O +
min O +
at O +
90 O -
 O -
C O -
. O +

The O +
protein B-Gene +
concentration O +
of O +
the O +
lysates O +
was O +
determined O +
by O +
using O +
Micro O +
BCA O +
( O -
Pierce O -
, O +
Rockford O -
, O +
IL O -
) O -
. O +

All O +
lysates O +
were O +
used O +
immediately O +
or O +
aliquoted O +
and O +
stored O +
at O +
70 O -
 O -
C O +
for O +
further O +
use O -
. O +

2.4 O +
Immunoblotting O +
Equal O +
amounts O +
of O +
lysate O +
protein B-Gene +
( O -
40 O +
g O -
/ O -
lane O -
) O +
were O +
run O +
on O +
816 O -
% O +
SDS O -
- O -
PAGE O +
and O +
electrophoretically O +
transferred O +
to O +
nitrocellulose O -
. O +

The O +
nitrocellulose O +
blot O +
was O +
blocked O +
with O +
10 O -
% O +
non O -
- O -
fat O +
dry O +
milk O +
in O +
TBST O +
buffer O +
( O -
20 O +
mM O +
Tris O -
 O -
HCl O -
, O +
pH O +
7.4 O -
, O +
500 O +
mM O +
NaCl O -
, O +
and O +
0.01 O -
% O +
Tween-20 O -
) O +
and O +
then O +
incubated O +
with O +
primary O +
antibodies O +
( O -
phospho B-Gene -
- I-Gene -
specific I-Gene +
ERK I-Gene -
, O +
ERK2 B-Gene -
, O +
phospho B-Gene -
- I-Gene -
specific I-Gene +
p38 I-Gene +
MAPK I-Gene -
, O +
or O +
PY99 B-Gene -
, O +
1:1000 O -
) O +
in O +
TBST O +
containing O +
5 O -
% O +
BSA B-Gene +
overnight O +
at O +
4 O -
 O -
C O -
. O +

The O +
immunoreactive O +
bands O +
were O +
detected O +
by O +
sequential O +
incubation O +
with O +
horseradish B-Gene -
- I-Gene -
peroxidase I-Gene -
- O -
conjugated O +
secondary O +
antibody B-Gene +
( O -
1:5000 O -
, O +
Jackson O +
ImmunoResearch O +
Laboratories O -
, O +
West O +
Grove O -
, O +
PA O -
) O +
and O +
Renaissance O +
substrate O +
( O -
DuPont O -
; O +
Boston O -
, O +
MA O -
) O -
. O +

For O +
control O +
of O +
protein B-Gene +
loading O -
, O +
immunoblotting O +
with O +
ERK2 B-Gene +
was O +
performed O +
using O +
either O +
a O +
sister O +
gel O +
or O +
a O +
stripped O +
blot O -
. O +

For O +
quantitative O +
studies O -
, O +
the O +
band O +
was O +
quantified O +
with O +
the O +
NIH O +
Image O +
1.55 O +
Program O -
. O +

The O +
results O +
were O +
normalized O +
to O +
fold O +
of O +
control O +
and O +
presented O +
as O +
meansS.E.M. O +
2.5 O +
Measurement O +
of O +
mitogenesis O +
The O +
procedures O +
were O +
described O +
elsewhere O +
[ O -
31 O -
] O +
. O +

C6-D2L O +
cells O +
( O -
1 O -
 O -
105 O +
/ml O -
, O +
0.2 O +
ml O -
/ O -
well O -
) O +
were O +
plated O +
in O +
a O +
96-well O +
plate O +
and O +
grown O +
for O +
24 O +
h. O +
The O +
cells O +
were O +
rinsed O +
twice O +
with O +
serum O -
- O -
free O +
DMEM O +
and O +
starved O +
for O +
8 O +
h O +
in O +
serum O -
- O -
free O +
medium O +
containing O +
0.025 O -
% O +
ascorbic O +
acid O -
. O +

After O +
that O -
, O +
the O +
cells O +
were O +
incubated O +
with O +
DA O +
for O +
23 O +
h O +
and O +
pulsed O +
with O +
2 O +
Ci O +
[ O -
3 O +
H O +
] O -
thymidine O +
per O +
well O +
for O +
an O +
additional O +
6 O +
h. O +
The O +
cells O +
in O +
each O +
well O +
were O +
fixed O +
with O +
ice O -
- O -
cold O +
5 O -
% O +
trichloroacetic O +
acid O -
, O +
washed O +
three O +
times O +
with O +
cold O +
STE O +
buffer O +
( O -
150 O +
mM O +
NaCl O -
, O +
50 O +
mM O +
Tris O -
 O -
HCl O -
, O +
pH O +
7.2 O -
, O +
1 O +
mM O +
EDTA O -
) O -
, O +
and O +
solubilized O +
with O +
0.1 O +
ml O +
of O +
a O +
mixture O +
of O +
0.1 O -
% O +
SDS O +
and O +
0.01 O +
N O +
NaOH O -
. O +

Incorporated O +
[ O -
3 O +
H O +
] O -
thymidine O +
was O +
counted O +
with O +
a O +
Beckman O +
liquid O +
scintillation O +
counter O +
and O +
expressed O +
as O +
counts O +
per O +
minute O +
per O +
well O +
( O -
cpm O -
/ O -
well O -
) O -
. O +

2.6 O +
Cell O +
cycle O +
analysis O +
by O +
flow O +
cytometry O +
Cell O +
cycle O +
analysis O +
was O +
performed O +
according O +
to O +
the O +
method O +
by O +
Chrest O +
et O +
al. O +
[ O -
9 O -
] O +
. O +

Briefly O -
, O +
C6-D2L O +
cells O +
were O +
plated O +
in O +
35 O +
mm O +
dishes O -
, O +
and O +
seeded O +
overnight O -
. O +

The O +
cells O +
were O +
starved O +
for O +
8 O +
h O +
by O +
replacing O +
the O +
mixture O +
of O +
DMEM O +
plus O +
0.025 O -
% O +
ascorbic O +
acid O +
and O +
stimulated O +
for O +
29 O +
h. O +
The O +
cells O +
were O +
then O +
collected O +
and O +
suspended O +
in O +
complete O +
cell O +
culture O +
medium O -
. O +

The O +
cells O +
( O -
1 O -
 O -
106 O +
cells O -
/ O -
ml O -
) O +
were O +
treated O +
with O +
1 O +
M O +
Hoechst O +
33342 O +
for O +
30 O +
min O +
at O +
37 O -
 O -
C O -
. O +

Cells O +
were O +
analyzed O +
for O +
DNA O +
content O +
using O +
a O +
FACStarplus O +
flow O +
cytometer O +
( O -
Becton O +
Dickinson O +
Immunocytometry O +
System O -
, O +
San O +
Jose O -
, O +
CA O -
) O +
equipped O +
with O +
argon O +
and O +
krypton O +
lasers O -
. O +

Hoechst O +
33342 O +
stained O +
cells O +
were O +
excited O +
with O +
350356 O +
nm O +
wavelength O +
UV O +
light O +
from O +
the O +
krypton O +
laser O +
and O +
the O +
fluorescence O +
emission O +
was O +
collected O +
with O +
a O +
424-nm O +
filter O -
. O +

DNA O +
histograms O +
were O +
acquired O +
by O +
collecting O +
a O +
total O +
of O +
10,000 O +
events O -
. O +

Cell O +
compartments O -
, O +
including O +
G1 O +
, O +
S O -
, O +
and O +
G2 O +
/M O +
phases O -
, O +
were O +
determined O +
using O +
the O +
Multicycle O +
software O +
( O -
Phoenix O +
Flow O +
Systems O -
, O +
San O +
Diego O -
, O +
CA O -
) O -
. O +

3 O +
Results O +
3.1 O +
DA O +
stimulates O +
mitogenesis O +
We O +
have O +
previously O +
reported O +
that O +
nanomolar O +
levels O +
of O +
DA O +
stimulated O +
mitogenesis O +
in O +
C6-D2L O +
cells O +
[ O -
30 O -
] O +
. O +

The O +
maximal O +
[ O -
3 O +
H O +
] O -
thymidine O +
incorporation O +
into O +
DNA O +
occurs O +
at O +
17 O +
h O +
after O +
exposure O +
to O +
100 O +
nM O +
DA O +
concentration O -
. O +

We O +
extended O +
this O +
study O +
by O +
observing O +
the O +
cell O +
response O +
at O +
high O +
DA O +
concentrations O +
and O +
longer O +
exposure O -
. O +

Interestingly O -
, O +
micromolar O +
levels O +
of O +
DA O +
also O +
stimulate O +
DNA O +
synthesis O +
but O +
with O +
a O +
slower O +
time O +
course O +
( O -
about O +
29 O +
h O +
after O +
DA O +
stimulation O -
, O +
data O +
not O +
shown O -
) O -
. O +

Under O +
these O +
conditions O -
, O +
DA O +
stimulated O +
[ O -
3 O +
H O +
] O -
thymidine O +
incorporation O +
in O +
a O +
concentration O -
- O -
dependent O +
manner O +
( O -
Fig. O +
1 O +
a O -
) O -
. O +

The O +
[ O -
3 O +
H O +
] O -
thymidine O +
incorporation O +
into O +
DNA O +
was O +
linearly O +
increased O +
from O +
0.1 O +
to O +
500 O +
M O +
DA O -
. O +

The O +
mitogenic O +
activity O +
at O +
500 O +
M O +
DA O +
was O +
about O +
3.20.2 O +
times O +
higher O +
than O +
that O +
of O +
control O +
group O -
. O +

This O +
DA O -
- O -
induced O +
mitogenesis O +
could O +
be O +
completely O +
inhibited O +
in O +
the O +
presence O +
of O +
aphidicoline O +
( O -
20 O +
g O -
/ O -
ml O -
, O +
data O +
not O +
shown O -
) O -
, O +
a O +
potent O +
DNA B-Gene +
polymerase I-Gene +
a O +
inhibitor O -
. O +

To O +
confirm O +
the O +
DA O +
mitogenic O +
activation O -
, O +
we O +
also O +
determined O +
the O +
cell O +
cycle O +
distribution O -
. O +

As O +
shown O +
in O +
Table O +
1 O +
, O +
200 O +
M O +
DA O +
increased O +
the O +
percentage O +
of O +
the O +
cells O +
in O +
S O +
phase O +
and O +
decreased O +
the O +
percentage O +
of O +
cells O +
in O +
G1 O +
phase O -
, O +
suggesting O +
that O +
DA O +
promotes O +
progression O +
through O +
the O +
cell O +
cycle O -
. O +

Next O -
, O +
we O +
tested O +
whether O +
this O +
DA O -
- O -
stimulated O +
mitogenesis O +
requires O +
activation O +
of O +
D2 B-Gene +
receptors I-Gene -
. O +

Pretreatment O +
of O +
the O +
C6-D2L O +
cells O +
with O +
10 O +
M O +
( O -
+ O -
) O -
-butaclamol O -
, O +
a O +
potent O +
D2 B-Gene +
receptor I-Gene +
antagonist O -
, O +
completely O +
inhibited O +
DA O -
- O -
induced O +
DNA O +
[ O -
3 O +
H O +
] O -
thymidine O +
incorporation O -
, O +
while O +
10 O +
M O +
( O -
 O -
) O -
-butaclamol O -
, O +
an O +
inactive O +
form O +
of O +
( O -
+ O -
) O -
-butaclamol O -
, O +
had O +
no O +
effect O +
on O +
the O +
DA O -
- O -
stimulated O +
mitogenesis O +
( O -
Fig. O +
1 O +
b O -
) O -
. O +

To O +
confirm O +
these O +
results O -
, O +
we O +
determined O +
the O +
effect O +
of O +
quinpirole O -
, O +
a O +
specific O +
D2 B-Gene +
receptor I-Gene +
agonist O -
, O +
on O +
cell O +
cycling O -
. O +

Like O +
the O +
effect O +
of O +
micromolar O +
levels O +
of O +
DA O -
, O +
micromolar O +
levels O +
of O +
quinpirole O +
promoted O +
cell O +
proliferation O -
. O +

Quinpirole O +
increased O +
the O +
percentage O +
of O +
cells O +
in O +
S O +
phase O +
and O +
decreased O +
the O +
percentage O +
in O +
G1 O +
phase O +
( O -
Table O +
1 O +
) O -
. O +

Furthermore O -
, O +
we O +
did O +
not O +
observe O +
any O +
mitogenic O +
effect O +
within O +
a O +
DA O +
concentration O +
range O +
of O +
0500 O +
M O +
in O +
wild O -
- O -
type O +
C6 O +
cells O +
without O +
expression O +
of O +
D2L B-Gene +
receptors I-Gene +
( O -
Fig. O +
1 O +
a O -
) O -
. O +

Instead O -
, O +
[ O -
3 O +
H O +
] O -
thymidine O +
incorporation O +
into O +
DNA O +
of O +
wild O -
- O -
type O +
C6 O +
cells O +
was O +
decreased O +
about O +
2026 O -
% O +
at O +
DA O +
concentrations O +
from O +
10 O +
to O +
500 O +
M O +
( O -
Fig. O +
1 O +
a O -
) O -
. O +

Pretreatment O +
of O +
the O +
C6-D2L O +
cells O +
with O +
100 O +
ng O -
/ O -
ml O +
PTX B-Gene -
, O +
a O +
G B-Gene +
protein I-Gene -
- I-Gene -
receptor I-Gene +
uncoupler O -
, O +
partially O +
blocked O +
DA O -
- O -
stimulated O +
[ O -
3 O +
H O +
] O -
thymidine O +
incorporation O +
into O +
DNA O +
( O -
Fig. O +
1 O +
b O -
) O -
. O +

Thus O -
, O +
it O +
appears O +
that O +
this O +
DA O -
- O -
stimulated O +
mitogenesis O +
requires O +
DA O +
D2 B-Gene +
receptor I-Gene +
activation O -
. O +

3.2 O +
Effects O +
of O +
kinase B-Gene +
inhibitors O +
on O +
DA O -
- O -
induced O +
mitogenesis O +
In O +
order O +
to O +
examine O +
the O +
signaling O +
that O +
mediates O +
the O +
DA O -
- O -
stimulated O +
mitogenesis O -
, O +
we O +
first O +
tested O +
the O +
effect O +
of O +
DA O +
on O +
the O +
activity O +
of O +
ERK B-Gene -
, O +
a O +
protein B-Gene +
serine I-Gene +
kinase I-Gene +
that O +
is O +
linked O +
to O +
cell O +
proliferation O +
stimulated O +
by O +
growth O +
factors O -
, O +
cytokines O +
and O +
neurotransmitters O +
[ O -
11 O -
, O +
34 O -
] O +
. O +

As O +
shown O +
in O +
the O +
phospho O -
- O -
specific O +
ERK B-Gene +
immunoblot O +
of O +
Fig. O +
2 O +
a O -
, O +
DA O +
had O +
little O +
or O +
no O +
effect O +
on O +
ERK B-Gene +
phosphorylation O +
at O +
concentrations O +
corresponding O +
to O +
its O +
mitogenic O +
effect O +
( O -
10500 O +
M O -
) O -
, O +
although O +
DA O +
at O +
lower O +
concentrations O +
did O +
stimulate O +
ERK B-Gene +
phosphorylation O +
and O +
activity O +
[ O -
30 O -
] O +
. O +

The O +
bottom O +
panel O +
in O +
Fig. O +
2 O +
a O +
shows O +
ERK2 B-Gene +
immunoblot O +
of O +
a O +
sister O +
gel O -
, O +
indicating O +
that O +
a O +
similar O +
amount O +
of O +
protein B-Gene +
was O +
loaded O -
. O +

To O +
confirm O +
that O +
ERK B-Gene +
was O +
not O +
involved O +
in O +
DA O -
- O -
induced O +
mitogenesis O -
, O +
we O +
also O +
examined O +
the O +
effect O +
of O +
PD098059 O -
, O +
a O +
selective O +
MEK1 B-Gene +
inhibitor O +
[ O -
3 O -
] O +
, O +
on O +
DA O -
- O -
induced O +
mitogenesis O -
. O +

As O +
shown O +
in O +
Fig. O +
2 O +
b O -
, O +
the O +
DA O -
- O -
stimulated O +
DNA O +
synthesis O +
was O +
only O +
partially O +
inhibited O +
by O +
pretreatment O +
of O +
the O +
cells O +
with O +
PD O +
098059 O +
( O -
1050 O +
M O -
) O +
( O -
Fig. O +
2 O +
b O -
) O -
. O +

With O +
application O +
of O +
either O +
10 O +
or O +
50 O +
M O +
PD O +
098059 O -
, O +
bFGF B-Gene -
- O -
stimulated O +
ERK B-Gene +
activity O -
, O +
as O +
indicated O +
by O +
ERK B-Gene +
phosphorylation O -
, O +
was O +
greatly O +
or O +
completely O +
inhibited O -
, O +
respectively O +
( O -
Fig. O +
2 O +
c O -
) O -
, O +
which O +
serves O +
as O +
a O +
positive O +
control O +
of O +
the O +
inhibitory O +
effect O +
of O +
PD098059 O +
on O +
MEK1ERK B-Gene +
pathway O -
. O +

Taken O +
together O -
, O +
these O +
data O +
suggest O +
that O +
the O +
mitogenesis O +
induced O +
by O +
micromolar O +
levels O +
of O +
DA O +
is O +
not O +
mediated O +
by O +
a O +
MEK B-Gene -
 O -
ERK B-Gene +
activation O +
pathway O -
. O +

We O +
have O +
also O +
tested O +
other O +
kinase B-Gene +
inhibitors O +
on O +
DA O -
- O -
stimulated O +
mitogenesis O -
. O +

These O +
inhibitors O +
included O +
Wortmannin O +
for O +
PI3 B-Gene +
kinase I-Gene -
, O +
rapamycin O +
for O +
S6 B-Gene +
kinase I-Gene -
, O +
and O +
SB203580 O +
for O +
p38 B-Gene +
MAP I-Gene +
kinase I-Gene -
. O +

Staurosporine O +
and O +
H7 O +
are O +
inhibitors O +
for O +
a O +
broad O +
spectrum O +
of O +
protein O +
kinases O -
, O +
which O +
include O +
protein O +
kinase O +
A O -
, O +
protein O +
kinase O +
C O -
, O +
protein O +
kinase O +
G O -
, O +
CaM O +
kinase O -
, O +
and O +
myosin O +
light O +
chain O +
kinase O -
. O +

The O +
effect O +
of O +
depletion O +
of O +
PKC B-Gene +
on O +
DA O -
- O -
stimulated O +
[ O -
3 O +
H O +
] O -
thymidine O +
incorporation O +
into O +
DNA O +
was O +
also O +
examined O +
by O +
prolonged O +
treatment O +
of O +
the O +
cells O +
with O +
PMA O -
. O +

The O +
data O +
are O +
summarized O +
on O +
Table O +
2 O +
. O +

All O +
these O +
treatments O +
had O +
no O +
effect O +
on O +
DA O -
- O -
induced O +
DNA O +
synthesis O -
. O +

3.3 O +
DA O +
stimulates O +
mitogenesis O -
- O -
associated O +
protein B-Gene +
tyrosine O +
phosphorylation O +
DA O +
stimulated O +
protein B-Gene +
tyrosine O +
phosphorylation O +
in O +
a O +
time- O +
and O +
concentration O -
- O -
dependent O +
manner O +
( O -
Fig. O +
3 O +
a O +
and O +
b O -
) O -
. O +

The O +
phosphorylated O +
tyrosine O -
- O -
containing O +
proteins B-Gene +
were O +
easily O +
immunodetected O +
with O +
monoclonal B-Gene +
anti I-Gene -
- I-Gene -
phosphotyrosine I-Gene +
IgG I-Gene +
( O -
PY99 B-Gene -
) O -
. O +

When O +
C6-D2L O +
cells O +
were O +
treated O +
with O +
200 O +
M O +
DA O -
, O +
protein B-Gene +
tyrosine O +
phosphorylation O +
rapidly O +
increased O +
within O +
5 O +
min O -
, O +
reached O +
a O +
maximum O +
between O +
15 O +
and O +
30 O +
min O -
, O +
then O +
decreased O +
by O +
1 O +
h O +
( O -
Fig. O +
3 O +
a O -
) O -
. O +

A O +
majority O +
of O +
tyrosine B-Gene -
- I-Gene -
phosphorylated I-Gene +
proteins I-Gene +
were O +
located O +
within O +
the O +
molecular O +
size O +
range O +
of O +
50200 O +
kDa O -
, O +
some O +
of O +
which O +
are O +
indicated O +
by O +
arrows O +
in O +
Fig. O +
3 O +
a. O +
DA O -
- O -
stimulated O +
tyrosine O +
phosphorylation O +
was O +
evident O +
within O +
DA O +
concentrations O +
ranging O +
from O +
10 O +
to O +
500 O +
M O +
( O -
Fig. O +
3 O +
b O -
) O -
, O +
which O +
paralleled O +
the O +
DA O +
concentrations O +
for O +
stimulation O +
of O +
mitogenesis O +
( O -
Fig. O +
1 O +
a O -
) O -
. O +

To O +
monitor O +
the O +
amounts O +
of O +
protein B-Gene +
loaded O -
, O +
all O +
blots O +
were O +
stripped O +
and O +
then O +
immunoblotted O +
with O +
anti B-Gene -
- I-Gene -
ERK2 I-Gene -
. O +

The O +
lower O +
anti B-Gene -
- I-Gene -
ERK2 I-Gene +
immunoblottings O +
in O +
Fig. O +
3 O +
a O +
and O +
b O +
show O +
that O +
a O +
similar O +
amount O +
of O +
protein B-Gene +
was O +
loaded O -
. O +

This O +
protein B-Gene +
tyrosine O +
phosphorylation O -
, O +
mostly O +
at O +
molecular O +
sizes O +
between O +
50 O +
and O +
150 O +
kDa O -
, O +
required O +
D2 B-Gene +
receptor I-Gene +
activation O -
. O +

Preincubation O +
of O +
C6-D2L O +
cells O +
30 O +
min O +
with O +
( O -
+ O -
) O -
-butaclamol O -
, O +
a O +
specific O +
D2 B-Gene +
receptor I-Gene +
antagonist O -
, O +
could O +
block O +
DA O -
- O -
induced O +
protein B-Gene +
tyrosine O +
phosphorylation O +
( O -
Fig. O +
3 O +
c O -
) O -
. O +

This O +
antagonistic O +
effect O +
was O +
concentration O -
- O -
dependent O -
. O +

Increasing O +
( O -
+ O -
) O -
-butaclamol O +
from O +
1 O +
to O +
100 O +
M O +
resulted O +
in O +
significant O +
inhibition O +
of O +
protein B-Gene +
tyrosine O +
phosphorylation O -
. O +

Especially O +
in O +
the O +
presence O +
of O +
100 O +
M O +
( O -
+ O -
) O -
-butaclamol O -
, O +
the O +
cells O +
failed O +
to O +
respond O +
to O +
200 O +
M O +
DA O +
stimulation O +
( O -
upper O +
left O +
panel O -
, O +
Fig. O +
3 O +
c O -
) O -
. O +

This O +
blocking O +
effect O +
was O +
specific O +
to O +
D2 B-Gene +
receptors I-Gene +
since O +
application O +
of O +
the O +
same O +
amount O +
of O +
( O -
 O -
) O -
-butaclamol O -
, O +
an O +
inactive O +
form O +
of O +
( O -
+ O -
) O -
-butaclamol O -
, O +
did O +
not O +
show O +
any O +
effect O +
on O +
DA O -
- O -
stimulated O +
tyrosine O +
phosphorylation O -
. O +

We O +
have O +
also O +
directly O +
tested O +
the O +
effect O +
of O +
quinpirole O -
, O +
a O +
D2 B-Gene +
receptor I-Gene +
agonist O -
, O +
on O +
protein B-Gene +
tyrosine O +
phosphorylation O -
. O +

As O +
shown O +
in O +
the O +
right O +
panel O +
of O +
Fig. O +
3 O +
c O -
, O +
increasing O +
quinpirole O +
from O +
10 O +
to O +
200 O +
M O +
resulted O +
in O +
a O +
great O +
increase O +
in O +
the O +
amount O +
of O +
tyrosine B-Gene -
- I-Gene -
phosphorylated I-Gene +
proteins I-Gene -
. O +

Furthermore O -
, O +
we O +
could O +
not O +
observe O +
significant O +
changes O +
in O +
tyrosine B-Gene -
- I-Gene -
phosphorylated I-Gene +
proteins I-Gene +
in O +
wild O -
- O -
type O +
C6 O +
cells O +
treated O +
with O +
DA O +
concentrations O +
from O +
10 O +
to O +
500 O +
M O +
( O -
data O +
not O +
shown O -
) O -
. O +

Inactivation O +
of O +
cellular O +
PTX B-Gene -
- B-Gene -
sensitive I-Gene +
G I-Gene +
proteins I-Gene +
by O +
PTX B-Gene +
partially O +
blocked O +
DA O -
- O -
induced O +
protein B-Gene +
tyrosine O +
phosphorylation O -
. O +

We O +
have O +
quantified O +
tyrosine B-Gene -
- I-Gene -
phosphorylated I-Gene +
proteins I-Gene +
between O +
50 O +
and O +
150 O +
kDa O +
by O +
using O +
the O +
NIH O +
Image O +
1.55 O +
Program O -
. O +

Pretreatment O +
of O +
the O +
cells O +
with O +
500 O +
ng O -
/ O -
ml O +
PTX B-Gene +
inhibited O +
DA O +
( O -
200 O +
M O -
) O -
-stimulated O +
tyrosine O +
phosphorylation O +
by O +
5715 O -
% O +
( O -
n O +
= O -
3 O -
) O -
. O +

PTX B-Gene +
at O +
a O +
concentration O +
of O +
100 O +
ng O -
/ O -
ml O +
also O +
reduced O +
the O +
tyrosine B-Gene -
- I-Gene -
phosphorylated I-Gene +
proteins I-Gene +
by O +
2413 O -
% O +
( O -
n O +
= O -
3 O -
) O -
. O +

Coincidentally O -
, O +
this O +
percentage O +
of O +
reduction O +
of O +
tyrosine O +
phosphorylation O +
by O +
100 O +
ng O -
/ O -
ml O +
PTX B-Gene +
is O +
close O +
to O +
its O +
inhibitory O +
ability O +
( O -
3210 O -
% O -
, O +
n O +
=3 O -
, O +
Fig. O +
1 O +
b O -
) O +
to O +
DA O -
- O -
stimulated O +
mitogenesis O -
. O +

Thus O -
, O +
these O +
results O +
suggest O +
that O +
D2 B-Gene +
receptor I-Gene +
activation O +
is O +
associated O +
with O +
protein B-Gene +
tyrosine I-Gene +
kinase I-Gene +
activity O -
. O +

In O +
order O +
to O +
test O +
the O +
idea O +
that O +
tyrosine B-Gene +
kinase I-Gene +
is O +
involved O +
in O +
DA O -
- O -
stimulated O +
mitogenesis O -
, O +
we O +
examined O +
the O +
effect O +
of O +
genistein O -
, O +
a O +
potent O +
tyrosine B-Gene +
kinase I-Gene +
inhibitor O -
, O +
on O +
DA O -
- O -
induced O +
tyrosine O +
phosphorylation O +
and O +
mitogenesis O -
. O +

As O +
shown O +
in O +
Fig. O +
4 O +
a O -
, O +
preincubation O +
of O +
either O +
genistein O +
or O +
herbimycin O +
( O -
another O +
tyrosine B-Gene +
kinase I-Gene +
inhibitor O -
) O +
significantly O +
blocked O +
the O +
protein B-Gene +
tyrosine O +
phosphorylation O +
stimulated O +
by O +
200 O +
M O +
DA O -
. O +

Application O +
of O +
10 O +
M O +
genistein O +
completely O +
inhibited O +
the O +
DNA O +
synthesis O +
induced O +
by O +
DA O +
( O -
Fig. O +
4 O +
b O -
) O -
. O +

These O +
observations O +
indicate O +
that O +
the O +
activation O +
of O +
protein B-Gene +
tyrosine I-Gene +
kinase I-Gene +
is O +
required O +
for O +
the O +
promotion O +
of O +
mitogenesis O +
induced O +
by O +
DA O -
. O +

3.4 O +
DA O -
- O -
induced O +
mitogenesis O +
is O +
involved O +
in O +
an O +
intracellular O +
redox O -
 O -
tyrosine O +
phosphorylation O +
pathway O +
Although O +
reactive O +
oxygen O +
species O +
( O -
ROS O -
) O +
are O +
implicated O +
in O +
pathological O +
cellular O +
processes O -
, O +
including O +
oxidative O +
stress O +
damage O +
[ O -
47 O -
] O +
and O +
ischemic O +
neuronal O +
injury O +
[ O -
10 O -
] O +
, O +
recent O +
evidence O +
suggests O +
that O +
ROS O +
are O +
involved O +
in O +
cell O +
signaling O +
that O +
regulates O +
proliferation O +
and O +
DNA O +
synthesis O +
[ O -
22 O -
] O +
. O +

To O +
test O +
the O +
idea O +
that O +
D2 B-Gene +
receptors I-Gene +
stimulate O +
mitogenesis O +
through O +
regulation O +
of O +
an O +
intracellular O +
redox O -
 O -
tyrosine B-Gene +
kinase I-Gene +
cascade O -
, O +
we O +
examined O +
the O +
effect O +
of O +
diphenylene O +
iodonium O +
( O -
DPI O -
) O +
and O +
N O +
-acetyl O +
cysteine O +
( O -
NAC O -
) O +
on O +
DA O -
- O -
induced O +
tyrosine O +
phosphorylation O +
and O +
mitogenesis O -
. O +

DPI O +
is O +
an O +
inhibitor O +
of O +
flavonoid O -
- O -
containing O +
oxidases B-Gene +
that O +
can O +
catalyze O +
the O +
formation O +
of O +
superoxide O +
from O +
oxygen O +
with O +
NADH O -
/ O -
NADPH O +
as O +
an O +
electron O +
donor O +
[ O -
28 O -
, O +
43 O -
] O +
. O +

Some O +
flavonoid O -
- O -
containing O +
oxidases B-Gene -
, O +
such O +
as O +
NADPH B-Gene -
- I-Gene -
dependent I-Gene +
oxidase I-Gene -
, O +
have O +
been O +
shown O +
to O +
be O +
regulated O +
by O +
a O +
variety O +
of O +
membrane O +
receptors B-Gene -
, O +
such O +
as O +
intrinsic O +
tyrosine B-Gene -
- I-Gene -
kinase I-Gene -
- B-Gene -
containing I-Gene +
receptors I-Gene +
and O +
G B-Gene -
- I-Gene -
protein I-Gene -
- B-Gene -
coupled I-Gene +
receptors I-Gene +
[ O -
22 O -
, O +
23 O -
] O +
. O +

NAC O +
is O +
an O +
antioxidant O +
that O +
can O +
scavenge O +
free O +
radicals O -
. O +

Pretreatment O +
of O +
C6-D2L O +
cells O +
with O +
either O +
1 O +
M O +
DPI O +
or O +
20 O +
mM O +
NAC O +
greatly O +
reduced O +
tyrosine O +
phosphorylation O +
and O +
consequent O +
mitogenesis O +
induced O +
by O +
DA O +
( O -
Fig. O +
5 O +
a O +
and O +
b O -
) O -
. O +

Either O +
DPI O +
or O +
NAC O +
itself O +
has O +
no O +
effect O +
on O +
tyrosine O +
phosphorylation O +
of O +
proteins B-Gene +
( O -
Fig. O +
5 O +
) O -
. O +

The O +
anti B-Gene -
- I-Gene -
ERK2 I-Gene +
immunoblotting O +
of O +
same O +
stripped O +
blot O +
shows O +
that O +
a O +
similar O +
amount O +
of O +
protein B-Gene +
was O +
loaded O +
in O +
each O +
lane O +
( O -
lower O +
panel O -
, O +
Fig. O +
5 O +
a O -
) O -
. O +

Thus O -
, O +
these O +
results O +
suggest O +
that O +
the O +
protein B-Gene +
tyrosine I-Gene +
kinase I-Gene +
and O +
consequent O +
mitogenesis O +
may O +
be O +
regulated O +
by O +
intracellular O +
ROS O -
, O +
which O +
are O +
assumed O +
to O +
be O +
produced O +
by O +
flavonoid O -
- O -
containing O +
oxidases B-Gene -
. O +

Next O -
, O +
we O +
tested O +
the O +
roles O +
of O +
ROS O +
in O +
DA O -
- O -
induced O +
tyrosine O +
phosphorylation O +
and O +
mitogenesis O +
by O +
application O +
of O +
exogenous O +
H2 O +
O2 O +
. O +

We O +
assumed O +
that O +
the O +
protein B-Gene +
tyrosine I-Gene +
kinase I-Gene +
could O +
be O +
activated O +
by O +
DA O -
- O -
stimulated O +
increase O +
of O +
intracellular O +
ROS O -
. O +

If O +
this O +
is O +
the O +
case O -
, O +
exogenous O +
application O +
of O +
low O +
concentrations O +
of O +
H2 O +
O2 O +
may O +
enhance O +
protein B-Gene +
kinase I-Gene +
activity O +
and O +
subsequent O +
mitogenesis O +
induced O +
by O +
DA O -
. O +

As O +
shown O +
in O +
Fig. O +
6 O +
a O -
, O +
increasing O +
extracellular O +
H2 O +
O2 O +
concentrations O +
did O +
result O +
in O +
increase O +
of O +
DA O -
- O -
induced O +
tyrosine B-Gene -
- I-Gene -
phosphorylated I-Gene +
proteins I-Gene -
. O +

The O +
upper O +
panel O +
shows O +
anti B-Gene -
- I-Gene -
phosphotyrosine I-Gene +
immunoblotting O -
, O +
while O +
the O +
lower O +
panel O +
is O +
a O +
quantified O +
data O +
( O -
from O +
50 O +
to O +
150 O +
kDa O -
) O +
of O +
at O +
least O +
three O +
experiments O +
using O +
the O +
NIH O +
Image O +
1.55 O +
Program O -
. O +

The O +
sister O +
gel O +
was O +
run O +
and O +
immunostained O +
with O +
anti B-Gene -
- I-Gene -
ERK2 I-Gene +
to O +
monitor O +
protein B-Gene +
loading O -
. O +

The O +
nanomolar O +
levels O +
of O +
H2 O +
O2 O +
enhanced O +
by O +
about O +
2.7-fold O +
amounts O +
of O +
tyrosine B-Gene -
- I-Gene -
phosphorylated I-Gene +
proteins I-Gene +
stimulated O +
by O +
10 O +
M O +
DA O -
, O +
although O +
H2 O +
O2 O +
levels O +
below O +
1 O +
nM O +
show O +
only O +
a O +
small O +
effect O +
( O -
Fig. O +
6 O +
a O -
) O -
. O +

Furthermore O -
, O +
an O +
enhancement O +
effect O +
of O +
H2 O +
O2 O +
on O +
DA O -
- O -
stimulated O +
mitogenesis O +
was O +
also O +
observed O +
( O -
Fig. O +
6 O +
b O -
) O -
. O +

However O -
, O +
the O +
capability O +
of O +
increasing O +
DA O -
- O -
induced O +
mitogenesis O +
at O +
nanomolar O +
levels O +
of O +
H2 O +
O2 O +
was O +
reduced O +
when O +
compared O +
with O +
that O +
at O +
0.1 O +
pM O +
H2 O +
O2 O +
( O -
Fig. O +
6 O +
b O -
) O -
. O +

This O +
may O +
be O +
due O +
to O +
a O +
dual O +
effect O +
of O +
ROS O +
in O +
cell O +
proliferation O -
: O +
a O +
stimulatory O +
effect O +
at O +
low O +
concentrations O +
and O +
a O +
toxic O +
effect O +
at O +
high O +
concentrations O +
[ O -
22 O -
] O +
. O +

With O +
the O +
application O +
of O +
H2 O +
O2 O +
alone O +
without O +
DA O -
, O +
C6-D2L O +
cells O +
did O +
exhibit O +
such O +
a O +
dual O +
mitogenic O +
effect O +
( O -
data O +
not O +
shown O -
) O -
. O +

3.5 O +
DA O +
increases O +
GFAP B-Gene +
expression O +
In O +
addition O +
to O +
stimulating O +
DNA O +
synthesis O -
, O +
DA O +
at O +
micromolar O +
levels O +
also O +
significantly O +
increased O +
the O +
expression O +
of O +
GFAP B-Gene -
, O +
a O +
sensitive O +
parameter O +
serving O +
as O +
another O +
criterion O +
of O +
reactive O +
astrocytes O +
[ O -
33 O -
] O +
. O +

As O +
shown O +
in O +
Fig. O +
7 O +
a O -
, O +
C6-D2L O +
cells O +
responded O +
to O +
DA O +
( O -
200 O +
M O -
) O +
treatment O +
with O +
an O +
increase O +
in O +
GFAP B-Gene +
expression O +
in O +
a O +
time O -
- O -
dependent O +
manner O -
. O +

Between O +
0 O +
and O +
48 O +
h O +
after O +
stimulation O -
, O +
the O +
amount O +
of O +
GFAP B-Gene +
was O +
increased O +
about O +
2.10.1-fold O +
( O -
Fig. O +
7 O +
a O -
) O -
. O +

Concentration O +
dependence O +
studies O +
carried O +
out O +
at O +
24 O +
h O +
showed O +
that O +
maximal O +
stimulation O +
of O +
GFAP B-Gene +
expression O +
occurred O +
at O +
200 O +
M O +
DA O +
( O -
Fig. O +
7 O +
b O -
) O -
. O +

Interestingly O -
, O +
GFAP B-Gene +
production O +
was O +
decreased O +
when O +
the O +
cells O +
were O +
exposed O +
to O +
500 O +
M O +
DA O +
for O +
24 O +
h O +
( O -
Fig. O +
7 O +
b O -
) O -
, O +
which O +
differs O +
from O +
the O +
dose O -
 O -
response O +
data O +
of O +
DA O -
- O -
induced O +
mitogenesis O +
( O -
Fig. O +
1 O +
) O -
. O +

This O +
observation O +
suggests O +
that O +
DA O +
stimulatory O +
GFAP B-Gene +
synthesis O +
may O +
be O +
regulated O +
by O +
a O +
different O +
pathway O +
from O +
mitogenesis O -
. O +

Alternatively O -
, O +
this O +
decrease O +
of O +
GFAP B-Gene +
expression O +
at O +
500 O +
M O +
DA O +
may O +
be O +
due O +
to O +
widespread O +
mitogenesis O +
since O +
immature O +
astrocytes O +
have O +
a O +
less O +
amount O +
of O +
GFAP B-Gene +
expression O -
. O +

3.6 O +
DA O -
- O -
induced O +
GFAP B-Gene +
generation O +
involves O +
activation O +
of O +
p38 B-Gene +
MAPK I-Gene +
It O +
became O +
important O +
to O +
determine O +
whether O +
DA O -
- O -
stimulated O +
GFAP B-Gene +
production O +
might O +
also O +
be O +
required O +
to O +
activate O +
the O +
D2 B-Gene +
receptor I-Gene -
 I-Gene -
tyrosine I-Gene +
kinase I-Gene +
pathway O -
. O +

To O +
test O +
this O +
idea O -
, O +
we O +
used O +
a O +
paradigm O +
similar O +
to O +
that O +
for O +
DA O -
- O -
stimulated O +
mitogenesis O +
in O +
C6-D2L O +
cells O +
( O -
Fig. O +
1 O +
) O -
. O +

Surprisingly O -
, O +
the O +
GFAP B-Gene +
stimulation O +
did O +
not O +
appear O +
to O +
be O +
regulated O +
by O +
D2 B-Gene +
receptors I-Gene +
since O +
it O +
was O +
not O +
influenced O +
by O +
the O +
D2 B-Gene +
receptor I-Gene +
antagonist O -
, O +
( O -
+ O -
) O -
-butaclamol O +
( O -
Fig. O +
8 O +
a O -
) O -
. O +

Application O +
of O +
DA O +
to O +
wild O -
- O -
type O +
C6 O +
cells O +
also O +
resulted O +
in O +
a O +
similar O +
increase O +
in O +
GFAP B-Gene +
expression O +
as O +
that O +
in O +
C6-D2L O +
cells O +
( O -
data O +
not O +
shown O -
) O -
. O +

Moreover O -
, O +
direct O +
application O +
of O +
quinpirole O +
( O -
200 O +
M O -
) O -
, O +
a O +
D2 B-Gene +
receptor I-Gene +
agonist O -
, O +
had O +
no O +
effect O +
on O +
GFAP B-Gene +
expression O +
( O -
Fig. O +
8 O +
a O -
) O -
. O +

Pretreatment O +
of O +
the O +
C6-D2L O +
cells O +
with O +
PTX B-Gene +
for O +
6 O +
h O +
had O +
no O +
effect O +
on O +
DA O -
- O -
stimulated O +
GFAP B-Gene +
generation O +
( O -
Fig. O +
8 O +
a O -
) O -
, O +
suggesting O +
that O +
PTX B-Gene -
- B-Gene -
sensitive I-Gene +
G I-Gene +
proteins I-Gene +
might O +
also O +
not O +
be O +
involved O -
. O +

Pretreatment O +
of O +
the O +
cells O +
with O +
either O +
10 O +
M O +
genistein O +
or O +
20 O +
mM O +
NAC O +
also O +
had O +
no O +
effect O +
on O +
GFAP B-Gene +
expression O +
due O +
to O +
DA O +
( O -
Fig. O +
8 O +
a O -
) O -
, O +
while O +
the O +
identical O +
treatments O +
resulted O +
in O +
the O +
blocking O +
of O +
DA O -
- O -
induced O +
mitogenesis O +
( O -
Fig. O +
4 O +
b O -
, O +
Fig. O +
5 O +
b O -
) O -
. O +

PD098059 O +
also O +
had O +
no O +
effect O +
on O +
DA O -
- O -
stimulated O +
GFAP B-Gene +
expression O +
( O -
Fig. O +
8 O +
a O -
) O -
. O +

Thus O -
, O +
unlike O +
DA O -
- O -
induced O +
mitogenesis O -
, O +
GFAP B-Gene +
stimulation O +
does O +
not O +
seem O +
to O +
involve O +
the O +
D2 B-Gene +
receptor I-Gene -
 I-Gene -
tyrosine I-Gene +
kinase I-Gene +
pathway O -
. O +

However O -
, O +
we O +
have O +
found O +
that O +
GFAP B-Gene +
expression O +
stimulated O +
by O +
DA O +
could O +
be O +
inhibited O +
by O +
pretreatment O +
of O +
the O +
cells O +
with O +
SB203580 O -
, O +
a O +
selective O +
p38 B-Gene +
MAPK I-Gene +
inhibitor O +
[ O -
13 O -
, O +
27 O -
] O +
. O +

As O +
shown O +
in O +
Fig. O +
8 O +
b O -
, O +
application O +
of O +
10 O +
M O +
SB O +
203580 O +
completely O +
blocked O +
the O +
increases O +
in O +
GFAP B-Gene +
generation O +
stimulated O +
by O +
DA O +
at O +
concentrations O +
ranging O +
from O +
10 O +
to O +
200 O +
M O -
, O +
suggesting O +
that O +
activation O +
of O +
p38 B-Gene +
MAPK I-Gene +
might O +
be O +
required O +
for O +
the O +
regulation O +
of O +
GFAP B-Gene +
generation O -
. O +

By O +
using O +
anti B-Gene -
- I-Gene -
phospho I-Gene -
- I-Gene -
specific I-Gene +
p38 I-Gene +
MAPK I-Gene +
immunoblotting O -
, O +
we O +
examined O +
the O +
effect O +
of O +
DA O +
on O +
p38 B-Gene +
MAPK I-Gene +
phosphorylation O -
, O +
a O +
requirement O +
for O +
p38 O +
MAPK O +
activity O +
[ O -
42 O -
] O +
. O +

With O +
the O +
application O +
of O +
100 O +
M O +
DA O +
to O +
C6-D2L O +
cells O -
, O +
p38 B-Gene +
MAPK I-Gene +
was O +
rapidly O +
phosphorylated O +
within O +
5 O +
min O -
, O +
reached O +
a O +
maximum O +
at O +
15 O +
min O -
, O +
then O +
gradually O +
decreased O +
to O +
basal O +
level O +
by O +
about O +
1 O +
h O +
( O -
Fig. O +
9 O +
a O -
) O -
. O +

The O +
p38 B-Gene +
MAPK I-Gene +
phosphorylation O +
was O +
greatly O +
increased O +
when O +
the O +
cells O +
were O +
exposed O +
to O +
DA O +
concentrations O +
ranging O +
from O +
10 O +
to O +
200 O +
M O +
for O +
15 O +
min O +
( O -
Fig. O +
9 O +
b O -
) O -
. O +

Pretreatment O +
of O +
the O +
cells O +
with O +
( O -
+ O -
) O -
-butaclamol O +
had O +
no O +
effect O +
on O +
DA O -
- O -
stimulated O +
phosphorylation O +
of O +
p38 B-Gene +
MAPK I-Gene +
( O -
Fig. O +
9 O +
c O -
) O -
. O +

These O +
data O +
suggest O +
that O +
DA O -
- O -
activated O +
p38 B-Gene +
MAPK I-Gene +
may O +
not O +
be O +
mediated O +
by O +
D2 B-Gene +
receptors I-Gene -
. O +

4 O +
Discussion O +
In O +
this O +
paper O -
, O +
we O +
report O +
that O +
micromolar O +
levels O +
of O +
DA O +
stimulate O +
mitogenesis O +
in O +
C6-D2L O +
cells O -
. O +

In O +
contrast O +
with O +
our O +
previous O +
report O +
for O +
earlier O +
mitogenesis O +
( O -
peaking O +
at O +
17 O +
h O -
) O +
induced O +
by O +
nanomolar O +
levels O +
of O +
DA O +
[ O -
30 O -
] O +
, O +
this O +
mitogenesis O +
stimulated O +
by O +
micromolar O +
levels O +
of O +
DA O +
occurs O +
at O +
about O +
29 O +
h. O +
Biochemically O -
, O +
the O +
earlier O +
phase O +
of O +
mitogenesis O +
requires O +
D2 B-Gene +
receptor I-Gene -
 I-Gene -
MAPK I-Gene +
signaling O -
, O +
while O +
the O +
later O +
phase O +
requires O +
the O +
D2-receptor B-Gene -
 I-Gene -
tyrosine I-Gene +
kinase I-Gene +
pathway O -
. O +

Although O +
relationship O +
of O +
the O +
two O +
phases O +
of O +
DA O -
- O -
induced O +
mitogenesis O +
is O +
not O +
clear O -
, O +
the O +
different O +
signaling O +
mechanisms O +
suggest O +
that O +
they O +
are O +
not O +
likely O +
to O +
be O +
dependent O +
on O +
each O +
other O -
. O +

For O +
example O -
, O +
nanomolar O +
levels O +
of O +
DA O +
strongly O +
stimulate O +
MAPK B-Gene +
without O +
significant O +
protein B-Gene +
tyrosine O +
phosphorylation O +
and O +
the O +
mitogenesis O +
can O +
be O +
inhibited O +
by O +
blockers O +
of O +
MAPK B-Gene +
pathway I-Gene -
. O +

Micromolar O +
levels O +
of O +
DA O +
strongly O +
stimulate O +
protein B-Gene +
tyrosine I-Gene +
kinase I-Gene +
without O +
effect O +
on O +
MAPK B-Gene -
, O +
and O +
the O +
consequent O +
mitogenesis O +
can O +
be O +
blocked O +
by O +
tyrosine B-Gene +
kinase I-Gene +
inhibitors O +
but O +
not O +
by O +
blockers O +
of O +
the O +
MAPK B-Gene +
pathway I-Gene -
. O +

Under O +
normal O +
physiological O +
conditions O -
, O +
striatal O +
astrocytes O +
surround O +
dopaminergic O +
neurons O -
. O +

Although O +
the O +
astrocytes O +
do O +
not O +
have O +
synaptic O +
contact O +
with O +
dopaminergic O +
neurons O -
, O +
D2 B-Gene +
receptors I-Gene +
in O +
astrocytes O +
may O +
sense O +
DA O +
( O -
low O +
concentrations O -
) O +
that O +
might O +
escape O +
from O +
the O +
synapse O +
and O +
play O +
a O +
physiological O +
role O +
via O +
the O +
MAPK B-Gene +
pathway I-Gene -
. O +

In O +
pathologic O +
conditions O -
, O +
such O +
as O +
ischemia O -
, O +
hypoxia O +
and O +
excitatory O +
amino O +
acid O -
- O -
induced O +
neurotoxicity O -
, O +
the O +
extracellular O +
DA O +
concentration O +
in O +
striata O +
is O +
significantly O +
increased O +
to O +
micromolar O +
levels O +
[ O -
2 O -
, O +
6 O -
, O +
45 O -
] O +
. O +

Although O +
the O +
length O +
of O +
DA O +
exposure O +
in O +
our O +
cell O +
culture O +
was O +
relatively O +
long O -
, O +
the O +
signaling O +
responses O -
, O +
such O +
as O +
protein B-Gene +
tyrosine O +
phosphorylation O +
and O +
p38 B-Gene +
MAPK I-Gene +
phosphorylation O -
, O +
were O +
rapid O -
, O +
within O +
a O +
few O +
minutes O +
( O -
Fig. O +
3 O +
a O -
, O +
Fig. O +
9 O +
a O -
) O -
. O +

Thus O -
, O +
the O +
micromolar O +
level O +
DA O -
- O -
induced O +
activation O +
of O +
astrocytes O +
may O +
be O +
implicated O +
in O +
these O +
pathologic O +
conditions O -
. O +

Our O +
results O +
suggest O +
that O +
micromolar O +
levels O +
of O +
DA O +
activate O +
C6-D2L O +
cells O +
through O +
an O +
interaction O +
with O +
receptors B-Gene -
. O +

This O +
is O +
evident O +
since O +
DA O -
- O -
stimulated O +
mitogenesis O +
can O +
be O +
blocked O +
by O +
( O -
+ O -
) O -
-butaclamol O -
, O +
a O +
selective O +
D2 B-Gene +
DA I-Gene +
receptor I-Gene +
antagonist O -
, O +
with O +
no O +
effect O +
of O +
( O -
 O -
) O -
-butaclamol O -
, O +
an O +
inactive O +
isoform O +
of O +
( O -
+ O -
) O -
-butaclamol O -
. O +

Quinpirole O -
, O +
a O +
specific O +
D2 B-Gene +
receptor I-Gene +
agonist O -
, O +
also O +
promotes O +
cell O +
cycle O +
progression O -
. O +

Furthermore O -
, O +
wild O -
- O -
type O +
C6 O +
cells O -
, O +
lacking O +
the O +
expression O +
of O +
D2 B-Gene +
receptors I-Gene -
, I-Gene +
exhibit O +
no O +
mitogenic O +
response O +
to O +
stimulation O +
by O +
DA O -
. O +

This O +
also O +
ruled O +
out O +
the O +
possibility O +
that O +
the O +
mitogenesis O +
might O +
be O +
mediated O +
by O +
ROS O +
produced O +
by O +
DA O +
autoxidation O -
. O +

However O -
, O +
considering O +
the O +
fact O +
that O +
C6 O +
cells O +
contain O +
other O +
monoamine B-Gene +
receptors I-Gene -
, O +
such O +
as O +
 B-Gene +
adrenergic I-Gene +
receptors I-Gene +
[ O -
35 O -
] O +
, O +
we O +
can O -
not O +
exclude O +
the O +
possibility O +
that O +
micromolar O +
levels O +
of O +
DA O +
may O +
also O +
non O -
- O -
specifically O +
stimulate O +
these O +
receptors B-Gene +
and O +
may O +
cooperate O +
with O +
DA B-Gene +
receptors I-Gene -
. O +

A O +
receptor B-Gene -
- O -
mediated O +
mechanism O +
may O +
also O +
be O +
involved O +
in O +
GFAP B-Gene +
upregulation O +
stimulated O +
by O +
DA O +
since O +
GFAP B-Gene +
synthesis O +
could O +
not O +
be O +
prevented O +
by O +
preincubation O +
with O +
20 O +
mM O +
NAC O -
, O +
which O +
can O +
scavenge O +
ROS O +
generated O +
either O +
by O +
DA O +
oxidation O +
or O +
through O +
a O +
D2-receptor B-Gene -
- O -
mediated O +
redox O +
system O -
. O +

Although O +
the O +
type O +
of O +
receptor B-Gene +
involved O +
in O +
DA O -
- O -
stimulated O +
GFAP B-Gene +
expression O +
is O +
currently O +
unknown O -
, O +
it O +
would O +
appear O +
not O +
to O +
be O +
D2 B-Gene +
receptors I-Gene +
since O +
both O +
wild O -
- O -
type O +
C6 O +
and O +
C6-D2L O +
cells O +
gave O +
a O +
similar O +
GFAP B-Gene +
regulatory O +
response O +
to O +
DA O +
stimulation O -
. O +

One O +
potential O +
candidate O +
would O +
be O +
 B-Gene +
adrenergic I-Gene +
receptors I-Gene -
, O +
shown O +
to O +
stimulate O +
GFAP B-Gene +
expression O +
through O +
cAMP O +
[ O -
44 O -
] O +
. O +

High O -
- O -
concentration O +
DA O -
- O -
stimulated O +
mitogenesis O +
appears O +
to O +
involve O +
the O +
intracellular O +
production O +
of O +
ROS O +
as O +
supported O +
by O +
the O +
following O +
evidence O -
. O +

First O -
, O +
DA O -
- O -
stimulated O +
mitogenesis O +
can O +
be O +
inhibited O +
by O +
DPI O -
. O +

DPI O +
has O +
been O +
demonstrated O +
to O +
be O +
a O +
potent O +
and O +
selective O +
inhibitor O +
for O +
membrane O -
- O -
bound O +
NADPH B-Gene -
- I-Gene -
dependent I-Gene +
oxidase I-Gene +
through O +
a O +
binding O +
to O +
the O +
flavoprotein B-Gene +
component O +
of O +
the O +
oxidase B-Gene +
[ O -
12 O -
, O +
28 O -
, O +
43 O -
] O +
. O +

This O +
intracellular O +
NADPH B-Gene -
- I-Gene -
dependent I-Gene +
oxidase I-Gene +
can O +
directly O +
catalyze O +
substrate O +
oxygen O +
conversion O +
to O +
the O +
superoxide O +
anion O -
, O +
which O +
can O +
in O +
turn O +
generate O +
other O +
reactive O +
oxygen O +
intermediates O -
. O +

Secondly O -
, O +
DA O -
- O -
induced O +
mitogenesis O +
is O +
prevented O +
by O +
the O +
membrane O -
- O -
permeable O +
antioxidant O -
, O +
NAC O -
. O +

Finally O -
, O +
application O +
of O +
very O +
low O +
concentrations O +
of O +
H2 O +
O2 O +
can O +
enhance O +
both O +
DA O -
- O -
induced O +
protein B-Gene +
tyrosine O +
phosphorylation O +
and O +
mitogenesis O -
. O +

These O +
observations O +
suggest O +
that O +
ROS O +
may O +
serve O +
as O +
a O +
second O +
messenger O +
in O +
the O +
signaling O +
of O +
DA O -
- O -
stimulated O +
mitogenesis O -
, O +
adding O +
evidence O +
in O +
support O +
of O +
the O +
recent O +
notion O +
that O +
ROS O +
act O +
as O +
intracellular O +
messengers O +
of O +
cell O +
proliferation O +
[ O -
22 O -
] O +
. O +

Like O +
other O +
astrocyte O +
mitogens O -
, O +
such O +
as O +
endothelin O +
[ O -
7 O -
, O +
26 O -
] O +
, O +
micromolar O +
level O +
DA O -
- O -
induced O +
mitogenesis O +
requires O +
tyrosine O +
phosphorylation O -
. O +

Application O +
of O +
DA O +
to O +
C6-D2L O +
cells O +
rapidly O +
increases O +
protein B-Gene +
tyrosine O +
phosphorylation O -
. O +

Concentration O -
- O -
dependent O +
tyrosine O +
phosphorylation O +
studies O +
show O +
a O +
similar O +
profile O +
to O +
that O +
of O +
DA O -
- O -
induced O +
DNA O +
synthesis O -
. O +

Both O +
protein B-Gene +
tyrosine O +
phosphorylation O +
and O +
mitogenesis O +
can O +
be O +
effectively O +
blocked O +
by O +
preincubation O +
of O +
the O +
cells O +
with O +
genistein O -
, O +
a O +
potent O +
protein B-Gene +
tyrosine I-Gene +
kinase I-Gene +
inhibitor O +
[ O -
1 O -
] O +
. O +

However O -
, O +
unlike O +
for O +
the O +
mitogen O +
endothelin O -
, O +
DA O -
- O -
stimulated O +
mitogenesis O +
is O +
not O +
linked O +
to O +
the O +
tyrosine B-Gene +
kinase I-Gene -
 O -
ERK B-Gene +
pathway O +
since O +
DA O +
at O +
micromolar O +
levels O +
has O +
no O +
stimulatory O +
effect O +
on O +
ERK B-Gene +
activation O -
. O +

Furthermore O -
, O +
PD098095 O -
, O +
the O +
MEK1 B-Gene +
inhibitor O -
, O +
has O +
little O -
, O +
if O +
any O -
, O +
effect O +
on O +
high O +
concentration O +
of O +
DA O -
- O -
induced O +
mitogenesis O +
although O +
it O +
does O +
have O +
some O +
inhibitory O +
effects O +
on O +
basal O +
DNA O +
synthesis O -
. O +

DA O -
- O -
stimulated O +
mitogenesis O +
at O +
micromolar O +
levels O +
is O +
partially O +
mediated O +
by O +
PTX B-Gene -
- B-Gene -
sensitive I-Gene +
G I-Gene +
proteins I-Gene -
. O +

This O +
is O +
supported O +
by O +
the O +
following O +
evidence O -
. O +

( O -
1 O -
) O +
Pretreatment O +
of O +
the O +
cells O +
with O +
100 O +
ng O -
/ O -
ml O +
PTX B-Gene +
only O +
inhibits O +
DA O -
- O -
stimulated O +
mitogenesis O +
by O +
about O +
2450 O -
% O -
, O +
depending O +
on O +
concentrations O +
of O +
DA O +
( O -
Fig. O +
1 O +
b O -
) O -
. O +

( O -
2 O -
) O +
Application O +
of O +
PTX B-Gene -
, O +
even O +
in O +
a O +
very O +
high O +
concentration O +
( O -
500 O +
ng O -
/ O -
ml O -
) O -
, O +
only O +
partially O +
blocks O +
DA O -
- O -
induced O +
tyrosine O +
phosphorylation O -
. O +

( O -
3 O -
) O +
The O +
ability O +
of O +
PTX B-Gene +
to O +
inhibit O +
protein B-Gene +
tyrosine O +
phosphorylation O +
is O +
correlated O +
with O +
that O +
to O +
inhibit O +
DA O -
- O -
induced O +
mitogenesis O +
( O -
Fig. O +
1 O +
b O -
) O -
. O +

These O +
observations O +
raise O +
the O +
possibility O +
that O +
PTX B-Gene -
- B-Gene -
resistant I-Gene +
G I-Gene +
proteins I-Gene +
may O +
participate O +
in O +
the O +
signaling O +
of O +
high O +
concentration O +
of O +
DA O -
- O -
induced O +
mitogenesis O -
, O +
although O +
further O +
studies O +
are O +
required O -
. O +

Some O +
literature O +
reports O +
suggest O +
that O +
receptors B-Gene +
coupled O +
to O +
PTX B-Gene -
- B-Gene -
insensitive I-Gene +
G I-Gene +
proteins I-Gene +
or O +
the O +
small O +
G B-Gene +
protein I-Gene +
Ras B-Gene +
can O +
regulate O +
cell O +
proliferation O -
. O +

For O +
example O -
, O +
thrombin B-Gene -
, O +
an O +
astrocytic O +
mitogen B-Gene -
, O +
has O +
been O +
shown O +
to O +
stimulate O +
DNA O +
synthesis O +
in O +
1321N1 O +
astrocytoma O +
cells O +
through O +
coupling O +
with O +
G12 B-Gene +
, O +
a O +
Gq O +
subtype O +
of O +
GTP B-Gene +
binding I-Gene +
proteins I-Gene +
[ O -
41 O -
] O +
. O +

Recently O -
, O +
D2 B-Gene +
receptors I-Gene +
were O +
also O +
reported O +
to O +
stimulate O +
prolactin B-Gene +
release O +
via O +
coupling O +
of O +
a O +
PTX B-Gene -
- B-Gene -
insensitive I-Gene +
G I-Gene +
protein I-Gene +
pathway O +
[ O -
8 O -
] O +
. O +

Whether O +
or O +
not O +
D2 B-Gene +
receptors I-Gene +
might O +
be O +
coupled O +
to O +
PTX B-Gene -
- B-Gene -
insensitive I-Gene +
G I-Gene +
proteins I-Gene +
or O +
Ras B-Gene +
small I-Gene +
G I-Gene +
proteins I-Gene +
in O +
response O +
to O +
high O +
concentrations O +
of O +
DA O +
needs O +
further O +
study O -
. O +

Our O +
data O +
suggest O +
that O +
activation O +
of O +
p38 B-Gene +
MAPK I-Gene +
is O +
required O +
for O +
upregulation O +
of O +
GFAP B-Gene +
synthesis O +
following O +
high O +
concentrations O +
of O +
DA O +
stimulation O -
. O +

This O +
is O +
based O +
on O +
the O +
following O +
observations O -
. O +

( O -
1 O -
) O +
Micromolar O +
level O +
DA O -
- O -
stimulated O +
GFAP B-Gene +
production O +
can O +
be O +
completely O +
inhibited O +
by O +
pretreatment O +
of O +
the O +
cells O +
with O +
SB203580 O -
, O +
a O +
highly O +
selective O +
inhibitor O +
of O +
p38 B-Gene +
MAPK I-Gene +
[ O -
13 O -
, O +
27 O -
] O +
. O +

Inhibition O +
of O +
a O +
parallel O +
MAPK B-Gene +
pathway I-Gene +
by O +
PD098059 O +
has O +
no O +
effect O +
on O +
DA O -
- O -
induced O +
GFAP B-Gene +
expression O -
, O +
suggesting O +
that O +
a O +
relative O +
specificity O +
of O +
p38 B-Gene +
MAPK I-Gene +
may O +
play O +
a O +
role O +
in O +
GFAP B-Gene +
generation O -
. O +

( O -
2 O -
) O +
DA O +
activates O +
p38 B-Gene +
MAPK I-Gene +
activity O +
at O +
concentrations O +
similar O +
to O +
those O +
of O +
DA O -
- O -
induced O +
GFAP B-Gene +
expression O -
. O +

( O -
3 O -
) O +
Both O +
activation O +
of O +
p38 B-Gene +
MAPK I-Gene +
and O +
GFAP B-Gene +
synthesis O +
are O +
not O +
regulated O +
by O +
D2 B-Gene +
receptors I-Gene -
. O +

To O +
our O +
knowledge O -
, O +
this O +
is O +
the O +
first O +
report O +
regarding O +
the O +
regulation O +
of O +
GFAP B-Gene +
by O +
p38 B-Gene +
MAPK I-Gene -
. O +

In O +
C6 O +
cells O -
, O +
an O +
increase O +
in O +
intracellular O +
cAMP O -
, O +
either O +
by O +
stimulation O +
of O +
 B-Gene -
- I-Gene -
adrenergic I-Gene +
receptors I-Gene +
[ O -
44 O -
] O +
or O +
by O +
stimulation O +
of O +
adenylate B-Gene +
cyclase I-Gene +
by O +
forskolin O +
[ O -
44 O -
] O +
, O +
is O +
capable O +
of O +
stimulating O +
GFAP B-Gene -
. O +

The O +
relationship O +
of O +
cAMP O +
to O +
p38 B-Gene +
MAPK I-Gene +
deserves O +
further O +
investigation O -
. O +

In O +
our O +
cell O +
culture O +
studies O -
, O +
at O +
least O +
two O +
pathways O +
have O +
been O +
demonstrated O +
to O +
activate O +
C6-D2L O +
glioma O +
cells O -
. O +

One O +
is O +
the O +
D2-receptor B-Gene -
- O -
required O +
intracellular O +
redox B-Gene -
 I-Gene -
protein I-Gene +
tyrosine I-Gene +
kinase I-Gene +
pathway O -
, O +
which O +
is O +
involved O +
in O +
stimulation O +
of O +
cell O +
mitogenesis O -
. O +

Another O +
is O +
the O +
D2 B-Gene +
receptor I-Gene -
- O -
independent O +
p38 B-Gene +
MAPK I-Gene +
cascade O -
, O +
which O +
is O +
involved O +
in O +
stimulation O +
of O +
GFAP B-Gene +
synthesis O -
. O +

Interestingly O -
, O +
in O +
an O +
in O +
vivo O +
rat O +
model O -
, O +
reactive O +
astrocytes O +
in O +
the O +
brain O +
respond O +
differently O +
to O +
brain O +
injury O -
. O +

Some O +
astrocytes O +
undergo O +
proliferation O +
as O +
indicated O +
only O +
by O +
[ O -
3 O +
H O +
] O -
thymidine O +
incorporation O -
; O +
some O +
exhibit O +
hypertrophy O +
labeled O +
only O +
by O +
GFAP B-Gene -
; O +
some O +
are O +
labeled O +
by O +
both O +
GFAP B-Gene +
and O +
[ O -
3 O +
H O +
] O -
thymidine O +
[ O -
25 O -
, O +
48 O -
] O +
. O +

This O +
observation O +
suggests O +
that O +
these O +
two O +
separate O +
pathways O +
may O +
operate O +
in O +
the O +
in O +
vivo O +
situation O -
. O +

Taken O +
together O -
, O +
the O +
information O +
from O +
our O +
in O +
vitro O +
cell O +
culture O +
studies O +
may O +
provide O +
insight O +
into O +
the O +
mechanisms O +
of O +
in O +
vivo O +
striatal O +
astrocytic O +
response O +
and O +
help O +
to O +
elucidate O +
potential O +
roles O +
of O +
astrocytes O +
in O +
neurodegeneration O -
. O +

Acknowledgements O +

We O +
thank O +
Dr. O +
K.A. O +
Neve O +
for O +
providing O +
C6-D2L O +
cells O -
. O +

Malaria O +
is O +
still O +
the O +
most O +
important O +
parasitic O +
disease O +
in O +
the O +
world O -
, O +
causing O +
23 O +
million O +
deaths O +
every O +
year O +
( O -
WHO O -
, O +
1997 O +
) O -
. O +

The O +
rising O +
resistance O +
of O +
Plasmodium O +
spp O -
. O -
, O +
especially O +
Plasmodium O +
falciparum O +
, O +
to O +
known O +
antimalarials O +
such O +
as O +
chloroquine O +
makes O +
the O +
search O +
for O +
new O +
antimalarial O +
drugs O +
increasingly O +
important O -
. O +

Therefore O -
, O +
we O +
investigated O +
several O +
medicinal O +
plants O -
, O +
which O +
are O +
traditionally O +
used O +
as O +
antimalarial O +
or O +
antipyretic O +
remedies O +
by O +
the O +
indigenous O +
population O +
in O +
Latin O +
America O +
( O -
Duke O -
, O +
1975 O -
; O +
Hirschhorn O -
, O +
1981 O -
; O +
Joly O +
et O +
al. O -
, O +
1987 O -
; O +
Gupta O +
et O +
al. O -
, O +
1993 O +
) O -
. O +

During O +
a O +
screening O +
program O -
, O +
we O +
obtained O +
lipophilic O +
and O +
hydrophilic O +
extracts O +
of O +
these O +
plants O +
with O +
antiplasmodial O +
activity O +
and O +
we O +
selected O +
the O +
most O +
active O +
ones O +
for O +
further O +
investigation O +
( O -
Jenett O -
- O -
Siems O +
et O +
al. O -
, O +
1999 O +
) O -
. O +

Andira O +
inermis O +
( O -
W. O +
Wright O -
) O +
H.B.K. O +
( O -
Fabaceae O -
) O +
is O +
a O +
tall O +
tree O +
characterised O +
by O +
a O +
thick O +
trunk O +
and O +
red O -
- O -
purple O +
flowers O -
, O +
native O +
from O +
southern O +
Mexico O +
to O +
northern O +
South O +
America O -
. O +

As O +
a O +
febrifuge O -
, O +
the O +
bark O +
is O +
boiled O +
in O +
milk O -
, O +
sweetened O +
water O +
or O +
performed O +
in O +
pills O -
. O +

It O +
is O +
also O +
used O +
as O +
a O +
purgative O -
, O +
vermifuge O -
, O +
or O +
for O +
dermal O +
irritations O -
. O +

The O +
seeds O +
have O +
similar O +
uses O -
. O +

Large O +
doses O +
of O +
the O +
stem O +
bark O +
or O +
seeds O +
caused O +
vomiting O +
and O +
violent O +
diarrhoea O -
; O +
in O +
some O +
cases O +
they O +
were O +
even O +
fatal O +
( O -
Hirschhorn O -
, O +
1981 O -
; O +
Morton O -
, O +
1981 O +
) O -
. O +

From O +
this O +
species O -
, O +
several O +
isoflavones O +
and O +
related O +
structures O +
have O +
been O +
reported O +
( O -
Cocker O +
et O +
al. O -
, O +
1962 O -
; O +
Lock O +
de O +
Ugaz O +
et O +
al. O -
, O +
1991 O +
) O -
. O +

The O +
lipophilic O +
extracts O +
of O +
stems O +
and O +
leaves O +
showed O +
moderate O +
in O +
vitro O +
activity O +
against O +
P. O +
falciparum O +
in O +
this O +
screening O +
program O +
and O +
were O +
further O +
analysed O +
by O +
bioassay O -
- O -
guided O +
fractionation O +
to O +
isolate O +
the O +
active O +
compounds O -
. O +

2 O +
Material O +
and O +
methods O +
2.1 O +
General O +
For O +
fractionation O -
, O +
silica O +
gel O +
60 O +
( O -
70230 O +
mesh O -
) O +
was O +
utilised O -
. O +

Preparative O +
high O +
performance O +
liquid O +
chromatography O +
( O -
HPLC O -
) O +
was O +
performed O +
on O +
a O +
Knauer O +
Eurochrom O +
2000 O +
equipped O +
with O +
a O +
Nucleosil O +
P O +
300 O +
C-18 O +
( O -
10 O +
m O -
) O +
column O -
. O +

Mass O +
spectra O +
were O +
determined O +
with O +
a O +
Finnigan O +
MAT O +
CH7A O +
( O -
220 O -
 O -
C O -
, O +
ionisation O +
70 O +
eV O -
) O +
and O +
1 O +
H O -
- O -
NMR O +
spectra O +
were O +
obtained O +
using O +
acetone O -
- O -
D6 O +
as O +
a O +
solvent O +
with O +
a O +
Bruker O +
AVANCE O +
DPX O +
400 O +
( O -
400 O +
MHz O -
, O +
TMS O +
as O +
internal O +
standard O -
) O -
. O +

The O +
erythrocytes O +
were O +
harvested O +
with O +
an O +
Inotech O +
cell O +
harvester O +
and O +
the O +
 O -
- O -
radiation O +
of O +
the O +
incorporated O +
[ O -
3 O +
H O -
] O -
hypoxanthine O +
was O +
measured O +
with O +
a O +
Wallac O +
1450 O +
MicroBeta O +
plus O +
liquid O +
scintillation O +
counter O -
. O +

2.2 O +
Plant O +
material O +
Leaves O +
and O +
stems O +
of O +
A. O +
inermis O +
were O +
collected O +
in O +
the O +
area O +
of O +
Panama O +
City O +
( O -
at O +
the O +
road O +
El O +
Llano O -
- O -
Carti O -
) O -
, O +
Panama O -
, O +
during O +
March O +
1997 O -
. O +

Voucher O +
specimens O +
( O -
FLORPAN O +
2758 O -
) O +
were O +
identified O +
by O +
Professor O +
M.D. O +
Correa O +
A. O +
and O +
deposited O +
at O +
the O +
Herbarium O +
of O +
the O +
University O +
of O +
Panama O -
. O +

2.3 O +
Extraction O +
and O +
isolation O +
In O +
the O +
screening O +
program O -
, O +
the O +
air O -
- O -
dried O +
stem O +
bark O +
and O +
leaves O +
( O -
20 O +
g O -
) O +
were O +
extracted O +
three O +
times O +
for O +
2 O +
h O +
with O +
150 O +
ml O +
petroleum O +
ether O -
/ O -
ethyl O +
acetate O +
( O -
1:1 O -
) O +
at O +
room O +
temperature O -
. O +

Then O +
the O +
plant O +
material O +
was O +
air O +
dried O +
again O +
and O +
treated O +
three O +
times O +
with O +
150 O +
ml O +
methanol O -
/ O -
water O +
( O -
8:2 O -
) O +
to O +
yield O +
the O +
hydrophilic O +
extracts O -
. O +

The O +
solvents O +
were O +
evaporated O +
under O +
reduced O +
pressure O +
at O +
40 O -
 O -
C O -
. O +

For O +
further O +
investigations O -
, O +
the O +
crushed O +
stems O +
( O -
600 O +
g O -
) O +
were O +
air O +
dried O +
and O +
extracted O +
three O +
times O +
with O +
2 O +
l O +
of O +
petroleum O +
ether O -
/ O -
ethyl O +
acetate O +
( O -
1:1 O -
) O +
for O +
24 O +
h O +
at O +
room O +
temperature O -
. O +

The O +
solvents O +
were O +
evaporated O +
under O +
reduced O +
pressure O +
at O +
40 O -
 O -
C O -
. O +

The O +
oily O +
residue O +
( O -
3.3 O +
g O -
) O +
was O +
subjected O +
to O +
column O +
chromatography O +
on O +
silica O +
gel O +
60 O +
( O -
45 O +
g O -
) O +
and O +
eluted O +
with O +
cyclohexane O -
, O +
cyclohexane O -
/ O -
ethyl O +
acetate O +
mixtures O -
, O +
and O +
methanol O +
to O +
yield O +
seven O +
fractions O -
, O +
which O +
were O +
tested O +
against O +
P. O +
falciparum O +
. O +

Fraction O +
5 O +
and O +
6 O -
, O +
which O +
were O +
eluted O +
with O +
cyclohexane O -
/ O -
ethyl O +
acetate O +
( O -
8:2 O +
and O +
7:3 O -
, O +
respectively O -
) O -
, O +
proved O +
to O +
be O +
most O +
active O -
. O +

Further O +
separation O +
of O +
fraction O +
5 O +
( O -
150 O +
mg O -
) O +
by O +
HPLC O +
at O +
a O +
5 O +
ml O -
/ O -
min O +
flow O +
rate O +
of O +
methanol O -
/ O -
water O +
( O -
55:45 O -
) O +
yielded O +
the O +
compounds O +
1 O +
( O -
2.4 O +
mg O -
) O -
, O +
2 O +
( O -
6.1 O +
mg O -
) O -
, O +
and O +
3 O +
( O -
6.6 O +
mg O -
) O -
. O +

Fraction O +
6 O +
was O +
separated O +
with O +
methanol O -
/ O -
water O +
( O -
45:55 O -
) O +
to O +
give O +
the O +
compounds O +
4 O +
( O -
8.3 O +
mg O -
) O -
, O +
5 O +
( O -
8.5 O +
mg O -
) O -
, O +
and O +
6 O +
( O -
1.6 O +
mg O -
) O -
. O +

Compound O +
2 O +
( O -
prunetin O -
) O -
: O +
EI O -
- O -
MS O -
: O +
m O +
/z O +
( O -
rel O -
. O +

int. O -
) O -
=284 O +
( O -
M+ O +
, O +
100 O -
) O -
, O +
166 O +
( O -
35 O -
) O -
, O +
138 O +
( O -
22 O -
) O -
, O +
118 O +
( O -
15 O -
) O -
, O +
110 O +
( O -
10 O -
) O -
, O +
95 O +
( O -
13 O -
) O -
; O +
1 O +
H O -
- O -
NMR O +
( O -
400 O +
MHz O -
, O +
acetone O -
- O -
D6 O +
): O +
 O +
( O -
ppm O -
) O -
=3.93 O +
( O -
3 O +
H O -
, O +
s O -
, O +
CH3 O +
O-7 O -
) O -
, O +
6.36 O +
( O -
1 O +
H O -
, O +
d O -
, O +
J O +
= O -
2.3 O +
Hz O -
, O +
H-6 O -
) O -
, O +
6.55 O +
( O -
1 O +
H O -
, O +
d O -
, O +
J O +
= O -
2.4 O +
Hz O -
, O +
H-8 O -
) O -
, O +
6.91 O +
( O -
2 O +
H O -
, O +
d O -
, O +
J O +
= O -
8.5 O +
Hz O -
, O +
H-3,5 O -
) O -
, O +
7.47 O +
( O -
2 O +
H O -
, O +
d O -
, O +
J O +
= O -
8.5 O +
Hz O -
, O +
H-2,6 O -
) O -
, O +
8.22 O +
( O -
1 O +
H O -
, O +
s O -
, O +
H-2 O -
) O -
, O +
13.4 O +
( O -
1 O +
H O -
, O +
s O -
, O +
OH-5 O -
) O -
. O +

2.4 O +
Antiplasmodial O +
bioassay O +
In O +
this O +
study O -
, O +
the O +
chloroquine O -
- O -
sensitive O +
strain O +
of O +
P. O +
falciparum O +
poW O +
( O -
IC50 O +
= O -
0.015 O +
M O -
) O +
and O +
the O +
chloroquine O -
- O -
resistant O +
clone O +
Dd2 O +
( O -
IC50 O +
= O -
0.14 O +
M O -
) O +
were O +
used O -
. O +

They O +
were O +
maintained O +
in O +
continuous O +
culture O +
in O +
human O +
red O +
blood O +
cells O +
( O -
A+ O +
) O +
diluted O +
to O +
5 O -
% O +
haematocrit O +
in O +
RPMI O +
1640 O +
medium O +
supplemented O +
with O +
25 O +
mM O +
Hepes O -
, O +
30 O +
mM O +
NaHCO3 O +
, O +
and O +
10 O -
% O +
human O +
A+ O +
serum O -
. O +

Crude O +
extracts O +
and O +
isolated O +
compounds O +
were O +
dissolved O +
in O +
DMSO O +
( O -
1 O +
mg O -
/ O -
50 O +
l O -
) O +
and O +
diluted O +
in O +
RPMI O +
1640 O +
medium O +
( O -
Trager O +
and O +
Jensen O -
, O +
1976 O +
) O -
. O +

The O +
tests O +
were O +
performed O +
in O +
96-well O +
microtiter O +
plates O +
( O -
Desjardins O +
et O +
al. O -
, O +
1979 O +
) O +
which O +
contained O +
150 O +
l O +
of O +
a O +
parasitized O +
red O +
blood O +
suspension O +
( O -
A+ O +
, O +
2.5 O -
% O +
haematocrit O -
, O +
0.5 O -
% O +
parasitaemia O -
) O -
. O +

The O +
samples O +
were O +
added O +
to O +
give O +
final O +
concentrations O +
between O +
1.56 O +
and O +
100 O +
g O -
/ O -
ml O -
. O +

After O +
incubation O +
in O +
a O +
candle O +
jar O +
for O +
24 O +
h O -
, O +
0.5 O +
Ci O +
[ O -
3 O +
H O -
] O -
hypoxanthine O +
( O -
1 O +
mCi O -
/ O -
ml O -
, O +
ICN O -
) O +
was O +
added O +
to O +
each O +
well O +
and O +
the O +
plate O +
was O +
incubated O +
for O +
another O +
18 O +
h. O +
Incorporation O +
of O +
[ O -
3 O +
H O -
] O -
hypoxanthine O +
was O +
measured O +
by O +
liquid O +
scintillation O +
after O +
harvesting O +
the O +
cells O +
on O +
glass O +
fibre O +
filters O +
with O +
the O +
cell O +
harvester O -
. O +

All O +
tests O +
were O +
performed O +
in O +
triplicate O -
. O +

The O +
percentage O +
of O +
growth O +
inhibition O +
was O +
calculated O +
as O +
follows O -
: O +
( O -
1 O -
[ O -
cpm O +
in O +
drug O +
treated O +
cultures O -
/ O -
cpm O +
in O +
untreated O +
cultures O -
] O -
) O -
 O -
100 O -
. O +

The O +
concentration O +
at O +
which O +
growth O +
was O +
inhibited O +
by O +
50 O -
% O +
( O -
IC50 O +
) O +
was O +
estimated O +
by O +
interpolation O -
. O +

Extracts O +
with O +
IC50 O +
values O +
above O +
50 O +
g O -
/ O -
ml O +
were O +
considered O +
to O +
be O +
inactive O +
( O -
O'Neill O +
et O +
al. O -
, O +
1985 O +
) O -
. O +

3 O +
Results O +
The O +
isolated O +
compounds O +
16 O +
( O -
Fig. O +
1 O +
) O +
turned O +
out O +
to O +
be O +
isoflavones O -
. O +

Compound O +
1 O +
, O +
isolated O +
from O +
both O +
stems O +
and O +
leaves O +
was O +
identified O +
as O +
formononetin O +
by O +
comparison O +
with O +
an O +
authentic O +
sample O -
. O +

According O +
to O +
the O +
spectral O +
data O +
( O -
1 O +
H O -
- O -
NMR O -
, O +
EI O -
- O -
MS O -
) O -
, O +
compound O +
2 O +
proved O +
to O +
be O +
prunetin O -
. O +

To O +
the O +
best O +
of O +
our O +
knowledge O -
, O +
no O +
1 O +
H O -
- O -
NMR O +
values O +
for O +
prunetin O +
have O +
been O +
published O +
so O +
far O -
, O +
therefore O +
they O +
are O +
given O +
in O +
Section O +
2.3 O +
. O +

The O +
isoflavones O +
3 O +
, O +
4 O +
, O +
5 O +
, O +
and O +
6 O +
were O +
identified O +
as O +
biochanin O +
A O -
, O +
calycosin O -
, O +
genistein O -
, O +
and O +
pratensein O -
, O +
respectively O -
, O +
by O +
comparison O +
of O +
1 O +
H O -
- O -
NMR O +
and O +
EI O -
- O -
MS O +
with O +
published O +
data O +
( O -
Asres O +
et O +
al. O -
, O +
1985 O -
; O +
Kobayashi O +
et O +
al. O -
, O +
1985 O +
) O -
. O +

Prunetin O +
( O -
2 O -
) O +
, O +
calycosin O +
( O -
4 O -
) O +
, O +
and O +
pratensein O +
( O -
6 O -
) O +
were O +
detected O +
for O +
the O +
first O +
time O +
from O +
the O +
genus O +
Andira O +
. O +

The O +
lipophilic O +
extracts O +
of O +
A. O +
inermis O +
exhibited O +
IC50 O +
values O +
from O +
56.0 O +
g O -
/ O -
ml O +
( O -
leaves O -
) O +
to O +
108.7 O +
g O -
/ O -
ml O +
( O -
stems O -
) O +
against O +
P. O +
falciparum O +
in O +
vitro O +
( O -
Table O +
1 O +
) O -
. O +

The O +
hydrophilic O +
extracts O +
proved O +
to O +
be O +
inactive O -
. O +

For O +
all O +
tested O +
substances O +
the O +
antiparasitic O +
activity O +
against O +
the O +
chloroquine O -
- O -
sensitive O +
strain O +
poW O +
was O +
higher O +
( O -
factor O +
two O -
) O +
than O +
against O +
the O +
chloroquine O -
- O -
resistant O +
clone O +
Dd2 O -
. O +

Calycosin O +
( O -
IC50 O +
4.2 O +
g O -
/ O -
ml O +
for O +
poW O -
; O +
9.8 O +
g O -
/ O -
ml O +
for O +
Dd2 O -
) O +
and O +
genistein O +
( O -
IC50 O +
2.0 O +
g O -
/ O -
ml O +
for O +
poW O -
; O +
4.1 O +
g O -
/ O -
ml O +
for O +
Dd2 O -
) O +
proved O +
to O +
be O +
most O +
active O -
. O +

The O +
other O +
four O +
compounds O +
were O +
considered O +
to O +
be O +
inactive O -
. O +

4 O +
Discussion O +
Although O +
the O +
lipophilic O +
extracts O +
of O +
A. O +
inermis O +
showed O +
only O +
moderate O +
antiplasmodial O +
activity O +
compared O +
to O +
those O +
known O +
for O +
other O +
plant O +
remedies O +
( O -
O'Neill O +
et O +
al. O -
, O +
1985 O -
; O +
Jenett O -
- O -
Siems O +
et O +
al. O -
, O +
1999 O +
) O +
they O +
afforded O +
two O +
active O +
isoflavones O -
. O +

This O +
is O +
the O +
first O +
report O +
on O +
antiplasmodial O +
activity O +
of O +
isoflavones O +
against O +
P. O +
falciparum O +
. O +

The O +
low O +
concentration O +
of O +
calycosin O +
and O +
genistein O +
( O -
< O -
0.01 O -
% O +
w O -
/ O -
w O -
) O +
may O +
be O +
the O +
explanation O +
for O +
the O +
low O +
antiplasmodial O +
activity O +
of O +
the O +
crude O +
extract O -
. O +

It O +
is O +
known O +
that O +
calycosin O +
also O +
proved O +
to O +
be O +
active O +
against O +
Giardia O +
intestinalis O +
, O +
a O +
potent O +
protozoan O +
agent O +
for O +
enteric O +
diseases O +
( O -
ElSohly O +
et O +
al. O -
, O +
1999 O +
) O -
. O +

During O +
the O +
preparation O +
of O +
this O +
paper O +
a O +
patent O +
application O +
was O +
published O +
( O -
Khan O +
et O +
al. O -
, O +
1999 O +
) O -
, O +
which O +
claimed O +
a O +
method O +
of O +
treating O +
giardiasis O +
and/or O +
malaria O +
comprising O +
the O +
use O +
of O +
isoflavones O -
, O +
but O +
mentioning O +
no O +
data O -
, O +
proving O +
their O +
antiplasmodial O +
activity O +
against O +
P. O +
falciparum O +
. O +

In O +
our O +
study O -
, O +
we O +
have O +
focused O +
on O +
the O +
investigation O +
of O +
the O +
lipophilic O +
extract O -
. O +

The O +
indigenous O +
population O -
, O +
e.g. O +
in O +
Brazil O +
( O -
Morton O -
, O +
1981 O +
) O -
, O +
prefer O +
to O +
boil O +
the O +
stem O +
bark O +
with O +
milk O -
. O +

This O +
procedure O +
covers O +
the O +
bitter O +
taste O +
and O +
probably O +
causes O +
the O +
extraction O +
of O +
lipophilic O +
constituents O -
. O +

Interestingly O -
, O +
hydrophilic O +
extracts O +
( O -
methanol O -
/ O -
water O +
8:2 O -
) O +
from O +
A. O +
inermis O +
did O +
not O +
show O +
antiplasmodial O +
activity O +
in O +
our O +
test O +
system O -
. O +

The O +
evaluation O +
of O +
extracts O +
obtained O +
with O +
water O +
or O +
milk O +
is O +
still O +
in O +
progress O +
and O +
might O +
be O +
interesting O +
with O +
regard O +
to O +
the O +
ethnobotanical O +
use O +
of O +
this O +
species O -
. O +

Acknowledgements O +
The O +
authors O +
are O +
indebted O +
to O +
C. O +
Guerra O -
, O +
for O +
his O +
support O +
in O +
collecting O +
the O +
plant O +
material O -
, O +
and O +
to O +
Professor O +
M.D. O +
Correa O +
A. O -
, O +
Herbarium O +
of O +
the O +
University O +
of O +
Panama O -
, O +
Republic O +
of O +
Panama O -
, O +
for O +
her O +
identification O +
of O +
the O +
species O -
. O +

We O +
thank O +
Drs O +
D.S. O +
Kim O +
and O +
B. O +
Kleuser O -
, O +
Institut O +
fr O +
Pharmazie O -
, O +
Freie O +
Universitt O +
Berlin O -
, O +
Germany O -
, O +
for O +
their O +
advice O +
concerning O +
determination O +
of O +
radioactivity O -
. O +

This O +
study O +
was O +
supported O +
by O +
a O +
grant O +
from O +
the O +
Deutsche O +
Pharmazeutische O +
Gesellschaft O +
to O +
K. O +
Jenett O -
- O -
Siems O +
and O +
by O +
Charit O +
Grant O +
Nr O -
. O +

98 O -
- O -
700 O -
. O +

CIFLORPAN O +
acknowledges O +
the O +
Fundation O +
Natura O +
and O +
the O +
Organization O +
of O +
American O +
States O +
( O -
OAS O -
) O +
for O +
financial O +
support O -
. O +

